


JUNE 26-30, 2005 | WASHINGTON, DC



WASHINGTON CONVENTION CENTER

INGTONPROGRAM CHAIRPERSONENTIONRonald D. Fitzmartin, PhD, MBACENTERDaiichi Medical Research, Inc.

TABLE OF CONTENTS

4 Program Committee

Tutorials

- 5 Saturday, June 25, afternoon
- 7 Sunday, June 26, full-day
- 9 Sunday, June 26, morning
- 12 Sunday, June 26, afternoon

Certified Clinical Investigator Program

- 7 Review Course Saturday, June 25, afternoon
- 7 Examination Two Offerings Sunday, June 26, morning and afternoon
- **16** Conference Schedule

Conference Sessions

- 23 Saturday, June 25 to Monday, June 27
- 41 Tuesday, June 28
- 66 Wednesday, June 29
- **90** Thursday, June 30
- **101** Tutorial Pricing
- **102** Attendee Registration Form
- 103 Track CD-ROMs Order Form
- 104 Housing Information Hotel Reservation Instructions Hotel Locator Map

106 General Information

Track CD-ROMs Networking Dinner Poster Sessions Transportation Options Continuing Education Exhibit Hall Opportunities



Ronald D. Fitzmartin, PhD, MBA Vice President Global Technical Services Daiichi Medical Research, Inc.

Chairpersons' Message

The DIA Annual Meeting is "the event to attend" each year by biotechnology, pharmaceutical and regulatory professionals. There is no other industry meeting of its kind that can rival the breadth and depth of experience that this meeting delivers. With over 20 content-area tracks and 300 sessions, the presentations are geared to all experience levels of attendees, from R&D and regulatory leaders to professionals in specific functional areas. The DIA Annual Meeting, above all others, offers valuable professional cross-functional learning and networking experiences.

The DIA Program Committee has developed an operational action plan with the primary goal to maintain and enhance the overall quality of the tutorials, meeting tracks, sessions, and presentations. We have developed and have begun to deliver training to track and session chairs on procedures and processes

for enhancing the overall meeting experience of the attendee. We have developed and will implement session content difficulty levels. These levels will be assigned by the session chairs and will provide the attendee with a guide as to whether the session content is basic, intermediate or advanced. The levels will better assist the attendees in the selection of sessions to attend and thereby facilitate a more efficient use of their time at the meeting. We will link the tutorials to various tracks and sessions by noting which sessions complement the tutorial topic areas. There will be a number of plenary sessions that focus on special topics that range from health policy and international regulatory issues to the FDA's Critical Path Initiative. Dr. Bernadine Healy will be the first woman to deliver a DIA keynote address at the opening plenary.

The DIA Annual Meeting has one of the largest venues in the industry for exhibitors. Virtually every facet of the biopharmaceutical industry and related fields is represented by an exhibitor offering services or products in this extraordinary exhibit hall marketplace. From CROs, technology vendors to site research centers, academia and much more, the DIA Annual Exhibit Hall is one of the busiest places during the meeting. If someone wants to have a "one stop shopping" experience to see it all in one place, at one time – this is the meeting.

There is only one meeting that offers a total integrated experience of tutorials, posters, sessionbased learning with professional networking and exhibitor marketplace – *the DIA Annual Meeting*.

Ron Fitzmartin, PhD, MBA, is Vice President, Global Technical Services at Daiichi Medical Research, Inc., with global responsibility for biostatistics, data management, pharmacokinetics, bioanalysis, medical writing, and informatics. Previously, Ron was Group Executive Director, Biostatistics and Data Operations at Purdue Pharma L.P. At Purdue Pharma, Ron served as head of biostatistics and clinical data management, head of clinical information technology, and worldwide head of clinical data operations. Ron worked as a statistician and technologist in government, industry, and academia. These included: META Solutions, Inc., US Bureau of the Census, US Department of the Navy, and the University of Maryland, College Park. Ron received an MS in Statistics from Southern Connecticut State University, a PhD in Measurement and Statistics from the University of Maryland, College Park, and an MBA from the University of New Haven.



Bernadine Healy, MD Adviser on Bioterrorism and Weapons of Mass Destruction Preparedness, US White House

Keynote Speaker

Bernadine Healy, MD, currently serves as an adviser on bioterrorism and weapons of mass destruction preparedness to the US White House. Prior to this position she served for two years as president and chief executive officer of the American Red Cross.

Dr. Healy previously served as the Dean of the College of Medicine and Public Health and Professor of Medicine at Ohio State University. She is a past director of the National Institutes of Health, where she conceived and initiated the NIH Women's Health Initiative, a \$625 million effort to study the causes, prevention, and cures of diseases that affect women at midlife and beyond – the largest clinical research study ever.

Before her NIH appointment, Dr. Healy chaired the Research Institute of the Cleveland Clinic Foundation, directing the research programs of nine departments, more than doubling the size of the

Institute and expanding it into newly built research facilities. Dr. Bernadine Healy will be the first woman to deliver a DIA keynote address at the opening plenary session.

Don't miss the sessions on these exciting new topics!

A New Era of Transparency in Clinical Research: The Evolution, Impact, and Future of Clinical Trial Registers and Registries

Monday, June 27, 10:30 AM - 12:00 PM CLINICAL RESEARCH AND DEVELOPMENT TRACK

SESSION CHAIRPERSON

Craig A. Metz, PhD, Vice President, CEDD Regulatory Affairs, GlaxoSmithKline

This session will explore the seminal issues that led to the public outcry for transparency in the clinical research process and resulted in the evolution of the various clinical trial result registers currently supported by PhRMA and a number of its member pharmaceutical companies. The session will also address the expansion of the ClinicalTrials.gov National Library of Medicine database beyond the original mandate described in FDAMA 113. Presentations will be made regarding the development and experience to date with these databases, as well as procedures being developed to verify compliance with posting requirements. Panel discussants will include individual representatives from key stakeholder groups such as the US Congress/government agencies, American Medical Association, International Committee of Medical Journal Editors, World Health Organization, PhRMA, the US Food and Drug Administration, and the European Medicines Agency.

The ClinicalTrials.gov team will be available in Exhibit Hall A, lower level of the Washington Convention Center, on Monday and Tuesday, June 27 and 28 to answer any questions you may have about the Protocol Registration System (PRS) or about entering trials in ClinicalTrials.gov.

Presenters

Arthur L. Caplan, PhD, Professor of Bioethics, University of Pennsylvania

Deborah A. Zarin, MD, Director, ClinicalTrials.gov, National Library of Medicine; Assistant Director, Clinical Research Projects, National Institutes of Health

Alan Goldhammer, PhD, Associate Vice President, Regulatory Affairs, PhRMA

Frank W. Rockhold, PhD, Senior Vice President, Biomedical Data Sciences, GlaxoSmithKline

David McAvoy, MSES, JD, Director, Office of Scientific and Regulatory Policy, Global Regulatory Affairs, Eli Lilly and Company

Panelists

Representative Invited, CDER, FDA

Francis P. Crawley, PhD, Secretary General and Ethics Officer, European Forum for Good Clinical Practice, Belgium

Plenary Session Critical Path: Are We at the Fork in the Road?

Monday, June 27, 1:30 PM - 3:00 PM

CLINICAL RESEARCH AND DEVELOPMENT/REGULATORY AFFAIRS TRACKS SESSION CHAIRPERSONS

Stephen E. Wilson, DrPH, Capt. USPHS, Deputy Director, Division of Biometrics II, CDER, FDA

Ronald D. Fitzmartin, PhD, MBA, Vice President, Global Technical Services, Daiichi Medical Research, Inc.

The FDA has published a report entitled "Innovation or Stagnation – Challenge and Opportunity on the Critical Path to New Medical Products" (March 2004, available at http://fda.gov). The "Critical Path" report identifies the need for unprecedented improvement in the drug development process so that it is more efficient, predictable, and innovative, and less costly. The opportunities for dramatic change fall into three major dimensions and are identified as: assessing safety, demonstrating medical utility, and industrialization. This moderated plenary will have FDA and industry leaders engaged in an interactive Q & A panel session to address the goals, accomplishments to date and future of the Critical Path initiative.

Moderator

Debbie Henderson, Director, Office of Executive Programs, CDER, FDA

Panelists

Lawrence J. Lesko, PhD, Director, Office of Clinical Pharmacology and Biopharmaceutical Science, CDER, FDA

Janet Woodcock, MD, Acting Deputy Commissioner of Operations, FDA Robert J. Temple, MD, Director, Office of Medical Policy and Office of Drug Evaluation, CDER, FDA

Douglas C. Throckmorton, MD, Director, Division of Cardio-Renal Drug Products, CDER, FDA

Steven J. Miller, PhD, Vice President, Regulatory Affairs, AstraZeneca **Sean Harper, MD,** Vice President, Medical Sciences, Amgen Inc.

Two-part Session Medicines and Healthcare: Rebuilding the Trust, Reshaping the Future

Tuesday, June 28, 8:30 AM - 10:00 AM and 10:30 AM - 12:00 PM PUBLIC POLICY TRACK

SESSION CHAIRPERSONS

Raymond G. Starrett, MLS, Project Manager, GlaxoSmithKline **Jean Yager, PhD,** Director, Department of Methods and Training, Global Project Management, Pfizer Inc

The pharmaceutical industry is facing an unprecedented challenge to restore public confidence in the contribution of pharmaceuticals to healthcare and the value of new drug innovation. Without this confidence, the very fabric of the pharmaceutical and biotech industries and the future of new drug innovation are at risk. The potential long-term impact on patient welfare is enormous. In this session, panelists representing industry, regulatory authorities, academia, policy makers, media and patients will discuss some of the key issues affecting public perception of the industry. A moderator will guide the panelists through constructive discussion.

Moderator

Kenneth I. Kaitin, PhD, Director, Tufts Center for the Study of Drug Development, Tufts University

Panelists

Billy Tauzin, JD, President and CEO, Pharmaceutical Research and Manufacturers of America, (PhRMA)

Scott Gottlieb, MD, Resident Fellow, American Enterprise Institute for Public Policy Research

Robert J. Temple, MD, Director, Office of Medical Policy and Office of Drug Evaluation, CDER, FDA

Patient Group Representative Invited Member of the Press Invited

Annual Meeting Program Committee

ACADEMIC HEALTH CENTERS

Cheryl M. Chanaud, PhD, CCRA, St. Jude Children's Research Hospital, USA

ADVERTISING

Wayne L. Pines, APCO Worldwide, USA Teresa P. Dowling, PharmD, AstraZeneca, USA

BIOTECHNOLOGY

George F. Steinfels, PhD, MBA, Genomic Strategies, USA Bernard D. "Barney" King, MD, MBA, Macnas Consulting International, USA

CHEMISTRY, MANUFACTURING, AND CONTROLS/ GOOD MANUFACTURING PRACTICES

Dhiren N. Shah, PhD, sanofi-aventis, USA Charles P. Hoiberg, PhD, Pfizer Inc, USA Moheb M. Nasr, PhD, FDA, USA

CLINICAL DATA MANAGEMENT Keren K. Underkefler, SAIC, UK

Karen K. Underkofler, SAIC, USA

CLINICAL RESEARCH AND DEVELOPMENT

Thomas J. Newman, MD, PharmaNet, USA Craig Lipset, MPH, Compound Therapeutics, Inc., USA Françoise de Crémiers, PharmD, MS, ML, Wyeth Research, France

CLINICAL SAFETY AND PHARMACOVIGILANCE

Arnold J. Gordon, PhD, MS, Pharmaceutical Consultant, USA

Gaby L. Danan, MD, PhD, sanofi-aventis, France Annette Stemhagen, DrPH, MPH, Covance Periapproval Services Inc., USA

- CLINICAL SUPPLIES
 David F. Bernstein, PhD, Cato Research West, USA
- CLINICAL TRIAL MANAGEMENT/ESUBMISSIONS Becki S. Filice, MBA, Genentech, USA
- DOCUMENT MANAGEMENT/ESUBMISSIONS Mary L. Collins, Image Solutions, Inc., USA
- eCLINICAL
 Charles Jaffe, MD, PhD, SAIC, USA
- FINANCE

Michael Fedock, MBA, GloboMax LLC, USA

GOOD CLINICAL PRACTICES Michael R. Hamrell, PhD, RAC, MORIAH Consultants, USA Beat E. Widler, PhD, Roche Products Ltd., UK

IMPACT OF MEDICAL PRODUCTS AND THERAPIES Lynda G. Bryant-Comstock, MPH, GlaxoSmithKline Inc., USA

- INFORMATION TECHNOLOGY
 Jeffrey E. Kovalesky, Merck Research Laboratories, USA
- INVESTIGATOR SITES Karen E. Woodin, PhD, JKK Consulting LLC, USA
- MARKETING & SALES
 William R. Hahn, Shaw Science Partners, USA
- MEDICAL COMMUNICATIONS Timothy E. Poe, PharmD, GlaxoSmithKline Inc., USA

MEDICAL/SCIENTIFIC WRITING

Cathy Stein-Izsak, PhD, Daiichi Asubio Pharmaceuticals, Inc., USA

Virginia I. Watson, Cardinal Health, UK

NATURAL HEALTH PRODUCTS

Hubertus Cranz, PhD, PharmD, MS, AESGP, Belgium Floyd E. Leaders, PhD, Botanical Enterprises, Inc., USA

NONCLINICAL LABORATORY SAFETY ASSESSMENT James F. McCormack, PhD, FDA, USA Per Spindler, DVM, MSc, MBIRA, University of Copenhagen, Denmark

OUTSOURCING

James P. Burns, PhD, PharmaNet, USA

 PROJECT MANAGEMENT Michele C. Livesey, Barrier Therapeutics, USA

PUBLIC POLICY/LAW

Peter H. Rheinstein, MD, JD, MS, Severn Health Solutions, USA

REGULATORY AFFAIRS

Jacques Mascaro, PhD, F. Hoffmann-La Roche, Ltd., Switzerland Leyna T. Mulholland, PhD, PharmD, Merck & Co., Inc.,

USA

Patricia L. DeSantis, Johnson & Johnson PRD, USA

R&D STRATEGY

Kenneth I Kaitin, PhD, Tufts Center for the Study of Drug Development, Tufts University, USA

STATISTICS

Robert T. O'Neill, PhD, FDA, USA Joachim Vollmar, PhD, MSc, Executive Consultant, USA

- TRAINING
 Betty R. Kuhnert, PhD, MBA, Wyeth Research, USA
- VALIDATION
 Earl W. Hulihan, MEd, META Solutions, Inc., USA

Tutorials

For a schedule of tutorials by title only, see page 101 (pdf page 103).

Get the most out of this year's annual event with DIA's preconference tutorials designed to broaden your knowledge in specialized subject areas. Most tutorials will offer continuing education credit including CME, IACET, pharmacy, and nursing.

		the tutor	cks, listed below, and specific sessions that ials being offered. Please continue to mon so register early!	•	•
TRAC	K TITLES	CTM	Clinical Trial Management	MW	Medical/Scientific Writing
AD	Advertising	DM	Document Management/eSubmissions	NC	Nonclinical Laboratory Safety Assessment
AHC	Academic Health Centers	eCLIN	eClinical	NHP	Natural Health Products
BT		FI	Finance	OS	Outsourcing
	Biotechnology	GCP	Good Clinical Practices	PM	Project Management
CMC	Chemistry, Manufacturing, and Controls/	IMP	Impact of Medical Products and Therapies	PP	Public Policy/Law
0014	Good Manufacturing Practices	IS	Investigator Sites	RA	Regulatory Affairs
CDM	Clinical Data Management	IT	Information Technology	RD	R&D Strategy
СР	Clinical Safety and Pharmacovigilance	MA	Marketing & Sales	ST	Statistics
CR	Clinical Research and Development		0	TR	Training
CS	Clinical Supplies	MC	Medical Communications	VA	Validation

Saturday Afternoon Tutorials June 25, 1:00 PM - 4:30 PM

12:00 рм - 1:00 рм

TUTORIAL REGISTRATION Registration for Saturday tutorials ONLY; East Registration Area, Convention Center, Mount Vernon Place Entrance

#30 Active-controlled Noninferiority/Equivalence Trials: Methods and Practice (ST)

286-000-05-502-L04; 3.25 contact hours (.325 CEUs); .3 IACET CEUs Irving K. Hwang, PhD

Adjunct Professor/President, University of Medicine and Dentistry of New Jersey/Irving Consulting Group

In this tutorial, the methods and practice for the active-controlled noninferiority/ equivalence trials will be addressed. Critical definitions such as: assay sensitivity (AS), historical evidence of sensitivity-to-drug effects (HESDE), appropriate trial conduct (ATC), and constancy assumption (CA), will be discussed. Key notions of prespecification of a fixed margin and preservation of a fraction of active control effect for noninferiority trials will be specifically delineated, as well as a sample size comparison among these trial designs. In addition, switching objectives between superiority and noninferiority, and important issues in design and analysis of noninferiority trials will be further reiterated. Though this intermediate-level tutorial emphasizes concept and practical matters, prior knowledge and experience in clinical dug development in regulatory settings is required.

Learning Objectives

At the conclusion of this tutorial, participants should be able to:

- Describe the fundamentals of superiority vs. noninferiority/equivalence trials
- Comprehend the know-how of design and analysis of active-controlled noninferiority/equivalence trials

Target Audience

This tutorial is designed for clinical project teams in drug development, specifically project team leaders, biostatisticians, clinicians, and SAS programmers. Regulatory liaisons, project managers, and marketing directors would also benefit from this tutorial.

#31 Advanced Auditing of Clinical Research Systems for Validation (CR, VA)

.3 IACET CEUs

Earl W. Hulihan, MEd

Vice President, Regulatory Consulting, META Solutions, Inc.

Joanne Malia, MS, MS

Senior Manager, Medical Research Quality Management, Purdue Pharma L.P.

This tutorial explores how to identify and audit the various components of a clinical research system. Using the brief overview and discussion of international regulations relating to clinical research systems as a basis, the attendees will develop an understanding of what international regulators are looking for in regulated clinical systems. Various real-life clinical systems will be discussed during the practical portion of the tutorial.

These will allow the attendee to leave the tutorial with a good understanding of what should always be present in a quality clinical system and what some of the typical "breaking" points might be. A discussion of audit tools/aids followed by the initial creation of samples will be held to allow the attendee to have a solid understanding and platform on which to build and audit in this area.

Learning Objectives

At the conclusion of this tutorial, participants should be able to:

- Define all the components of a clinical research system
- · Identify common "breakdown" areas within clinical systems
- · Recognize what international regulators are looking for in regulated systems
- Develop audit tools and aids to use in auditing of clinical research systems

Target Audience: This tutorial is designed for personnel who have responsibility for clinical research systems within their company, such as senior management, project managers, monitors, medical monitors, clinical scientists, clinical associates, data managers, IT administrators, investigators, corporate-level managers, statisticians, site coordinators, as well as quality assurance, regulatory compliance, and regulatory affairs.

#32 Please note that this tutorial has been CANCELLED Contract Management: A Review of Industry Best Practices (OS, CR, FI)

.3 IACET CEUs

Tiffany Sizemore Cherry, JD, MBA, Principal, Kontrax Consulting Services

This tutorial is intended for procurement, outsourcing and finance managers and other biotech/pharmaceutical industry professionals responsible for the management or leadership of clinical contracts. You will learn the fundamentals of contract management and how they can be applied to best meet the needs of projects. The tutorial will include presentations, and nettradis the needs of projects. The tutorial will will take away an understanding of basic contract regarded provide provide principles in developing, interpreting and negotiating budgets, and contract management skills that can be immediately put to use in your work.

Key Topics

- · Initiating, planning, executing, and applying contracts
- Risk assessment, finance management
- Key legal terms and conditions

Learning Objectives

At the conclusion of this tutorial, participants should be able to:

- Describe the contract management process initiating, planning, executing, controlling and applying the contract and best practices
- · Recognize contract legalese, when and how it should be applied
- · Assess risk of financial error in contracts
- Apply tools and techniques to the part of the drug development process that you are engaged in within your organization
- Discuss sensitivities to working within a matrix organization and contract team

Target Audience: This tutorial will be of interest to new contract managers, experienced contract managers who are new to the biotech/pharmaceutical industry, clinical or other industry professionals who are responsible for managing contracts and procurement including CRAs, outsourcing and finance team members who wish to gain a deeper understanding of contract management processes.

#33 Developing Author Templates for Submission Documents (DM) .3 IACET CEUs

Robin Zumbrunnen

Associate Director, Document Management Technologies, Quintiles, Inc.

This tutorial will discuss how to develop authoring templates in MS Word for several electronic regulatory submission types including eCTD and electronic study reports to meet study tagging file specifications, and will include suggestions for authoring macros that will enable authors to more easily meet the guidance requirements in their documents.

Learning Objectives

At the conclusion of this tutorial, participants should be able to:

- Recognize what authors need for efficient authoring versus how the final submission document must appear
- · Design, train and use author templates to achieve both goals

Target Audience

This tutorial is designed for regulatory or support personnel who are responsible for developing authoring templates for regulatory submissions.

Receive additional information about this topic by attending the Monday, June 27, 10:30 AM-12:00 PM DM Track session entitled "A Standards-based Approach for Authoring through Distribution."

#34 Clinical Trial Performance and Risk Analysis: Using the Earned Value Method (PM, FI)

.3 IACET CEUs

Wolfgang Seifert, MD, PMP, MFPM

Clinical Pharmacologist, Advisor Drug Development, Schering AG, Germany

Earned Value Analysis measures the performance of projects or parts thereof. It integrates scope, cost and schedule and provides variances, key performance indicators and forecasts over cost and schedule. EVA allows for retrospective analyses and thus deriving the past performance. This may feed general performance monitoring systems for benchmarking and management of overall productivity. Prospective analysis of a running project reveals current performance and forecasts of time and money for completion. If these results are critical, methods from risk management may be applied. A concept for an Earned Value Management approach will be outlined.

Learning Objectives

At the conclusion of this tutorial, participants should be able to:

- Perform Earned Value Analysis (EVA) on clinical trials and other tasks during drug development
- Discuss how to model progress of a clinical trial for prospective analysis
- Distinguish between prospective (risk focused) and retrospective performance analysis
- · Set up the infrastructure for input data to EVA

Target Audience

This tutorial is designed for project managers; executives from benchmarking, performance and risk management; and managers of clinical trials.

#35 Identifying, Recruiting and Training Multiple Research Naïve Physicians for Participation in Simplified Clinical Trials (IS, CR)

.3 IACET CEUs

Charles Laudadio, MD, MBA

Director, Medical Affairs, McNeil Consumer & Specialty Pharmaceuticals, Inc.

Cynthia Verst-Brasch, PharmD, MS

Vice President, Late Phase, Kendle International, Inc.

Simplified trials conducted at a private physician's office or clinic can provide valuable insights into medical practice in a real world setting. Primary care physicians are willing to share their knowledge and expertise in this setting, but recruiting and training them to participate in a clinical trial can be a challenge. Barriers of time, overwork, claims forms, and disinterest have to be overcome before they are willing to participate. This tutorial will explore the operational challenges and solutions of simplified trial management through a case study approach.

Learning Objectives

At the conclusion of this tutorial, participants should be able to:

- Recognize the challenges of recruiting research naïve physicians to enroll patients into a simplified clinical trial
- Prepare training and materials that enable a primary care physician to successfully participate in a simplified clinical trial

Target Audience

This tutorial is designed for project managers, CRAs, site recruitment vendors, CROs, physicians, and study coordinators.

#36 New Challenges to IRBs, Sponsors, and Investigators (IS, PP)

3.25 category 1 credits; 286-000-05-503-L04; 3.25 contact hours (.325 CEUs); 3.9 nursing contact hours; .3 IACET CEUs

Paul W. Goebel, Jr., CIP Vice President, Chesapeake Research Review, Inc. Jill C. Alvarez, JD, LIM in Taxation Partner, Epstein, Becker, and Green

FDA compliance actions against investigators, IRBs and sponsors often come as a surprise. It is easy to be preoccupied with day-to-day business and fail to see the changing compliance landscape. An analysis of recent cases shows the shortcomings that invite actions, either by FDA or by private parties. The latest private action cases show that no one involved with the study is immune from being named as a defendant. This tutorial will discuss the recent actions and outline practices that are frequently named in complaints.

Learning Objectives

- At the conclusion of this tutorial, participants should be able to:
- Compare/contrast litigation-based and regulation-based penalties of noncompliance
- · Identify the common causes of action cited in law suits filed by research subjects
- Recognize the FDA enforcement process for noncompliance
- Identify the first steps to take in reorganizing your procedures to assure best practices are always observed

Target Audience

This tutorial is designed for IRB administrators, members, chairs, clinical investigators, sponsors, contract research organizations, and others with an interest in the changing legal aspects of protection of human research subjects.

***** Receive additional information about this topic by attending the Monday, June 27, 1:30-3:00 PM IS Track session entitled "I Am OK, I Am Indemnified! What Does This REALLY Mean?"

#37 European Regulatory Affairs: Current Regulatory Procedures and New Medicines Legislation Effective November 2005 (RA)

.3 IACET CEUs

Brenton E. James, FBIRA

Consultant in Strategic Regulatory Affairs in the European Union *Rolf Bass, MD*

Resident Twinning Advisor (PHARE), Head of Department, URPL (Polish Authority), Poland; BfArM, (German Authority), Germany

The current regulatory procedures, Centralized and Mutual Recognition will be discussed in detail, as well as business strategies impacting on the choice of procedures for a new chemical entity. A detailed review of the significant changes in regulatory procedures (Centralized, Mutual Recognition and Decentralized), which will take place in November 2005, will also be discussed.

Learning Objectives

- At the conclusion of this tutorial, participants should be able to:
- Explain the development of the European Union
- Evaluate both Centralized and Mutual Recognition Procedures
- Analyze the key business reasons for choosing the optional route
- Describe the impact of changes in the New Medicines Legislation

Target Audience

This tutorial is designed for anyone with an interest in European regulatory affairs, including professionals working in regulatory affairs, clinical research, and project management.

#38 Statistical Analysis Plan Made Easy (ST)

.3 IACET CEUs

Kazem Kazempour, PhD

Acting Director Biometrics, Amarex Clinical Research

Sally Breisch, MS

Vice President, Amarex Clinical Research

This tutorial will discuss the value of having a SAP at the beginning of a trial, in relation to regulatory affairs, science, and ethics; and understanding the different parts of a SAP and the relative importance of those parts.

Learning Objectives

At the conclusion of this tutorial, participants should be able to:

- Recognize the importance of having a statistical analysis plan (SAP) drafted before the start of a clinical trial from the perspectives of good science, regulatory affairs, and ethics.
- · Describe subjective vs. objective parts of an SAP
- Describe the different components of an SAP
- Identify optional parts of an SAP

Target Audience

This tutorial is designed for beginner through advanced statisticians, investigators, project managers, medical writers, regulatory affairs staff, and CRAs.

🚸 Also available

Saturday, June 25, 1:00 PM - 5:30 PM

Certified Clinical Investigator Examination Review Course (CR, IS) 4.25 category 1 credits; 286-000-05-012-L04;

4.25 contact hours (.425 CEUs)

As regulatory agencies, institutions, and research sponsors are setting stricter guidelines with regard to investigator training, this half-day Certified Clinical Investigator examination review course provides an in-depth review of the roles and responsibilities of the clinical investigator and others involved in clinical trials, the regulations and guidelines that govern clinical trials, and the practices that ensure effective and efficient study conduct.

Target Audience This Certified Clinical Investigator examination review course is designed to prepare physicians, pharmacists, physician assistants, nurse practitioners, and research scientists for the Certified Clinical Investigator examination.

Learning Objectives At the conclusion of this course, participants should be able to: differentiate the roles and responsibilities of the clinical investigator, sub-investigator, study staff, IRB, and sponsor; describe the regulations and guidelines applicable to conducting safe and effective clinical trials; successfully prepare a site to conduct a clinical trial including study design, patient recruitment, and protocol development; use appropriate methods to ensure compliance, subject safety, and protocol adherence.

Online registration is available for the CCI Examination Review Course at http://www.diahome.org/docs/Events/events_search_detail.cfm? EventID=05410

Two Offerings! Certified Clinical Investigator Examination Sunday, June 26, 9:00 AM - 12:00 PM and 2:00 PM - 5:00 PM

This examination is three hours in length and is administered by DIA Certification, Inc. It consists of 150 randomized multiple-choice questions, designed to objectively assess and measure professional knowledge of the materials covered in the Core Content for Certification Handbook.

For general information on the Certified Clinical Investigator Program, or specific information about qualifications for taking the examination, other examination dates, group discounts, or training opportunities, please contact Kia Gray at kia.gray@diahome.org.

Online registration is not available for the CCI examination. You must submit an application found at http://www.diahome.org/content/Events/ Clinical_Investigator_Guide_Application.pdf. Sunday, Full-day Tutorials June 26, 9:00 AM - 5:00 PM 8:00 AM - 9:00 AM TUTORIAL REGISTRATION Registration for Sunday, full-day or morning tutorials ONLY; East Registration Area, Convention Center, Mount Vernon Place Entrance

#40 Clinical Statistics for Nonstatisticians (CR)

6.5 category 1 credits; 286-000-05-504-L04; 6.5 contact hours (.65 CEUs); 7.8 nursing contact hours; .7 IACET CEUs

Michael C. Mosier, PhD Director, Biostatistics, EMB Statistical Solutions, LLC James Whitmore, PhD

Director, Statistics, Programming and Data Management, Berlex, Inc.

This tutorial is intended to introduce basic statistical concepts that are fundamental to clinical research, and is designed for individuals with some exposure to statistics (either through course work, or on the job experience), that is equivalent to an introductory statistics course. While a few formulae are included for individuals who are interested in computational details, the overall emphasis of the tutorial is on the application of the statistical concepts to clinical investigation.

Learning Objectives

At the conclusion of this tutorial, participants should be able to:

- Discuss basic statistical concepts such as variability, confidence intervals, hypothesis testing and p-values
- · Distinguish various study designs and identify techniques to avoid bias
- Use basic statistical terminology with ease
- · Discuss information needed for determining sample size

Target Audience

This tutorial is designed for professionals in the pharmaceutical industry involved in clinical research, medical affairs, medical writing, and other disciplines that must be familiar with statistical concepts.

#41 Computer Validation from A to Z: Practical Reality for User Acceptance of GXP Systems (IT, VA)

.7 IACET CEUS Teri Stokes, MT (ASCP), MS, PhD Director, <u>GXP</u> International Richard Chamberlain, MS, PhD President, ECS, Inc.

This busy day provides an immersion learning experience in the reality of computer validation. Participants will be actively involved in working group discussions, case study analysis, and a hands-on test experience to illustrate concepts given in interactive presentations. Come prepared to analyze, open to reality-based discussions, and ready for fun while you work. We will cover computer validation from A to Z!

For hands-on testing, attendees should bring the following: laptop with a USB port and MS EXCEL (98 or higher) to test a spreadsheet and laptop powerpack. Without the laptop you can still participate as a witness or recorder of the testing.

Learning Objectives

At the conclusion of this tutorial, participants should be able to:

- Describe the essential regulatory requirements for computerized system validation (CSV)
- Compare and contrast the content and focus of IQ, OQ, and PQ system validation packages and define the roles and responsibilities needed for each package
- Analyze the need for and difference between Validation Plan and Test Plan and their respective summary reports
- Identify the key elements for auditable test documentation and experience formal testing practices by executing a test script

Target Audience

This tutorial is designed for any manager with a GXP system to be validated, end user and IT teams facing a systems validation project, quality assurance professionals auditing GXP systems, suppliers of GXP systems (applications, e-diaries), and suppliers of GXP data services (CROs).

Receive additional information about this topic by attending the Monday, June 27, 10:30 AM-12:00 PM VA Track session entitled "General Validation Issues."

#42 Data Mining, Data Flow Modeling, Data Warehousing, and Knowledge Management (CDM)

.7 IACET CEUs

Andrew Kusiak, PhD

Professor, University of Iowa

Novel concepts of data mining, data flow modeling, data warehousing, knowledge management, and data integration are introduced. Basic steps needed to understand the flow of data, data flow management, and justification of data warehouses are presented. Any large data repository, for example a data warehouse, has implications on the data and knowledge management and supporting applications. One of the most significant drivers of data warehousing technology is data mining. Data mining tools extract knowledge from data repositories for use in downstream applications. The new knowledge can be applied, for example, for customized drug labeling, predicting adverse drug reactions, to increase understanding of genetic data, and improve bioprocesses. The knowledge discovery approach is integrated with process modeling methods for systematic data capture and management. The concepts introduced in the tutorial are illustrated with methodologies and software for data flow modeling and data mining.

Learning Objectives

At the conclusion of this tutorial, participants should be able to:

- Categorize and assess data mining tools
- Apply data mining algorithms
- Perform data mining tasks
- Construct and analyze process models

Target Audience

This tutorial is designed for data analysts, data and knowledge managers, data flow experts, clinicians interested in modern data analysis tools, biotech experts, professionals involved in data mining and data warehousing projects, and pharmaceutical industry experts interested in getting more value from the data.

Receive additional information about this topic by attending the Wednesday, June 29, 8:30-10:00 AM CP Track session entitled "Data Mining and Signal Detection: Where Are We?"

#43 Design and Statistical Analysis of Bioequivalence Studies (ST)

6.5 category 1 credits; 286-000-05-505-L04; 6.5 contact hours (.65 CEUs); .7 IACET CEUs

Scott D. Patterson, MSc, PhD Director, Statistical Sciences, GlaxoSmithKline Byron Jones, PhD

Senior Director, Development Operations, Pfizer Inc

This tutorial will review the design and analysis of bioequivalence trials from their inception in the 1970s through to the present day. These studies play a key role in the drug development process when manufacturers change methods or site of formulation and when generic manufacturers attempt to gain market access following patent expiration. The use of cross-over trials to evaluate average bioequivalence will be described. This and the use of population and individual metrics for bioequivalence assessment will be illustrated using case studies. Particular attention will be paid to the regulatory issues related to bioequivalence trials.

Learning Objectives

At the conclusion of this tutorial, participants should be able to:

- Design and analyze bioequivalence trials
- · Discuss their history and place within drug development

Target Audience

This tutorial is designed for clinical pharmacologists, pharmacokineticists, physicians, nursing staff, and statisticians in the pharmaceutical industry, universities, and international regulatory agencies. Regulators interested in this topic would also benefit from this tutorial.

#44 Pharmacokinetics and Pharmacodynamics: A Gentle Introduction (CR)

6.5 category 1 credits; 286-000-05-506-L04; 6.5 contact hours (.65 CEUs); 7.8 nursing contact hours; .7 IACET CEUs

Michael J. Fossler, PharmD, PhD, FCP

Principal Clinical Pharmacokineticist, GlaxoSmithKline

Pharmacokinetic/pharmacodynamic modeling (PK/PD) is assuming an increasingly important role in the drug development process. Go/no-go, dosing regimen, and

study design decisions are now made using PK/PD information. However, for the pharmaceutical professional not specifically trained in this area, the terminology and mathematics can be a bit overwhelming. In this full-day tutorial, the morning session will be devoted to explaining the basics of PK/PD using familiar terms and as little math as possible. The afternoon will be spent reviewing some special topics (building on the morning session), including population PK/PD modeling and clinical trials simulation, in order to provide the regulatory professional with a conceptual grasp of this important field.

Learning Objectives

At the conclusion of this tutorial, participants should be able to:

- Define the following pharmacokinetics concepts:
 - Clearance; volume of distribution; half-life; relative and absolute bioavailability; steady state; population pharmacokinetics/pharmacodynamics; clinical trials simulation
- Explain the difference between one compartment and two compartment PK models
 Define the following pharmacodynamics concepts:
- Emax; EC50; direct and indirect response models
- · Explain (in a general way) how simulation is used in contemporary drug development

Target Audience

This tutorial is designed for clinical research and regulatory affairs professionals, physicians, nurses, CRO personnel, or anyone working in the pharmaceutical industry desiring some additional information about pharmacokinetics and pharmacodynamics.

#45 Principles of Safety Surveillance (CP)

6.5 category 1 credits; 286-000-05-507-L04; 6.5 contact hours (.65 CEUs); 7.8 nursing contact hours; .7 IACET CEUs

Stanley B. Garbus, MD, MPH Chief Medical Officer, Sentrx Brandt Rowles, PhD

Vice President, Pharmacovigilance and Risk Management, Sentrx

Current FDA requirements mandate that the pharmaceutical industry maintain a competent adverse drug reaction monitoring system. Recognizing changing regulatory guidelines for monitoring reporting compliance, as well as understanding the risk implications of suspected adverse events, has become more critical with recent product recalls. Understanding the processes of pharmacovigilance and the changing regulations will assist pharmaceutical personnel in providing critical safety services.

Learning Objectives

At the conclusion of this tutorial, participants should be able to:

- · Define key elements and definitions of safety surveillance
- Implement methods for risk monitoring and surveillance systems to capture and process suspected adverse drug reactions
- · Ensure compliance when reporting adverse events to regulatory authorities
- · Recognize value of utilizing web-based pharmacovigilance

Target Audience

This tutorial is designed for those new to safety surveillance and to update others on current safety, risk management and regulatory issues in postmarketing surveillance.

#46 Techniques for Applying Risk Management Principles to Computer System Validation (IMP, VA)

.7 IACET CEUs

Frances E. Nolan, MBA

Vice President, Taratec Development Corporation *Arik Gorban*

Vice President, Taratec Development Corporation

Utilizing different case studies, this tutorial will demonstrate techniques for applying risk management principles to computer system validation (CSV) at each stage of the system life cycle (SLC), including planning and definition (vendor assessment/ vendor selection; user requirements specification); system design specification and design reviews; code development, review and testing, commissioning and qualification; ongoing operation (maintaining the validated state); and decommissioning/ retirement.

Learning Objectives

At the conclusion of this tutorial, participants should be able to:

- Identify the components and benefits of risk-based compliance management
- · Describe how risk-based compliance management differs from:

- Traditional system life cycle (SLC) and computer system validation (CSV) planning and execution
- Medical device risk analysis approaches that focus on individual system functions and determine testing requirements
- GxP applicability and 21 CFR Part 11 gap analysis
- System criticality categorization
- Apply risk management principles to the development, implementation and validation of computer systems in a regulated environment

Target Audience

This tutorial is designed for individuals who have experience planning and executing system life cycle (SLC) and computer system validation (CSV) processes in a regulated environment, but do not necessarily have experience and expertise with techniques to formally apply risk management principles to such processes.

#47 Update on the European Clinical Trial Legislation (CR, RA)

.7 IACET CEUs

Regina Freunscht

Head of Quality Assurance, Accovion GmbH, Germany

The new European clinical trial legislation has an impact on clinical trial management, conduct, surveillance, and reporting, with consequences for sponsors, investigators, ethical committees and regulatory authorities. The directive has been enforced since 2001 and enhanced upon by nine detailed guidance documents. Five of these detailed guidelines have been finalized and required implementation by May 2004 by each European Member State to comply with the European legislation. This interactive tutorial will provide an overview of the European legislation affecting clinical trials and provide information on the contents of each document: What is new, and what are the consequences for the conduct of clinical trials? Points of discussion will be the Clinical Trials Directive 2001/20/EC and the corresponding detailed guidance on the clinical trial application process, notification of substantial amendments, declaration of end of trial, the ethical committee opinion processes, the EUDRACT and EudraVigilance databases, and the reporting of adverse events. Furthermore, the impact of the European Data Protection Directive 95/46/EC, the retention times of essential documents (as of directive 2003/ 63) and the revised Annex 13 of GMP on clinical trial practices will be discussed.

Learning Objectives

At the conclusion of this tutorial, participants should be able to:

- Describe the legal environment for clinical trials in Europe
- · Identify the new requirements arising from this legislation
- · Identify responsibilities and relevant documents for day-to-day business
- Carefully plan clinical trials in order to meet regulatory milestones and submit valid applications and documents to competent authorities, ethical committees, investigators and clinical trial subjects

Target Audience

The tutorial will benefit any research professional involved with or supportive of clinical trial programs in Europe. This includes, but is not limited to, heads of clinical research departments, study or project managers, CRAs, monitors, trial investigators and CRCs. Furthermore, any person involved in QA, regulatory affairs or training should attend this tutorial.

Receive additional information about this topic by attending the Wednesday, June 29, 10:30 AM-12:00 PM RA7 Track session entitled "Regulation of Clinical Research in the EU: Impact of the Clinical Trials' Directive" and Wednesday, June 29, 3:30-5:00 PM RA4 Track session entitled "Clinical Trials Directive: EU Remains Attractive for Clinical Research."

Sunday Morning Tutorials

June 26, 8:30 ам - 12:00 рм

TUTORIAL REGISTRATION Registration for Sunday, full-day or morning tutorials ONLY; East Registration Area, Convention Center, Mount Vernon Place Entrance

#50 Overview of the 21 CFR 11 Regulations and Guidance: What Has Changed and What Is Now Required? (IT)

.3 IACET CEUs

8:00 ам - 9:00 ам

Kim W. Nitahara, MBA, MIT

Chief Executive Officer, META Solutions, Inc

FDA's "Electronic Records: Electronic Signatures" regulations (21 CFR Part 11) apply to all electronic records that are "created, modified, maintained, archived, retrieved, or

transmitted, under any records requirements set forth in agency regulations," including predicate regulations for GLPs, GCPs, GMPs, and regulatory submissions. The recent "21 CFR 11 Scope and Application Guidance" from the FDA indicates that Part 11 remains in effect, but provides FDA's new thoughts regarding their enforcement discretion, overall approach, and narrowing interpretation of scope. This tutorial will provide a comprehensive overview of the regulations and guidance, and their impact on existing and new computer systems in the R&D environment. Practical information and approaches to meet the requirements will be presented and discussed with participants, using actual inspection results from recent FDA-483's and warning letters regarding computer systems and validation observations.

Learning Objectives

At the conclusion of this tutorial, participants should be able to:

- Discuss and analyze the scope and application of the 21 CFR 11 regulations
- Interpret the changes in FDA guidance and expectations
- Formulate a realistic and justified position for their company's 21 CFR 11 plans and standards

Target Audience

This tutorial is designed for R&D, IT, regulatory and QA personnel and functional managers who are responsible for computerized systems and electronic records in a regulated environment.

***** Receive additional information about this topic by attending the Thursday, June 30, 10:30 AM-12:00 PM RA3 Track session entitled "21 CFR Part 11 and Electronic Source Documentation Requirements for Investigators."

#51 Case Studies on Signal Detection and Investigation (CP)

3.25 category 1 credits; 286-000-05-508-L04; 3.25 contact hours (.325 CEUs); .3 IACET CEUs

Monika Pietrek, MD, PhD, MSc

Senior Vice President, Global Medical and Safety Services PRA International, Germany

Robert C. Nelson, PhD, FISPE Consultant, RCN Associates, Inc. Rosalind Coulson Consultant in Pharmacovigilance Information Management

PRA International, Germany Safety signals may arise from various sources during development and postlaunch of

a drug, device or vaccine. This tutorial uses case studies of different safety signals and explains how signals and safety issues are distinguished and evaluated, how risks can be quantified and which data sources for investigation are available.

Learning Objectives

At the conclusion of this tutorial, participants should be able to:

- Describe signal identification and assess the impact of a potential safety concern
- · Classify different methods of investigations
- Describe the strengths and limitations of available data sources for investigations
 Interpret findings

Target Audience

This tutorial is designed for physicians and pharmacists in clinical research and drug safety, statisticians, clinical scientists, drug safety associates, clinical data coordinators in the pharmaceutical and CRO industries, academia and regulatory agencies.

#52 Best Practices When Using MedDRA® (CP, CDM)

.3 IACET CEUs

JoAnn Medbery, RN

Manager, Dictionary Management, Johnson & Johnson Pharmaceutical Research & Development, L.L.C

This tutorial will help MedDRA[®] users with the identification of "best practices" when implementing or using MedDRA[®] in organizations. MedDRA[®] is a complex terminology; therefore, having "best practices" will help guide users to practical, useful solutions from the implementation to the ongoing use of MedDRA[®]. The "best practices" will assist with data standardization, consistency and quality.

Learning Objectives

At the conclusion of this tutorial, participants should be able to:

- Recognize "MedDRA's[®] Best Practices"
- Analyze the need for establishment of "MedDRA's[®] Best Practices" within their environment

Describe at least two "MedDRA® Best Practices" and how they could be implemented within your organization

Target Audience

This tutorial is designed for anyone who uses MedDRA® or is responsible for the use of MedDRA® within their organization. This includes the use of MedDRA® for either eClinical trial or postmarketing data.

Receive additional information about this topic by attending the Thursday, June 30, 8:30-10:00 AM CP Track session entitled "The Use of Multilanguage MedDRA® in a Global Environment."

#53 Critical Issues and Important Considerations for Outsource Contracting (OS, PP)

.3 IACET CEUs

Daniel J. O'Connor

Assistant Vice President, Legal, ImClone Systems Incorporated President, CEO, Milestone Research, Inc.

This tutorial will cover important issues and considerations for: (1) sponsor/CRO contracts; (2) sponsor/consultant contracts; and (3) sponsor/CRO/investigator/site contracts. The tutorial will explain, in non-legalese, the legal and operational considerations for preparing and then managing these types of contracts. Participants in this tutorial will learn how to approach and negotiate difficult contractual issues, including: (1) the respective obligations of the parties to the contracts, e.g., sponsor/CRO; (2) clearly establishing the project costs vs. change orders; (3) payment schedule: fee-for-service vs. milestones; (4) insurance; (5) term and termination provisions; (6) confidentiality; (7) ownership of inventions and other intellectual property; (8) publication; (9) limitation of liability; (10) indemnification; (11) exclusive assignment of study personnel; (12) regulatory compliance; inspections, warranties; and (13) delays. Each topic will be illustrated, analyzed and discussed utilizing sample contract language.

Learning Objectives

At the conclusion of this tutorial, participants should be able to:

- Identify and describe the important legal and operational issues regarding certain outsourcing contracts
- · Design appropriate outsourcing contracts which will address the issues

Target Audience

This tutorial is designed for all professionals involved in the selection, hiring, contracting and/or negotiating process that occurs between biopharmaceutical companies and its service providers, such as CROs, investigators and institutions.

Receive additional information about this topic by attending the Tuesday, June 28, 8:30-10:00 AM OS Track session entitled "Are the Pharmaceutical Industry's New Initiatives for Managing Outsourcing Producing Better Results?"

#54 Compliance-driven Risk Detection: A New Approach within Drug Safety (CP)

3.25 category 1 credits; 286-000-05-509-L04; 3.25 contact hours (.325 CEUs); .3 IACET CEUs

Pradip K. Paul, MBBS, MS

Director, Global Medical Safety Surveillance, Berlex Pharmaceuticals, Inc. Carol L. Krueger, RN

Consumer Safety Officer, Division of Compliance, Risk Management, and Surveillance, CDER, FDA

Risk detection (RD) is the critical foundation for risk management (RM) activities to develop product safety profiles. A meaningful safety profile can only be achieved if a powerful risk detection program is in place. In a typical pharmaceutical or biotech company setup, RM is a multidepartmental function, with critical contributions from the RD performed by the drug safety (DS) department. Risk detection generates a pool of adverse drug effect (ADE) data which can be analyzed and utilized to reduce product risk. Risk detection activities establish and follow workflow procedures for adequate collection and analysis of adverse event (AE) data that support effective risk management. An imperfectly planned or executed risk detection scheme may produce a faulty risk management outcome, which may lead to serious scientific and regulatory consequences. The FDA inspectional program monitors postmarketing risk detection efforts to ensure that adequate data is available to support product safety analysis. This tutorial will discuss the planning, development, implementation,

assessment and modification of standard risk detection workflow that can be customized to support scientific goals and meet regulatory compliance standards.

Learning Objectives

At the conclusion of this tutorial, participants should be able to:

- Describe the role of the FDA CDER postmarketing inspection program in monitoring performance of risk management and risk detection activities
 Recognize risk management activities that can affect FDA compliance
- Optimize risk detection workflow leading towards risk management with newly learned processes
- Develop risk detection procedures within drug safety that support scientific goals and regulatory compliance

Target Audience

This tutorial is designed for professionals in drug safety, regulatory affairs, clinical development, outcomes research, and CROs.

#55 Dealing Effectively with Cultural Differences for Clinical Trial Professionals (CR, TR)

3.25 category 1 credits; 286-000-05-510-L04; 3.25 contact hours (.325 CEUs); 3.9 nursing contact hours; .3 IACET CEUs

Mary E. Briggs

President and Chief Training Officer, FOCUS, Inc.

One of the biggest challenges in the clinical trial industry is managing global work teams. Differing cultures, working practices and mannerisms often lead to miscommunication and conflict. Drug development organizations that are able to integrate many ways of thinking have seen an increase in productivity of their global teams. This tutorial addresses how to bridge the differences with multi-national teams in the clinical trial industry. We will explore North America, Western and Eastern Europe and Asia.

Learning Objectives

At the conclusion of this tutorial, participants should be able to:

- Practice skills to build rapport with colleagues and customers from different cultures
- Practice a process to gently address behaviors, attitudes and norms that do not promote an inclusive work environment
- Discuss cultural etiquette traditions and customs for the clinical trial business in Asia, countries in Eastern and Western Europe and North America
- Recognize the stereotypical behaviors that break down our ability to function effectively in global work teams

Target Audience

This tutorial is designed for clinical trial professionals who wish to work more effectively with colleagues and clients from other cultures.

#56 Please note that this is now Tutorial #84 being offered on Sunday, 1:00 pm - 4:30 pm (effective 4-7-05)

EU Regulatory Requirements: Pharmacovigilance in the Pre- and Postmarketing Phase and the EudraVigilance Database (CP, RA)

#57 Getting Your Clinical Operations on the Right Track: Strategy, Knowledge, People and Process (CR) .3 IACET CEUS

Laurie Halloran, MS

President, Halloran Consulting Group, Inc.

What is clinical operations and why are some of the most successful companies realizing the importance of it? How does the clinical operations function contribute to the overall success of the organization? Who is successfully establishing or running clinical operations? Many organizations find themselves struggling to determine how and when to establish the function. Professionals new to the position quickly realize there's very little information out there to learn how to do their job effectively. A thorough overview of the functions and responsibilities of clinical operations will be followed by comprehensive exploration of the processes, tools, and technologies to enhance the department's output and value to the organization.

Learning Objectives

- At the conclusion of this tutorial, participants should be able to:
- Describe and explain the role, responsibilities and activities of a clinical operations management position
- Identify the competencies for a successful clinical operations manager/ director
- · Discuss major technologies that manage and improve clinical operations functions
- · Plan for use of tools to project and maximize clinical trial resources and
 - efficiencies

Target Audience

This tutorial is designed for executives considering the establishment of clinical operations to improve their development organizations, as well as seasoned clinical research professionals who are considering or have recently made a change into clinical operations positions.

#58 Leadership: How to Organize and Lead People in Group Work (TR)

.3 IACET CEUs

Mike Laddin, MS, MBA

President, LeaderPoint

The role of a manager in organizing and leading a group is often misunderstood and, as a consequence, the group may not perform up to expectations or may spend a considerable amount of time dealing with dysfunctional group dynamics instead of the work to be accomplished. This tutorial addresses those issues by exploring the different types of work groups, how they can be more effective, and how individuals can correct group dynamics and help the group achieve higher levels of performance.

Learning Objectives

At the conclusion of this tutorial, participants should be able to:

- Identify and correct dysfunctional group dynamics
- · Create and maintain cooperation among team members
- Respond to distracting influences on group work to minimize impact on quality of work

Target Audience

This tutorial is designed for individuals who must manage group activities on a permanent or project basis, and individuals to whom project managers report. In addition, those who must work on teams but are not in charge of the teams can learn how to exert influence over group behavior. Past participants of the DIA Leadership Experience will also find this an excellent review as well as an opportunity to cover new materials.

#59 Preparation of Integrated Clinical and Statistical Reports for Individual Studies (MW, CR)

3.9 nursing contact hours; .3 IACET CEUs

George H. D'Addamio, PhD, MS, President, PharmConsult, Inc.

This tutorial will focus on the activities of the clinical team, interaction with supporting disciplines, and documents needed for report preparation. The ICH guideline for report structure and content will be reviewed and samples of key tables will be discussed. Participants are encouraged to play an active role in the tutorial by asking questions, exchanging ideas, and addressing problem areas of report generation. This tutorial will: 1) provide an understanding of how a study report fits into overall product development; 2) explore the process of preparing a clinical study report; and 3) discuss ways to improve the writing and review process.

Learning Objectives

At the conclusion of this tutorial, participants should be able to:

- Identify critical documents and personnel required to prepare an integrated study report
- Outline a process for preparing an integrated clinical study report in a matrix organization
- Describe the information required for and content of key sections of the integrated report.

Target Audience

This tutorial is designed for clinical research professionals with less than two years of experience in preparing integrated study reports, individuals in related disciplines (data management, statistics, clinical research associates, etc.), and managers or supervisors interested in an overview of the reporting process.

#60 Basic Audit Preparation: What You Should Know About Being Audited (VA, GCP)

.3 IACET CEUs Ken O'Brien

Associate Director, Process Quality Management, Perceptive Informatics, Inc. James H. Graffam, MS

Manager, Software Quality Management, Perceptive Informatics, Inc.

Lack of training and preparation is a significant contribution to the fear, apprehension, and stress often associated with being audited. This half-day tutorial is designed to instruct potential auditees in the fine art of preparing for and responding during audits. Three main areas of focus will be covered: preparing for the audit, auditee responsibilities, and auditor techniques.

Learning Objectives

At the conclusion of this tutorial, participants should be able to:

- Approach an audit with new-found confidence and recognize how a well prepared auditee will affect the outcome of the audit in a positive manner
- · Create a process to support a client audit
- Apply learnings to internal training programs at their company

Target Audience: This tutorial is designed for auditees of any level.

Receive additional information about this topic by attending the Monday, June 27, 10:30 AM-12:00 PM GCP Track session entitled "Managing Regulatory Inspections."

#61 Japan Regulatory Environment: Overview of the Organization, Processes, Systems and Changes Affecting Pharmaceutical Development (RA)

.3 IACET CEUs

Robert Fike, MS, PhD, Assistant Vice President, Regulatory Affairs Japan, Wyeth Research Division of Wyeth

J.D. Rafizadeh-Kabe, MD, JD, RAC, Associate Director, Global Regulatory Strategy, Bristol-Myers Squibb Pharmaceutical Research Institute

Major changes in the Japanese pharmaceutical regulations are impacting the development of new drugs in Japan. The impact of the new Pharmaceutical and Medical Device Agency (PMDA), and regulatory processes during development (consultations) and CTD review will be described. Several development strategies necessary to meet Japanese requirements for new drug approval will be identified, and the interest and results of bridging strategies will be analyzed. Postmarket surveillance and pricing reimbursement process will be reviewed, and finally, the impact of the changing regulatory system on global strategies will be identified throughout development, registration, and postmarket stages.

Learning Objectives

At the conclusion of this tutorial, participants should be able to:

- Identify the major elements of the Japanese regulatory system including the newly created agency
- Describe the regulatory processes during development, registration, and post approval safety and pricing in Japan
- Recognize specific attributes in the Japanese regulatory system and their impact on multinational development strategies

Target Audience

This tutorial is designed for pharmaceutical industry and regulatory agency employees with an interest in Japanese drug development, registration, pricing and postmarketing support.

#62 Please note that this tutorial has been CANCELLED

Trust, Relationships and the Negotiation Process .3 IACET CEUs

Ira G. Asherman, Consultant, Asherman Associates Barry Sagotsky, MBA, Consultant, Magnolia Lane Consulting

Through the use of lecture, small group discussion and practice negotiations the participants will explore the impact of furt on the negotiation process. The participants will explore the importance statistication regulating with bulk co-workers, vendors and agency personnel. Emphasis will be placed on identifying the steps they can take to enhance relationships where trust has been compromised.

Learning Objectives

- At the conclusion of this tutorial, participants should be able to:
- Describe the importance of trust to negotiation success
- List the factors critical to building trust
- · Identify the steps to follow when trust is not present
- Describe the six step successful negotiator process

Target Audience

This tutorial is designed for clinical research staff, regulatory liaison staff, and anyone who is faced with seeking help from others.

Sunday Afternoon Tutorials

12:30 рм - 1:00 рм

on Tutorials June 26, 1:00 PM - 4:30 PM TUTORIAL REGISTRATION Registration for Sunday, afternoon tutorials ONLY; East Registration Area, Convention Center, Mount Vernon Place Entrance

#70 Auditing the Vendor: Keys to Making It Work Before and After the Audit (OS, CR)

.3 IACET CEUs

Jonathan R. Andrus, MS, CQA

Vice President, Quality Assurance and Compliance, Phoenix Data Systems

This tutorial is intended to provide the participant with information he/she can use to effectively select, audit, and manage vendors. The management of vendors, after the initial selection, is one of the most important aspects of the vendorsponsor relationship. Audits are a snapshot in time, and as such, vendors must be continuously evaluated and expectations must be clearly defined to avoid potential misinterpretation and misunderstanding.

Learning Objectives

At the conclusion of this tutorial, participants should be able to:

- Prepare for pre-contract success
- Perform the audit process
- · Communicate and manage corrective actions
- Develop effective communication documents between organizations and manage change throughout the relationship

Target Audience

This tutorial is designed for QA managers, vendor managers, project managers, outsourcing specialists, vendors, and purchasing personnel.

#71 Introduction to Capacity Management, Tools and Techniques (PM)

.3 IACET CEUs

Paul Bunch

Manager, Capacity Planning and Management, Eli Lilly and Company

Joseph F. Pekny, PhD

Professor, School of Chemical Engineering, Purdue University

This tutorial will provide a basic understanding of the theory and practice of capacity management as it applies to an R&D setting. Several examples of practical application will also be reviewed. Ample time for hands-on Q&A will be provided.

Learning Objectives

At the conclusion of this tutorial, participants should be able to:

- · Operate with a basic understanding of capacity management
- Apply the basic concepts in an R&D setting
- Recognize how to optimize project resources using a variety of capacity management tools and techniques that lead to improved project and portfolio performance

Target Audience

This tutorial is designed for project managers, line managers, and functional managers in the pharmaceutical and biotechnical industry.

Receive additional information about this topic by attending the Monday, June 27, 3:30-5:00 PM PM1 Track session entitled "Enterprise Project Management and Capacity Management: An Interactive Session."

#72 CTD Preparation: Module 2 Clinical Overview and Clinical Summary (MW, RA, ST)

.3 IACET CEUs Michael J. Umen, PhD President Michael Umen & Co

President, Michael Umen & Co., Inc. *Mary Vanderhoof, MS* Senior Medical Writer, Michael Umen & Co., Inc.

The Guidance for Industry, M4E: The CTD – Efficacy will be reviewed with particular emphasis on those sections that apply to preparing a Clinical Overview (CTD Module 2, Section 2.5) and a Clinical Summary (CTD Module 2, Section 2.7) for an NDA or BLA. FDA's Clinical Review Template (FDA's MAPP 6010.3) will be analyzed from the perspective of how it can assist sponsors in preparing better Clinical Overviews and Clinical Summaries. Package inserts of approved products will be analyzed for the kinds of supporting tables, figures and analyses that could be expected to be found in the corresponding CTD Clinical Summaries and/or in various reports of data from more than one study (e.g., ISE, ISS, etc.) which might be placed in CTD Module 5, Section 5.3.5.3. Sample tables and figures excerpted from medical and statistical reviews of approved drugs and biologics will be used as instructional tools.

Learning Objectives

- At the conclusion of this tutorial, participants should be able to:
- Interpret and apply the Guidance for Industry, M4E: The CTD Efficacy, to the writing of an effective Clinical Overview (CTD Module 2, Section 2.5) and an effective Clinical Summary (CTD Module 2, Section 2.7) for an NDA or BLA
- Use FDA's Clinical Review Template as a guide to writing an effective Clinical Overview (CTD Module 2, Section 2.5) and an effective Clinical Summary (CTD Module 2, Section 2.7) for an NDA or BLA
- Determine when a stand alone ISE may be useful in addition to a Summary of Clinical Efficacy (Module 2, Section 2.7.3)
- Determine when a stand alone ISS may be useful in addition to a Summary of Clinical Safety (Module 2, Section 2.7.4)

Target Audience

This tutorial is designed for medical writers, pharmaceutical physicians, biostatisticians, clinical pharmacologists, and regulatory affairs professionals.

#73 Effective, Legal Rx Drug Promotion for the Year 2005: A Regulatory Primer (MA, RA)

3.25 category 1 credits; 286-000-05-511-L04; 3.25 contact hours (.325 CEUs); 3 IACET CEUs

Lucy Rose, MBA, PA-C

President, Lucy Rose and Associates, LLC

This highly interactive tutorial will provide a basic primer of US law and regulations affecting the promotion of prescription drugs to health care providers and consumers. Additionally, the tutorial will address the FDA's enforcement of those regulations, utilizing actual enforcement actions as examples for discussion, and the potential impact of those enforcement activities on pharmaceutical manufacturers. We will also address such topics as: how to work with FDA on promotional issues, challenges and opportunities of recent court decisions impacting the promotion of Rx drugs, opportunities and pitfalls of preapproval promotional activities, use of public relations activities, what is meant by fair balance, continuing medical education, and many other topics.

The tutorial will be conducted in a very informal manner, providing a highly interactive environment designed to elicit audience participation and address those issues most important to the attendees. This tutorial is designed to provide timely information for multiple disciplines, such as: legal, regulatory, marketing, medical/clinical, communications/public relations, and training.

Learning Objectives

At the conclusion of this tutorial, participants should be able to:

- Describe the current regulatory and legal environment impacting the promotion of Rx drugs
- Describe the FDA regulatory basics and FDA review process governing the regulation of Rx drugs
- Apply on an introductory level, FDA regulations on Rx drugs to many common advertising and promotional programs

Target Audience

This tutorial is designed for professionals new to the area of Rx drug advertising and promotion regulation, regulatory professionals looking for a refresher or update in this area, and other professionals from related disciplines desiring an introduction to this subject matter.

#74 Effective Presentation Skills for Clinical Trial Professionals (CR, TR)

286-000-05-512-L04; 3.25 contact hours (.325 CEUs); 3.9 nursing contact hours; .3 IACET CEUs

Mary E. Briggs

President and Chief Training Officer, FOCUS, Inc.

This tutorial focuses on the number one goal for effective speakers in the clinical trial industry – credibility! Participants will get a crash course on effective delivery skills and techniques to reduce performance anxiety. This fast-paced tutorial provides updated information on mental organization, as well as how to add some pizzazz to your business talks.

Learning Objectives

At the conclusion of this tutorial, participants should be able to:

- Apply presentation fundamentals (preparation, delivery and style) to future business/clinical talks
- · Build confidence with personal presentation style
- Recognize and manage symptoms of performance anxiety
- · Gain credibility as a speaker in the clinical trial industry

Target Audience

This tutorial is designed for clinical trial professionals that need or want to speak effectively at a variety of industry specific meetings, including investigator meetings, launch meetings, annual meetings, team meetings, sales functions, and various drug association events.

#75 Please note that this tutorial has been CANCELLED

Writing Effective Emails for a Multinational Audience (TR) .3 IACET CEUS

Bill Whelan, BS, Program Facilitator, LinguaCall Jennifer Thompson, BA, President, LinguaCall

This tutorial provides examples, illustrations and interactions that permit participants to explore their style and content for improvement. By learning cues from cultural research, participants are able to adjust their written expressions to reflect greater sensitivity for their audience while focusing on the essential elements of the message. The goal is to produce a document that achieves a shared sense of understanding that

lessens the chance of miced standing check the chance of miced standing check the chance of miced standing check the chance of t

Learning Objectives

At the conclusion of this tutorial, participants should be able to:

- Discuss the practical background and techniques in crafting "emails" for a multinational audience
- Recognize the value of mastering core cross-cultural skills and how to use that knowledge to improve the content of worldwide "emails"
- Describe cultural differences and similarities
- Identify the principles of effective "email" business writing and improve meaning when communicating with a culturally diverse audience

Target Audience

This tutorial is designed for people who wish to improve the quality of their multinational business emails while acquiring cross-cultural communications training. It would also be beneficial for administrators and middle management executives.

#76 Ensuring the Integrity of Electronic Records and Signatures: An Internal Controls Approach (CR, IT, GCP)

3.9 nursing contact hours; .3 IACET CEUs

Leonard A. Grunbaum, MBA President, META Solutions, Inc.

This tutorial will answer the following question: what internal controls must an organization employ, as part of the business infrastructure, to help ensure the integrity of electronic records and signatures in the most effective and efficient manner? It will (1) define and describe the concept of internal controls, (2) provide a detailed description of the pertinent internal controls, and (3) relate the internal controls to the requirements of 21 CFR Part 11 and applicable predicate regulations.

Learning Objectives

At the conclusion of this tutorial, participants should be able to:

- Describe the control environment that is conducive to compliant and efficient automated clinical trials operations
- · Identify the pertinent internal controls
- · Relate the internal controls to requirements of applicable regulations

Target Audience

This tutorial is designed for those responsible for various aspects of clinical trial operations, including the trials themselves (how data integrity can be maximized), systems development (what requirements should a system be designed to meet), IT operations (what controls must exist to protect pertinent corporate assets), and quality assurance (what disciplines must be brought to the table to help ensure quality).

#77 FDA Enforcement: What You Need to Know to Avoid or Respond to the FDA (RA, GCP)

3.25 category 1 credits; 286-000-05-513-L04; 3.25 contact hours (.325 CEUs); .3 IACET CEUs

Michael A. Swit, JD

Vice President, Life Sciences, THE WEINBERG GROUP INC.

This tutorial will review and discuss the legal, regulatory and practical nuances of 1) FDA enforcement priorities for 2005 and beyond (e.g., application of data integrity policy and good clinical practice requirements), 2) FDA administrative enforcement weapons and how the Agency uses them (e.g., inspections, warning letters, publicity, recalls, and investigator disqualification proceedings), and 3) the civil and criminal penalties for GCP violations (e.g., seizure, injunction, criminal prosecution). The tutorial will also address how to handle an FDA enforcement action should you face one, particularly in the wake of an inspection or warning letter at a clinical site or of a sponsor. These interactive discussions will focus on how FDA operates and makes decisions; how to respond effectively, using tactics ranging from negotiation to, when appropriate, litigation.

Learning Objectives

- At the conclusion of this tutorial, participants should be able to:
- Discuss FDA's enforcement priorities for 2005 and beyond
- · Describe FDA's compliance review and decision making process
- Recognize the legal risks and penalties for noncompliance
- Respond appropriately to FDA enforcement actions with regard to sponsor records in clinical studies as well as inspections at the clinical site

Target Audience

This tutorial is designed for personnel at sponsor and clinical sites, and investigators and CROs that have responsibility for ensuring compliance with FDA's Good Clinical Practice ("GCP") requirements, regardless of whether in a supervisory or direct role.

#78 Fourteen Steps from Research to Development (RD, RA)

3.9 nursing contact hours; .3 IACET CEUs

Judi Weissinger, PhD President and CEO, Weissinger Solutions, Inc. Michael R. Hamrell, PhD, RAC President, MORIAH Consultants

There are 14 steps from research to development (R to D) and initiation of phase 3 clinical studies; the majority of time committed to drug development occurs during this period. A discussion of the 14 critical steps from R to D will include identifying ways to streamline the process and interactions with FDA. With each of the 14 steps used to develop the optimal strategic plan, discussion will address the resources and various approaches to tailoring the plan to a sponsor's specific product under development and obtaining FDA concurrence with the strategic plan. A smooth progression through the preclinical process into early clinical programs will be presented in this half-day tutorial targeted to familiarize pivotal staff in start-up companies with the terminology and functions required, to pharmaceutical/biological companies that have yet to file INDs, and to those who want to improve their early development approach.

Learning Objectives

At the conclusion of this tutorial, participants should be able to:

- · Recognize the terminology and process involved in product development
- Identify ways to tailor the development, streamline the process and interact with FDA for unique products
- · Explain the specialties and resources needed to develop a product
- Guide your company smoothly through the progression of research and development through the preclinical process into early clinical programs

Target Audience

This tutorial is designed for pivotal staff in start up companies, pharmaceutical/biological companies that have yet to file INDs, and all personnel that want to broaden their knowledge of product development.

#79 Investigator Site and Monitor Training to Improve Data Quality and Optimize MedDRA® Coding (IS)

.3 IACET CEUs

Judy Harrison, MD

Clinical Research Consultant, Harrison Clinical Consulting, LLC (Consultant to Northrop Grumman/MedDRA MSSO)

One of the most significant aspects of MedDRA implementation is training of organization personnel. Training of coding personnel about the size, structure and specificity of MedDRA is necessary to achieve accurate and meaningful data for subsequent analysis; however, both the encoding and analysis of MedDRA-coded data are highly dependent on the initial quality of the data received from reporters, including investigators. This tutorial will focus on how the quality of initial data impacts MedDRA coding and analysis and will describe training strategies to optimize the quality of reported data from investigators.

Learning Objectives

At the conclusion of this tutorial, participants should be able to:

- Describe how the quality of initial data from investigators impacts MedDRA coding and subsequent data analysis
- Define the role of MedDRA training for investigators, CRAs and CROs in the effort to improve data quality

Target Audience

This tutorial is designed for CRAs, physicians, data managers and CRO personnel engaged in clinical research; clinical safety personnel; investigators and study coordinators; and training managers.

#80 Please note that this tutorial has been CANCELLED Quantitative Clinical Imaging in Clinical Trials: Operational and Statistical Issues (ST)

James M. Dancy, MBA Vice President, Operations, dKb Technologies Robert J. Buck, PhD Statistician, Pfizer Inc

This tutorial will describe the strategic use of clinical imaging for quantitative biomarkers, and will explain common imaging modalities (CT, MRI, PET, fMRI). The operational data capture process from 'machine format' to sponsor database will be described. Statistical study of a photan was is use v the discussed, including variance sources and approaches to control variance.

Learning Objectives

At the conclusion of this tutorial, participants should be able to:

- Communicate the purpose and clinical use of common imaging modalities (CT,
- PET, MRI, and fMRI) that are being used as quantitative endpoints in clinical trials
 Demonstrate the data management and data monitoring process for imaging data collection in a clinical trial regardless of imaging modality
- Describe the statistical analysis factors relevant to study design and analysis
- Explain existing industry use of imaging biomarkers in the drug development decision process as well as regulatory submission process

Target Audience

This tutorial is designed for individuals involved in the implementation of clinical trials with a significant imaging based endpoint. The focus is on operational roles such as data management, study monitoring, regulatory, clinicians, and statisticians.

#81 Evidence-based Medicine Throughout the Clinical Drug Development Process (CP)

3.25 category 1 credits; .3 IACET CEUs

Matthew W. Reynolds, PhD

Senior Director, Risk Management and Safety Services, MetaWorks, Inc. Susan D. Ross, MD

Chief Scientific Officer and Co-founder, MetaWorks, Inc.

It is not always necessary to conduct expensive studies to acquire new information when there is a wealth of easily accessible, already existing, evidence that can help to promote better, quicker, and more affordable answers to scientific questions in clinical development. Evidence-based medicine is the application of currently available best evidence to guide the clinical research decision process. The principles of evidencebased medicine should be applied early and often in the clinical drug development process to assist in making optimal decisions based on available clinical evidence from early phase clinical trials though postlaunch activities. Drug development programs should utilize evidence-based tools, such as systematic reviews of the literature to better understand disease characteristics and progression, alternative treatments, and characteristics of competitor drugs from both a safety and efficacy perspective. This tutorial will identify and present a variety of evidence-based tools for use in improving research in clinical drug development. Case studies and group exercises will be used to illustrate a variety of applications for these tools such as determining optimal clinical trial sample size, identification of optimal trial endpoints, placing safety issues into appropriate population context, improving the prediction of efficacy and safety outcomes, determining new possible indications, and other applications.

Learning Objectives

At the conclusion of this tutorial, participants should be able to:

- Discuss the concept of evidence-based medicine
- Identify a variety of evidence-based tools and methods for use in improving efficiency in the clinical drug development process
- Apply evidence-based medicine principles to the clinical drug development process

Target Audience

This tutorial is designed for individuals that are involved in clinical drug development (Phase I, II, III, and post-marketing) epidemiology, biostatistics, regulatory affairs, medical affairs, and outcomes research.

#82 The Building Blocks for Patient Recruitment and Retention (IS, CR, BT)

.3 IACET CEUs

Elizabeth A. Moench President, MediciGroup® Inc. Lisa Fell Vice President, Recruitment Operations, MediciGroup® Inc.

When today's patient recruitment processes are riddled with inefficiencies that slow, sideline and sometimes stop clinical trials, and more than three-quarters of all clinical trials fail to meet their recruitment deadlines, steps to streamline processes, accelerate patient recruitment and improve the margin of study success are critical. This tutorial will address the following themes:

- Recruitment Feasibility: Practical, realistic case study examples in clinical trial recruitment. Participants will collaborate to forecast, analyze and set performance markers, identify hidden pitfalls and solutions for clinical trial recruitment.
- Recruitment Strategy Design: Realistic development of recruitment programs to
 recruit different patient populations assessing different media methods and cost
 per acquisition analysis. This module incorporates case-studies based on historical
 data and published articles.
- Recruitment Performance Metrics: Cost and performance management are key to tracking progress and monitoring recruitment timelines.
- Site Accountability for Recruitment: Setting achievable timelines, performance parameters and fostering study commitment. Using realistic case study examples, strategic options are reviewed within an IRB framework.
- Return on Investment for Retention: Retention programs are not necessary for every study. Determining which studies will require implementing such programs early rather than watchful waiting requires evaluating study costs and potential overruns versus the value of time and potentially data.

Learning Objectives

- At the conclusion of this tutorial, participants should be able to:
- · Identify realistic recruitment forecasts and budgets to avoid future budget creep
- Determine the critical steps to recruitment strategy design
- Discuss which metrics to collect, to track recruitment effectiveness and where to direct ongoing investment
- Motivate sites to deliver on recruitment milestones

Target Audience

This tutorial is designed for therapeutic area leaders, clinical team leaders, clinical directors/managers, clinical directors/project managers, clinical procurement professionals, and individuals involved with clinical operations, clinical outsourcing, and product marketing.

Receive additional information about this topic by attending the Tuesday, June 28, 8:30-10:00 AM CTM Track session entitled "Strategies for Achieving Recruitment Goals in Pediatric Trials" and the Tuesday, June 28, 3:30-5:00 PM CR1 Track session entitled "Town Meeting on Patient Enrollment: What DO We Know? What Can We Do?"

#83 Structured Product Labeling (CR, IT, RA)

.3 IACET CEUs

Steven Gitterman, MD, PhD

Deputy Director, Director of Special Pathogens and Immunologic Drug Products, CDER, FDA

Lisa Stockbridge, PhD, MS

Regulatory Reviewer, Office of Information Management, CDER, FDA

Kristofer Spahr

Associate Director, Regulatory and Labeling Applications, Wyeth

This tutorial will be an overview of FDA implementation of the Structured Product Labeling (SPL). Topics will include the current status of SPL at FDA and implementation timelines, the content and development of an SPL document, the mechanism for submission of SPL to FDA, and FDA/sponsor interactions regarding SPL submissions.

Learning Objectives

At the conclusion of this tutorial, participants should be able to:

- · Describe the basic structure of an SPL document
- Discuss the timelines for submission of SPL to FDA
- · Recognize the coding and data elements used in SPL
- Explain the mechanism for submitting SPL To FDA

Target Audience

This tutorial is designed for industry personnel involved in the development and submission of labeling to FDA. Aspects of the tutorial will be relevant to clinical, regulatory, and information technology personnel.

#84 Please note that this was formerly Tutorial #56, offered on Sunday from 8:30 am - 12:00 pm (effective 4-7-05)

EU Regulatory Requirements: Pharmacovigilance in the Pre- and Postmarketing Phase and the EudraVigilance Database (CP, RA)

.3 IACET CEUs

Sabine Brosch, MSc, PhD Deputy Head of Sector, EMEA, European Medicines Agency, EU

Gaby L. Danan, MD, PhD

Head, Pharmacovigilance and Epidemiology Department, sanofi-aventis, France

This tutorial will focus on the new regulatory framework that has been put in place in the EU to strengthen the conduct of pharmacovigilance throughout the lifecycle of medicinal products. Aspects that will be addressed are:

- Responsibilities of the sponsor in the collection, verification and presentation of adverse reaction reports arising from clinical trials conducted in the EU
- Responsibilities of the qualified person for pharmacovigilance and the notification of adverse reactions occurring either in the Community or in a third country for marketed products

- Mandatory electronic reporting (save in exceptional circumstances) of adverse reactions by November 2005 independent of the authorization procedure of the medicinal products in the EU
- The main functionalities of the EudraVigilance database, which is one of the pillars of the EU Risk Management Strategy and methodologies for the effective detection of potential safety signals
- Access by healthcare professionals, marketing authorization holders and the public to the EudraVigilance database, taking into account personal data protection
- Pharmacovigilance inspections to monitor the implementation of the obligations of marketing authorization holders by the European Medicines Agency (EMEA) and competent authorities.

Learning Objectives

- At the conclusion of this tutorial, participants should be able to:
- Describe the new regulatory environment with regard to adverse reaction management during clinical trials and the postauthorization phase including the mandated electronic reporting in the EU coming into force in November 2005
- Recognize the main system components of EudraVigilance including access to adverse reaction data by pharmaceutical industry, sponsors of clinical trials, healthcare professionals and patients
- Discuss the pharmacovigilance inspections process

Target Audience

This tutorial is designed for drug safety and pharmacovigilance managers and personnel, regulatory affairs professionals, clinical trial sponsors and all personnel who need to understand the impact of the new Community legislation related to the dayto-day pharmacovigilance activities in the EU.

* Receive additional information about this topic by attending the Monday, June 27, 3:30-5:00 PM CP Track session entitled "Electronic Submissions of ICSRs."

Tutorial Pricing (effective 5-4-05)

Tutorials will take place on Saturday, June 25 and Sunday, June 26, 2005, prior to the Annual Meeting. *Many tutorials have been updated with new content, and new topics have been added.* Topics range from professional development to specialized areas within the pharmaceutical industry. Continuing medical, pharmacy, and nursing education credits and IACET continuing education units will be available for various tutorials. DIA will continue to add tutorials to the overall schedule at this year's Annual Meeting. Tracks that complement the tutorial topic area are indicated by the track acronym in parentheses. See page 5 for acronym definitions and tutorial overviews. Please continue to monitor www.diahome.org for tutorial updates and online registration. *Space is limited so register early!*

Tutorial instructors and schedule are subject to change without notice. Recording of DIA tutorial/workshop information in any type of media, is prohibited without prior written consent from DIA. Statements made by instructors are their own opinion and not necessarily that of the organization they represent, or that of the Drug Information Association.

Saturday Afternoon Tutorials Tutorial Fee: \$350 June 25, 2005 1:00 PM - 4:30 PM

- #30 Active-controlled Noninferiority/Equivalence Trials: Methods and Practice (ST)
- #31 Advanced Auditing of Clinical Research Systems for Validation (CR, VA)
- **#32 This tutorial has been CANCELLED:** Contract Management: A Review of Industry Best Practices (OS, CR, FI)
- #33 Developing Author Templates for Submission Documents (DM)
- #34 Clinical Trial Performance and Risk Analysis: Using the Earned Value Method (PM, FI)
- #35 Identifying, Recruiting and Training Multiple Research Naïve Physicians for Participation in Simplified Clinical Trials (IS, CR)
- #36 New Challenges to IRBs, Sponsors, and Investigators (IS, PP)
- #37 European Regulatory Affairs: Current Regulatory Procedures and New Medicines Legislation Effective November 2005 (RA)
- #38 Statistical Analysis Plan Made Easy (ST)

Also available – Certified Clinical Investigator Review Course (CR, IS) Course Fee: Members \$250/Nonmembers \$300

Sunday Full-day Tutorials

Tutorial Fee: \$500

June 26, 2005 9:00 AM - 5:00 PM

- #40 Clinical Statistics for Nonstatisticians (CR)
- #41 Computer Validation from A to Z: Practical Reality for User Acceptance of GXP Systems (IT, VA)
- #42 Data Mining, Data Flow Modeling, Data Warehousing, and Knowledge Management (CDM)
- #43 Design and Statistical Analysis of Bioequivalence Studies (ST)
- #44 Pharmacokinetics and Pharmacodynamics: A Gentle Introduction (CR)
- #45 Principles of Safety Surveillance (CP)
- #46 Techniques for Applying Risk Management Principles to Computer System Validation (IMP, VA)
- #47 Update on the European Clinical Trial Legislation (CR, RA)

Sunday Morning Tutorials

Tutorial Fee: \$350

- June 26, 2005 8:30 AM 12:00 PM
- #50 Overview of the 21 CFR 11 Regulations and Guidance: What Has Changed and What Is Now Required? (IT)
- #51 Case Studies on Signal Detection and Investigation (CP)
- #52 Best Practices When Using MedDRA® (CP, CDM)
- #53 Critical Issues and Important Considerations for Outsource Contracting (OS, PP)
- #54 Compliance-driven Risk Detection: A New Approach within Drug Safety (CP)
- #55 Dealing Effectively with Cultural Differences for Clinical Trial Professionals (CR, TR)

- #56 (now #84) This tutorial is now being offered as Tutorial #84 on Sunday, 1:00 pm - 4:30 pm
- #57 Getting Your Clinical Operations on the Right Track: Strategy, Knowledge, People and Process (CR)
- #58 Leadership: How to Organize and Lead People in Group Work (TR)
- #59 Preparation of Integrated Clinical and Statistical Reports for Individual Studies (MW, CR)
- #60 Basic Audit Preparation: What You Should Know About Being Audited (VA, GCP)
- #61 Japan Regulatory Environment: Overview of the Organization, Processes, Systems and Changes Affecting Pharmaceutical Development (RA)
- **#62 This tutorial has been CANCELLED:** Trust, Relationships, and the Negotiation Process

Sunday Afternoon Tutorials

June 26, 2005 1:00 рм - 4:30 рм

#70 Auditing the Vendor: Keys to Making It Work Before and After the Audit (OS, CR)

Tutorial Fee: \$350


- #71 Introduction to Capacity Management, Tools and Techniques (PM)
- #72 CTD Preparation: Module 2 Clinical Overview and Clinical Summary (MW, RA, ST)
- #73 Effective, Legal Rx Drug Promotion for the Year 2005: A Regulatory Primer (MA, RA)
- #74 Effective Presentation Skills for Clinical Trial Professionals (CR, TR)
- **#75** This tutorial has been CANCELLED: Writing Effective Emails for a Multinational Audience (TR)
- #76 Ensuring the Integrity of Electronic Records and Signatures: An Internal Controls Approach (CR, IT, GCP)
- #77 FDA Enforcement: What You Need to Know to Avoid or Respond to the FDA (RA, GCP)
- #78 Fourteen Steps from Research to Development (RD, RA)
- #79 Investigator Site and Monitor Training to Improve Data Quality and Optimize MedDRA[®] Coding (IS)
- **#80 This tutorial has been CANCELLED:** Quantitative Clinical Imaging in Clinical Trials: Operational and Statistical Issues
- #81 Evidence-based Medicine Throughout the Clinical Drug Development Process (CP)
- #82 The Building Blocks for Patient Recruitment and Retention (IS, CR, BT)
- #83 Structured Product Labeling (CR, IT, RA)
- #84 (formerly #56) EU Regulatory Requirements: Pharmacovigilance in the Pre- and Postmarketing Phase and the EudraVigilance Database (CP, RA)

Also available – TWO OFFERINGS! Please see page 7 for details. Certified Clinical Investigator Examination Sunday, June 26, 9:00 am-12:00 pm and 2:00 pm-5:00 pm

Please indicate the tutorials you plan to attend on the registration form, page 102.



JUNE 26-30, 2005 | WASHINGTON, DC



WASHINGTON CONVENTION CENTER Ronald D. Fitzmartin, PhD, MBA Dailichi Medical Research, Inc.

To view the most current information about sessions and scheduling online, please click on the links below.

Monday, June 27

Tuesday, June 28

Wednesday, June 29

Thursday, June 30

Conference Schedule by Day and Time

Sessions are organized and presented according to the interest area codes below. Several sessions may also be of interest to professionals in other specialties or disciplines. For these sessions, the primary interest area code, displayed in bold face type, is followed by the code for secondary or tertiary interest areas.

Level of Difficulty

The difficulty level of each session has been determined by the session chairperson and is indicated by one of the following symbols, providing a guide for registrants in their selection of sessions to attend.

• Ba	asic Level Content	Attende	Attendee has 3 years or less experience in the session topic area.				
E Pr	imarily Intermediate Level Content	Attende	e has more than 3 years experience in the s	ession top	ic area.		
◆ Pi	imarily Advanced Level Content	Session may be a more focused topic within a content area. Attendee has master area. (Usually only 2 speakers to allow for more in-depth presentations.)			•		
AD	Advertising	DM	Document Management/eSubmissions	NC	Nonclinical Laboratory Safety Assessment		
AHC	Academic Health Centers	eCLIN	eClinical	NHP	Natural Health Products		
BT	Biotechnology	FI	Finance	0 S	Outsourcing		
СМС	Chemistry, Manufacturing, and Controls/	GCP	Good Clinical Practices	PM	Project Management		
	Good Manufacturing Practices	IMP	Impact of Medical Products and Therapies	PP	Public Policy/Law		
CDM	Clinical Data Management	IS	Investigator Sites	RA	Regulatory Affairs		
СР	Clinical Safety and Pharmacovigilance	IT	Information Technology	RD	R&D Strategy		
CR	Clinical Research and Development	MA	Marketing and Sales	ST	Statistics		
CS	Clinical Supplies	MC	Medical Communications	TR	Training		
СТМ	Clinical Trial Management	MW	Medical/Scientific Writing	VA	Validation		

Session		Difficul	ty	Intere	est Areas	
Number	Session Title	Level		Primary	Associated	Room Number
	MONDAY 8:30 AM - 10:00 AM					
	PLENARY SESSION					Ballroom ABC 3rd Floor
	Welcome, Award Presentations, Keynote Address			ALL	ALL	Conv. Center
	МОЛДАУ 10:30 ам - 12:00 рм					
	Drug Advertising and Promotion: A Regulatory Primer	LEVEL	•	AD	MA, RA	202B
	Pharmaceutical Quality Assessment: The New CMC Review Paradigm	LEVEL		СМС	RA	150B
	The Application of Good Pharmacovigilance Practices	LEVEL		СР	CR, PP, RA	207A
	Real Life Safety and Efficacy of Levitra [®] (REALISE): Operational Aspects of a Postmarketing Surveillance Study	LEVEL	•	CR1	СР	145A
	Human Phase 0 (Microdosing) Studies: Regulatory and Scientific Aspects	LEVEL		CR2	RA	145B
	Is the Analgesic Drug Development Pipeline Drying Up?	LEVEL		CR3	—	147A
	A New Era of Transparency in Clinical Research: The Evolution, Impact, and Future of Clinical Trial Registers and Registries	LEVEL	•	CR4	RA	144ABC
	Clinical Trial Offices: Boon or Boondoggle?	LEVEL	•	СТМ	AHC, IS	140B
	A Standards-based Approach for Authoring Through Distribution	LEVEL	•	DM	_	206
	Tools Sponsors Need to Implement Industry-wide Data Standards	LEVEL	•	eCLIN	CR, RA	207B
	The Red Team Review: Avoiding Study Delays and Expenses from the Outset	LEVEL	•	FI	CR	140A
	Managing Regulatory Inspections	LEVEL	•	GCP	RA	202A
	Compliance and Clinical Trials Finance	LEVEL	٠	IS	CR, FI	101
	PDUFA and Information Technology	LEVEL		IT	RA	204BC
	CTD: Practical Solutions for Mixed Applications, Herbals and Biologics	LEVEL	•	MW	RA	102AB

140B

206 207B

140A

202A

101

204BC

102AB

103B

154AB

147B

150A 143AB

145A

103A

149AB

201

151A

209AB

– RA

0S

RA

RA

CR

AHC, IS

AHC, CR eCLIN

ession			Difficulty		est Areas		
umber	Session Title	Level		Primary	Associated	Room Number	
	MONDAY 10:30 AM - 12:00 PM continued						
	Biological Markers: Validations and Points to Consider	LEVEL	•	NC	_	103B	
	Examining Use of Best Practices in CRO Outsourcing	LEVEL		OS	CR, FI	150A	
	Fostering Innovation, Efficiency, and Effectiveness on Project Teams	LEVEL		PM1	_	143AB	
	Drug Development Teams: Heavyweights versus Lightweights - What Is the Score?	LEVEL	•	PM2	_	143C	
	Immunogenicity of Biotechnology-derived Medicinal Products and Biosimilars/ Follow-on Biologics: Regulatory Update and Recommendations	LEVEL		RA1	BT	151B	
	Registering Drugs for Pediatric Use	LEVEL		RA2	CR	152A	
	Regulations of Botanical Drugs in the US	LEVEL	•	RA3	NHP	152B	
	FDA Initiative's Influence on Approval and Scale-up of Biotechnology Products	LEVEL		RA4	BT, CMC	146B	
	Generic Applications in the EU after Review 2001	LEVEL	٠	RA5	_	154AB	
	When to Specify the Statistical Analysis	LEVEL		ST	_	201	
	Effectively Managing the Challenges of Global Training	LEVEL		TR	GCP	151A	
	General Validation Issues	LEVEL		VA	_	209AB	
	MONDAY 1:30 рм - 3:00 рм						
	Update on FDA Enforcement of Promotional Activities	LEVEL		AD	MA, RA	202B	
	ICH Quality Guidances: Q8, Q9, and Q10	LEVEL		СМС	RA	150B	
	Regulatory Inspections of Company Pharmacovigilance Departments	LEVEL	•	СР	RA	207A	
	PLENARY SESSION Critical Path: Are We at the Fork in the Road?	LEVEL		CR/RA	RD	Ballroom AB	
	Clinical Supply Management	LEVEL		CS	CR	143C	

ICH Quality Guidances: Q8, Q9, and Q10	LEVEL		СМС
Regulatory Inspections of Company Pharmacovigilance Departments	LEVEL	•	СР
PLENARY SESSION Critical Path: Are We at the Fork in the Road?	LEVEL		CR/RA
Clinical Supply Management	LEVEL		CS
Emerging World Clinical Development: Learning from Each Other	LEVEL		СТМ
FDA Data Standards Initiatives	LEVEL	•	DM
Clinical Data Interchange Standards (CDISC), from Protocol Through Submission	LEVEL		eCLIN
Outsourcing in Europe: Guidance to US Companies	LEVEL		FI
GCP Audits and Inspections: Determination of What Is, and What Is Not, Investigational Site Staff Misconduct	LEVEL		GCP
I Am OK, I Am Indemnified! What Does This REALLY Mean?	LEVEL	•	IS
EDC Vendor Selection: Do We Really Need a Pool?	LEVEL	•	IT
ICH CTD Guidelines and Current Status of Implementation in DMFs, INDs, NDAs, BLAs and ANDAs	LEVEL		MW
 The In Vitro Clastogen Conundrum	LEVEL		NC
Evaluating Natural Health Products in Patients with Serious and Life-threatening Conditions	LEVEL	•	NHP
A Look at Today's Drug Development Outsourcing Practices: Successes, Failings, and Ways to Improve Them – Part 1 of 2	LEVEL		OS1
Functional Outsourcing: How Are Different Project Management Models Being Applied?	LEVEL		OS2
 Resource Management: Key Success Factors and Lessons Learned	LEVEL	•	PM1

.....

.....

RD CR ____ Resource Management: Key Succ PIVI LEVEL eXtreme Project Management: How to Succeed in the Face of Volatility PM2 LEVEL Clinical Trials on Trial: Potential Legal Liability Arising from Clinical Trials LEVEL PP CR Monitoring and Managing a Changing Investigative Site Landscape LEVEL RD AHC, CR, IS • Analyze as You Randomize? LEVEL ST ___ Pros and Cons of Web-based Training in a Global Research and **Development Setting** LEVEL • TR **Current Regulatory Issues** LEVEL VA IT, RA

Conference Schedule by Day and Time

Session Number	Session Title		Difficulty Level		st Areas Associated	Room Number	
	МОNDAY 3:30 рм - 5:00 рм						
	The OIG/US Attorney/Attorney General Update: Where They've Been, Where They Are, and Where They're Going	LEVEL		AD	MA, RA	202B	
	ICH Quality Guidance: Q5E	LEVEL		CMC	RA	150B	
	Electronic Submission of ICSRs	LEVEL		СР	eClin, RA	207A	
	Global Pediatric Trials	LEVEL	•	CR1	RA	145A	
	Monitoring of Clinical Endpoint Trials	LEVEL		CR2	ST	145B	
	How to Get Reliable Results from Feasibility Studies: Factors and Metrics	LEVEL		CR3		147A	
	The Clinical, Technical, and Regulatory Validation of Novel Surrogate Endpoints	LEVEL		CR4	 RA	147A	
		LEVEL		CR5	RA	147B 146A	
	A Key to Success in Bringing a Product to Market Is Proper Protocol Design						
	Handling the Tough Logistical Issues in Clinical Supplies	LEVEL		CS	RA	143C	
	A Comprehensive Analysis of Factors Influencing the Length and Corresponding Cost	LEVEL	٠	СТМ	FI	140B	
	Submission Standards (CDISC, etc.)	LEVEL	•	DM	RA	206	
	The National Health Information Network (NHIN): Changing the Role of Biopharma in Clinical Research	LEVEL	•	eCLIN	CR	207B	
	Impact of SOX Act on R&D Costs of the Pharmaceutical Industry	LEVEL	٠	FI	RD	140A	
	The Rising Cost of Quality: Is It Making a Difference?	LEVEL		GCP	CR, RA	202A	
	Designing and Executing Studies that Meet Patient Needs	LEVEL		IS	CR	101	
	The Ease of Paper, the Speed of Electronics: The Next Generation of Data						
	Collection	LEVEL		IT	eCLIN, IS	204BC	
	Pharmaceutical Excipient Development: A Preclinical Challenge	LEVEL		NC	CMC, RA	103B	
	A Look at Today's Drug Development Outsourcing Practices: Successes, Failings, and Ways to Improve Them – Part 2 of 2	LEVEL		os	RD	150A	
	Enterprise Project Management and Capacity Management: An Interactive Session	LEVEL		PM1	_	144ABC	
	Go/No Go Decisions	LEVEL	•	PM2	RD	143AB	
	Clinical Trials: Legal and Regulatory Jeopardy	LEVEL		PP	CR, RA	103A	
	The New Europe for Pharmaceuticals: From Research and Development to Marketing Authorization and Marketing	LEVEL		RA1	RD	151A	
	PMDA and Related Drug Safety Activities	LEVEL	•	RA2	CP, CR, RD	152A	
	Making International Nonproprietary Names (INNs) User-friendly	LEVEL		RA3	PP	152B	
	Trial Design and the Study Data Tabulation Model	LEVEL		RA4	CR	154AB	
	Risk/Management Throughout Product Development: Clarifying Requirements						
	and Managing Expectations	LEVEL		RA5	СР	151B	
	Electronic Management of Drug Information and Labeling	LEVEL	•	RA6	_	146B	
	Medical Affairs for Biotechnology/Pharmaceutical Start-ups: Strategies for Launch (Research and Medical Communications)	LEVEL		RD	BT, PM	149AB	
	Multiregional Trial: Global and Japanese View in Biostatistics	LEVEL		ST	CR	201	
	Training and Clinical Research in the 21st Century: You Can Get Your Drug to						
	Market Faster!	LEVEL		TR	CR	146C	
	Validation in the Real World: Global System and Revalidation Approaches	LEVEL		VA	_	209AB	
	TUESDAY 8:30 ам - 10:00 ам						
	Support for CME: How Difficult? How Dangerous?	LEVEL		AD	MA, PP, TR	202B	
	Validation of Immunogenicity Testing Methods	LEVEL	•	BT	NC, VA	154AB	

Session			ty	Intere		
lumber	Session Title	Level		Primary	Associated	Room Number
	TUESDAY 8:30 AM - 10:00 AM continued					
	FDA Drug Substance and Drug Product Guidances	LEVEL		СМС	RA	147A
	Risk Minimization Through Risk Communication: The Impact of New Regulatory					
	Developments in Safety Labeling	LEVEL		СР	CR, RA	207A
	Conjugated Vaccines	LEVEL		CR1	BT, RA	145B
	Cardiovascular Safety and QT Assessment	LEVEL		CR2	СР	146A
	Future Trends in Clinical Supplies	LEVEL		CS	СТМ	149AB
	Strategies for Achieving Recruitment Goals in Pediatric Trials	LEVEL		СТМ	CR	140B
	eCTD: Lifecycle Management	LEVEL		DM	RA	206
	Electronic Patient-reported Outcomes (ePRO) 2005: A Town Meeting	LEVEL	•	eCLIN	CR, RA	145A
	Establish and Maintain a CAPA System	LEVEL		GCP	_	202A
	Revolutionizing the Role of Quality Assurance	LEVEL		IS	AHC	101
	Testing Security in a Regulated Environment: The What, When, and Where	LEVEL	٠	IT1	_	152A
	Distributed Systems in Clinical Data Management	LEVEL	٠	IT2	CDM, eCLIN	146B
	The Role of Medical Communications Departments in Risk Management Programs	LEVEL	٠	МС	СР	209AB
	Document Reviews: Bridge to Quality or Roadblock to Completion?	LEVEL	٠	MW	_	102AB
	Extrapolating Nonclinical Animal Data to the Clinic	LEVEL		NC	RA	103B
	Regulatory Requirements versus Financial Benefit: Justifying Natural Health					
	Products from a Private Sector Perspective	LEVEL		NHP	RA, RD	140A
	Are Changes in Pharmaceutical Outsourcing Meeting the Needs of Investors,					
	Sponsors, and Vendors?	LEVEL		OS	FI	150A
	Maintaining the Talent Pipeline: Options for Identifying, Training, and Developing			DM4		14240
	Pharmaceutical Project Managers	LEVEL		PM1	_	143AB
	Lead, Follow, or Get Out of the Way!	LEVEL		PM2	-	143C
	Medicines and Healthcare: Rebuilding the Trust – Reshaping the Future – Part 1 of 2	LEVEL	-	PP	RA, RD	144ABC
	New Horizons for the EMEA: Priorities for 2005-2006	LEVEL		RA1	_	146C
	Implementation of the August 30 WTO Decision: Access to Medicines	LEVEL	-	RA2	-	151B
	Global Development: Focus on Asia	LEVEL	-	RA3	RD	151A
	CBER Update	LEVEL	•	RA4	-	152B
	Workload Management and Performance Monitoring	LEVEL		RD	FI, OS	150B
	Statisticians and Standards: Emerging Tools and Processes for Faster, Cleaner			ст	D۸	201
	Results from Clinic to Submission	LEVEL	•	ST	RA	201
	Investigative Site Readiness	LEVEL	•	TR	CR, IS	207B
	Validation Methodology II	LEVEL	•	VA	—	147B

TUESDAY 10:30 AM - 12:00 PM

LEVEL		AD	MA, RA	202B
LEVEL		ВТ	RA, RD	154AB
LEVEL	•	CDM	СР	204BC
LEVEL		СМС	RA	147A
LEVEL		СР	RA	207A
LEVEL	•	CR1	RA	145B
LEVEL	•	CR2	IS	145A
LEVEL		CR3	_	149AB
LEVEL	•	CR4	_	147B
-	LEVEL LEVEL LEVEL LEVEL LEVEL LEVEL	LEVEL • LEVEL ■ LEVEL ■ LEVEL • LEVEL •	LEVEL BT LEVEL CDM LEVEL CMC LEVEL CP LEVEL CP LEVEL CR1 LEVEL CR2 LEVEL CR3	LEVEL BT RA, RD LEVEL CDM CP LEVEL CMC RA LEVEL CP RA LEVEL CP RA LEVEL CR1 RA LEVEL CR2 IS LEVEL CR3 –

Conference Schedule by Day and Time

Session		Difficulty		Intere	est Areas	
lumber	Session Title	Level		Primary	Associated	Room Number
	TUESDAY 10:30 AM - 12:00 PM continued					
	Innovative, Objective, Data-based Approach to Trial Planning and Implementation	LEVEL	•	СТМ	_	140B
	eCTD: Case Studies	LEVEL	٠	DM	RA	206
	Town Hall Forum on Current GCP Issues	LEVEL		GCP	RA	202A
	Successful Selection of an ePRO Technology Provider	LEVEL		IMP	eCLIN, OS	152A
	Accelerating Subject Enrollment: A Handbook for Sites and Sponsors	LEVEL		IS	CR, CTM	101
	Lightweight Integration for Clinical Trial Operations	LEVEL		IT	СТМ	146B
	Integrating Field Medical Liaisons with Clinical Drug Development	LEVEL		МС	CR	209AB
	Post Red Apple Conference Update	LEVEL		NC/VA	RA	103B
	The New Legislative Environment for Herbal Products in Europe	LEVEL		NHP	RA	102AB
	Exploring Both Sides of the Perfect CRO/Pharmaceutical Partnership	LEVEL		OS	PM	150A
	Risk Management	LEVEL		PM1	RD	143AB
	Alliance Management: From Partner Selection to Joint Program Teams	LEVEL		PM2	BT, RD	143C
	Medicines and Healthcare: Rebuilding the Trust - Reshaping the Future - Part 2 of 2	LEVEL	٠	PP	RA, RD	144ABC
	New Pharmaceutical Legislation – Part 1 of 3: Tools for Quick Access to Medicines	LEVEL		RA1	_	146C
	Self-medication and OTCs	LEVEL	٠	RA2	CP, MC	151B
	Public Clinical Trials Data: Preparing for the Registry	LEVEL	٠	RA3	CR	151A
	Labeling and Drug Development: Product Information and Company Core Data Sheet	LEVEL	٠	RA4	_	152B
	SPL Is Coming Will You Be Ready?	LEVEL	٠	RA5	IT	146A
	Update from China	LEVEL		RA6	_	140A
	Managing the Discovery-development Transition	LEVEL		RD	РМ	150B
	Design and Analyses Issues in Prevention Trials	LEVEL	•	ST	CR	201
	The Career Trends and Challenges for Clinical Research Professionals	LEVEL		TR	CR	207B

TUESDAY 1:30 рм - 3:00 рм

Clinical Database Registries	LEVEL		AD	CR, RA	202B
Hot Topics in Biotechnology	LEVEL		BT	CMC, RD	154AB
A Discreet Professional Discipline: What Initiated the Evolution/Revolution of					
Clinical Data Management	LEVEL	•	CDM	—	204BC
Quality by Design	LEVEL		СМС	RA	147A
Regulatory Changes in EU Pharmacovigilance	LEVEL		СР	RA	207A
Innovative Recruitment and Retention Techniques in Europe	LEVEL	•	CR1	_	149AB
Prevention of Fraud and Noncompliance in Clinical Research: What Was and Is Being Done?	LEVEL	•	CR2	PP	145A
Managing Late Phase in the Global Environment	LEVEL		CR3	RA, RD	145B
Drug Supply Doesn't Always Have to Be Rate Limiting in Clinical Development	LEVEL		CR4	CS	147B
FDA Labeling Update: Target Product Profile	LEVEL	•	CR5	_	146A
Achieving Win/Win Results for Sponsors and Sites: Metrics and Budgeting					
Practices that Encourage Partnership and Performance	LEVEL		СТМ	FI, PM	140B
eCTDs: Regional Progress and Lessons Learned from the Regulatory Authority					
Perspective	LEVEL	•	DM	RA	206
Clinical Development for Drug-device Combination Products	LEVEL		GCP	CR, RA	202A
Effective Operation of Clinical Research Units	LEVEL		IS	AHC	101
Integrating Multivendor Clinical Trial Systems	LEVEL	•	IT1	OS	152A
PhRMA IMPACC's Strategic View of the Future of Healthcare IT and Associated					
Implications for the Biopharmaceutical Industry	LEVEL		IT2	-	146B
Survey of Medical Liaison Practices Across the Pharmaceutical Industry	LEVEL	•	МС	MA	209AB

Session		Difficulty			Interest Areas	
Number	Session Title	Level		Primary	Associated	Room Numbe
	TUESDAY 1:30 PM - 3:00 PM continued					
	Medical Writing and Biostatistics: A Significant Interaction	LEVEL	•	MW	ST	102AB
	Update on the Use of Juvenile Animals for Safety Assessment of Pediatric Drugs	LEVEL		NC	CR, RA	103B
	High-tech Outsourcing: Computerizing the Selection Process	LEVEL		OS	_	150A
	PLENARY SESSION Transforming the Product Development Lifecycle:					
	Where Are the Opportunities and What Happens if We Don't Start Changing the	LEVEL		РМ		1/2AD
	Way Drugs Are Developed?	LEVEL		FIVI	CR, PP, RA, RD	143AD
	Publication and Availability of Clinical Trial Results: Ethical, Public Health, Confidentiality, Commercial and Other Critical Issues – A Panel Discussion	LEVEL		PP	CR, RA	144ABC
	New Pharmaceutical Legislation - Part 2 of 3: Decentralized Procedure and				- ,	
	Mutual Recognition Procedure	LEVEL		RA1	_	146C
	Regulatory Impact in Drug Development of Integrating Toxicogenomics into					
	Nonclinical Development	LEVEL	•	RA2	CR, NC	151B
	Drug Importation: At What Cost?	LEVEL	•	RA3	PP	151A
	CDER Hot Topics	LEVEL		RA4	_	152B
	Clinical Trials in China: Progress and Future Perspective	LEVEL		RA5	_	140A
	Increase in Expected Net Present Value Through Design Modifications	LEVEL	٠	RD	_	150B
	Genomic Statistical Approaches for the Use and Validation of Genomic					
	Biomarker Information	LEVEL	•	ST	CR	201
	Status of Study Nurse Qualification in Europe and the US	LEVEL	•	TR	IS	207B
	TUESDAY 3:30 рм - 5:00 рм					
	Getting the Claims You Want	LEVEL		AD	MA, RA	202B
	The State of Biopharmaceuticals: Where the Jobs Are	LEVEL	•	BT	TR	154AB
	Multiple Inputs/Multiple Destinations: How Project Management Can Help	LEVEL		CDM	PM	204BC
	Challenges and Opportunities in Setting Specifications	LEVEL		СМС	RA	147A
	FDA Office of Drug Safety: Update on Regulatory Initiatives	LEVEL	•	СР	PP, RA	207A
	Town Meeting on Patient Enrollment: What Do We Know? What Can We Do?	LEVEL		CR1	IS	146A
	Applying Medical Imaging in Cardiovascular Drug Development	LEVEL	•	CR2	_	145A
	Integrated Placebo Database: An Idea Whose Time Has Come	LEVEL	•	CR3	RA	145B
	Emerging Regulatory Trends in Human Research Protection: Accrediting Institutions					
	and the Use of Data Monitoring Committees	LEVEL		CR4	PP, RA	147B
	Multicenter Trials Done in Phase I Clinical Research Units		•	CR5	—	149AB
		LEVEL				
	Evaluation, Implementation, and Integration of a Clinical Trials Management System	LEVEL	•	СТМ	-	140B
			•	CTM DM	— RA	140B 206
	Evaluation, Implementation, and Integration of a Clinical Trials Management System	LEVEL			RA TR	
	Evaluation, Implementation, and Integration of a Clinical Trials Management System eINDs	LEVEL		DM		206
	Evaluation, Implementation, and Integration of a Clinical Trials Management System eINDs Training in QA Issues According to GCP The Site Is the Client	LEVEL LEVEL LEVEL LEVEL	•	DM GCP	TR	206 202A
	Evaluation, Implementation, and Integration of a Clinical Trials Management System eINDs Training in QA Issues According to GCP	LEVEL LEVEL LEVEL	•	DM GCP IS	TR	206 202A 101
	Evaluation, Implementation, and Integration of a Clinical Trials Management System eINDs Training in QA Issues According to GCP The Site Is the Client Building Reliable, Secure IT Infrastructures in the Pharma Industry	LEVEL LEVEL LEVEL LEVEL LEVEL	•	DM GCP IS IT	TR CR, OS —	206 202A 101 146B
	Evaluation, Implementation, and Integration of a Clinical Trials Management System eINDs Training in QA Issues According to GCP The Site Is the Client Building Reliable, Secure IT Infrastructures in the Pharma Industry Developing Risk Communications: The ABCs of Health Literacy	LEVEL LEVEL LEVEL LEVEL LEVEL	•	DM GCP IS IT	TR CR, OS —	206 202A 101 146B
	Evaluation, Implementation, and Integration of a Clinical Trials Management System eINDs Training in QA Issues According to GCP The Site Is the Client Building Reliable, Secure IT Infrastructures in the Pharma Industry Developing Risk Communications: The ABCs of Health Literacy Adding Value: The Role of Technical Editors in Cross-functional Document	LEVEL LEVEL LEVEL LEVEL LEVEL LEVEL	•	DM GCP IS IT MC	TR CR, OS —	206 202A 101 146B 209AB
	Evaluation, Implementation, and Integration of a Clinical Trials Management System elNDs Training in QA Issues According to GCP The Site Is the Client Building Reliable, Secure IT Infrastructures in the Pharma Industry Developing Risk Communications: The ABCs of Health Literacy Adding Value: The Role of Technical Editors in Cross-functional Document Development Teams of Biopharmaceutical Organizations	LEVEL LEVEL LEVEL LEVEL LEVEL LEVEL	•	DM GCP IS IT MC MW	TR CR, OS — CR, RA —	206 202A 101 146B 209AB 102AB
	Evaluation, Implementation, and Integration of a Clinical Trials Management System eINDs Training in QA Issues According to GCP The Site Is the Client Building Reliable, Secure IT Infrastructures in the Pharma Industry Developing Risk Communications: The ABCs of Health Literacy Adding Value: The Role of Technical Editors in Cross-functional Document Development Teams of Biopharmaceutical Organizations Can Single Dose Toxicity Study Support First Dose in Humans?	LEVEL LEVEL LEVEL LEVEL LEVEL LEVEL LEVEL LEVEL	•	DM GCP IS IT MC MW NC	TR CR, OS — CR, RA — CR, RA	206 202A 101 146B 209AB 102AB 103B
	Evaluation, Implementation, and Integration of a Clinical Trials Management System elNDs Training in QA Issues According to GCP The Site Is the Client Building Reliable, Secure IT Infrastructures in the Pharma Industry Developing Risk Communications: The ABCs of Health Literacy Adding Value: The Role of Technical Editors in Cross-functional Document Development Teams of Biopharmaceutical Organizations Can Single Dose Toxicity Study Support First Dose in Humans? Controlling the Quality of Natural Health Products	LEVEL LEVEL LEVEL LEVEL LEVEL LEVEL LEVEL LEVEL	•	DM GCP IS IT MC MW NC NHP	TR CR, OS — CR, RA — CR, RA	206 202A 101 146B 209AB 102AB 103B 140A
	Evaluation, Implementation, and Integration of a Clinical Trials Management System eINDs Training in QA Issues According to GCP The Site Is the Client Building Reliable, Secure IT Infrastructures in the Pharma Industry Developing Risk Communications: The ABCs of Health Literacy Adding Value: The Role of Technical Editors in Cross-functional Document Development Teams of Biopharmaceutical Organizations Can Single Dose Toxicity Study Support First Dose in Humans? Controlling the Quality of Natural Health Products Does Consolidation Among Outsourcing Firms Matter?	LEVEL LEVEL LEVEL LEVEL LEVEL LEVEL LEVEL LEVEL LEVEL	•	DM GCP IS IT MC MW NC NHP OS	TR CR, OS — CR, RA — CR, RA CMC —	206 202A 101 146B 209AB 102AB 103B 140A 150A

Conference Schedule by Day and Time

Session	Constant Title		lty	Inter	Decret	
lumber	Session Title	Level		Primary	Associated	Room Numb
	TUESDAY 3:30 PM - 5:00 PM continued					
	New Pharmaceutical Legislation - Part 3 of 3: Other Practical Aspects	LEVEL		RA1	_	146C
	Comparison of Alternatives for Transferring Personal Data Outside the EU	LEVEL		RA2	_	151B
	Effective Switching from Prescription to Over-the-counter Status: Role in Product					
	Life Cycle Development	LEVEL		RA3	MA	152A
	Progress and Challenges with Combination Product Development	LEVEL	•	RA4	CR	152B
	The Target Product Profile Practical Implementation: FDA and Sponsor Perspective	LEVEL	•	RA5	CR	151A
	How Can Statistics Contribute to Pharmacovigilance?	LEVEL		ST	СР	201
	Clinical Research Is a Contact Sport	LEVEL	•	TR	CR	207B
	WEDNESDAY 8:30 AM - 10:00 AM					
	Human Subject Protection: Organization and Training of IRBs and Clinical Sites	LEVEL		AHC	CR, IS	103B
	Integrating Pharmacogenetics in Clinical R&D: From Data Acquisition to Data					
	Management and Exchange	LEVEL		вт	CR	154AB
	Data Management and the Globalization of the Japanese Clinical Trial Industry	LEVEL		CDM	_	202B
	Updates on FDA GMP Initiatives and Guidances	LEVEL		СМС	RA	147A
	The CIOMS VI Project on Managing Clinical Trial Safety	LEVEL		СР	RA	207A
	The Secret Code for Efficient Clinical Research	LEVEL		CR1	_	140B
	Clinical and Regulatory Update on Imaging in Oncology Trials	LEVEL		CR2	RA	145A
	Experiences with the New Ethics Committee Systems in Europe	LEVEL		CR3	RA	145B
	How to Establish and Successfully Run Data Monitoring Committees	LEVEL	•	CR4		146A
	Differing Viewpoints? An In-depth Look at Patients' Experiences in Clinical Trials versus Media Coverage of the Clinical Trials Industry and Its Impact on Public Perception and Patient Participation Rates	LEVEL		СТМ	CR, PP	101
	Managing the Living Global Dossier	LEVEL		DM	RA	206
	Virtual Realities: Quality Considerations when Using Contract Organizations	LEVEL		GCP	OS	202A
	Web Services: The Glue for a Fractured Infrastructure	LEVEL	•	IT	_	146B
	Value Optimization of Medical Products Reflecting Development and Marketing Strategies	LEVEL	•	MA	RD	204BC
	Field-based Medical Involvement Beyond Scientific Thought Leaders: Reaching Out to Help Healthcare Decision Makers	LEVEL		мс	МА	209AB
	Discovering and Reporting Safety Issues in Clinical Trial Data	LEVEL		MW	CR	102AB
	Avoiding Regulatory Blunders in Promoting Natural Health Products	LEVEL	•	NHP	AD, RA	140A
	The CRO Response to Emerging Drug Development Trends Using New Technology				, NA	
	and Best Business Practices	LEVEL		os	RD	150A
	Does Breaking Up Have to Be Hard to Do? Dissolving Partnerships, Changing CROs	LEVEL	•	PM1	0S	143C
	Critical Chain Project Management in Pharmaceuticals Development	LEVEL	•	PM2	_	143AB
	The European Situation on Pediatrics within a Global Environment	LEVEL		RA1	CR	152A
	Lessons Learned from Hormone Therapy: WHI Experience	LEVEL		RA2	CR	151B
	Case Studies in Risk Management	LEVEL	•	RA3	CP, CR	146C
	Is Data Privacy Possible? A 360° View	LEVEL		RA4	CR	151A
	The Effect of Japanese Pharmaceutical Affairs Law's Revision and PMDA's Activities		_			
	on Pharmaceutical Industries	LEVEL		RA5	RD	152B
	Don't Sweat SOX: Implementing Reporting for Sarbanes-Oxley (SOX)	LEVEL	•	RA6	FI	147B
	Implementing Clinical Modeling and Simulation: A Practical Guide	LEVEL	•	RD	CR	150B
	Randomization	LEVEL		ST	CR	201
	Facilitation Magic: Conjuring Up Extraordinary Results in Teams and Groups	LEVEL		TR	PM	207B
	Current International Regulatory Issues	LEVEL		VA	RA	103A

ion		Difficu	ty		est Areas	
ber	Session Title	Level		Primary	Associated	Room Numbe
	WEDNESDAY 10:30 AM - 12:00 PM					
	Clinical Trials from the Pharmaceutical Company (Sponsor) Viewpoint	LEVEL	•	AHC	CR, IS	103B
	ECGs on First, EDCs on Second, and CROs on Third: Creating Teamwork Between					
	Clinical Service Providers	LEVEL	•	BT	CR, OS	154AB
	Advancing Data Quality in the 21st Century	LEVEL		CDM	RA	202B
	Combination Products: Challenges and Opportunities	LEVEL		CMC	RA	147A
	Data Mining and Signal Detection: Where Are We?	LEVEL		СР	RA	207A
	Integrating Pharmacogenomics into Clinical Trials	LEVEL		CR1	_	146A
	GCP Compliance Considerations for Drugs, Devices and Biologics, and			CD 2	000	1454
	Combination Products	LEVEL		CR2	GCP	145A
	How to Navigate the NIH for Grants and Contracts	LEVEL	•	CR3	AHC	145B
	Clinical Trials: More Sensible Arrangements for Dealing with Serious Adverse Events	LEVEL		СТМ	CR	101
	eCTD: The Impact on the Organization	LEVEL	•	DM	RA 	206
	Training Late-phase Investigators: GCP Still Matters!	LEVEL		GCP	TR	202A
	Use of Drug Utilization Data for Risk Assessment and Risk Management	LEVEL		IMP	CP, RA	149AB
	Industry Standards and Web Services: Are We Ready for an Industry Architecture?	LEVEL		IT	_	146B
	Salud! Reaching Foreign-born Patients in the US Market	LEVEL	•	MA	_	204BC
	Thinking Outside the Medicine Box: Creative Ways of Getting Health Information to Consumers	LEVEL	•	мс	МА	209AB
	Clinical Trial Registry: Build It and They Will Come?	LEVEL	•	MW	CR	102AB
	Strategies for Improving Botanical Medicine Acceptance in a Conventional Medical Setting	LEVEL	•	NHP	CR	140A
	Functional Partnerships: A New, Robust Model for Pharmaceutical Industry-					
	CRO Contracting	LEVEL		OS	—	150A
	Strategic Planning for Drug Development Projects	LEVEL		PM1	_	143AB
	Are Portfolio Management Processes Really Working in Dealing with Current Issues within the Pharmaceutical Industry?	LEVEL		PM2	_	143C
	Impact of Significant Payments of Other Sorts (SPOOS) on Clinical Research	LEVEL		PP	CR, FI	103A
	Voluntary Pharmacogenetics Data Submissions 1 Year Later	LEVEL	٠	RA1	_	147B
	Reporting and Assessing Inclusion of Subpopulations in Clinical Trials	LEVEL	•	RA2	CR	151B
	The Radioactive Drug Research Committee: Academic Research or Drug Development Tool?	LEVEL	•	RA3	CR	151A
	Pediatric Medicine: New Challenge in Japan	LEVEL	•	RA4	CR	152A
	Current Issues with 505(B)(2) Applications	LEVEL		RA5	_	152B
	Regulation of Clinical Research in the EU: Impact of the Clinical Trials Directive	LEVEL	٠	RA6	CR	146C
	Innovation or Stagnation: When the Obvious Choice Is Also the More Difficult Choice	LEVEL		RD	_	150B
	Analysis of Responder Data	LEVEL		ST	_	201
	Training and Development of New and Experienced CRAs	LEVEL	•	TR	CR	207B
	WEDNESDAY 1:30 рм - 3:00 рм					
	Financial Checks and Balances: Making Sure You're Getting What You Negotiate	LEVEL		AHC	IS	103B
	Current Process for Follow-on Proteins in Europe: The Biosimilars Products	LEVEL		BT	RA	154AB
	Experiences with MedDRA® Translations	LEVEL		CDM	_	202B

СМС

СР

CR1

RA

CR

RD

147A

207A

140B

LEVEL

LEVEL

LEVEL

COX-2 Inhibitors: Where Are We in 2005?

Global Expanded Access Program: The Ins and Outs

IND CMC Issues

Conference Schedule by Day and Time

ession		Difficu	ty		rest Areas	
Imber	Session Title WEDNESDAY 1:30 pm - 3:00 pm continued	Level		Primary	Associated	Room Numbe
			-	602		4454
	Generic Biologics: Fact or Fiction?	LEVEL	_	CR2	BT, RA	145A
	Development of New Antibiotics	LEVEL	-	CR3	RA	146A
	Imaging of Alzheimer's and Other Neurodegenerative Diseases: Role in Clinical Trials	LEVEL	•	CR4	RA	145B
	Why Would You Want to Do a Registry?	LEVEL	•	СТМ	CR	101
	Guidance-compliant eCTDs – Part 1 of 2	LEVEL	•	DM	RA	206
	Planning for Electronic Data Quality in Clinical Trials	LEVEL		GCP	eCLIN, CR	202A
	Update on FDA's Draft Guidance on Patient-reported Outcomes	LEVEL		IMP	CR, RA	149AB
	Advancing Patient Recruitment with Technology and Metrics	LEVEL		IT	CTM	146B
	Moving to Higher Levels of Launch Excellence	LEVEL		MA	_	204BC
	Outsourcing Medical Communications Services	LEVEL		МС	OS	209AB
	Nonclinical Regulatory Writing	LEVEL		MW	NC, RA	102AB
	Botanical Drug Development: It Starts at the Beginning - Control of the Plant	LEVEL		NHP	_	140A
	The State of Clinical Outsourcing: Industry Practices and Perceptions	LEVEL		OS	CR	150A
	Who Reads the Development Plan Anyway!	LEVEL	٠	PM1	_	143AB
	Project Management's Role in the Pharmaceutical Industry of the Future	LEVEL		PM2	_	143C
	Formulary Decisions in the US and UK	LEVEL	٠	PP	IMP	103A
	US-EU Agreement to Exchange Scientific Advice: A Status Report	LEVEL		RA1	_	146C
	Outlook for Changes in Japanese Regulatory and Clinical Development Environment –					
	Part 1 of 2	LEVEL		RA2	CR	152A
	Development of Oncology Products in the US and EU: More Stagnation					
	than Innovation?	LEVEL		RA3	CR	151A
	Scientific Advice in Europe: State of the Art	LEVEL		RA4	—	151B
	Managing Communications with Regulatory Agencies in Global Decentralized					
	Matrix Organizations	LEVEL		RA5	_	147B
	CDER Hot Topics	LEVEL		RA6	_	152B
	Intercompany Auditing Agreement as Part of Strategic Risk Management	LEVEL	٠	RD	_	150B
	Statistical Considerations in the Evaluation of Red Blood Cell Products	LEVEL	•	ST	CR, RA	201
	WEDNESDAY 3:30 рм - 5:00 рм					
	The Right to Publish: A Sword of Many Blades	LEVEL	•	AHC	CR, MW	103B
	Use of Toxicogenomics for Drug Candidate Selection, Rescuing and Biomarker					
	Discovery	LEVEL	•	BT	RD	154AB
	Data Management Models for Multicenter and Multinational Clinical Trials:		_	CDM		2020
	Case Histories	LEVEL	_	CDM	_	202B
	Follow-on Biotechnology/Biological Products - Part 1 of 2	LEVEL		СМС	RA	147A
	Unblinding: Need to Know Basis?	LEVEL		СР	CR	207A
	Conducting Clinical Trials in Erectile Dysfunction (ED)	LEVEL	•	CR1	_	145B
	Application of Critical Path Principles to the Development of Drugs for Menopausal Symptom Therapy After the Women's Health Initiative	LEVEL		CR2	RA	145A
	Incorporating Formal Economic Analysis in Evaluating Trial, Development, and Portfolio Strategies	LEVEL	•	CR3	RD	140B
	New Expectations for Drug Development: Lessons Learned from the COX-2 Inhibitors	LEVEL		CR4	_	146A
	Skating to Where the Puck Is Going: Understanding Tomorrow's Challenges in					
	Oncology Drug Development and Creating Infrastructure to Pave the Way	LEVEL		CR5	—	143C
	Sometimes It Takes Two or More to Tango: Managing Trials in a Global Collaboration	LEVEL		СТМ	BT, RD	101

Session		Difficul	ty	Inter	est Areas	
Number	Session Title	Level		Primary	Associated	Room Number
	WEDNESDAY 3:30 PM - 5:00 PM continued					
	Preparing for and Surviving an FDA Inspection: US and International Perspectives					
	from Industry and Regulators	LEVEL	•	GCP	RA	202A
	IT Services: Delivering High Value in the New Pharmaceutical Environment	LEVEL	•	IT	-	146B
	Discovering and Meeting Customer Expectations of Medical Communications	LEVEL	•	МС	_	209AB
	Exploring Natural Health Products: Promotion and International Coordination	LEVEL		NHP	_	140A
	Calculation Comparison of Pharma Internal Costs and Outsourced CRO Costs	LEVEL	•	OS	CR	150A
	Ten Things You Never Thought I Would Say (About Leading Teams)	LEVEL		PM1	_	149AB
	A Community Response to the Critical Path	LEVEL	٠	PP	RA, RD	103A
	Use of Color Coding/Branding on Pharmaceutical Product Labels, Labeling, and					
	Packaging	LEVEL	•	RA1	—	146C
	Outlook for Changes in Japanese Regulatory and Clinical Development Environment -					
	Part 2 of 2	LEVEL		RA2	CR	152A
	Clinical Trials Directive: EU Remains Attractive for Clinical Research	LEVEL		RA3	CR	151A
	Various Roles and Implementation Techniques of Quality Systems in a Regulatory Agency	LEVEL	•	RA4	-	151B
	Research in Developing Drug Interactions and Dose Adjustments Model and					
	Terminology Assessment for Drug Labeling	LEVEL	•	RA5	_	147B
	Developing Medications in Ethnically Diverse Populations	LEVEL		RD	CR	150B
	Clinical Data to Information to Knowledge	LEVEL	•	ST	_	201
	Training Approaches for MedDRA®	LEVEL		TR	CR	207B

THURSDAY 8:30 AM - 10:00 AM

 Remote Management of Rural Diabetic Patients Using a Web-based Monitoring Device	LEVEL	•	AHC	CR	103B
Viral Safety: Impact of Advances in Technology	LEVEL	٠	BT	_	154AB
Clinical Data Management: An Integral Part of the Drug Development Process	LEVEL	•	CDM	RA	103A
Follow-on Biotechnology/Biological Products – Part 2 of 2	LEVEL		СМС	BT, RA	209AB
The Use of Multilanguage MedDRA® in a Global Environment	LEVEL		СР	_	145B
 What Sponsors and CROs Need to Know About Accreditation	LEVEL		CR1	_	140B
 Integrated Clinical Development	LEVEL		CR2	RA	145A
 Burnout, Workload, and Job Satisfaction in Clinical Trial Coordinators	LEVEL		СТМ	_	101
 Compliance Portals: The Gateway to eSubmissions	LEVEL	•	DM	RA	152A
 FIREBIRD: Implementing an Electronic Global Investigator Registry	LEVEL	•	IT	CR	146B
 The CDISC Operational Data Model (ODM): It's Not Just Data Exchange!	LEVEL		IT/CDM	eCLIN	149AB
 Assessing Value-based Performance in the Eyes of Our Customers (Thought Leaders)	LEVEL		мс	MA	201
 The Future of Medical Writing	LEVEL		MW	_	102AB
 Nonclinical Testing Strategies to Support Clinical Trials	LEVEL		NC	CR, RA	147B
 Chinese Herbal Medicines Development	LEVEL	•	NHP	_	140A
 Capturing Drivers of Outsourcing Growth and Quantifying Outsourcing Value	LEVEL	•	OS	RD	150A
 Cross-cultural Challenges in Multinational Pharmaceutical Companies: Differences					
 in Communication and Decision-making Practices Between Japan and the West	LEVEL		PM1	_	143C
 Approaches to Reducing Risk and Improving Success in R&D Project Management	LEVEL	•	PM2	_	143AB
 Recent and Pending Case Law in the EU	LEVEL	•	PP	RA	150B
 CDER Town Meeting – Part 1 of 2	LEVEL	•	RA1	_	146A
 How to Avoid Trademark-related Delays of NDA Approvals: The FASLODEX Experience	LEVEL		RA2	PP	151B
 DSMBs from an IRB Perspective	LEVEL	•	RA3	CR	151A

Session		Difficu	lty		st Areas	
Number	Session Title	Level		Primary	Associated	Room Numbe
	THURSDAY 8:30 AM - 10:00 AM <i>continued</i>					
	European Clinical Trials Directive Implementation: An Actual Status	LEVEL		RA4	CR	144ABC
	Prescription Drug Labeling: Implementation of FDA's New Regulation for the					
	Content and Format of the USPI and an Update on the Status of the USPI Guidance Documents	LEVEL		RA5	_	152B
	Statistical Considerations in Human Drug Abuse Potential Studies		•	ST		146C
	Did the Training Do What It Was Supposed to Do? Evaluating the Employee and					
	the Training Program	LEVEL		TR	_	147A
	ТНURSDAY 10:30 ам - 12:00 рм					
	Regulatory Obligations of an IND Sponsor-investigator	LEVEL		AHC	IS, RA	103B
	Overcoming Hurdles to Develop Clinically Validated Standardized, Quantitative, Quality Controlled, Next Generation, Multigene Expression Biomarker Assays					
	Suitable for Clinical Trials	LEVEL		BT	CR	154AB
	Evidence-based Medicine: Evaluating the Data from Outcome-based Clinical Trials	LEVEL		CDM	IMP	103A
	Analyses Using MedDRA®-coded Data	LEVEL		СР	_	145B
	Clinical Studies in Psychiatry: New Variations on the Placebo Response	LEVEL	•	CR1	_	140B
	Patient Safety: Ethics, Pharmaceuticals for Children, and Human Research Protections	LEVEL		CR2	_	145A
	Patient Insights from the Frontlines of Medical Communication	LEVEL		СТМ	MC	101
	Structured Product Labeling (SPL): Requirements, Challenges, and Best Practices	LEVEL	•	DM	RA	152A
	Risk Management Focus in Clinical QA	LEVEL	•	GCP	_	149AB
	The Use and Impact of Patient-level Electronic Data in Healthcare Decision Making	LEVEL	•	IMP/CP	eCLIN	152B
	Assessing Global Adoption of Electronic Data Collection Technologies	LEVEL		IT/CDM	_	146B
	Re-engineering Document Preparation: Setting the Stage for Study Tagging Files	LEVEL		MW	DM	102AB
	Immunotoxicity Testing of Human Pharmaceuticals	LEVEL		NC	RA	147B
	Regulatory Issues in the Development of Heterogeneous Products: Town Hall Meeting					
	with the FDA CDER Botanical Review Team and Center for Biologics	LEVEL	•	NHP	RA	151B
	The Real World of Outsourcing: Outsourcing Fact and Fiction	LEVEL	•	OS	IT	150A
	Drug Development Projects: A Vehicle for Organizational Learning	LEVEL		PM1	_	143C
	Increased Productivity Through Effective Resource Management	LEVEL		PM2	-	143AB
	FDAMA Part 113: ClinicalTrials.gov - Where Are We Now?	LEVEL		PP	RA	150B
	CDER Town Meeting - Part 2 of 2	LEVEL	•	RA1	_	146A
	21 CFR Part 11 and Electronic Source Documentation Requirements for Investigators	LEVEL		RA3	eCLIN, IS	151A
	Clinical Trials in Latin America: A Review of the Regulatory Framework	LEVEL		RA4	_	144ABC
	Global Development Program and Data Quality	LEVEL	•	ST	_	146C
	Communication Tools/Practices that Work	LEVEL	•	TR	-	147A

ATTENDEE REGISTRATION FORM Attendees may register online at www.diahome.org

Online registration is NOT available to speakers or exhibitors. The appropriate registration forms will be included with the exhibitor or speaker packet.

41st ANNUAL MEETING ID #05001 June 26-30, 2005, Washington, DC, USA

This registration form should be used by paying **ATTENDEES ONLY**. If paying by credit card, return this completed form to DIA by mail to 800 Enterprise Road, Suite 200, Horsham, PA 19044-3595, USA, or by fax to +1-215-442-6199. If paying by check, follow instructions under Payment Methods below.

All registrations received at the DIA office in Horsham, PA, USA, by 5:00 PM on May 20, 2005, will be included in the Advance Registration Attendee List.

PLEASE NOTE This page must be completed and submitted for each person attending any portion of this event.

PAYMENT METHODS REGISTER ONLINE at www.diahome.org or please check payment method:

- □ CHECK drawn on a US bank payable to and mailed along with this form to: Drug Information Association, Inc., PO Box 827192, Philadelphia, PA, USA 19182-7192. Please include a copy of this registration form to facilitate identification of attendee.
- CREDIT CARD number may be faxed to: +1-215-442-6199. You may prefer to pay by check or bank transfer since non-US credit card payment will be subject to the currency conversion rate at the time of the charge.

		Expiration Date	
Card #			

Signature			
o.B.iararo			

□ BANK TRANSFER in the currency of your choice to: PNC Bank, 1600 Market Street, Philadelphia, PA 19103, USA. DIA Account # 8606072742. ABA # 031000053. SWIFTCODE # PNCCUS33. Your name and company, as well as the above Meeting I.D. Number, must be included on the transfer document to ensure payment to your account.

CANCELLATION POLICY

All cancellations must be in writing and received at the DIA office by 5:00 PM on June 10, 2005. Registrants who do not cancel by June 10, 2005 and do not attend will be responsible for the full applicable fee. **Registrants are responsible for canceling their own airline and hotel reservations.** You may transfer your registration to a colleague at any time, but membership is not transferable. Please notify DIA of any such substitutions as soon as possible. **Substitute registrants will be responsible for nonmember fee. if applicable.**

DIA reserves the right to alter the venue, if necessary. If an event is cancelled, DIA is not responsible for any airfare, hotel, or other costs incurred by registrants. Speakers and program agenda are subject to change. **Cancellations received in writing on or before June 10, 2005, will be processed as follows.**

FULL MEETING CANCELLATION

Government/Nonprofit/Academia - Registration fee paid minus \$100 = Refund Amount All Others - Registration fee paid minus \$200 = Refund Amount

ONE-DAY REGISTRATION CANCELLATION

There will be **NO REFUNDS** given for cancellations of one-day registrations or one-day no shows.

NETWORKING DINNER CANCELLATION

On or before June 10, 2005 = Full Refund

TUTORIAL AND CERTIFIED CLINICAL INVESTIGATOR (CCI) EVENTS CANCELLATION

On or before June 10, 2005 – Registration fee paid minus \$50 = Refund Amount

PARTICIPANTS WITH DISABILITIES DIA meeting facilities and overnight accommodations are accessible to persons with disabilities. Arrangements can be made for sensory-impaired persons attending the meeting if requested at least 15 days prior to meeting. Contact the DIA office to indicate your needs. **FULL-MEETING REGISTRATION** (attendance of 2 or more days) includes admission to all scientific sessions, exhibits, coffee breaks, luncheons and receptions. *If DIA cannot verify your membership upon receipt of registration form, you will be charged the nonmember fee. All fees are in US dollars.*

TUTORIALS See pages 5-15 for tutorial descriptions and page 101 for tutorial pricing. Space is limited and preregistration is encouraged. Please indicate the ID number and fee for each tutorial you plan to attend.

Tutorial #	Fee
Tutorial #	Fee

Tutorial #	Fee	Tutorial Subtotal

CERTIFIED CLINICAL INVESTIGATOR REVIEW COURSE #05410 See page 7 for details. MEMBER US \$ 250 Nonmember US \$ 300 Common Second 7 for information

CERTIFIED CLINICAL INVESTIGATOR EXAMINATION	See page 7 for information.	

NETWORKING DINNER See page 104 for further information. US \$ 70

PREREGISTRATION FEES Attendees will be required to produce their confirmation letter to avoid the \$150 surcharge. To ensure that your registration is processed and sufficient time is allowed for receipt of confirmation letter, a completed registration form and payment must be received by the preregistration deadline of June 17, 2005. An email address must be included below for confirmation process. A surcharge of \$150 will apply to all on-site full-meeting registrations.

MEMBER FEE Join DIA now to qualify for member fee and to receive all the benefits of membership for a full year! www.diahome.org/docs/Membership	US \$1050 🗖 US \$ 130 🗖
NONMEMBER FEE	US \$1180 🗖
A one-year membership to DIA is available to those paying a NONMEMBE meeting registration fee. If paying a nonmember fee, please indicate if yo or do not, want membership. I do 🖵 I do NOT 🖵 want to be a	u do,
DISCOUNT FEES MEMBER	NONMEMBER*
Government (Full-time) US \$ 300 🗆	US \$ 430 🗖
Charitable Nonprofit/Academia (Full-time) US \$ 625 🗆	US \$ 755 🗖
*If paying a nonmember fee, please check one box above, indicating whether y	ou want membership.
ONE-DAY REGISTRATION FEE MEMBER	NONMEMBER*
You must indicate which day you will attend. US \$ 505 🗆	US \$ 635 🗖
Monday, June 27 🔲 Tuesday, June 28 🔲 Wednesday, June 29 🔲 1	
*If paying a nonmember fee, please check one box above, indicating whether y	ou want membership.
APPLICABLE MEETING REGISTRATION FEE	US \$
TUTORIAL REGISTRATION FEE	US \$
CCI REVIEW COURSE REGISTRATION FEE	US \$
NETWORKING DINNER FEE	US \$

TOTAL	PAYMENT	DUE	US	\$
-------	---------	-----	----	----

Last Name	First Name			МІ	_
Degrees		DIA PIN # (optio	onal)	- 🖸 Dr. 🖸 Mr. 🗖 Ms.	
Job Title					
Сотралу					
Mailing Address					
City	State	Zip/Postal Code	Country		_
Telephone #	Fax #				_

Pre-order and SAVE \$100 off the on-site price and \$200 off the post-conference price!

June 26-30, 2005

Washington, DC, USA

DRUG INFORMATION ASSOCIATION

ANNUAL

available synchronized

PowerPoints and audio

as released for inclusion

Individual sessions on audio CD will not be available this year ...

So take advantage and pre-order your track CD-ROMS which provides you with as many as 19 sessions at the minimal cost of \$95 (that's as little as \$5.00 per presentation for a true multimedia recreation of the session), but ONLY if you are a full paid registered attendee and order PRIOR to the Conference.

Pre-order at an incredible savings of \$100.00 OFF the on-site price and \$200.00 OFF the post-Conference price, PER TRACK CD-ROM!

TAKE ADVANTAGE OF SOME OF THE LISTED OFFERS BELOW AND SAVE AS MUCH AS \$2000.

<u>CD-ROM**</u> A	ttendee (full paid/registered) Pre-Conference	Attendee On-Site	Attendee Post-Meeting or Non-Attendee	[]
• TRACK CD-ROMs	\$95.00	\$195.00	\$295.00	For a list of sessions in each track.
 Complete Clinical Research Track (4 CDs) \$325.00	\$645.00	\$975.00	please visit DIA's
 Complete Regulatory Track (5 CDs) 	\$395.00	\$795.00	\$1195.00	homepage at:
• Complete Conference Track Package (28 **All CD-ROMs = synch'd with available PowerPoints and	2	\$2995.00	\$3995.00	http://www.diahome.org
CD-DOM track coloctions HEDE	100 Clinical Researc	h and Developm	ent 🛛 200 Project N	Aanagement Track 1 – 13

\vee CD-ROM track selections here

- 010...Advertising/ Marketing and Sales Tracks – 9 sessions
- 020...Biotechnology/Non-Clinical Laboratory Safety Assessment Tracks – 19 sessions
- **030...Academic Health Centers/Investigator** Sites Tracks - 13 sessions
- □040...Clinical Data Management/Validation Tracks – 15 sessions
- 050...Chemistry, Manufacturing and Controls/ Good Manufacturing Practices Track – 12 sessions
- 060...Clinical Safety and Pharmacovigilance Track – 13 sessions
- □070...Clinical Research and Development Track 1 – 13 sessions
- 080...Clinical Research and Development Track 2 - 11 sessions
- 090...Clinical Research and Development Track 3/Clinical Supplies Track – 12 sessions

- Tracks 4 & 5 11 sessions
- 110...Clinical Trial Management 13 sessions
- 120...Document Management/eSubmissions Track – 13 sessions
- 130...eClinical/Good Clinical Practices Track - 17 sessions
- 140...Finance/R&D Strategy Tracks 12 sessions
- □ 150...Impact of Medical Products and Therapies/Public Policy/Law Tracks - 15 sessions
- 160...Information Technology Track - 16 sessions
- 170...Medical Communications and Medical/Scientific Writing Tracks – 19 sessions
- 180...Natural Health Products Track 10 sessions

Signature

Ship to:

190...Outsourcing Track – 14 sessions

sessions

- 210...Project Management Track 2 11 sessions
- 220...Regulatory Track 1 12 sessions
- 230...Regulatory Track 2 12 sessions
- 240...Regulatory Track 3 12 sessions
- 250...Regulatory Track 4 12 sessions
- 260...Regulatory Tracks 5 & 6 & 7 16 sessions
- 270...Statistics Track 12 sessions
- 280...Training Track 13 sessions

All Track CD-ROMs may be ordered individually or...

By discounted packages below: (see pricing above)

- Complete Clinical Research (4 CD-ROMs)
- Complete Regulatory (5 CD-ROMs)
- Complete Conference (All Tracks) (28 CD-ROMs

ORDER: When ordering, please identify program by #250626

• BY PHONE: With credit card, please call: (800) 747-8069; (818) 957-0874 - 8:30-4 PST, M - F

• BY MAIL: Complete this form, with payment to: Content Management Corp., 3043 Foothill Blvd., Suite #2, La Crescenta, CA 91214

BY FAX: FAX your order form with credit card information to: (818) 957-0876

• ON-LINE: visit our secure order site at:

πττρ://	www.so	rtconre	rence.	com/	250620

TOTAL AMOUNT ALL PRICES ARE IN U.S. FUNDS.

 <u>BY EMAIL</u>: Submit your order with credit card information to: craigm@cmcgc.com

total CD-ROM Tracks @ \$each	\$
Complete Clinical Research (4 CD-ROMs)	.\$
Complete Regulatory (5 CD-ROMs)	. \$
Complete Conference (All Tracks) (28 CD-ROMs)	. \$
Shipping	
in North America: \$3 - 1st CD-ROM; \$1 ea. additional to a \$15 max	.\$
Outside North Amer. \$5 - 1st CD-ROM; \$2 ea. additional to \$75 max	

				e - Defective items will be replaced UM WITH EACH 8 CD-ROM
				, & personal/company checks
payable to	CONTENT	MANAG	EMENT CO	<u>RP.</u>
Check		П МС	AmEx	Exp. Date
Credit Card	d Acct Num	iber		

Name			

DIA customer number/PIN

Company _

Address

City/State/Zip

Daytime Phone Number____

Email Address

* The number of sessions per CD-ROM are accurate as of the time of this printing. The final number may vary due to last minute cancellation

AI fre Pι

Hotel Reservation Instructions

Attendees are strongly encouraged to make hotel reservations early to guarantee hotel rates and availability. Room requests for all convention hotels will be handled by the DIA Housing Bureau. This is a service provided to DIA attendees by the Washington Convention & Tourism Corporation. **DIA DOES NOT PROCESS HOTEL RESERVATIONS.**

Attendees can make hotel reservations by any of the following methods:

ONLINE To make online reservations, log on to DIA's website www.diahome.org or go directly to hotel reservations https://resweb.passkey.com/Resweb.do?mode=welcome_ei_new&eventID=18364

Fax +1-506-433-3033 *Tel* +1-866-578-1996 (US & Canada) or +1-506-432-4850 (International)

Mail DIA 2005/WCTC Housing, 901 7th Street, NW, Washington, DC 20001, USA. Attention: Housing Monday-Sunday, 9 am - 8 pm EST

MAKING RESERVATIONS Please have the following information available if reserving by phone.

- 1. Name of convention: DIA Annual Meeting
- 6. Number of person in party
- 7. Arrival time

- 10. Address to which confirmation is to be sent
- 11. Daytime telephone number
- 12. Fax number (if you would like a confirmation faxed)

5. Type of room (single/double, etc.)

4. Number of rooms requested

2. 1st, 2nd and 3rd choice of hotel

3. Arrival/departure dates

- Credit card type, account number and expiration date
 Names of all occupants of room
- **DEPOSIT** A one-night room deposit, **plus 14.5% tax** is required for **all** reservations. The deposit amount is payable by credit card (online only), check (if you are paying by check, all funds must be in US dollars, drawn on a US bank) or money order. **No reservation will be processed without a deposit.**

CREDIT CARD Your credit card will be used as a guarantee and will not be charged immediately. Most major credit cards are accepted (VISA, MasterCard, American Express, Discover). You will not receive a confirmation from each hotel. Each hotel will honor the housing bureau acknowledgement.

CHECKS Your deposit check should be made out to DIA 2005/WCTC Housing and mailed to DIA 2005/WCTC Housing, 901 7th Street, NW, Washington, DC 20001 *Attn: Housing*. **No checks will be accepted after June 3, 2005.**


CHANGES/CANCELLATIONS/REFUNDS Prior to June 3, 2005, all changes and cancellations should be made directly with the DIA Housing Bureau. After June 3, 2005, changes and cancellations should be made directly with the hotel. Cancellation policy is as follows: Cancellations made after May 20, 2005, will be charged a processing fee of \$150.00.

Cancellations made within 72 hours of arrival will be charged the first night's room and tax by the hotel.

Please complete the following information and submit to DIA/WCTC prior to June 3, 2005.

Name	
Company/Institution	
Address	
 Tel Fax	email
	d based on availability. If your choices are not available, we will select \Box distance to the meeting (prefer to be closer to the event)
1	Arrival Date Departure Date
2	Smoking 🗆 Nonsmoking
3	Single 🛛 Double 🖓 Triple 🖓 Quad
SPECIAL NEEDS (attach a note if you need more room)	
Sharing with the following person(s)	
PAYMENT INFORMATION Uisa MasterCard	Discover AMEX Other
Credit Card #	Expiration Date
Signature	

104



Hotel	Address	Single Rate	Double Rate	Distance to Conv. Center	Distance to Metro Stop	Shuttle Offered
1 Capital Hilton Hotel	16th & K Streets, NW	\$208	\$228	8 blocks	2 blocks	Yes
2 Courtyard by Marriott Conv. Center	900 F Street, NW	\$195	\$195	4 blocks	3 blocks	Yes
3 Four Points Sheraton	1201 K Street, NW	\$189	\$189	3 blocks	3 blocks	No
4 Grand Hyatt Washington	1000 H Street, NW	\$232	\$232	3 blocks	At hotel	Yes
5 Hamilton Crowne Plaza	14th & K Streets, NW	\$199	\$199	5 blocks	1 block	Yes
6 Henley Park Hotel	926 Massachusetts Ave., NW	\$195	\$195	1 block	At Cnv. Ctr.	No
7 Holiday Inn on Capitol Hill	415 New Jersey Ave., NW	\$199	\$209	10 blocks	2 blocks	Yes
8 Holiday Inn Downtown	1155 14th Street, NW	\$199	\$209	5 blocks	3 blocks	Yes
9 Hotel Washington	515 Pennsylvania Ave.	\$190	\$190	8 blocks	2½ blocks	Yes
10 Hyatt Regency Washington	400 New Jersey Ave., NW	\$217	\$217	10 blocks	2 blocks	Yes
11 JW Marriott Hotel	1331 Pennsylvania Ave., NW	\$228	\$228	8 blocks	At hotel	Yes
12 Marriott Metro	775 12th Street, NW	\$205	\$216	4 blocks	½ block	Yes
13 Marriott Wardman Park Hotel	2660 Woodley Rd., NW	\$205	\$205	30 blocks	½ block	No
14 Phoenix Park Hotel	520 North Capitol Street, NW	\$189	\$219	11 blocks	1 block	Yes
15 Red Roof Inn	500 H Street, NW	\$115	\$115	4 blocks	2 blocks	Yes
16 Renaissance Mayflower Hotel	1127 Connecticut Ave., NW	\$210	\$210	10 blocks	2 blocks	Yes
17 Renaissance Washington DC	999 9th Street, NW	\$213	\$224	1 block	At Cnv. Ctr.	No
18 Sofitel Lafayette Square	806 15th Street, NW	\$209	\$209	8 blocks	2 blocks	Yes
19 Wyndham City Center	1143 New Hampshire Ave., NW	\$169	\$189	17 blocks	3 blocks	Yes
20 Wyndham Washington, DC	1400 M Street, NW	\$169	\$189	6 blocks	3 blocks	Yes

General Information

HOTEL RESERVATIONS AND MEETING REGISTRATION

All hotel reservations are being handled by the DIA HOUSING BUREAU in Washington, DC.

Early registration is advised in order to ensure space in one of the participating hotels. The published rates will continue until June 3, 2005. After June 3, 2005, room rates cannot be guaranteed. To ensure that your registration is completed properly, it is imperative that you submit each of the two forms to the proper location:

Hotel Reservations

See page 106 for reservation instructions. All housing questions should be directed to the DIA Housing Bureau in Washington, DC.

By mail:	DIA 2005/WCTC Housing, 901 7th Street, NW,
	Washington, DC 20001, USA Attn: Housing
By fax:	+1-506-433-3033
By email:	kristen@washington.org

Meeting Registration

The **ONLY** form that should be returned to DIA in Horsham is the attendee registration form on page 102. Register online at **www.diahome.org** or return the form to Drug Information Association, 800 Enterprise Road, Suite 200, Horsham, PA 19044-3595, USA, Fax +1-215-442-6199.

Important Points

TRACK CD-ROMS Audio CDs for individual sessions will not be available this year. True multimedia recreations of the sessions are available on track CD-ROMS to fully registered attendees. See page 103 for pre-ordering instructions. Recording of DIA tutorial/workshop information in any type of media, is prohibited without prior written consent from DIA. Statements made by speakers are their own opinion and not necessarily that of the organization they represent, or that of DIA.

DRESS CODE The dress code for the Annual Meeting is business casual. Slacks and casual dresses are encouraged for wear throughout the meeting. Neckties, business suits, or other business attire are acceptable, but not necessary. *Comfortable shoes are a must!*

MEDDRA® USER GROUP MEETING MedDRA® User Group will meet at the conclusion of the Annual Meeting on Thursday, June 30 from 12:30 PM to 4:30 PM. The specific location will be included in the final program.

NETWORKING DINNER The networking dinner, on Sunday, June 26 at 6:30 PM at the Renaissance Washington, DC Hotel, will provide attendees with just the right atmosphere for informal conversation with old friends and new acquaintances. The fee for the networking dinner is \$70.00.

PLEASE NOTE Attendance at the networking dinner is limited; reservations must be confirmed; purchase on site cannot be guaranteed.

Cancellation Policy for Networking Dinner only: If received in writing on or before June 10, 2005, a full refund will be given. Please collect your badge and dinner tickets on June 26 at the DIA registration desk.

POSTER SESSIONS An area has been set aside to provide certain attendees with an opportunity to exhibit scientific developments associated with the pharmaceutical development and registration process. The chairpersons for the poster sessions are Françoise G. Pradel, PhD, and Francis B. Palumbo, PhD, JD, both from the University of Maryland School of Pharmacy. The **Students' Poster Session** will take place on Monday, June 27 from 10:00 AM to 6:00 PM in the entrance to Exhibit Hall A on the Lower Level of the Convention Center. The **Professionals' Poster Session** will take place on Tuesday, June 28 from 9:00 AM to 5:30 PM in the same location.

PRESS REGISTRATION Only individuals who are working for and representing a recognized news organization may register as press. Preregistration for press badges is strongly suggested as on-site registration is also subject to approval. To obtain a press badge, you must present identification certifying that you are a working member of the print, broadcast or online (writers working for webbased media) media. Acceptable identification includes press credentials or a business card. All freelancers must present a letter of assignment. DIA has the right to inspect the credentials of anyone registering as press and reserves the right to refuse to register any individual as press. Be advised that based on space requirements, DIA reserves the right to limit the number of on-site press badges issued.

An application for a press pass is available for download from the preliminary program posted on **www.diahome.org.** Return this form by fax to Andrea Pawlowski of Tattar Richards-DBC Public Relations at +1-215-957-1297.

PRIVATE SOCIAL FUNCTIONS POLICY Social functions to which attendees are invited *are not permitted to occur* during any DIA activity. For further information contact DIA, 800 Enterprise Road, Suite 200, Horsham, PA 19044-3595, USA, tel +1-215-442-6100, fax +1- 215-442-6199, email dia@diahome.org.

RECEPTIONS DIA will host one reception on Monday, June 27 from 5:00 PM to 6:00 PM, in the Exhibit Hall.

SCIENTIFIC EXHIBITS There will be approximately 500 companies exhibiting in Washington, DC. The exhibit area will also serve as the site of coffee breaks, luncheons, and the Poster Sessions on Monday, June 27, and Tuesday, June 28.

Transportation

Save through Area Pricing and Discount Fees

UNITED AIRLINES To obtain schedule information and the best fares, call United Airlines's Specialized Meeting Reservations Center at 1-800-521-4041. Make sure you refer to Meeting ID Number 571AK. Dedicated reservationists are on duty 7 days a week from 8:00 AM to 10:00 PM EST.

US AIRWAYS US Airways' Group and Meeting Reservations staff can assist you in obtaining flight, fare and availability information toll-free at +1-877-874-7687. **Be sure to refer to Gold File Number 22633254**.

AMTRAK Discount pricing available!

Amtrak offers a 10% discount off the lowest available fare to Washington, DC between June 22 and July 3, 2005. Travel dates are approved three days prior to the convention start date and three days following the last day of the meeting. To book your reservation call Amtrak at +1 (800) 872-7245 or contact your local travel agent. Conventions cannot be booked via Internet. Please be sure to refer to Convention Fares Code X20G-936 when making your reservation. This offer is not valid on Auto Train. Fare is valid on Metroliner and Acela service for all departures seven days a week, except for holiday blackouts. Offer valid with Sleepers, Business Class or First Class seats with payment of the full applicable accommodation charges.

PARTICIPANTS WITH DISABILITIES DIA meeting facilities and overnight accommodations are accessible to persons with disabilities. Arrangements can be made for sensory-impaired persons attending the meeting if requested at least 15 days prior to meeting. Contact the DIA office to indicate your needs.

Statements made by speakers are their own opinion and not necessarily that of the organization they represent, or that of the Drug Information Association. Speakers and agenda are subject to change without notice. Recording of DIA tutorial/workshop information in any type of media, is prohibited without prior written consent from DIA.

Continuing Education

Learning Objectives

At the conclusion of this meeting, participants should be able to:

- Describe the current regulatory and public policy environment pertaining to pharmaceuticals with an emphasis on the Food and Drug Administration;
- Discuss the international regulations and economic factors that impact the global biopharmaceutical industry;
- Recognize the challenges facing the FDA and the pharmaceutical industry in areas such as research study design and statistical methodology;
- Recognize state-of-the-art clinical and statistical systems and implementations;
- Recognize the written and communication skills needed to promote your career and your company's objectives;
- Enhance your working relationship with colleagues, both locally and internationally;
- Describe legal, advertising, and marketing issues related to providing product information:
- Discuss statistics, economics, and quality of life science;
- Enhance your knowledge of risk assessment and management in the areas such as computer systems validation and drug safety and pharmacovigilance;
- Discuss issues in safety reporting, data analysis, epidemiology, and regulations regarding adverse events.

Target Audience

This program is designed for the full continuum of disciplines in the pharmaceutical and related industries to improve your understanding and skills as related to issues and solutions for a variety of pharmaceutical development interest areas.

Continuing Education

Select tutorials and sessions will offer category 1 credits, pharmacy contact hours, and nursing contact hours. Credits for tutorials are clearly identified in this program, and the credits for sessions will be indicated in the final program.

Accreditation and Credit Designation

The Drug Information Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Drug Information Association designates this educational activity for a maximum of 29.25 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.



The Drug Information Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Participants may earn up to

29.25 contact hours or 2.925 continuing education units (CEUs) for participating in the tutorials and annual meeting sessions.



The Drug Information Association (DIA) has been reviewed and approved as an Authorized Provider by the International Association for Continuing Education and Training (IACET), 1620 I Street,

NW, Suite 615, Washington, DC 20006. The DIA has awarded up to 2.9 continuing education units (CEUs) to participants who successfully complete the tutorials and annual meeting sessions.

The maximum number of credits noted above includes attendance at tutorials and the annual meeting sessions; this does not include the Plenary Session Monday morning.

Tutorials

Full-day tutorials (9:00 AM - 5:00 PM) - up to 6.5 category 1 credits or contact hours (.65 CEUs), or .7 IACET CEUs per tutorial

Half-day tutorials (8:30 AM - 12:00 PM or 1:00 PM - 4:30 PM) - up to 3.25 category 1 credits or contact hours (.325 CEUs), or .3 IACET CEUs per tutorial

Annual Meeting Sessions

June 26-30, 2005 - 286-000-05-501-L04; up to 19.5 category 1 credits or contact hours (1.95 CEUs), or 2 IACET CEUs (up to 1.5 hours per session)

Nursing

The Drug Information Association will offer nursing credits for various tutorials and sessions in collaboration with Corexcel. Corexcel is accredited as a provider of continuing education in nursing by the American Nurses Credentialing Center's Commission on Accreditation.

PMI



Project Management The Drug Information Association has been reviewed and Project R.E.R Institute approved as a provider of project management training by the Project Management Institute (PMI).

If you would like to receive a statement of credit, you must attend the program (and tutorial, if applicable), and return the credit request form to the DIA. Statements of credit will be issued within 10 weeks of receipt of this form.

Disclosure Policy

It is Drug Information Association policy that all faculty participating in continuing education activities must disclose to the program audience (1) any real or apparent conflict(s) of interest related to the content of their presentation and (2) discussions of unlabeled or unapproved uses of drugs or medical devices. Faculty disclosure will be included in the course materials.

Exhibit Hall Opportunities



DIA eLearning Demo, Contest, and Giveaway Win an iPod!

The Demo: Experience an exclusive DIA eLearning module first hand at one of our computer stations and chat with our design team about this and other offerings.

The Contest: Test your new knowledge with interactive games based on content from the module and get your name up on the leader board each day's highest scorer wins a \$50 gift certificate!

The Giveaway: Stop by, see all that DIA eLearning has to offer, and enter to win an iPod at the drawing on Wednesday, June 29!

Scientific Exhibits There will be approximately 500 companies exhibiting in Exhibit Halls A, B and C, located on the Lower Level of the Convention Center. This area also serves as the site of coffee breaks and luncheons as well as the Poster Sessions on June 27 and 28.

Employment Opportunities In an effort to be more technologically driven, DIA is providing employment opportunities electronically. Participants will also have the ability to post positions on this system throughout the meeting.

Exhibit Locator Visitors to the Exhibit Hall will be able to easily obtain a company's booth number by searching electronically for exhibiting companies using the workstations located in the entrance to Exhibit Hall A. They will be able to search by company name, by their services provided, or, using the keyword search engine, for any term used in the company description found in the 2005 Exhibitors' Services Summaries.

CONTACT INFORMATION

Drug Information Association			
http://www.diahome.org			
800 Er	terprise Road, Suite 200		
Horsham, PA 19044-3595, USA			
Tel	+1-215-442-6100		
Fax	+1-215-442-6199		
email	dia@diahome.org		

Washington, DC Convention Center http://www.dcconvention.com 801 Mount Vernon Place, NW Washington, DC 20001, USA Tel +1 202-249-3000 800-368-9000 +1 202-249-3533 Fax

THE Networking Event in the Pharmaceutical Industry

DIA's 41st Annual Meeting provides a perfect forum for attendees and speakers to network and evaluate approximately 500 exhibiting companies. Meet with a wide range of companies to learn about new offerings and technologies, all in one event. From CROs and technology vendors to site research centers, academia, and much more, the DIA Annual Exhibit Hall is one of the busiest places during the meeting. Visitors to the Exhibit Hall will be able to easily obtain a company's booth number by searching electronically for exhibiting companies using the workstations conveniently located in the Exhibit Hall.

TOP REASONS WHY PEOPLE ATTEND DIA'S ANNUAL MEETING

- Networking opportunities
- Quality and value of information and speaker presentations
- Relevance of content to their profession
- Timeliness of topics

AAHRPP

Accelovance Accovion Inc.


AAI Development Services Abt Associates Inc.

ACM Medical Laboratory

Breadth and depth of topics

Limited space is still available.

Visit www.diahome.org for an application form. Exhibiting companies, as of February 25, 2005, are listed below.



Aris Global, LLC ARS, Inc. Aspire IRB **Assist Technologies** AstraZeneca Astrolabe Analytica, Inc. Atlantic Institute of Clinical Research Averion Inc. AXIS Healthcare Communications LLC B & C Group BARC - The Central Laboratory BASi (Bioanalytical Systems, Inc.) **Baxa** Corporation BBK Healthcare, Inc. Beacon Bioscience, Inc. Beardsworth **Benchmark Research** BioCor **BioExecutive International** Bio-Imaging Technologies, Inc. **Biomedical Research Institute of America Biomedical Systems** BioResearch Monitors, Inc. bioskin GmbH Biospace, Inc. Biotechnical Services, Inc.

ADAllen Pharma Ltd. AdClin Adobe Systems, Inc. Advanced Biologics, LLC Advanced Biomedical Research, Inc. Advanced Clinical Services Advanced Clinical Software Aerotek Scientific Affymetrix ALMEDICA Amarillo Center for Clinical Research, Ltd. American Medical Writers Association American Pharmaceutical Review/American Pharmaceutical Outsourcing AmeriTrial OTC Research AMG IT Systems Amgen Inc. **APEX International** Applied Clinical Trials Magazine Appligent, Inc. Apyx, Inc.

Biotrial International Biovail Contract Research Booz Allen Hamilton Borgess Health Alliance Brecon Pharmaceuticals BusinessEdge Solutions California Clinical Trials Cambridge Group, Ltd., The Cambridge Regulatory Services Ltd. Canadian Rheumatology Research Consortium CanReg Inc. **Cardinal Health** Cardiocore CardioDynamics CareStat, Inc. Carpermor, SA de CV CCA, Inc. CCRI CDISC **CEDRA Clinical Research** Center for Drug Evaluation CenteRXperts CentraLabS Clinical Research Certus International, Inc. Charterhouse Clinical Research & EPA EURO PHARMA Children's Hospital of Orange County Chiltern International, Inc. Christiana Care Research Institute **CIF-BIOTEC** Cincinnati Children's Research Foundation Cirion Clinical Trial Services Inc. City List Clarix **Clarkston Consulting** ClickFind, Inc. Clin Axys DBA Clinical Systems, Inc. **ClinAudits LLC** ClinForce, Inc. **Clinical Business Solutions** Clinical DataFax Systems, Inc Clinical Financial Services **Clinical Network Services Clinical Research Atlanta** Clinical Research Center at Tampa General Hospital Clinical Research Networks (CRNets) Clinical Resource Network, The **Clinical Trial Media Clinical Trial Services** Clinical Trials & Epidemiology Research Unit Clinical Trials Services, Inc. Clinilabs ClinLogic ClinPhone, Inc. **Clintrak Pharmaceutical Services** Cmax Pty Ltd. CMIC Co., Ltd.

CNS Vital Signs Coast IRB, LLC Cognitive Drug Research Cogtest plc Colortrieve Record Systems, Inc. **Community Research** Comprehensive NeuroScience, Inc. **Concepts Worldwide** Constella Clinical Informatics, Inc. **Contract Pharma Copernicus Group IRB** Covance Inc. CRF Inc CRL.Medinet CSA Associates, LLC CSS Informatics CTMS, Inc. Cu-Tech, LLC CYA Technologies, Inc. D. Anderson & Company Data Capture International Data Communique International DataCeutics, Inc. Datafarm, Inc. DataForm Software DataLabs, Inc. Datapharm Australia Pty Ltd. **DATATRAK** International Datatrial DaVita Clinical Research **DCL Medical Laboratories** DDS Medicines Research Ltd. Degge Group, Ltd., The **Dendrite International Designing Events** DGP export Ltd. DIA **Diamond Medical Group Dimensional HealthCare DOCS** International Document Control Systems, Inc. Drexel University College of Medicine Drug Safety Alliance DrugLogic Inc. DSG (Document Solutions Group, Inc.) **Duke Clinical Research Institute DxS** Limited Dynarand DZS Software Solutions, Inc. ECRON Edinger Medical Group & Research Center Elsevier EMC/Documentum EMEA **Endpoint Research Engel Publishing**

Exhibiting Companies

Enterprise Ireland Envision Pharma, Inc. ePharmaLearning, Inc. ERBI eResearchTechnology, Inc. Esoterix Essential CRO/AmericasDoctor, Inc. eStudySite etrials Worldwide Eurotrials EXAKT Technologies, Inc. Examination Management Services, Inc. Excel PharmaStudies, Inc. Fast Track Systems FDA/CBER FDA/CDER FDAnews F-D-C Reports, Inc. First Consulting Group **Fisher Clinical Services** Fleishman-Hillard Clinical Trials Division Fleury Diagnostics Focus Bio-Inova, Inc. FOI Services, Inc. Food and Drug Law Institute ForeignExchange Translations Forest Laboratories, Inc. Formedix Ltd. Fulcrum Pharma Developments, Inc. Galt Gene Logic Inc. Gentiae Clinical Research Geny Research Corp. George Washington University Medical Center **GFI Research Center Glemser Technologies Corporation** Global Languages & Cultures, Inc. Global Medical Institutes, LLC **GPA** International GroupNet Harris Interactive Harrison Clinical Hawaii Clinical Research Center **HCL** Technologies Health Decisions Healthcare Communications Group HealthCore Hillicon TrainingCampuses HungaroTrial Hurley Consulting Associates Ltd. i3 Research i3 Statprobe **IBIC Clinical Research Center** IBIS **IBM** Corporation **ICON Clinical Research**

ICTI iD Globe Image Solutions, Inc. iMedRIS Data Corp. **IMFORM International Clinical Research** IMIC - Mexican Institute of Clinical Research Impact Clinical Trials Imperial Graphics, Inc. IMRO TRAMARKO International **INC Research** InfoMedics, Inc. Innovative Print & Media Group Innovus Research Inc. Inprint USA Integic Corporation Integrated Clinical Systems, Inc. Integrated Development Associates Co., Ltd. IntegReview, Inc. Ethical Review Board Integrex Integrium Intermountain Clinical Research International Dermatology Research Interspond, LLC IntraLinks, Inc. Inveresk Research Group, Inc. invivodata Iowa Clinical Research Corporation **IVRAS** J&S Studies, Inc. Jeiven Pharmaceutical Consulting, Inc. Johnson & Johnson Professional Recruiting Joule Clinical Solutions Kcentrix Software Kelly Scientific Resources Kendle International Keris, Inc. Kforce Clinical Research Staffing Klein Management Systems LabConnect, LLC LabCorp Laboratorio Hidalgo LabWare, Inc. LatinTrials LEADPHARMA Leake Lernia Training Solutions LifeTree Technology Liquent Logos Technologies Ltd. LORENZ Life Sciences Group Lovelace Scientific Resources M+BIOLAW MAJARO InfoSystems Marken Time Critical Express Mayne Pathology Mayo Clinical Trial Services

McCarthy Consultant Services Inc. McElroy Translation Company McGuire Research Institute, Inc. McKesson BioServices MDS Pharma Services MedDRA® MSSO MedFocus, LLC Medical Staffing Network MediciGroup Inc. Medidata Solutions Medifacts International Medpace, Inc. MedPoint Communications, Inc. MedQualis MedSource Medstat **MEDTOX Laboratories** MedTrials, Inc. MedXview, Inc. Merck & Co., Inc. META Solutions, Inc. MetaWorks, Inc. MHRA **Microsoft Corporation** Microsystems Mid*Lands IRB Midwest Research Specialists MonitorForHire.com Monitoring Force USA, Inc. Mortara Instrument MSOURCE National Death Index, NCHS, CDC Neeman Medical International Ness Technologies New England Institutional Review Board New Horizons Clinical Research New Orleans Center for Clinical Research Nextrials, Inc. Northwest Clinical Research Center Northwest Kinetics, Inc. NOTOX BV Novotech NUCRO-TECHNICS Ocasa Inc. Octagon Research Solutions **Odyssey Research Services Omnicare Clinical Research** Omnicia, Inc. OmniComm Systems, Inc. **On Assignment Clinical Research Open Text Corporation Optimed Research Oracle Corporation** ORIAM Origin Pharmaceutical Services Ltd. **Orlando Clinical Research Center**

Outcome **Ovation Research Group** Pacific Biometrics, Inc. Pacific Data Designs Paragon Biomedical PDP Courier Services Ltd. Pediatric Clinical Trials International PeerView, Inc. Penn Pharmaceutical Services Ltd. PerMedics, Inc. Pfizer Global Research and Development Pharmaceutical C-Trials, Inc. Pharmaceutical Executive Magazine Pharmaceutical Information Associates, Ltd. Pharmaceutical Research Network Pharmaceutical Research Plus, Inc. Pharmaceutical Resource Corp. Pharmafile Ltd. PharmaLinkFHI PharmaNet PharmaSeek, LLC PharmaSys, Inc. PharmaTech Solutions, Inc. PharmaVOICE PharmData, Inc. Pharm-Olam International PharmSource Phase Forward Phoenix Data Systems, Inc. Phoenix Pharma Central Services (S) Pte Ltd. **Phoenix Software International Phoenix Translations** PHRP PHT Corporation (Pi) Patient interaction PII **PJB** Publications **Placemart Personnel Service** PLANISWARE USA Inc. PPD, Inc. PRA International PRACS Institute, Ltd. PreAnalytix **Precept Life Sciences** Premier Research, a Division of CRC Development Ltd. **PRL Central Laboratory Services** ProGene Biomedical/IBT Reference Laboratory **Prologue Research** Promedica International Prometrika Protech Pharmaservices Corporation ProTrials Research, Inc. **PRTM Management Consultants** PSI International, Inc. PSI Pharma Support Intl Quality & Compliance Consulting, Inc.

Quality Associates, Inc. Quality Data Services, Inc. Quantum Research **Ouest Diagnostics Quest Pharmaceutical Services** Quintiles QUMAS **Ouorum Review IRB Radiant Research** RadPharm RCRC IRB **Recruitech International Regional Clinical Research** REGISTRAT, Inc. Relsys International, Inc. **Research Across America Research Dynamics** Research Investigator's Source Research Solutions, LLC Rho, Inc. **Richmond Pharmacology Romar Consulting** RPS, Inc. RWD Technologies, Inc. Rx Trials, Inc. RxCCI - Regulatory/Clinical Consultants, Inc. SAFE - BioPharma SAS Institute Schulman Associates IRB, Inc. Science Applications International Corp. SCIREX Corporation Sentrx SFBC International SGS Life Science Services SH3 Inc. Sierra Scientific Software, Inc. Simpson Healthcare Executives Siris Pharmaceutical Services Site Support Institute Co., Ltd. SleepMed, Inc. Smith Hanley **SNOMED** International Society of Quality Assurance Source4 Spacelabs Medical Data Spectra Clinical Research Spotfire SRG Woolf Group, Inc. Standard Register STATKING Consulting, Inc. Stelex Sterling Research Group, Ltd. Strata SunTech Medical, Inc. Symbiance, Inc. **SYMFO**

SYNARC, Inc. Synchron Research Services Synteract, Inc. Tablus, Inc. Tandem Labs Taratec Target Health Inc. Target Research Associates Technical Resources International, Inc. Therapak Corporation Thesaurus Information and Strategies, Inc. ThinSpring Thomson Center for Clinical Research Practice Thomson CenterWatch Thomson PDR Thywill LatAm Solutions TKL Research, Inc. TNT **TransPerfect Translations TRC Clinical** Trial Management Group Inc. TrialsNet Trident Clinical Research Pty Ltd. Trio Clinical Research, LLC UBC **UK Clinical Research Organization** UMC Products & Services, The Uniform Data System for Medical Rehabilitation University Clinical Research, Inc. University of California, San Diego University of Florida University of Medicine & Dentistry of New Jersey University of Vermont VA Cooperative Studies Program Veritas Research, Inc. **VIASYS Healthcare Clinical Services** ViPS Biomedical Services, Inc. Vitalograph Ltd VivoMetrics Inc. Volt Life Sciences Waban Software Wellspring Pharmaceutical West Coast Clinical Trials Winchester Business Systems Winnertech Consulting Woodley Equipment Company Ltd. World Class International World Courier Inc. WorldCare Clinical, Inc. Wyeth Xenobiotic Laboratories, Inc. XERIMIS Inc. XTrials Research Services Yoh Scientific Yourway Transport Inc. Zenosis Ltd.

EXHIBITOR REGISTRATION FORM

Exhibitors should return this form to the attention of the Exhibits Department at DIA.

41st ANNUAL MEETING ID #05001 June 26-29, 2005, Washington, DC, USA

If registering for tutorials or the networking dinner and paying by credit card, return this completed form to DIA by fax to **+1-215-442-6199** or by mail to 800 Enterprise Road, Suite 200, Horsham, PA 19044-3595, USA. If paying by check, follow instructions under Payment Methods below.

All registrations received at the DIA office in Horsham, PA, USA, by 5:00 PM on May 20, 2005, will be included in the Advance Registration Attendee List.

Each 10' x 10' booth includes one (1) complimentary full-meeting registration and
three (3) exhibit booth personnel registrations. Please fill out a separate form for each
exhibitor registrant. To expedite your registration, please check the appropriate category:

COMPLIMENTARY FULL-MEETING REGISTRATION

PLEASE NOTE This page must be completed and submitted for each person attending any portion of this event.

PAYMENT METHODS Please check payment method:

- □ CHECK drawn on a US bank payable to and mailed along with this form to: Drug Information Association, Inc., PO Box 827192, Philadelphia, PA, USA 19182-7192. Please include a copy of this registration form to facilitate identification of attendee.
- □ CREDIT CARD number may be faxed to: +1-215-442-6199. You may prefer to pay by check or bank transfer since non-US credit card payment will be subject to the currency conversion rate at the time of the charge.

□ VISA □ MC □ AMEX Expiration Date _

Card # _

Signature _

□ BANK TRANSFER in the currency of your choice to: PNC Bank, 1600 Market Street, Philadelphia, PA 19103, USA. DIA Account # 8606072742. ABA # 031000053. SWIFT-CODE # PNCCUS33. Your name and company, as well as the above Meeting I.D. Number, must be included on the transfer document to ensure payment to your account.

CANCELLATION POLICY

All cancellations must be in writing and received at the DIA office by 5:00 PM on June 10, 2005. Registrants who do not cancel by June 10, 2005 and do not attend will be responsible for the full applicable fee. **Registrants are responsible for canceling their own airline and hotel reservations.** You may transfer your registration to a colleague at any time, but membership is not transferable. Please notify DIA of any such substitutions as soon as possible. **Substitute registrants will be responsible for nonmember fee, if applicable**. DIA reserves the right to alter the venue, if necessary. If an event is cancelled, DIA is not responsible for any airfare, hotel, or other costs incurred by registrants. Speakers and program agenda are subject to change. **Cancellations received in writing on or before June 10**,

2005, will be processed as follows.

FULL MEETING CANCELLATION

Government/Nonprofit/Academia – Registration fee paid minus \$100 = Refund Amount All Others – Registration fee paid minus \$200 = Refund Amount

NETWORKING DINNER CANCELLATION On or before June 10, 2005 = Full Refund

On or before June 10, 2005 – Registration fee paid minus \$50 = Refund Amount

PARTICIPANTS WITH DISABILITIES DIA meeting facilities and overnight accommodations are accessible to persons with disabilities. Arrangements can be made for sensory-impaired persons attending the meeting if requested at least 15 days prior to meeting. Contact the DIA office to indicate your needs. FULL-MEETING REGISTRATION (attendance of 2 or more days) includes admission to all scientific sessions, exhibits, coffee breaks, luncheons and receptions. If DIA cannot verify your membership upon receipt of registration form, you will be charged the nonmember fee. All fees are in US dollars.

CERTIFIED CLINICAL INVESTIGATOR	REVIEW COURSE	#05410 See webs	ite for details.
MEMBER	US\$ 250 🗖	NONMEMBER	US \$ 300 🗖

CERTIFIED CLINICAL INVESTIGATOR EXAMINATION See website for registration information.

ONE-DAY ONLY REGISTRATION FEE will be available closer to the meeting date at a cost of \$505 for members and \$680 for nonmembers.

TUTORIALS See the website for the tutorial schedule. Space is limited and preregistration is encouraged. Please indicate the ID number and fee for each tutorial you plan to attend.

Tutorial #	Fee
Tutorial #	Fee

Tutorial #	Fee	Tutorial Subtotal

NETWORKING DINNER Sunday, June 26, 6:30 pm.

PREREGISTRATION FEES Attendees will be required to produce their confirmation letter. To ensure that your registration is processed and sufficient time is allowed for receipt of confirmation letter, a completed registration form and payment must be received by the preregistration deadline of **June 17, 2005. An email address must be included below for confirmation process.**

MEMBER EARLY-BIRD OPPORTUNITY Available on nondiscount member fee only.	On or before JAN 31*	After JAN 31
Member Fee	US 💲 950 🖵	US \$1050 🗆
Join DIA now to qualify for the early-bird member fee! www.diahome.org/docs/Membership)	US \$ 130 🗆
*To qualify for the early-bird discount, registration for date above. Does not apply to government/ academia	. , . ,	st be received by the
Nonmember Fee		US \$1180
I do 🔲 I do NOT 🗍 want to be a DIA mami	har	
I do I do NOT want to be a DIA mem	MEMBER	NONMEMBER
		Nonmember US \$ 430 [US \$ 755]
Discount Fees Government (Full-time)	MEMBER US \$ 300 US \$ 625	US \$ 430 US \$ 755
Discount Fees Government (Full-time) Charitable Nonprofit/Academia (Full-time) * If paying a nonmember fee, please check one bu	MEMBER US \$ 300 - US \$ 625 - ox above, indicating whether you	US \$ 430 US \$ 755
Discount Fees Government (Full-time) Charitable Nonprofit/Academia (Full-time) * If paying a nonmember fee, please check one bu MEETIN	MEMBER US \$ 300 US \$ 625 ox above, indicating whether you	US \$ 430 US \$ 430 US \$ 755 US \$ 100 US

ETWORKING	DINNER	FEE	US \$	
-----------	--------	-----	-------	--

US \$ 70 🗅

TOTAL	PAYMENT	DUE	US	\$	_
-------	---------	-----	----	----	---

Last Name	First Name			MI	
Degrees		DIA PIN #	# (optional)	—— Dr.	О мг. О м
Job Title					
Company					
Mailing Address					
City S	State	Zip/Postal Code	Country		
Telephone #	Fax #				

Registration Form for TUTORIALS & NETWORKING DINNER ONLY

Can't attend the entire Annual Meeting? Register for weekend Tutorials

Already registered for the Annual Meeting? Add on the Networking Dinner or Tutorials

41st ANNUAL MEETING ID #05001 June 26-30, 2005 Washington, DC, USA

Return this form by MAIL or FAX ONLY DIA, 800 Enterprise Road, Suite 200, Horsham, PA 19044-3595 • Fax +1-215-442-6199

PLEASE CHECK IF: Vou are already registered for the meeting but wish to add Tutorials or the Networking Dinner to your registration. Vou do not wish to register for the meeting but would like to register for a Tutorial(s) or the Networking Dinner.

Please PRINT or TYPE in the space below.

Last Name		First Name	МІ
Degrees		DIA PIN # (optional)	Dr. 🗋 Mr. 🗋 Ms.
Job Title			
Company			
Mailing Address	Please indicate if this is your D Home Address or D Office Address		
City	State	Zip/Postal Code	Country
Telephone #		Fax #	

email (email address is required for confirmation)

Participants with disabilities: DIA meeting facilities and overnight accommodations are accessible to persons with disabilities. Arrangements can be made for sensory-impaired persons attending the meeting if requested at least 15 days prior to meeting. Contact the DIA office to indicate your needs.

PLEASE NOTE: This page must be completed and submitted for each person registering for the Networking Dinner or Tutorials.				
YES, I am registered for the meeting and I would like to add the Networking Dinner and/or the following Tutorials to my registration.	 PAYMENT METHODS CHECK drawn on a US bank payable to and mailed along with this form to: Drug Information Association, Inc., PO Box 827192, Philadelphia, PA, USA 19182-7192. 			
NO, I do not wish to register for the meeting but I would like to register for the Networking Dinner and/or the fol- lowing Tutorials.	 Please include a copy of this registration form to facilitate identification of attendee. CREDIT CARD number may be faxed to: +1-215-442-6199. You may prefer to pay by check or bank transfer since non-US credit card payment will 			
Networking Dinner\$70.00TutorialsPlease indicate all applicable Tutorial Number(s) and fee(s).	be subject to the currency conversion rate at the time of the charge. VISA MC AMEX Exp. Date			
Tutorial # Fee \$ Tutorial # Fee \$	Card #			
Tutorial # Fee \$	Signature BANK TRANSFER in the currency of your choice to: PNC Bank, 1600 Market Street,			
Total Tutorial Fee Due \$	Philadelphia, PA 19103, USA. DIA Account # 8606072742. ABA # 031000053. SWIFT- CODE # PNCCUS33. Your name and company, as well as the above Meeting I.D.			
TOTAL PAYMENT DUE \$	Number, must be included on the transfer document to ensure payment to your account.			

Join DIA now to qualify for the member fee, save and receive all the benefits of membership for a full year!

CANCELLATION POLICY All cancellations must be in writing and received at the DIA office by 5:00 PM on June 10, 2005. Registrants who do not cancel by June 10, 2005 and do not attend will be responsible for the full applicable fee. **Registrants are responsible for canceling their own airline and hotel reservations**. You may transfer your registration to a colleague at any time, but membership is not transferable. Please notify DIA of any such substitutions as soon as possible. **Substitute registrants will be responsible for nonmember fee, if applicable**. DIA reserves the right to alter the venue, if necessary. If an event is cancelled, DIA is not responsible for any airfare, hotel, or other costs incurred by registrants. Speakers and program agenda are subject to change. **Cancellations received in writing on or before June 10, 2005, will be processed as follows**.

FULL MEETING CANCELLATION: On or before June 10, 2005

Government/Nonprofit/Academia – Registration fee paid minus \$100 = Refund Amount

All Others – Registration fee paid minus \$200 = Refund Amount

\$130.00

NETWORKING DINNER CANCELLATION: On or before June 10, 2005 – Full Refund

TUTORIAL CANCELLATION: On or before June 10, 2005 – Registration fee paid minus \$50 = Refund Amount

Press Pass Request Form

REGISTRATION POLICIES AND PROCEDURES

The Drug Information Association's (DIA) events are attended by a number of international and domestic journalists who represent a variety of well-respected media outlets. DIA welcomes qualified representatives of news organizations to attend these events for the purpose of reporting and publishing articles.

Press passes will be given to all who qualify as members of the press. The DIA reserves the right to screen all requests and refuse the registration of those who do not qualify. In order to obtain a press pass, applicants must be affiliated with an established media outlet and posses an editorial title. Publishers, sales representatives and other non-editorial staff will not be granted a press pass. Publications and marketing materials may not be distributed at DIA conferences. Upon arrival, all media must present confirmation letters, press credentials and/or a letter of assignment from the media outlet at the check-in location.

Please fill out this form and fax it to Andrea Pawlowski of Tattar Richards-DBC Public Relations at 215.957.1297. If you have any questions, please call Andrea at 215-957-0300.

Course Code for DIA Event:	
(The five-digit number that appear	rs near the event's title on DIA's Web site.)

Title of DIA Event:	
Date of DIA Event:	
Name:	
Job Title:	
Media Outlet:	
Address:	
City/State/Zip:	
Telephone Number:	
Email:	

Confirmed Registration: Written confirmation is forwarded via email within five (5) business days upon receipt. Email apawlowski@dbcommunications.net if you have not received confirmation within seven (7) business days from submittal of registration.

Deadline: Registration should be received at least two weeks before the conference. Registrations received after the deadline and on-site registrations will be accepted upon space availability. For space availability, contact apawlowski@dbcommunications.net.

Meeting Cancellation: DIA reserves the right to cancel any conference at its sole discretion, whereupon all registration fees will be refunded. DIA will not be responsible for airfare penalties or other costs incurred due to a cancellation.

Agenda/Speakers: Subject to change without notice. Check www.diahome.org for updates.

Resources: Conference agendas will be provided to news representatives. At the respective speaker's discretion, printed speaker handouts (not including reference CD-ROMs) will be available to the press at no extra cost. They may be quoted, but not reproduced in whole or in part without explicit permission from DIA. They are provided as a helpful resource to news reporters and may not be redistributed or sold.

Recording: Recording at sessions is allowed for the purpose of taking notes. Permission is needed in advance if the intention is to broadcast any taped session, in full or in part. Videotaping is prohibited.

Please help DIA maintain a thorough archive of press coverage by providing DIA with a clipping, e-copy or URL of articles developed from information presented at conferences. Mail clippings to:

Fax: 215-957-1297

Email: apawlowski@dbcommunications.net

*By signing my name below, I am verifying that I have read and agree to the policies and procedures above and that the information I have provided is correct. Further, I am granting permission to the DIA to publish any articles that I produce about the above meeting in *DIA Today*.

Signature:

Saturday, June 25 - Monday, June 27 (some speaker changes will occur before the event.)

Saturday, June 25

12:00 рм - 1:00 рм	TUTORIAL REGISTRATION
	Registration for Saturday tutorials ONLY
	East Registration Area, Convention Center
	Mount Vernon Place Entrance
12:00 рм - 5:00 рм	EXHIBITOR REGISTRATION
	East Registration Area, Convention Center
	Mount Vernon Place Entrance
1:00 рм - 5:30 рм	CERTIFIED CLINICAL INVESTIGATOR REVIEW COURSE

Renaissance Washington, DC Hotel

Sunday, June 26

8:00 am - 9:00 am	TUTORIAL REGISTRATION Registration for Sunday morning or full-day tutorials ONLY East Registration Area, Convention Center Mount Vernon Place Entrance
8:00 am - 6:30 pm	EXHIBITOR REGISTRATION East Registration Area, Convention Center Mount Vernon Place Entrance
9:00 am - 12:00 pm	CERTIFIED CLINICAL INVESTIGATOR EXAMINATION Renaissance Washington, DC Hotel
12:30 pm - 1:00 pm	TUTORIAL REGISTRATION Registration for Sunday afternoon tutorials ONLY East Registration Area, Convention Center Mount Vernon Place Entrance
2:00 pm - 5:00 pm	CERTIFIED CLINICAL INVESTIGATOR EXAMINATION Renaissance Washington, DC Hotel
3:00 pm - 6:30 pm	ATTENDEE REGISTRATION East Registration Area, Convention Center Mount Vernon Place Entrance
3:00 pm - 6:30 pm	SPEAKER REGISTRATION East Registration Area, Convention Center Mount Vernon Place Entrance
4:00 рм - 6:00 рм	EXHIBITS OPEN Exhibit Hall A, B and C, Lower Level, Convention Center
6:30 рм - 8:30 рм	NETWORKING DINNER Grand Ballroom, Renaissance Washington, DC Hotel

Monday, June 27

7:30 ам - 6:00 рм	ATTENDEE REGISTRATION
	East Registration Area, Convention Center
	Mount Vernon Place Entrance
7:30 ам - 6:00 рм	EXHIBITOR REGISTRATION
	East Registration Area, Convention Center
	Mount Vernon Place Entrance

7:30 am - 6:00 pm	SPEAKER REGISTRATION East Registration Area, Convention Center Mount Vernon Place Entrance
7:30 am - 8:15 am	CONTINENTAL BREAKFAST Ballroom Foyer, 3rd Floor, Convention Center
10:00 am - 6:00 pm	STUDENTS' POSTER SESSION Exhibit Hall A Entrance, Lower Level, Convention Center
10:00 am - 6:00 pm	EXHIBITS OPEN Exhibit Hall A, B & C, Lower Level, Convention Center
5:00 рм - 6:00 рм	MONDAY RECEPTION

8:30 am - 10:00 am

Plenary Session Ballroom ABC, 3rd Floor, Convention Center

Exhibit Hall A, B & C, Lower Level, Convention Center

Welcome and Awards Presentation



THERESA K. MUSSER

Senior Director Project Management and Clinical Operations Rigel Pharmaceuticals *Acting President, DIA*

Opening Remarks



RONALD D. FITZMARTIN, PHD, MBA Vice President Global Technical Services Daiichi Medical Research, Inc.

2005 DIA Annual Meeting Chairperson

Keynote Address



BERNADINE HEALY, MD

Medical and Health Columnist, *US News & World Report*; Former Head, National Institutes of Health and the American Red Cross

10:00 ам - 10:30 ам

REFRESHMENT BREAK

Exhibit Halls ABC, Lower Level Convention Center

Session 101 AD - Advertising, MA, RA

10:30 AM - 12:00 PM LEVEL = •

Room 202B *Pharmacy credits offered*

Drug Advertising and Promotion: A Regulatory Primer SESSION CHAIRPERSON

Glenn N. Byrd, MBA, RAC

Chief, Advertising and Promotional Labeling Branch, CBER, FDA

Drug advertising and promotion is a hot topic in today's environment. Direct-toconsumer (DTC) advertising, First Amendment issues, FDA compliance, and offlabel promotion are all "in the news."

Who should attend: Regulatory, legal, public relations, marketing, and management staffs of pharmaceutical, veterinary medicine, biologics, and medical device companies, as well as consultants to these companies with less than 2-3 years of experience in the areas of advertising, public relations, legal issues, and marketing communications.

Jean-Ah Kang, PharmD

Senior Regulatory Affairs Consultant, Science Applications International Corporation (SAIC)

Lesley R. Frank, MSFS, PhD, JD

Acting Group Leader, Professional Review Group II, Division of Drug Marketing, Advertising, and Communications, CDER, FDA

Ann Karen Henry, PharmD

Director, Regulatory Affairs, Biogen Idec

Session 102 CMC - CHEMISTRY, MANUFACTURING,

AND CONTROLS, RA 12:00 PM LEVEL = ■

10:30 am - 12:00 pm

Room 150B

Pharmaceutical Quality Assessment: The New CMC Review Paradigm

SESSION CHAIRPERSON

Moheb M. Nasr, PhD

Director, Office of New Drug Chemistry, CDER, FDA

This session will discuss the FDA Office of New Drug Chemistry's (ONDC) implementation of a new quality assessment system and concurrent reorganization. ONDC is establishing a modern, risk-based pharmaceutical quality assessment system consistent with the FDA's initiative concerning modernization of the regulation of pharmaceutical manufacturing and product quality (Pharmaceutical Current Good Manufacturing Practices for the 21st Century: A Risk-based Approach). The new system encompasses several initiatives whose objectives are to allow rapid introduction of new technologies into pharmaceutical manufacturing and expedite review of applications without compromising the high quality of drugs in the United States. Major features will be examined including emphasis on quality by design in the evaluation of critical aspects of pharmaceutical quality attributes, dedicated premarketing and postmarketing divisions, a strong focus in manufacturing science, integration of review and inspection functions, and improved usage of modern statistical methodologies. Industry perspectives and concerns with implementation will also be discussed.

FDA Perspectives

Moheb M. Nasr, PhD Director, Office of New Drug Chemistry, CDER, FDA

Industry Perspective

Jeffrey J. Blumenstein, PhD

Group Director, Regulatory, CMC and Quality Assurance, Pfizer Inc

Panel Discussion/Q&A Period

Session 103 CP - CLINICAL SAFETY AND PHARMACOVIGILANCE, CR, PP, RA 10:30 AM - 12:00 PM LEVEL = ■

Room 207A *CME credits offered*

The Application of Good Pharmacovigilance Practices

SESSION CHAIRPERSONS Robert C. Nelson, PhD, MBA

President, RCN Associates, Inc. Penelope Przekop, MSQA, CQM

Director, Global Quality Management, Johnson & Johnson Pharmaceuticals Group

This session will consist of topics that address how the application of good pharmacovigilance practices and managment of pharmacovigilance processes using business metrics can improve long-term results such as: accuracy of benefit risk assessment, compliance, individual adverse event quality, aggregate report quality, and minimization of tort liability.

Johnson & Johnson Pharmacovigilance Quality and Compliance System *Penelope Przekop, MSQA, CQM*

Associate Director, Global Quality Management, Johnson & Johnson Pharmaceutical Research and Development, LLC

On the Proper Handling and Assessment of Spontaneous Reports *Robert C. Nelson, PhD, MBA* President, RCN Associates, Inc.

Issues in the Adoption and Implementation of Pharmacovigilance Data Mining *Michael D. Blum, MD, MPH*

Assistant Vice President, Wyeth Pharmaceuticals

Session 104 CR1 - CLINICAL RESEARCH AND

DEVELOPMENT, **C**P

10:30 ам - 12:00 рм LEVEL = •

Room 145A *CME and Pharmacy credits offered*

Real Life Safety and Efficacy of Levitra® (REALISE): Operational Aspects of a Postmarketing Surveillance Study SESSION CHAIRPERSON

Dawn Bradway, PhD

Associate Director, Medical Science, US Phase IV Grants and Studies, Bayer HealthCare, Pharmaceuticals

The REALISE study was initiated to collect data on safety and patient acceptance of erectile dysfunction (ED) treatment with Levitra[®] under daily life conditions and included 30,000 subjects in the United States.

REALISE: From Concept to Study Start

Dawn Bradway, PhD

Associate Director, Medical Science, US Phase IV Grants and Studies, Baver HealthCare, Pharmaceuticals

REALISE: Study Execution

Dawn Bradway, PhD

Associate Director, Medical Science, US Phase IV Grants and Studies, Bayer HealthCare, Pharmaceuticals

$\label{eq:REALISE: Overview from the CRO Perspective and Comparison with \\ Other Phase IV Studies$

Jill Conner, MSM

Director, Project Management, Late Stage Group, UBC

Session 105 CR2 - Clinical Research and Development, RA

10:30 ам - 12:00 рм LEVEL =

Room 145B CME credits offered

Human Phase 0 (Microdosing) Studies: Regulatory and Scientific Aspects

SESSION CHAIRPERSON

R. Colin Garner, PhD, DSc, FRCPath Chief Executive Officer, Xceleron Ltd., UK

The earlier introduction of drug candidates into humans is a prerequisite for improving attrition rates in clinical development. Ultrasensitive big physics instruments such as accelerator mass spectrometry (AMS) and positron emission tomography (PET) have allowed a new concept known as human microdosing to be developed. These screening human ADME studies allow smarter candidate selection prior to committing large resources to full-scale Phase I studies.

Human Phase 0 (Microdosing) Studies: Scientific Aspects *R. Colin Garner, PhD, DSc, FRCPath* Chief Executive Officer, Xceleron Ltd., UK

New Drug Initiatives: Something Old and Something New Orhan Suleiman, MS, PhD, FAAPM Senior Science Policy Advisor, CDER, FDA

Human Phase 0 Studies: Practical Examples Using Renin Inhibitors J. Chris Jensen, PhD

Director, Pharmacology, Speedel Experimenta AG, Switzerland

Session 106 CR3 - Clinical Research and Development

10:30 AM - 12:00 PMLEVEL = ■Room 147ACME and Pharmacy credits offered

The Critical Path for Analgesic Drug Development SESSION CHAIRPERSON

Raymond A. Dionne, DDS, PhD

Chief, Pain and Neurosensory Mechanisms Branch, NIDCR, National Institutes of Health

The intent of the workshop is to address the dichotomy between the unmet need for analgesic drugs that improve upon the two drug classes (opioids, aspirin-like drugs) that are still predominantly used to treat acute and chronic pain and the opportunities created by increasing understanding of the molecular-genetic mechanisms of pain and analgesia. The workshop will examine the factors that influence analgesic drug development from differing perspectives to identify opportunities for improvements in the critical path for analgesic drug development.

The FDA Critical Path Initiative Janet Woodcock, MD

Acting Deputy Commissioner of Operations, FDA

Clinical Analgesic Drug Trials: Targets, Research Strategies and Individualizing Outcome Measures *Raymond A. Dionne, DDS, PhD*

Chief, Pain and Neurosensory Mechanisms Branch, NIDCR, National Institutes of Health

The Optimal Model for Evaluating Acute Pain Drugs Steven A. Cooper, DMD, PhD

Senior Vice President, Global Clinical and Medical Affairs, Wyeth Consumer Healthcare

Development of Opioids for Analgesic Indications William K. Sietsema, PhD Vice President, Clinical and Regulatory Strategic Planning, Kendle

SESSION 107 CR4 - CLINICAL RESEARCH AND DEVELOPMENT, RA

10:30 ам - 12:00 рм LEVEL = •

Ballroom A 3rd Floor

CME, Nursing, and Pharmacy credits offered

A New Era of Transparency in Clinical Research: The Evolution, Impact, and Future of Clinical Trial Registers and Registries

SESSION CHAIRPERSON

Craig A. Metz, PhD

Vice President, CEDD Regulatory Affairs, GlaxoSmithKline

This session will explore the seminal issues that led to the public outcry for transparency in the clinical research process and resulted in the evolution of the various clinical trial result registers currently supported by PhRMA and a number of its member pharmaceutical companies. The session will also address the expansion of the ClinicalTrials.gov National Library of Medicine database beyond the original mandate described in FDAMA 113. Presentations will be made regarding the development of and experience to date with these databases, as well as procedures being developed to verify compliance with posting requirements. Presentations will be made by representatives from key stakeholder groups including the National Institutes of Health, academia, PhRMA, and individual pharmaceutical companies.

The Case for Transparency in Clinical Research: A Journey Just Begun Arthur L. Caplan, PhD

Professor of Bioethics, University of Pennsylvania

The Origin and Evolution of ClinicalTrials.gov Deborah A. Zarin, MD

Director, ClinicalTrials.gov, National Library of Medicine Assistant Director, Clinical Research Projects, National Institutes of Health

Clinical Trial Register Case Study 1: The PhRMA Experience Alan Goldhammer, PhD

Associate Vice President, Regulatory Affairs, PhRMA

Clinical Trial Register Case Study 2: The GSK Experience *Frank W. Rockhold, PhD*

Senior Vice President, Biomedical Data Sciences, GlaxoSmithKline

Evaluating Compliance David McAvoy, MSES, JD

Director, Office of Scientific and Regulatory Policy, Global Regulatory Affairs, Eli Lilly and Company

Session 108 CTM - CLINICAL TRIAL MANAGEMENT, AHC, IS

10:30 AM - 12:00 PM LEVEL = •

Room 140B

Clinical Trial Offices: Boon or Boondoggle?

SESSION CHAIRPERSON John F. Bender. PharmD

Vice President, Clinical Research, Favrille, Inc.

Many research institutions are setting up clinical trial offices (CTOs) to handle the process of implementing clinical trials at their institutions. We will explore the pros and cons of CTOs and let you help decide if CTOs are a boon to clinical research or the latest boondoggle.

Susan K. Langley

Manager, Clinical Projects, Favrille, Inc.

Laurie Smith Director of Research, Rush University Medical Center

SESSION 109 DM - DOCUMENT MANAGEMENT/ ESUBMISSIONS

10:30 AM - 12:00 PM LEVEL = •

Room 206

A Standards-based Approach for Authoring Through Distribution

SESSION CHAIRPERSON

Christopher M. Lee, MS, MPA Director, Pfizer Inc

This session will present an overview of advantages to migrating from unstructured to structured authoring within a standards-based infrastructure.

Authoring and Distribution of Content: A Standards-based Approach Anthony N. Brown

Associate Director, Pfizer Inc

Achieving Competitive Advantage Through XML Technology Joe E. Jenkins Marketing Director, Life Sciences, Arbortext, Inc.

SESSION 110 ECLIN - ECLINICAL, CR, RA

10:30 AM - 12:00 PM LEVEL = •

Room 207B

Tools Sponsors Need to Implement Industry-wide Data Standards

SESSION CHAIRPERSON

Susan P. Duke, MS

Assistant Director, Novel Opportunity Assessment, GlaxoSmithKline

Now that the Study Data Tabulation Model (SDTM) is part of FDA guidance and the Analysis Data Model (ADaM) is close behind, it is a good time to consider next steps for industry-wide technical solutions. A discussion among more than 50 representatives from sponsors, vendors, CROs, FDA, and others was held in October 2004 to elucidate the needs of pharma. This session will highlight the tools prioritized from this discussion and relevant progress made since that time.

Plug and Play Tools: Why and How Industry-wide Clinical Data Standards Can Make the Difference

Susan P. Duke, MS

Assistant Director, Novel Opportunity Assessment, GlaxoSmithKline

Statistical Computing Environments: What It Is, Why It's Hot Alan Hopkins, PhD

President, PharmaStat LLC

Tools Wish List: Protocol Authoring, ODM Connectors, Standards Management, and a Standard Investigator Interface *Diane E. Wold, PhD*

Director, Data Standards Development and Management, GlaxoSmithKline

Session 111 FI - FINANCE, CR

10:30 ам - 12:00 рм LEVEL = •

Room 140A

The Red Team Review: Avoiding Study Delays and Expenses from the Outset

SESSION CHAIRPERSON

Christopher T. Speh, MA, MBA Independent Consultant

Many clinical studies are doomed to encounter costly delays simply because bid specifications on which proposals are based do not meet expectations of management or reflect the needs of the protocol. The Red Team Review uses knowledgable, but disinterested, personnel within the sponsor's own environment to assure that the bid spec "maps" back to the outsourcing requirement. In so doing, sponsors can avoid costly time delays and unnecessary study expenses.

The CRO Perspective Linda M. Orovitz Director, Contracts and Resource Management, Constella Clinical Informatics

The Third-Party Perspective Lani M. Hashimoto-Little Vice President, Recruitment Services, PharmaTech Solutions, Inc.

The Sponsor Perspective *Rhonda L. Caudill, Esg.*

Senior Purchasing Manager, Global R&D Clinical Sourcing, The Procter & Gamble Pharmaceuticals Company

SESSION 112 GCP - GOOD CLINICAL PRACTICES, RA

10:30 ам - 12:00 рм LEVEL = •

Room 202A Nursing and Pharmacy credits offered

Managing Regulatory Inspections

SESSION CHAIRPERSON

David B. Barr

Vice President, Pharmaceutical Services, AAC Consulting Group, Inc.

FDA and other regulatory agencies perform inspections of sponsors-monitors, clinical investigators, IRBs, clinical supply manufacturing sites and other associated sites as part of their approval process for new drugs, as well as for many other programmatic reasons. Knowing how to manage these inspections effectively can dramatically decrease the chances of compliance problems with the regulatory agencies, shorten the inspection time, and help assure successful results from these inspections.

Matthew T. Thomas, MD

Pharmacologist, Office of Medical Policy, Division of Scientific Investigations, CDER, FDA

David B. Barr

Vice President, Pharmaceutical Services, AAC Consulting Group, Inc.

M. Scott Harris, MD, MS, FACP

Clinical Professor of Medicine, University of Wisconsin Medical School President, Middleburg Consultants

SESSION 113 IS - INVESTIGATOR SITES, CR, FI

10:30 ам - 12:00 рм LEVEL = •

Room 101 CME credits offered

Compliance and Clinical Trials Finance

SESSION CHAIRPERSON

Harriett Singer, MS Instructor, Baylor College of Medicine

This session will discuss compliance risks in clinical trial finances and suggest approaches and some best practice models to ameliorate these risks. This session will discuss information of interest to beginners through experienced study personnel, and may represent a new perspective on financial risks in clinical research.

Compliance and Risk

Angela Fornataro McMahill, JD, CCP, CCRA

Director, Central Clinical Trials Office and Research Compliance, University of California-San Diego Health Sciences

Where Finance and Compliance Intersect Harriett Singer, MS Instructor, Baylor College of Medicine

instructor, baylor conege of medicin

Coordination Issues Germaine Luyckx, CCRC

Clinical Program Manager, Scripps Research Institute

Session 114 IT - INFORMATION TECHNOLOGY, RA

10:30 ам - 12:00 рм LEVEL =

Room 204BC

PDUFA and Information Technology

SESSION CHAIRPERSON

Thomas Scarnecchia, MS

Vice President, Corporate Informatics, Millennium Pharmaceuticals, Inc.

PDUFA III established a series of information technology goals for the FDA and industry. These goals cover aspects of IT organization, infrastructure, governance, common systems, and technology to enable electronic submissions. Members of PhRMA's Information Management Policy and Affairs Coordinating Committee (IMPACC) and FDA will lead a series of discussions covering the activities and accomplishments related to these goals and the implications for the industry. The session will also provide a preview of the themes under consideration for setting IT goals for PDUFA IV.

PDUFA III Information Technology Goals and Status Mark A. Gray

PDUFA IT Program Manager, Gateway Project Officer, Office of the Commissioner, FDA

IMPACC Strategic Agenda

Dennis X. Murray

North American Regional Head, Lifecycle and Licensing Information Management, Hoffmann-La Roche Pharmaceuticals

Themes Under Consideration for PDUFA IV IT Goals Thomas Scarnecchia, MS

Vice President, Corporate Informatics, Millennium Pharmaceuticals, Inc.

Session 115 MW - MEDICAL/SCIENTIFIC WRITING, RA

10:30 AM - 12:00 PM LEVEL = •

Room 102AB

CTD: Practical Solutions for Mixed Applications, Herbals and Biologics

SESSION CHAIRPERSON

Leonardo C.I. Ebeling, PhD, MD

General Manager, Dr. Ebeling & Assoc. GmbH, Germany

Practical problems and solutions in preparing the CTD modules 2.4 to 2.7 for applications with both original and bibliographical data and with respect to the concept of (essentially) similar products will be presented and discussed.

CTD: Practical Problems for Mixed Applications of Pharmaceutical Drugs Leonardo C.I. Ebeling, PhD, MD

General Manager, Dr. Ebeling & Assoc. GmbH, Germany

CTD: Practical Problems for Herbal Medicinal Products and the Reference to Bibliographical Literature/Documentation *Burt H. Kroes*

Senior Assessor for Quality, Department for the Assessment of Herbal and Homeopathic Medicinal Products, Medicines Evaluation Board, Netherlands CTD: Practical Problems for Biologics and the Concept of Comparability/Similarity *William D. Schwieterman, MD* Founder, Tekgenics, Inc., Biopharm Consultants

Session 116 NC - Nonclinical Laboratory Safety

10:30 ам - 12:00 рм LEVEL = •

Room 103B CME credits offered

Biological Markers: Validations and Points to Consider SESSION CHAIRPERSON

Philip R. Oldfield, DPhil, MSc Scientific Director, Charles River Laboratories - CTBR, Canada

Verification that a biomarker assay is specific for its intended purpose poses a formidable challenge. Biological markers are endogenous molecules present at some baseline concentration in the biological matrix of interest. It would be of interest from a regulatory point of view to consider the methods validation, and subsequent determination of biomarkers and their interpretation. Real case examples will be described with a number of points to consider.

Validation of Analytical Methods for the Determination of Biomarkers *Ralph McDade, PhD*

Strategic Development Officer, Rules-Based Medicine Inc.

Validation of a Biomarker Model Aurore Varela, DVM, IPSAV, MSc

Research Scientist, Charles River Laboratories - CTBR, Canada

Biomarkers: Regulatory Aspects

Douglas C. Throckmorton, MD Director, Division of Cardio-Renal Drug Products, CDER, FDA

SESSION 117 OS - OUTSOURCING, CR, FI

10:30 ам - 12:00 рм LEVEL =

Room 150A

Examining Use of Best Practices in CRO Outsourcing

SESSION CHAIRPERSON Mary Jo Lamberti, PhD

Senior Manager, Market Intelligence, Thomson CenterWatch

CenterWatch has collected metrics on sponsor outsourcing practices for two consecutive years. We will explore the following: the most common metrics that sponsors use; any changes that are occurring in outsourcing practices; and current approaches to best practices. The data provided will benefit companies in implementing more effective outsourcing strategies and tactics and will examine trends in the data over a two-year time period.

Vendor and Outsourcing Data Examining Best Practices Among Sponsor Companies

Mary Jo Lamberti, PhD Senior Manager, Market Intelligence, Thomson CenterWatch

CRO Perspective on Best Practices in Sponsor Outsourcing Joseph Bedford, PhD

Associate Director, Global Market Research, Covance

Creating an Effective Outsourcing Network Dennis J. LaCroix, JD

Director and Senior Counsel, Genzyme Corporation

SESSION 118 **PM1 - PROJECT MANAGEMENT**

10:30 AM - 12:00 PM

LEVEL =

Room 143AB

Project Management Institute credits offered

Fostering Innovation, Efficiency, and Effectiveness on **Project Teams**

SESSION CHAIRPERSON

Cindy Faulkner, MS

Associate Director, Regulatory Project Management, AstraZeneca

Doing more with less, being more efficient and effective, and tapping the full creative power of teams can be difficult, especially in large, matrix-structured organizations. This session will explore the factors that can stifle or promote a team's ability to be more innovative. A practical example of a unique program designed to drive creativity, efficiency, and effectiveness will be presented, along with suggestions to consider in designing a program to meet your own organization's needs.

A Case Study of an Innovation Initiative in Regulatory Project Management

Cindy Faulkner, MS

Associate Director, Regulatory Project Management, AstraZeneca

A Framework for Improving Innovation

Jean M. Egmon, EdD, MA

President, Third Angle, Inc.; Director, Center for Learning and Organizational Change, Northwestern University

Collaboration Across Domains to Improve Care of the Critically III Alvin Lever

Executive Vice President and Chief Executive Officer, American College of **Chest Physicians**

SESSION 119 **PM2 - PROJECT MANAGEMENT**

10:30 AM - 12:00 PM LEVEL = •

Room 143C

Project Management Institute credits offered

Drug Development Teams: Heavyweights versus Lightweights - What Is the Score?

SESSION CHAIRPERSON

Martin D. Hynes, III, PhD

Director, Quality and Operations, Pharmaceutical Product Research and Development, Eli Lilly and Company

This session will be a review of the processes companies utilize to establish team structures within the pharmaceutical industry and the results obtained using these methods.

Introduction: Team Constructs

Martin D. Hynes, III, PhD

Director, Quality and Operations, Pharmaceutical Product Research and Development, Eli Lilly and Company

Heavyweight Teams: A Retrospective

Russell L. Barton, MS

Director, Project Management Procedure Teams, Eli Lilly and Company

Lightweight Teams to Heavyweight and Back Again Carol S. Meyer

Senior Director, Project Planning and Management, Takeda Pharmaceutical Company

Panel Discussion

SESSION 120 **RA1 - REGULATORY AFFAIRS, BT**

10:30 AM - 12:00 PM LEVEL =

Room 146B

CME credits offered

Immunogenicity of Biotechnology-derived Medicinal **Products and Biosimilars/Follow-on Biologics: Regulatory Update and Recommendations** SESSION CHAIRPERSON

Iman Barilero, PhD, PharmD

Associate Director, European Regulatory Affairs, Global Regulatory Affairs and Quality Assurance, Johnson & Johnson Pharmaceutical Research and Development, LLC, UK

All experts from regulatory agencies (EMEA/CHMP, FDA), industry, and academia have stressed the need for a proactive and integrated approach to prediction, detection and management of harmful immunogenic properties of biotech-derived proteins. The prediction of risk of immunogenicity is based on previous experience, nature of the active substance, impurities accompanying the active substance and formulation of the final product (excipients, aggregates, etc.), route of administration, dosing regimen, and target patient population. The assessment of immune response in recipients requires an optimal antibody testing strategy, characterization of the observed immune response, as well as evaluation of the correlation between antibodies and clinical findings during phase III. If the risk is regarded high (considering above mentioned risk factors), a special risk management program should be proposed and will be required post-marketing by both FDA and the EMEA.

This session will provide with a regulatory update and experience sharing from the EMEA/CHMP and FDA on the current and future guidances for the assessment of immunogenicity for biotechnology-derived medicinal products and biosimilars/followon biologics, as a part of the overall guidance to assess the application of biosimilars/ follow-on biologics. This session will also be an opportunity to share industry experience and provide best practices in managing immunogenic response and risk management plan for biotechnology-derived medicinal products throughout product life cycle.

Regulatory Update and Experience from the EMEA/CHMP on the Assessment of Immunogenicity Jean-Hughes Trouvin, PhD

Chairman of CHMP Biotechnology Working Group; Director, AFSSAPS, France

Regulatory Update from the FDA: Scientific Evaluation and Recommendations for the Assessment of Immunogenicity Susan L. Kirshner, PhD Biologist, CDER, FDA

Industry Experience: Monitoring Changes in Immunogenicity of Biologics Following Manufacturing Changes Through Risk Management and Postmarketing Surveillance

Adrian P. Thomas, MD

Vice President, Benefit Risk Management, Johnson & Johnson Pharmaceutical Research and Development, LLC

SESSION 121 **RA2 - REGULATORY AFFAIRS, CR**

10:30 AM - 12:00 PM

Room 152A CME and Pharmacy credits offered

Registering Drugs for Pediatric Use

SESSION CHAIRPERSON Anne Tomalin

Chief Executive Officer, CanReg Inc., Canada

This session will focus on the development of drugs for pediatric use, including a discussion of research difficulties involved in preclinical and clinical development of pediatric drugs. Incentive programs in various countries will be

LEVEL =

discussed, including programs that exist to encourage pediatric research outside of the national departments of health. Guidelines and Expert Advisory Committees focused on pediatric review of drug products will also be reviewed.

Regulatory Framework for Pediatric Drug Development and Registration in the US

Shirley Murphy, MD Director, Division of Pediatric Drug Development, FDA

European Pediatric Initiative

Agnès Saint-Raymond, MD, PhD Head of Sector, Orphan Drugs and Scientific Advice; Preauthorization Evaluation of Medicines for Human Use, EMEA, EU

Challenges in Pediatric Research Stuart M. MacLeod, MD

Children's and Women's Health Centre of BCACB, Canada

SESSION 122 RA3 - REGULATORY AFFAIRS, NHP

10:30 AM - 12:00 PM LEVEL = •

Room 152B *CME and Pharmacy credits offered*

Regulations of Botanical Drugs in the US

SESSION CHAIRPERSON

Faraneh Attarchi, PhD, RAC

Director, Regulatory and Technical Services, Quintiles Inc.

Botanical products have been used for centuries in many parts of the world for their medical properties. These products are widely used in the United States as dietary supplements, but the focus of this session is their use and regulations as drugs.

This session will provide information on FDA guidance for conducting investigations and marketing botanical products as drugs in the United States. A member of the Botanical Review Team from the Center for Drug Evaluation and Research (CDER) will highlight the current submission trends and important points to consider for applicants.

Faraneh Attarchi, PhD, RAC

Director, Regulatory and Technical Services, Quintiles Inc.

Leslie A. Vaccari, RAC Regulatory Project Manager, CDER, FDA

SESSION 123 RA4 - REGULATORY AFFAIRS, BT, CMC

10:30 ам - 12:00 рм LEVEL =

Room 151B

FDA Initiative's Influence on Approval and Scale-up of Biotechnology Products

SESSION CHAIRPERSON

Andrea Chamblee, JD

Manager, Regulatory Affairs, Cambrex BioScience Walkersville Inc.

Scale-up raises a myriad of issues and questions for any manufacturer, and additional ones for manufacturers of biotechnology. It is unclear how FDA's modernization programs will be implemented by center officials and at the reviewer level in order for sponsors to realize the benefits. Also, the modernization program is centered in CDER; it is unclear whether biotechnology products in CBER, or even those now in CDER, will be treated as other drugs under PAT.

FDA's PAT Initiative Michael VanDerWerf Senior Regulatory Affairs Scientist, SAIC

FDA Initiatives and CMC Review and Approval

Ajaz S. Hussain, PhD Deputy Director, Office of Pharmaceutical Science, CDER, FDA

FDA Initiatives and Biologics/Biotechnology Scale-up: Impediment or Opportunity? Nita Upendra Patel, PhD

Vice President, Regulatory Affairs, GenVec, Inc.

Session 124 RA5 - REGULATORY AFFAIRS

10:30 ам - 12:00 рм LEVEL = •

Room 154AB

Generic Applications in the EU after Review 2001 SESSION CHAIRPERSON

John A. Lisman, MPharm, LLM

Policy Advisor, Medicines Evaluation Board, Netherlands

Review 2001 provides for some important changes with respect to generic applications. These changes are discussed in the context of ECJ case law and the practice of generic authorization in the EU.

Data Exclusivity after Review 2001 John A. Lisman, MPharm, LLM

Policy Advisor, Medicines Evaluation Board, Netherlands

Generics after Review 2001: Position of the Generic Industry *Beata Stepniewska, MS*

Pharmacist, Regulatory Affairs and EU Accession, European Generic Medicines Association, Belgium

Generics after Review 2001: Position of the Innovative Industry *Christine-Lise Julou, PharmD*

Manager, Scientific and Regulatory Affairs, EFPIA, Belgium

SESSION 125 ST - STATISTICS

10:30 ам - 12:00 рм LEVEL =

Room 201 CME credits offered

When to Specify the Statistical Analysis

SESSION CHAIRPERSON

Simon Day, PhD

Statistics Unit Manager and Scientific Advice Coordinator, Licensing Division, Medicines and Healthcare products Regulatory Agency (MHRA), UK

The speakers will discuss the advantages and disadvantages of specifying the detailed statistical analysis for a study very early or very late. We will discuss how much detail can be left to (or changed in) the blind review of the analysis plan.

Prespecifying Details of the Statistical Analysis: What, Where, When, and Why?

Robert Hemmings, MSc

Senior Statistical Assessor, Medicines and Healthcare products Regulatory Agency (MHRA), UK

To Be (Late) or Not to Be (Late): What's the Reason? Jorgen Seldrup, PhD

Development Director, Quintiles, France

Statistical Analysis Plans: An FDA Reviewer's Perspective J. Todd Sahlroot, PhD

Statistics Team Leader, CDER, FDA

Session 126 TR - TRAINING, GCP

10:30 ам - 12:00 рм LEVEL =

Room 151A

Effectively Managing the Challenges of Global Training SESSION CHAIRPERSON

Janet F. Zimmerman, MS, RN

Senior Director, Training Services, PharmaNet

When planning worldwide training, what operational or resource issues need to be addressed? How do trainers balance delivering global company policies and procedures with local office or affiliate practices and customs? During this session, speakers from sponsor and contract research organizations will present case studies from their global training programs. The emphasis will be on explaining the challenges encountered in implementing worldwide training and how they were effectively managed.

Case Study 1: Global SOP Training Liz Wool Clinical Research Trainer, SCIOS, Inc.

Case Study 2: Global Introductory Course in Clinical Development Sibylle Roth, MA

Manager, International Training, ALTANA Pharma, Germany

Case Study 3: Global Monitor Training Bruce A. Edelman, MS Senior Training Associate, Eli Lilly and Company

SESSION 127 VA - VALIDATION

10:30 ам - 12:00 рм LEVEL =

Room 209AB

General Validation Issues

SESSION CHAIRPERSON *Martin Browning, MS* President, EduQuest Inc.

The lack of understanding, the myth, and the reality of validation are explored. A mechanism for determining the degree of validation and an approach to validation are presented.

When is Enough, Enough?

Martin Browning, MS President, EduQuest Inc.

An Ethical Approach to Validation K. T. Oxford

Director, META Solutions, Inc.

12:00 рм - 1:30 рм

LUNCHEON

Lunches will be distributed from 12:00 PM to 1:00 PM in Exhibit Hall C, Lower Level, Convention Center

Session 128 AD - Advertising, MA, RA

LEVEL =

1:30 рм - 3:00 рм **Room 202B**

Pharmacy credits offered

Update on FDA Enforcement of Promotional Activities

SESSION CHAIRPERSON Wayne L. Pines

President, Regulatory Services and Healthcare, APCO Worldwide

FDA's active enforcement of promotion regulations provides insight into how the agency regards certain promotional activities. This session will provide a review of the latest enforcement actions by DDMAC and APLB and the practices that the agency is concerned about.

Update from DDMAC

Thomas W. Abrams, MBA, RPh

Director, Division of Drug Marketing, Advertising and Communications, CDER, FDA

Update from APLB Glenn N. Byrd, MBA, RAC Chief, Advertising and Promotional Labeling Branch, CBER, FDA

Session 129

CMC - CHEMISTRY, MANUFACTURING, AND CONTROLS, RA

1:30 рм - 3:00 рм

Room 150B

ICH Quality Guidances: Q8, Q9, and Q10

LEVEL =

session chairperson **Robert G. Baum, PhD** Executive Director, Pfizer Global R&D

Updates on three quality guidelines being developed by the International Committee on Harmonization Working Groups will be presented. ICH Q8 on Pharmaceutical Development, ICH Q9 on CMC Risk Management, and ICH Q10 on Quality System Life Cycle Management will be discussed from industry's and the Agency's perspectives.

Industry Perspective Robert G. Baum, PhD Executive Director, Pfizer Global R&D

FDA Perspective Norman R. Schmuff, PhD Deputy Director, Division of New Chemistry III, CDER, FDA

LEVEL = •

Panel Discussion/Q&A Period

Session 130

CP - CLINICAL SAFETY AND PHARMACOVIGILANCE, RA

1:30 рм - 3:00 рм **Room 207A**

Regulatory Inspections of Company Pharmacovigilance Departments

CME credits offered

SESSION CHAIRPERSON

Carol L. Krueger

Consumer Safety Officer, Division of Compliance, Risk Management, and Surveillance, CDER, FDA

LEVEL =

An international pharmacovigilance program expert, an FDA CDER compliance officer, and a field investigator will discuss their experiences with postmarketing adverse drug event (PADE) reporting inspectional programs and provide guidance on preparing for PADE inspections. They will discuss common deficiencies found during PADE inspections, and review strategies to enhance regulatory compliance and pharmacovigilance capabilities.

Helen Politis-Norton

Director, UK & Ireland, Vigilex Ltd., The Innovation Centre, UK

Carl Anderson

QA Auditor and Consultant

SESSION 131 CR/RA - CLINICAL RESEARCH AND DEVELOPMENT/REGULATORY AFFAIRS, RD

1:30 рм - 3:00 рм LEVEL =

Ballroom AB, 3rd Floor

PLENARY SESSION

Critical Path: Are We at the Fork in the Road? SESSION CHAIRPERSONS

Ronald D. Fitzmartin, PhD, MBA

Vice President, Global Technical Services, Daiichi Medical Research, Inc.

Stephen E. Wilson, DrPH, Capt. USPHS Deputy Director, Division of Biometrics II, CDER, FDA

The FDA has published a report entitled *"Innovation or Stagnation – Challenge and Opportunity on the Critical Path to New Medical Products"* (March 2004, available at http://fda.gov). The "Critical Path" report identifies the need for unprecedented improvement in the drug development process so that it is more efficient, predictable, and innovative, and less costly. The opportunities for dramatic change fall into three major dimensions and are identified as: *assessing safety, demonstrating medical utility, and industrialization.*

This moderated plenary will have FDA and industry leaders engaged in an interactive Q & A panel session to address the goals, accomplishments to date and future of the Critical Path initiative.

Moderator

Debbie Henderson

Director, Office of Executive Programs, CDER, FDA

Panelists

Lawrence J. Lesko, PhD

Director, Office of Clinical Pharmacology and Biopharmaceutical Science, CDER, FDA

Janet Woodcock, MD Acting Deputy Commissioner of Operations, FDA

Robert J. Temple, MD Director, Office of Medical Policy and Office of Drug Evaluation, CDER, FDA

Douglas C. Throckmorton, MD Director, Division of Cardio-Renal Drug Products, CDER, FDA

Steven J. Miller, PhD Vice President, Regulatory Affairs, AstraZeneca

Sean Harper, MD

Vice President, Medical Sciences, Amgen Inc.

SESSION 132 CS - CLINICAL SUPPLIES, CR

1:30 рм - 3:00 рм

Room 143C

Pharmacy credits offered

Clinical Supply Management

session chairperson Douglas Meyer, MBA, RPh

Senior Vice President, Pharmaceutical Science, InfoPro Solutions

The entire clinical supply chain is usually not visible to clinicians, except when there is a supply problem. This session provides a comprehensive picture of the diverse clinical supply service providers: CROs, IVRS vendors, distributors, clinical packagers, and clinical sites. Topics include forecasting models, resupply models, and automated data exchange among these providers.

Mastering the Extended Clinical Supply Chain

Douglas Meyer, MBA, RPh

Senior Vice President, Pharmaceutical Science, InfoPro Solutions

Integration Between Clinical Supply Management and IVR/EDC Systems *Tom O'Connell*

Vice President, Operations, DynaRand, LLC

IVRS Systems and Other Technologies to Manage Limited Drug Supply Jean-Remy Behaeghel, MS

Director, IVRS, Perceptive Informatics, Inc.

Session 133	CTM - CLINICAL TRIAL MANAGEMENT
1:30 рм - 3:00 рм	LEVEL =

Room 140B *CME credits offered*

Emerging World Clinical Development: Learning from Each Other

SESSION CHAIRPERSON

Nermeen Varawalla, PhD, MD, MBA

Vice President, Business Development International, PRA International, UK

Emerging countries represent compelling opportunities for cost-effective patient recruitment. However, sponsors have concerns related to data quality and nascent regulatory and ethics processes. Because of a similarity between the individual emerging countries and their varying degrees of advancement on the clinical development "learning curve," there is a valuable opportunity for them to share experiences and jointly develop solutions to the challenges they face. This session will do just this.

Cezary Statuch, PhD

Executive Director, Regional Clinical Operations - International, Global Development Operations, Bristol-Myers Squibb

Andy Lee, MA Senior Director, Pfizer Global Research and Development

William D. Schwieterman, MD

Founder, Tekgenics, Inc., Biopharm Consultants

Session 134 DM - DOCUMENT MANAGEMENT/ ESUBMISSIONS, RA

1:30 рм - 3:00 рм LEVEL = •

Room 206

FDA Data Standards Initiatives – Part 1 of 2 SESSION CHAIRPERSON

Randv Levin. MD

Director, Office of Information Management, CDER, FDA

Part 2 of this session is being held on Monday at 3:30 PM.

FDA is actively pursuing data standards designed to streamline and expedite the regulatory review process. This session will focus on the need for data standards, current FDA data standardization initiatives, the impact on the review process, and the anticipated benefits of these initiatives.

Stability Data and CDISC

Randy Levin, MD

Director, Office of Information Management, CDER, FDA

SPL

Steven Gitterman, MD, PhD

Deputy Director, Director of Special Pathogens and Immunologic Drug Products, CDER, FDA

Update on the Health Level Seven Individual Case Safety Report Standard Lise Stevens-Hawkins

Consumer Safety Officer, Office of Biostatistics and Epidemiology, Division of Epidemiology, CBER, FDA

Session 135 **ECLIN - ECLINICAL**

1:30 рм - 3:00 рм

LEVEL =

Room 207B CME credits offered **Clinical Data Interchange Standards (CDISC), from Protocol Through Submission**

SESSION CHAIRPERSON

Rebecca D. Kush, PhD President, CDISC

CDISC, the Clinical Data Interchange Standards Consortium, has made significant progress in the past year. Independently and through collaborations with Health Level 7 (HL7), NCI, and FDA, standards developed to facilitate the exchange of clinical trial information now span the realm from protocols through electronic submissions and are beginning to link clinical research with clinical care.

This session will include information on the business case for standards and global adoption of the CDISC standards; an update on CDISC progress over the past year, including progress towards harmonization of the CDISC standards with the HL7 Reference Information Model; and implementation experiences with the CDISC standards, including submissions to FDA.

Global Adoption of CDISC Standards and a Business Case for Standards Edward Helton, PhD

Chief Strategist, Regulatory and Biomedical Affairs, SAS Institute

The Business Cases for CDISC Standards Carol Rozwell

Vice President and Research Director, Life Sciences Industry Research, Gartner Group

FDA Experiences with CDISC Standards Armando Oliva, MD

Associate Director for Policy, Office of New Drugs, CDER, FDA

SESSION 136 FI - FINANCE, OS

1:30 рм - 3:00 рм LEVEL =

Room 140A

Outsourcing in Europe: Guidance to US Companies SESSION CHAIRPERSON

Francisco Harrison, MD

Chairman, Harrison Clinical Research GmbH, Germany

Europe is a crucial market for pharmaceuticals and product development. With the expansion of the European Union, the complexity of the European clinical trials performance requires a deep understanding of the advantages and disadvantages of this market as a whole and as individual countries.

Europe: Expectations and Reality Lesley J. Groves, PhD Senior Director, Clinical Operations, Santarus, Inc.

Why and When to Go to Europe

Barbara J. Geiger, RN President and Clinical Director, Clinical Research Management Services, Inc.

The Reality of Collaborating with US Companies Nancy Meyerson-Hess, MPhil Director, Clinical Operations, Harrison Clinical Research GmbH, Germany

GCP - GOOD CLINICAL PRACTICES, SESSION 137 AHC, IS LEVEL =

1:30 рм - 3:00 рм

Room 202A CME, Nursing, and Pharmacy credits offered

GCP Audits and Inspections: Determination of What Is, and What Is Not, Investigational Site Staff Misconduct SESSION CHAIRPERSON

Vernette J. Molloy, MBA, RN Vice President, GCPA, Inc.

This session will explore advanced auditing and instances of misconduct discovery; discussion will include determinants of what constitutes misconduct and will identify ways to mitigate charges of misconduct.

Misconduct: A GCP Auditor's Perspective Douglas R. Mackintosh, DrPH, MBA President, GCPA, Inc.

GCP Inspections: Investigational Site Misconduct from the FDA Perspective

Leslie Ball, MD Branch Chief, Medical Officer, CDER, FDA

Misconduct: A Regulatory Attorney's Perspective Michael D. Petty, JD, MPH Partner, Ropes and Gray

SESSION 138 **IS - INVESTIGATOR SITES, AHC, CR**

1:30 pm - 3:00 pm **Room 101**

LEVEL = • CME credits offered

I Am OK, I Am Indemnified! What Does This REALLY Mean? SESSION CHAIRPERSON

Nadina C. Jose, MD, CPI

President and CEO, Research Strategies, Inc.

Is there a real understanding of what it means to be "indemnified"? Does one truly know what coverage is received when a subject suffers a serious adverse event that is determined to have been caused by the study product? Sponsor-CRO-site perspectives will be presented in addressing the issues surrounding "indemnification."

Issues in Site Indemnification: The CRO Perspective Arthur Gertel, PhD, MS

Vice President, Clinical Services, Regulatory and Medical Writing, Beardsworth Consulting Group, Inc.

Managing Risks in Clinical Trials J. Andrew Lemons, JD Attorney at Law, Alston & Bird LLP

Issues in Indemnification Nadina C. Jose, MD, CPI President and CEO, Research Strategies, Inc.

SESSION 139 IT - INFORMATION TECHNOLOGY, ECLIN

1:30 рм - 3:00 рм

Room 204BC

EDC Vendor Selection: Do We Really Need a Pool? SESSION CHAIRPERSON

LEVEL = •

Kimberly Tiefenbach

Director, Clinical Services and Support, OmniComm Systems Inc.

With all of the electronic data capture vendors out there, both large and small, determining which vendor will be the best fit for your company can be a daunting task. The importance of knowing not only what the different vendors have to offer but also what your internal needs are will be stressed. A pharmaceutical company and a CRO will discuss the process they used to choose an EDC vendor.

One CRO's Criteria and Process in Selecting an EDC Vendor Lloyd J. Baroody, MBA

Chief Executive Officer, Target Research Associates

Selecting an EDC Vendor from the Pharmaceutical Perspective Mark J. Holdbrook

Director, Data Management and Biostatistics, Santen, Inc.

Session 140 MW - MEDICAL/SCIENTIFIC WRITING, RA

1:30 рм - 3:00 рм LEVEL =

Room 102AB

ICH CTD Guidelines and Current Status of Implementation in DMFs, INDs, NDAs, BLAs and ANDAs

SESSION CHAIRPERSON

Justina A. Molzon, JD, MPharm

Associate Director for International Programs, CDER, FDA

Globalization of the pharmaceutical industry has created the need to harmonize recommendations for the development of new pharmaceuticals as well as regulatory requirements. To address this need, the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) was created in 1990. ICH has generated over 50 harmonized guidelines on the information to be submitted to ICH regulatory authorities for pharmaceuticals. The next logical step was to arrange the information in a common format for submission, and ICH has established the Common Technical Document (CTD). The concept of the CTD has been extended from the NDA to DMFs, INDS, BLAs, and ANDAs. CDER staff will discuss implementation and review aspects of this extension to various submission formats.

ICH CTD Guidelines Implementation and Current Status Justina A. Molzon, JD, MPharm

Associate Director for International Programs, CDER, FDA

e-CTD Use in CDER Submissions Gary Gensinger

Director, Review Technology Staff, Office of Information Management, CDER, FDA

CTD and e-CTD: A Reviewer's Perspective Mark R. Seggel, PhD Chemist, CDER, FDA

SESSION 141 NC - NONCLINICAL LABORATORY SAFETY, RA

1:30 рм - 3:00 рм LEVEL =

Room 103B

The In Vitro Clastogen Conundrum

SESSION CHAIRPERSON

Carl L. Alden, MD, DVM

Vice President, Drug Safety Evaluation, Millennium Pharmaceuticals, Inc.

Since 26% of the drugs in the PDR are in vitro clastogens across therapeutic indications, the predictiveness (for in vivo genotoxicity) of this assay has been questioned. However, the in vitro clastogen assessment is required in drug development. The finding of a molecule that is an in vitro clastogen but that is an in vivo clastogen negative and Ames negative molecule represents a common situation in drug development necessitating additional testing prior to repeat dosing in humans. The current regulatory guidance in this situation as well as strategies to reduce the high false positive rate will be the focus of discussion.

Evolution in Regulatory Guidance for Ames Negative, In Vivo Micronucleus Negative but In Vitro Clastogen Drug Candidates David Jacobson-Kram, PhD, DABT

Associate Director for Pharmacology and Toxicology, Office of New Drugs, CDER, FDA

Strategies for Reducing the High False Positive Rate in In Vitro Clastogen Testing *Maik Schuler, PhD*

Senior Principal Scientist, Pfizer Inc

SESSION 142 NHP - NATURAL HEALTH PRODUCTS, CR

1:30 рм - 3:00 рм	LEVEL =
Room 154AB	CME and F

CME and Pharmacy credits offered

Evaluating Natural Health Products in Patients with Serious and Life-threatening Conditions

session chairpersons Freddie Ann Hoffman, MD

Chief Executive Officer, HeteroGeneity, LLC

Shaw T. Chen, MD, PhD

Team Leader, Botanical Review Team, Associate Director, Office of Drug Evaluation V, CDER, FDA

Although Natural Health Products (NHPs) are being sold in the United States as "foods" (including dietary supplements), many NHPs are now being evaluated for their potential as drugs. This session will examine clinical trials assessing NHPs for serious and life-threatening conditions. A discussion of the selection of starting dose, use of prior history of human use, protocol design, and the filing of an Investigational New Drug Application and New Drug Application with the US Food and Drug Administration will be discussed.

A Phase I/II Study of the Botanical Drug (PHY906) Plus Capecitabine Advanced in Unresectable Hepatocellular Carcinoma *Robert Tilton, PhD*

Vice President, Science and Technology, Phytoceutica, Inc.

Treatment for Hypertriglyceridemia: The Approval of a Heterogeneous "New" Drug

Robert A. Shalwitz, MD

Executive Director, Clinical Development, Reliant Pharmaceuticals, Inc.

Role of the National Center for Complementary Medicine (NCCAM) in Developing Natural Health Products as Drugs: Scientific Requirements for NIH Funding and Funding Programs

Johnathan (Josh) Berman, MD, PhD, FAAP

Director, Office of Clinical and Regulatory Affairs, National Center for Complementary and Alternative Medicine, National Institutes of Health

SESSION 143 OS1 - OUTSOURCING, RD

1:30 рм - 3:00 рм LEVEL =

Room 147B

A Look at Today's Drug Development Outsourcing Practices: Successes, Failings, and Ways to Improve Them – Part 1 of 2

SESSION CHAIRPERSON John R. Vogel, PhD Drug Development Consultant, John R. Vogel Associates, Inc.

Part 2 of this session is being held on Monday at 3:30 PM.

This two-part session will begin with a presentation and discussion of the results of a recent comprehensive survey on sponsor views of the effectiveness of clinical drug development outsourcing. The second part of the session will focus on identifying practical approaches to ensuring successful outsourcing.

David Ginsberg, DO

Chief Medical Officer and Senior Vice President, Omnicare Clinical Research

James Kirwin

Assistant Vice President, Clinical Development, Wyeth Research

SESSION 144 OS2 - OUTSOURCING, CR

1:30 рм - 3:00 рм LEVEL =

Room 150A

Functional Outsourcing: How are Different Project Management Models Being Applied?

SESSION CHAIRPERSON Barbara J. Birch

Alliance Business Director, i3 Statprobe

Over the past several years, sponsors have focused on functional outsourcing to expand the capacity of internal teams while retaining close control of clinical development projects. Can functional outsourcing be successful without project management? How can PM processes be streamlined? Where are the sponsor's greatest opportunities for cost savings? This session will address these questions and examine alternative approaches to project management in a functional alliance relationship.

Cynthia R. Rutgers, MS

Associate Director, Business Operations, Valeant Pharmaceuticals International

David P. Facklam, MS Senior Director, Clinical Research, Astellas Pharma, Inc.

Mark A. Sanders, MBA

Director, Site Lead - New London, Contracts and Outsourcing, Pfizer Inc

Session 145 PM1 - PROJECT MANAGEMENT

1:30 рм - 3:00 рм LEVEL = •

Room 143AB

Resource Management: Key Success Factors and

Project Management Institute credits offered

Lessons Learned SESSION CHAIRPERSON

Michael Deagle, MBA

Principal, PRTM

The scarcity of blockbuster launches combined with the expiration of existing patents is forcing many drug discovery and development companies to reexamine how to gain the most from their limited resources. Improving R&D productivity through optimized resource management is emerging as a critical core competency to accelerate time to market and maximize portfolio value. This session will highlight for participants resource management approaches and lessons learned within big pharma on key areas such as adapting to scale, integrating planning and control processes and methods for estimating demand.

Portfolio and Resource Management: Adapting to Scale

Michael D. Taylor, PhD Senior Vice President, Global Project Management, Pfizer Global Research & Development

Integrating the Planning and Control Processes Leah Goldbroch, MBA

Director, Global Project Management, Abbott Laboratories

Developing a Standard and Validated Approach to Estimating Resource Demand

Linda Martin, MBA Principal, KMR Group, Inc.

Session 146 PM2 - PROJECT MANAGEMENT

LEVEL =

1:30 рм - 3:00 рм **Room 145A**

Project Management Institute credits offered

eXtreme Project Management: How to Succeed in the Face of Volatility

SESSION CHAIRPERSON

Doug DeCarlo

Principal, The Doug DeCarlo Group

Agility, not rigidity, is the key to success on extreme projects. This often requires that we break the rules and abandon the rigor and regimentation of traditional project management. Our panel will share experiences along a number of dimensions critical to delivering value in the face of change and uncertainty.

The eXtreme Project Management Framework Doug DeCarlo

Principal, The Doug DeCarlo Group

An Immunomodulatory Oligonucleotide: The Race to the Clinic J. Michael Grindel, PhD President, EPD Pharma Solutions LLC

An Immunomodulatory Oligonucleotide: The Race to the Clinic *Timothy M. Sullivan, PhD*

Vice President, Development, Hybridon, Inc.

SESSION 147 PP - PUBLIC POLICY/LAW, CR

1:30 рм - 3:00 рм

LEVEL = •

Room 103A

CME, Nursing, and Pharmacy credits offered

Clinical Trials on Trial: Potential Legal Liability Arising from Clinical Trials

SESSION CHAIRPERSON

Mark C. Hegarty, JD

Partner, Shook Hardy & Bacon LLP

In this session, experienced lawyers will conduct a mock trial involving issues that may arise in clinical trial lawsuits. The mock trial will include opening statements and closing arguments, as well as realistic direct and crossexamination of the primary witnesses in the case, including video evidence. At the conclusion of the mock trial, the lawyers will entertain questions about the mock trial.

Mark C. Hegarty, JD

Partner, Shook Hardy & Bacon LLP

John F. Kuckelman, JD

Attorney, Shook Hardy & Bacon LLP

SESSION 148 RD - R&D STRATEGY, AHC, CR, IS

1:30 PM - 3:00 PM LEVEL = ● **Room 149AB** Nursing cr

Nursing credits offered

Monitoring and Managing a Changing Investigative Site Landscape SESSION CHAIRPERSON

Kenneth A. Getz, MS, MBA

Research Fellow, Tufts Center for the Study of Drug Development, Tufts University; Chairman, CISCRP

This session reviews and discusses the structure and longitudinal changes in the investigative site market. Representatives from the Tufts Center for the Study of Drug Development and the University of the Sciences in Philadelphia will present original research on the changing investigative site market and offer insights into ways that sponsors can more effectively and efficiently manage their investigative sites.

A Look at the Changing Structure of the PI Landscape Kenneth A. Getz, MS, MBA

Research Fellow, Tufts Center for the Study of Drug Development, Tufts University; Chairman, CISCRP

R&D Trends and Their Impact on the Study Conduct Market *Christopher P. Milne, DVM, MPH, JD*

Assistant Director, Tufts Center for the Study of Drug Development, Tufts University

Implications of a Changing PI Landscape on Site Selection and Site Management

Harold E. Glass, PhD

Professor and Director, Graduate Program in Pharmaceutical Business, University of the Sciences in Philadelphia

SESSION 149 ST - STATISTICS

1:30 рм - 3:00 рм LEVEL =

Room 201 CME credits offered

Analyze as You Randomize?

SESSION CHAIRPERSON Michael P. O'Kelly, PhD, MA

Statistical Consultant, Quintiles Ireland Ltd., Ireland

"Analyze as you randomize" is a principle of Fisher's which almost all statisticians feel they must follow. The history of the principle is explained and practical responses to it, from strict adherence to loose approximation, are described and argued for. Practical examples of where the issue arises include baseline adaptive randomization, and dose-escalation trials where a control is pooled across a number of separately randomized cohorts.

A Regulatory Perspective on Adaptive Randomization *H. M. James Hung, PhD*

Team Leader and Acting Deputy Director, Division of Biometrics I, Office of Biostatistics, CDER, FDA

Role of Randomization in Early Phase II Trials

Ad Theeuwes

Project Statistician, CNS, Solvay Pharmaceuticals, Netherlands

Biased Coin Randomization: When Can a Nominal Analysis of Covariance Be Appropriate? James W. Frane, PhD

Statistical Consultant

SESSION 150 TR - TRAINING

1:30 рм - 3:00 рм LEVEL = •

Room 151A

Pros and Cons of Web-based Training in a Global Research and Development Setting

SESSION CHAIRPERSON

Michael van der Burght, MD, MBA

Director, Department of Planning and Administration, Clinical R&D, Ferring Pharmaceuticals A/S, Denmark

Web-based training represents a great opportunity within the area of global training. The speakers will share experiences after introducing this tool into an academic R&D setting. The steps involved in introducing web-based training will be provided.

Assessing if You Should Use Web-based Training

Kimberly N.M. Andrews, MEd Performance Consulting Manager, PPD Development

Delivering Content Using Web-based Training: To Whom? Bo Maach-Moller, MS

Clinical Operations Manager, Nordic Area, Eli Lilly and Company, Denmark

How to Implement Web-based Training Michael van der Burght, MD, MBA

Director, Department of Planning and Administration, Clinical R&D, Ferring Pharmaceuticals A/S, Denmark

Session 151 VA - Validation, IT, RA

1:30 рм - 3:00 рм LEVEL = •

Room 209AB

Current Regulatory Issues

session chairperson Harry C. Huss, MS

Manager, Quality Auditing Services, Stelex, Inc.

This session will address three topics that generate a great deal of discussion within the pharmaceutical industry. First, risk assessment strategies and management related to computer system validation have been employed unofficially for a long time, but recent guidelines issued by FDA have called for documented and justified risk assessments related to computer system controls. Second, the cost/benefit of computer system validation has long been a controversial topic, especially when discussed between company management and quality assurance. Finally, with modern pharmaceutical companies operating routinely on a global basis, the issue of regulatory requirements of authorities outside the US can be confusing. By addressing these topics, the session will provide a broad range of information that all pharmaceutical professionals with computer system control responsibilities should find interesting and useful.

Risk Assessment and Management Specific to Computer Validation *Leonard A. Grunbaum, MBA*

Partner, The Practical Solutions Group, LLC

Cost/Benefit of Validation Breffni K. Martin Company Director, RegIntel Ltd., Ireland

International Regulations on Quality Systems and Risk Affecting Manufacturing and Validation: Current and Future Initiatives *Louis A. Angelucci, III* Vice President, AAC Consulting Group, Inc.

3:00 рм - 3:30 рм **REFRESHM**

REFRESHMENT BREAK

Exhibit Halls ABC, Lower Level Convention Center

Session 152 AD - Advertising, MA, RA

LEVEL =

Room 202B *Pharmacy credits offered*

The OIG/US Attorney/Attorney General Update: Where They've Been, Where They Are, and Where They're Going SESSION CHAIRPERSON

Norman A. Drezin, RPh, JD President, Drezin Consultants, LLC

3:30 рм - 5:00 рм

The OIG Compliance Program Guidance, the PhRMA Code on Interactions with Healthcare Professionals, and the enforcement posture of federal and state law enforcement agencies have significantly changed the concerns and compliance issues involved with the marketing of prescription drugs.

This session will examine the concerns of agencies other than FDA over the last ten years – from their initial concerns through lessons learned from the cases they've pursued, to where they are going tomorrow. It will examine the interests of federal and state law enforcement agencies in the marketing practices of the prescription drug, biologic, and medical device industries, and

provide an understanding of why the authorities select or pursue certain cases, the types of conduct that concern these agencies, and what their concerns are for the future.

Thomas Kanwit, JD

Assistant US Attorney, US Attorney's Office

T. Reed Stephens, JD

Partner, Sonnenschein Nath & Rosenthal LLP

Session 153

AND CONTROLS, RA

CMC - CHEMISTRY, MANUFACTURING,

3:30 рм - 5:00 рм Room 150B

ICH Quality Guidance: Q5E

SESSION CHAIRPERSON

Keith Webber, PhD

Acting Director, Office of Biotechnology Products, CDER, FDA

The ability to make changes to a pharmaceutical manufacturing process is critical to ensuring the availability of drugs of the highest quality and affordability. The ICH Q5E document provides for a harmonized set of principles to assess the impact of manufacturing changes on biotechnology drug products to ensure that there has been no adverse impact on quality, safety, or efficacy. This session will provide an overview of the ICH Q5E document and will explore aspects of its utilization.

Industry Perspective

Anthony S. Lubiniecki, ScD

Vice President, Technology Transfer and Project Planning, Centocor

FDA Perspective

Barry Cherney, PhD Deputy Director, Division of Therapeutic Proteins, Office of Biotechnology Products, CDER, FDA

Panel Discussion/Q&A Period

SESSION 154

CP - CLINICAL SAFETY AND PHARMACOVIGILANCE, ECLIN, RA

3:30 рм - 5:00 рм LEVEL = ■

Room 207A

Electronic Submission of ICSRs

session chairpersons *William W. Gregory, PhD* Director, Regulatory Affairs, Pfizer Inc

Sabine Brosch, MSc, PhD

Deputy Head of Sector, Pharmacovigilance, EMEA, EU

Technical and regulatory hurdles for electronic transmission of Individual Case Safety Reports (ICSRs) by companies to regulatory authorities have been overcome in the three ICH regions. Indeed, paperless submission of expedited ICSRs to the FDA, EMEA, MHLW, and other national authorities is now a reality, and other business partners are actively engaged. The scope now includes reports from both clinical trial and spontaneous sources. In November 2005 new regulation in Europe will impact products approved under the Central Authorisation Procedure, Mutual Recognition Procedure, and National Authorisation Procedure. Electronic trading of ICSRs requires careful integration of the ICH E2B(M), M2, and M1 (MedDRA®) standards, which are interdependent. In this session, the current status of electronic case reporting in Europe, Japan, and the US will be discussed from the perspectives of regulators and industry, with the focus on the situation in the US and Europe. Summary statements from each region and a public update from the ICH E2B(M) and M5 Working Groups will be followed by a panel discussion.

Electronic Case Reporting: Bird's Eye View of the Terrain

William W. Gregory, PhD Director, Regulatory Affairs, Pfizer Inc

Status of Electronic Case Reporting in the US and the AERS Database Roger A. Goetsch, PharmD Director, Regulatory Affairs, Office of Drug Safety, CDER, FDA

Status of EudraVigilance and Related Electronic Reporting with All Stakeholders Sabine Brosch, MSc, PhD

Deputy Head of Sector, Pharmacovigilance, EMEA, EU

Industry Perspectives on Electronic Case Reporting with Multiple Trading Partners

Kostas Kidos, MSc

Senior Director, Regulatory Services, Merck & Company, Inc.

Panel Discussion

Michael A. Ibara, PharmD Director, Information Resources, Worldwide Safety, Pfizer Inc

LEVEL = •

SESSION 155 CR1 - CLINICAL RESEARCH AND DEVELOPMENT, RA

3:30 рм - 5:00 рм

Nursing and Pharmacy credits offered

Global Pediatric Trials

SESSION CHAIRPERSON

Room 145A

Daniel Brasseur, MD, PhD

Chairman of CHMP at EMEA, EU; Ministry of Public Health, Belgium

This session will address the New European Pediatric Regulation within the global context of drug development, most particularly in the US. The Pediatric Regulation will be described and its impact assessed from a global industry viewpoint.

European Situation Daniel Brasseur, MD, PhD Chairman of CHMP at EMEA, EU; Ministry of Public Health, Belgium

Pediatric Regulation *Magali Lecomte-Bekkaï, PharmD, MS* Director, Regulatory Information - IDRAC, Thomson Scientific, France

EMEA Activities in Preparation of the Pediatric Regulation Agnès Saint-Raymond, MD, PhD

Head of Sector, Orphan Drugs and Scientific Advice; Preauthorization Evaluation of Medicines for Human Use, EMEA, EU

Session 156 CR2 - Clinical Research and Development, ST

3:30 рм - 5:00 рм LEVEL = ●

Pharmacy credits offered

Monitoring of Clinical Endpoint Trials

SESSION CHAIRPERSON

Room 145B

Nacer E. Abrouk, PhD

Director, Department of Statistics and Data Management, ALZA Corporation

The design, execution, analysis and interpretation of large endpoint trials have many challenges. Interim monitoring of data pertinent to safety and efficacy can be an intricate process involving several committees with differing discipline affiliations. This session will provide an indispensable discussion of the challenges encountered, and some best practices recommendations.

Overview of Clinical Endpoint Trials Nacer E. Abrouk, PhD

Director, Department of Statistics and Data Management, ALZA Corporation

Overview of Product Safety Assessment Strategies *Noel Mohberg, PhD* Consultant/Advisor

Session 157 CR3 - CLINICAL RESEARCH AND DEVELOPMENT

3:30 PM - 5:00 PM LEVEL = ■ **Room 147A** Pharmacy

Pharmacy credits offered

How to Get Reliable Results from Feasibility Studies: Factors and Metrics

SESSION CHAIRPERSON

Didier Saur, MD

European Medical Director, MDS Pharma Services, France

Feasibility studies have the potential to provide powerful results, but are exposed to serious inherent pitfalls, which should be controlled, to obtain confident results. This session will present the methodological considerations (what are the factors impacting on results and their interactions), and provide some quality metrics, which will allow us to determine the "confidence interval" of the results.

Feasibility Studies: What Is It? What Are the Stakes? What Are the Challenges?

Simon Larkin, PhD Vice President, Drug Development, Europe, Kyowa Hakko Ltd., UK

Factors Impacting the Feasibility Results Gernot Wagner, MD

Senior Consultant, Corporate External Services, Merck KgaA, Germany

How to Assess the Quality of the Feasibility Study *Didier Saur, MD*

European Medical Director, MDS Pharma Services, France

LEVEL =

Session 158

CR4 - CLINICAL RESEARCH AND DEVELOPMENT, RA

3:30 рм - 5:00 рм Room 147В

CME and Pharmacy credits offered

The Clinical, Technical, and Regulatory Validation of Novel Surrogate Endpoints

SESSION CHAIRPERSON

David S. Lester, PhD Senior Director, Pfizer Inc

The opportunity to leverage novel surrogate endpoints to improve decision making in a clinical development program has been recognized, but significant confusion and inconsistency remain in establishing criteria for validation. This session will address the major issues for validation of a surrogate endpoint and standards for achieving a claim of validation.

A Pharmaceutical Industry Perspective of Validation in Bioimaging **Clinical Trials** David S. Lester. PhD

Senior Director, Pfizer Inc

A Regulatory Perspective on the Validation of Surrogate Endpoints Lawrence J. Lesko, PhD

Director, Office of Clinical Pharmacology and Biopharmaceutical Science, CDER, FDA

The Technical Validation of Surrogate Endpoints for Clinical Development

Craig H. Lipset, MPH

Senior Program Director, Oncology, Compound Therapeutics, Inc.

CR5 - CLINICAL RESEARCH AND SESSION 159 **DEVELOPMENT, RA**

3:30 рм - 5:00 рм

LEVEL = Room 146A Pharmacy credits offered

A Key to Success in Bringing a Product to Market Is

Proper Protocol Design

SESSION CHAIRPERSON

Lynda Y. Sutton

Chief Operating Officer and Chief Regulatory Officer, Cato Research, Ltd.

Success in bringing a drug to market depends on factors that must be addressed long before initiating clinical trials. One such factor is proper protocol design. A good protocol depends on specific, carefully conceived objectives. Without clear objectives, the chance for success is at risk.

Avoid the Landmines: Concentrate on the Right Objectives Allen Cato, MD, PhD

President, Cato Research, Ltd.

Examples of Where Protocol Design Became a Critical Factor in the Success or Failure of a Product Robert J. Temple, MD

Director, Office of Medical Policy and Office of Drug Evaluation, CDER, FDA

Human Performance Factor Analysis to Predict and Mitigate Protocol Violations

Lawrence A. Meinert, MD, MPH

Vice President, Medical and Scientific Affairs, Covance, Inc.

CS - CLINICAL SUPPLIES, RA Session 160

3:30 pm - 5:00 pm LEVEL =

Room 143C

Handling the Tough Logistical Issues in Clinical Supplies SESSION CHAIRPERSON

David F. Bernstein, PhD

Vice President, Pharmaceutical Science and Regulatory Compliance, Cato Research West

One of the more challenging aspects of the clinical supply process is the determination of expiry dating (retest date, use-by date) for investigational products when there is little or no prior data available. A common approach is to monitor the stability of investigational products concurrently with their clinical use to ensure that the drug products continue to meet their quality attributes and specifications. However, the EU requirement for investigational products to bear an expiry date on the actual supplies poses a difficult challenge when an originally short expiry date needs to be extended. In this case, a relabeling procedure is required and poses potential procedural, regulatory, and documentation issues. This session will also include a look at the unique challenges of transport and use of investigational products in Eastern Europe and Russia.

Automated Tools for Drug Expiry Management and Reconciliation David B. Sundin, MS, MBA, MPH

Director, Client Services, Dynarand, LLC

Clinical Trial Material Issues in Eastern Europe and Russia Sergei Varshavsky, PhD, MD Evidence Clinical and Pharmaceutical Research

Global Regulatory Requirements for Expiry Dates David F. Bernstein, PhD

Vice President, Pharmaceutical Science and Regulatory Compliance, Cato Research West

SESSION 161 **CTM - CLINICAL TRIAL MANAGEMENT,** FL

3:30 рм - 5:00 рм

Room 140B CME credits offered

LEVEL = 🔶

A Comprehensive Analysis of Factors Influencing the Length and Corresponding Cost

SESSION CHAIRPERSON

Harold E. Glass. PhD

Professor and Director, Graduate Program in Pharmaceutical Business, University of the Sciences in Philadelphia

This session will address the issue of why some phase III clinical trials are completed more quickly and efficiently than others, and the financial consequences of these variations. The results of our research will be determined by thoroughly analyzing in-field clinical data provided by 10 major pharmaceutical companies, in addition to extensive interviews conducted with representatives of those companies.

Harold E. Glass, PhD

Professor and Director, Graduate Program in Pharmaceutical Business, University of the Sciences in Philadelphia

Jeffrey J. DiFrancesco, MS, ME

Managing Director, Jeffrey Group Inc.

Mark Travers, PhD

Vice President, Global Trial Coordination for Global Clinical Operations, Johnson & Johnson Pharmaceutical Research and Development, LLC

SESSION 162 **DM - DOCUMENT MANAGEMENT/**

ESUBMISSIONS, RA

3:30 рм - 5:00 рм

Room 206

Data Standards Initiatives - Part 2 of 2

LEVEL = •

SESSION CHAIRPERSON Gary G. Walker

Senior Document Management Advisor, Electronic Regulatory Submissions, Regulatory and Technical Services, Quintiles, Inc.

Part 1 of this session is being held on Monday at 1:30 PM.

Clinical Data Interchange Standards Consortium (CDISC) and Health Level 7 (HL7) have been at the lead in creating standards for data interchange and submissions. FDA has been collaborative in creating these standards and has pointed to them as the standards to use when submitting data. This presentation will provide an update on the current state of these initiatives and their impact on the submission and review of datasets.

The Case Report Tabulation Data Definition Specification (CRTDDS) (Alias "Define.XML"): The What and Why William J. Qubeck, MBA, MS

Electronic Submission Data Group Leader, Pfizer Inc

Standard for Exchange of Nonclinical Data (SEND) Thomas Papoian, PhD, DABT

Senior Pharmacologist, Cardio-renal Drug Products, CDER, FDA

Case Study: Perspectives on Implementing the FDA Digital ECG Initiative Brian Hoffman

Director, ECG/IVR Services, Quintiles, Inc.

Randy Spaulding Vice President, Clinical Research, Mortara Instrument

SESSION 163 ECLIN - ECLINICAL, CR

3:30 PM - 5:00 PM LEVEL = •

Room 207B

The National Health Information Network (NHIN): Changing the Role of Biopharma in Clinical Research SESSION CHAIRPERSON

Charles Jaffe, MD, PhD Vice President, Life Sciences, SAIC

The United States has embarked on an ambitious 10-year plan to computerize healthcare. This will require the seamless integration of systems and the exchange of interoperable data. The biopharmaceutical industry will benefit from the development of standards to achieve this end, as well as from the integration of clinical research into the healthcare continuum.

Evolution of the Regional Health Information Organization with the NHIN *William A. Yasnoff, MD, PhD*

Managing Partner, NHII Advisors

Implications of Connecting the Cancer Bioinformatics Grid (caBIG) to the NHIN

Sue Dubman, MA NCICB Director, Applications, National Cancer Institute, Center for Bioinformatics, National Institutes of Health

Global Trial Bank: Connecting Clinical Research to Clinical Care Don E. Detmer, MD, MA

President and CEO, American Medical Informatics Association

Session 164 FI - Finance, RD

3:30 рм - 5:00 рм LEVEL = ●

Room 140A

Impact of SOX Act on R&D Costs of the Pharmaceutical Industry

session chairperson Joseph Curran, CPA

Senior Advisor, Relevante, Inc.

Operational and financial risks have greatly increased due to the competition among pharmaceutical companies to bring products to market faster. The Sarbanes-Oxley Act (SOX Act) has legislated a control regime whereby companies need to ensure that an internal control mechanism is established and that management attests to its effectiveness. Among the various risks, risks arising out of R&D cost management need to be constantly monitored and evaluated.

Impact of SOX Act on R&D Costs of the Pharmaceutical Industry Fred Kaplan, CPA, CBM

Director, Financial Consulting, Relevante, Inc.

Robert Rausch, MBA

Consultant (formerly Senior Vice President - Finance, AstraZeneca)

Session 165 GCP - GOOD CLINICAL PRACTICES, CR, RA

3:30 рм - 5:00 рм LEVEL = ■

Room 202A

The Rising Cost of Quality: Is It Making a Difference? SESSION CHAIRPERSON

Gregory M. Hockel, PhD, MBA

Senior Vice President, Regulatory Affairs, PharmaNet

There has been a steady, worldwide increase in the quality assurance effort relating to good clinical practice (GCP). Has the effort paid off? Are subjects/patients safer? Are fewer drugs being withdrawn from the market for safety reasons? Is the adoption of a more "risk-based" approach for adherence to GCP appropriate? These and other questions will be discussed by panelists representing both industry (US and Europe) and US/European regulatory authorities.

Today's Quality Assurance Mantra: More Is Never Enough Gregory M. Hockel, PhD, MBA Senior Vice President, Regulatory Affairs, PharmaNet

Did the Increase of Clinical Trial Requirements Improve Quality and Enhance Patients' Safety? *Regina Freunscht* Head, Quality Assurance, Accovion GmbH, Germany

Quality Assurance: Investment in the Future Donald W. Ashbrook, PhD, RAC

Chief Executive Officer, GPA International

SESSION 166 IS - INVESTIGATOR SITES, CR

3:30 рм - 5:00 рм LEVEL =	
---------------------------	--

CME, Nursing, and Pharmacy credits offered

Designing and Executing Studies that Meet Patient Needs SESSION CHAIRPERSON

Burt P. Koonsvitsky, PhD

Room 101

Director, Strategic Development, UBC

This session will explore how to scrutinize a study design to ensure that patients' needs are adequately addressed and how to assess the feasibility of conducting the study at a site. Some examples of successful and unsuccessful studies will be examined.

Sponsor Perspective

Julie Prejean Weikel, RN, OCN Clinical Trials Coordinator, Texas Cancer Care

CRO Perspective

Kathryn Hutchinson, MSc Managing Director, AMS - Advanced Medical Services - Europe, UK

Site Perspective Terri Gaffney

Associate Director, Clinical Operations, Procter & Gamble Pharmaceuticals, Inc.

IT - INFORMATION TECHNOLOGY,

Session 167

ECLIN, IS 5:00 PM LEVEL = ■

3:30 рм - 5:00 рм

Room 204BC

The Ease of Paper, the Speed of Electronics: The Next Generation of Data Collection SESSION CHAIRPERSON

Michael J. Rosenberg, MD, MPH President and CEO, Health Decisions, Inc. Adoption of technology for data collection has been slowed in part by user issues at clinical sites. A new method of data entry that combines the ease of traditional paper with electronic capture and transmission through a special pen with an optical sensor will be demonstrated and compared with other data collection options.

Strengths and Limitations of Different Methods of Data Collection *Rick Farris*

Chief Technology Officer, Health Decisions, Inc.

New Technology in the Regulated Environment Lisa A. Olson

Principal Compliance Consultant, SEC Associates, Inc.

Data Collection from the User Perspective David Archer, MD

Professor, Obstetrics-Gynecology, Eastern Virginia Medical School

Session 168 N

NC - NONCLINICAL LABORATORY SAFETY, CMC, RA

3:30 рм - 5:00 рм

Room 103B

Pharmaceutical Excipient Development: A Preclinical Challenge

SESSION CHAIRPERSON

Paul Baldrick, PhD

Head, Regulatory Affairs, Covance Laboratories Europe, UK

LEVEL =

The development of excipient materials for use in drug formulations represents a growing area of interest (and of invested time and cost) for pharmaceutical companies. Development has been fueled by the increasing need for more sophisticated excipients and/or new uses for established ones. A key consideration is, "How safe is the material?" Answering such a question is vital, especially since pharmaceutical excipients can no longer be regarded as totally inert/inactive substances within the formulation of pharmacologically active drugs. Thus, evaluation for potential toxicity is vital, and the proposed session will examine the safety evaluation process for excipients (new, "essentially" new, and established) from a preclinical perspective and will show that the role of the toxicologist is indeed a challenging one.

Preclinical Development of Excipients: Getting It Right! Paul Baldrick, PhD

Head, Regulatory Affairs, Covance Laboratories Europe, UK

Regulatory Experiences with Excipients David R. Jones, MSc

Principal Scientific Officer, Pharmacotoxicologist, Medicines and Healthcare products Regulatory Agency (MHRA), UK

Halt the Catch-22 Need for Innovating New Excipients Ashok V. Katdare, PhD Vice President, R&D Laboratories, Morton Grove Pharmaceuticals, Inc.

SESSION 169 OS - OUTSOURCING, RD

3:30 рм - 5:00 рм LEVEL = ■

Room 150A

A Look at Today's Drug Development Outsourcing Practices: Successes, Failings, and Ways to Improve Them – Part 2 of 2 SESSION CHAIRPERSON

John R. Vogel, PhD Drug Development Consultant, John R. Vogel Associates, Inc. Part 1 of this session is being held on Monday at 1:30 PM.

This two-part session will begin with a presentation and discussion of the results of a recent comprehensive survey on sponsor views of the effectiveness of clinical drug development outsourcing. The second part of the session will focus on identifying practical approaches to ensuring successful outsourcing.

David Ginsberg, DO

Chief Medical Officer and Senior Vice President, Omnicare Clinical Research

James Kirwin Assistant Vice President, Clinical Development, Wyeth Research

Kenneth A. Getz, MS, MBA Research Fellow, Tufts Center for the Study of Drug Development, Tufts University; Chairman, CISCRP

Session 170 PM1 - PROJECT MANAGEMENT

LEVEL =

3:30 рм - 5:00 рм Room 144ABC

Project Management Institute credits offered

Enterprise Project Management and Capacity Management: An Interactive Session SESSION CHAIRPERSON

Raymond G. Starrett, MLS

Project Manager, GlaxoSmithKline

Participants will engage in a roundtable, interactive working session to explore the state of the art of enterprise PM and capacity management within the biopharm industries.

Martin D. Hynes, III, PhD, MS

Director, Quality and Operations, Pharmaceutical Product Research and Development, Eli Lilly and Company

Randal J. Ofensend, MBA

Associate Director, Clinical IT&S, Cephalon

Session 171 PM2 - PROJECT MANAGEMENT, RD 3:30 PM - 5:00 PM LEVEL = ◆

Room 143AB

Project Management Institute credits offered

Go/No Go Decisions

SESSION CHAIRPERSON

Rajendra Mohabir, PhD

Therapeutic Area Head, Oncology, R&D Project Management, Amgen Inc.

This session will discuss factors that need to be considered when Go/No Go decisions are made during drug development. Wherever possible, case study examples will be provided without disclosure of proprietary information.

Decision Making Around Lead Product Candidates and Back-up/ Follow-on Molecules

Lewis K. Lee, MS, SM Director, Planning and Portfolio Management, Amgen Inc.

The Team's Role in GNG Decisions: Helping Management Actually Make One Joseph A. Carlino. PhD. MS

Former Senior Director, Biopharmaceuticals Development Management, Chiron Corporation

SESSION 172 PP - PUBLIC POLICY/LAW, CR, RA

3:30 рм - 5:00 рм

LEVEL =

Room 103A

CME, Nursing, and Pharmacy credits offered

Clinical Trials: Legal and Regulatory Jeopardy

SESSION CHAIRPERSON Mark C. Hegarty, JD

Partner, Shook Hardy & Bacon LLP

This session will include presentations on current legal and regulatory issues that affect sponsors, investigators, and IRBs in the conduct of clinical trials. This session will also feature preselected members of the audience playing a game utilizing a very popular television game show format. The questions will primarily be limited to legal and regulatory issues. It will be a lot of fun and the winner will be awarded a fabulous (but modest) prize.

John M. Isidor, JD

Chief Executive Officer, Schulman Associates IRB, Inc.

LEVEL =

Jeffrey N. Gibbs, JD

Director, Hyman Phelps & McNamara, P.C.

SESSION 173 RA1 - REGULATORY AFFAIRS, RD

3:30 рм - 5:00 рм

Room 151A

The New Europe for Pharmaceuticals: From Research and Development to Marketing Authorization and Marketing SESSION CHAIRPERSON

Rolf Bass, MD

Resident, Twinning Advisor (PHARE), Head of Department, URPL (Polish Authority), Poland; BfArM (German Authority), Germany

The new Europe for Pharmaceuticals is arriving everywhere. Companies from Central and Eastern Europe are as keenly interested to authorize and market their products (usually generics) in Western Europe – and beyond, as are Western companies to do so in Central and Eastern Europe – and beyond.

Whereas the EU system of European Commission, EMEA and national competent authorities have agreed with trade associations the conditions to be fulfilled for their products "to go East," no such arrangements have become available so far "to go West." Questions and problems span from manufacturing authorizations and GMP inspections to update of marketing authorizations of Central/Eastern locally marketed products before they would fulfill the EU-acquis communautaire, which is the precondition for any such pharmaceutical traveling westwards.

In such scenarios, economically driven decisions have to be taken including performance of studies and where, understanding market needs and opportunities, and outsourcing of which steps outside the originator country.

These issues and questions will be addressed from the viewpoint of a regulator (Austria), the European Generic Medicines Association (EGA), and a clinical CRO operating throughout Europe. Missing links will be introduced and filled in from the chair, who currently serves as Advisor to the Polish Ministry of Health.

Does West (East) Outsource (and Why) from East (West)? Special Aspects: European Trade Association (Namely Generics) *Beata Stepniewska, MS*

Pharmacist, Regulatory Affairs and EU Accession, European Generic Medicines Association, Belgium

Does West (East) Outsource (and Why) from East (West)? Special Aspects: Clinical Trials Conditions in Europe Veronique Larsimont, PhD

Director, Clinical Operations, IMFORM GmbH, International Clinical Research, Germany

Does West (East) Outsource (and Why) from East (West)? Special Aspects: European Regulator Viewpoint and Pharmaceutical Quality Documentation *Rolf Bass, MD*

Resident, Twinning Advisor (PHARE), Head of Department, URPL (Polish Authority), Poland; BfArM (German Authority), Germany

SESSION 174 RA2 - REGULATORY AFFAIRS, CP,

CR, RD

3:30 рм - 5:00 рм **LEVEL** = ●

Room 152A

PMDA and Related Drug Safety Activities

SESSION CHAIRPERSON

Deborah Yaplee

US FDA Mansfield Fellow, In Residence at MHLW, Tokyo, FDA

On April 1, 2004, Japan's Pharmaceuticals and Medical Devices Agency (PMDA) began conducting NDA reviews for the Ministry of Health Labour and Welfare. This session will be used to provide an overview and update on the PMDA's overview and an update on its postmarketing drug safety activities after its first year.

Kaori Nomura

Principal Official for Electronic Data Submissions, Office of Safety, Safety Information Division, PMDA, Japan

Hiroko Koyama

Senior Leader, Drug Safety Evaluation Department, Chugai Pharmaceutical Company, Ltd., Japan

Jennifer Driscoll, MS

Pharmacovigilance Officer, Banyu Pharmaceutical Company, Ltd., a Subsidiary of Merck & Co., Inc., Japan

SESSION 175 RA3 - REGULATORY AFFAIRS, PP

3:30 рм - 5:00 рм LEVEL = ■

Room 152B

Making International Nonproprietary Names (INNs) User-friendly

SESSION CHAIRPERSON

Raffaella G. Balocco-Mattavelli, PhD, PharmD

Responsible Officer, INN Programme, World Health Organization, Switzerland

This session focuses on efforts to streamline the process of assigning International Nonproprietary Names. It also highlights how transparency and efficiency can be improved in cooperation with the applicants and other involved parties such as regulators.

The Industry Perspective

Robert E. Lee, Jr.

Assistant General to Patent Counsel, Patents-therapeutic Areas Department, Eli Lilly and Company Pharmacopoeia Expert

The FDA Perspective

David Lewis, PhD Review Chemist, Office of New Drug Chemistry, CDER, FDA

The National and European Perspective *Noël Wathion, Pharm*

Head of Unit, Postauthorization Evaluation of Medicines for Human Use, EMEA, EU

SESSION 176 RA4 - REGULATORY AFFAIRS, CR

3:30 рм - 5:00 рм LEVEL = ■

Room 154AB

Trial Design and the Study Data Tabulation Model SESSION CHAIRPERSON

Diane E. Wold, PhD

Director, Data Standards Development and Management, GlaxoSmithKline

The Study Data Tabulation Model (SDTM) is now referenced as specification in FDA guidance. It includes the Trial Design Model, a completely new kind of data for submission. This session explains what the Trial Design Model is, how it can be implemented, and how it relates to the larger problem of representing the protocol in machine-readable form.

The Trial Design Model as Part of a Structured Protocol Representation *Cara Willoughby, MA*

Co-chair, Protocol Representation Group; Associate Consultant, Scientific Communications-Regulatory, Eli Lilly and Company

Introduction to the Trial Design Model

Diane E. Wold, PhD Director, Data Standards Development and Management, GlaxoSmithKline

Implementation of the Trial Design Model

Sherry G. Green

Director, Statistical Programming, Quintiles, Inc.

SESSION 177 RA5 - REGULATORY AFFAIRS, CP

3:30 рм - 5:00 рм LE

LEVEL =

Room 151B CME and Pharmacy credits offered

Risk/Management Throughout Product Development: Clarifying the Requirements and Managing Expectations SESSION CHAIRPERSON

Carrol Marcus, MSc

Vice President, Europe, Drug Development Consulting Practice, PAREXEL Consulting, UK

The session explores the current thinking in industry and the regulatory authorities about risk management strategies, how these can be built into drug development programs and how such a program impacts the development process.

Valerie E. Simmons, MD

Advisor and EU Qualified Person for Pharmacovigilance, Eli Lilly and Company, UK

Geoff J. Barton

Director, Regulatory Policy and Intelligence, Europe, GlaxoSmithKline, UK

Dr. June Raine

Group Manager, Medicines and Healthcare products Regulatory Agency (MHRA), UK

Discussant

Paul J. Seligman, MD, MPH Director, Office of Pharmacoepidemiology and Statistical Science, CDER, FDA

Session 178 RA6 - Regulatory Affairs

3:30 рм - 5:00 рм LEVEL = ●

Room 146B

Electronic Management of Drug Information and Labeling SESSION CHAIRPERSON

Lisa Stockbridge, PhD, MS Regulatory Reviewer, Office of Information Management, CDER, FDA To improve patient healthcare through better health information management, the FDA is moving toward the electronic management and standardization of drug information and labeling. Uniform standards for drug labeling and listing are fundamental to this goal. FDA, working with Health Level 7, has developed Structured Product Labeling (SPL) as a standard format for exchanging labeling information among computer systems. The Substance Registration System has been developed to generate and store unique, unambiguous identifiers for substances in FDA-regulated drug products. JANUS is a database modeled after the CDISC Study Data Tabulation (SDTM). The SDTM standardizes the submission of the results of clinical trials-demographics, raw data from case report forms, and derived data.

FDA's Structured Product Labeling Program Update Lisa Stockbridge, PhD

Regulatory Reviewer, Office of Information Management, CDER, FDA

FDA's Substance Registration System Jonathan Cook. MS

Operation Research Analyst, Office of Pharmaceutical Science, CDER, FDA

FDA's JANUS Data Warehouse Norman Stockbridge, MD, PhD

Acting Director, Division of Cardio-Renal Drug Products, CDER, FDA

Session 179 RD - R&D STRATEGY, BT, PM

3:30 рм - 5:00 рм LEVEL = ■

Room 149AB

Medical Affairs for Biotechnology/Pharmaceutical Start-ups: Strategies for Launch (Research and Medical Communications)

SESSION CHAIRPERSON

Ronald P. Evens, PharmD, FCCP

Clinical Professor, University of Florida; President, MAPS 4 Biotec, Inc.

For a first product launch by a start-up company, the medical affairs unit plays both a strategic and operational role, with both external and internal audiences. At a start-up, resources are limited, and the science and marketing divisions need bridging for optimal periapproval strategy. A strategy and plan for medical affairs must be integrated with corporate, product, and research strategies. Strategic analyses are needed, roadblocks should be anticipated, and compliance with new government regulations can be a significant demand. Many further needs exist that require research data and medical support, and outsourcing versus company staffing versus corporate alliances is another strategic consideration. This session will address strategies and related staffing, goals, timelines, and action plans for the medical affairs unit involved in a product launch for research and medical communications.

Strategic and Program Overview for Medical Affairs at a Start-up Company: What to Do, Why, How, When, and by Whom? *Ronald P. Evens, PharmD, FCCP*

Clinical Professor, University of Florida; President, MAPS 4 Biotec, Inc.

Product Experiences and Communications: Strategies and Programs Mario F. Sylvestri, PhD, PharmD

Senior Director, Regulatory and Medical Information, Amylin Pharmaceuticals, Inc.

Postmarketing Studies: Challenges – Strategies – Planning – Programs Stanfell Boone, MD, MBA

Associate Director, Amgen Inc.

SESSION 180 ST - STATISTICS, CR

3:30 рм - 5:00 рм

LEVEL =

Room 201

CME credits offered

Multiregional Trial: Global and Japanese View in Biostatistics

SESSION CHAIRPERSON

Tohru Uwoi, PhD

Division Manager, ICH Intelligence, Medical Support Business Unit, Bellsystem24, Inc., Japan

Global development and simultaneous worldwide launching has been a hot issue for several years. Due to the ICH E5 guideline, one approach to global submission became possible, but the E5 approach may result in delayed submission in some countries, especially Japan. With the experiences of bridging strategies, regulators and industries became aware of the effectiveness of the prospective bridging approach. Even with the prospective approach, delay problems in some regions are not solved because of the asymmetric nature of the bridging. This session is devoted to the alternative approach of multiregional trials taking into account the utilization of non-ICH region trials.

Development Strategy with Multiregional Trials *Kimihiro Kasamo, MD, PhD*

Deputy Head, Clinical Development Institute, Senior Director, Safety Information and Vigilance, Banyu Pharmaceutical Co., Ltd., Japan

Statistical Considerations on Design and Evaluation in Multiregional Trials

Toshiyuki Sato, PhD

Assistant Manager, Biostatistics and Pharmacokinetics Group, Data and Biostatistics Center, R&D Division, Daiichi Pharmaceutical Co., Ltd., Japan

Statistical and Regulatory Issues in Multiregional Trials Simon Day, PhD

Statistics Unit Manager and Scientific Advice Coordinator, Licensing Division, Medicines and Healthcare products Regulatory Agency (MHRA), UK

Discussant

Robert T. O'Neill, PhD Director, Office of Biostatistics, CDER, FDA

Session 181 TR - TRAINING, CR

3:30 рм - 5:00 рм LEVEL = ■

Room 146C

Training and Clinical Research in the 21st Century: You Can Get Your Drug to Market Faster!

session chairperson Jennifer Lansink

Founder and CEO, TRC Clinical, Inc.

In this highly interactive discussion, we will investigate how accelerated learning techniques, when applied effectively to a training environment, can positively impact sponsor-to-site communication and increase the amount of information retained by site personnel. This hands-on session requires participants to interact with their peers and apply newly learned techniques. This session also includes a review of the industry's leading online technology and distance learning principles. Get more from every site interaction!

Jennifer Lansink Founder and CEO, TRC Clinical, Inc.

Jeffrey D. Goldford Founding Partner, The Iris Group

Bernice Kuca, MS Director of Clinical Operations, Oscient Pharmaceuticals

Olivia Woodard Independent Consultant

SESSION 182 VA - VALIDATION

3:30 рм - 5:00 рм LEVEL = ■

Room 209AB

Validation in the Real World: Global System and Revalidation Approaches

SESSION CHAIRPERSON

Joanne S. Malia, MS, MS

Assistant Director, Medical Research Quality Management, Purdue Pharma L.P.

This session will discuss some of the more challenging validation situations in today's global pharmaceutical environment. These include, but are not limited to, implementation of global systems to benefit both business and regulatory compliance concerns and the revalidation of systems currently existing in a validated state. The session will provide a mixture of points to consider as well as examples from real-life experiences.

Case Study: Challenges in Implementing a Global SDLC Process *Marian M. Mutch, MSc*

Manager, Global IT Quality Systems, Europe, Covance Laboratories Ltd., UK

Managing the Validation Challenges Associated with Global Systems Implementation

Kate Townsend, MS Solutions Partner, Validation and Compliance, BusinessEdge Solutions

Revalidation Triggers Gregory D. Gogates

Vice President, Quality Management and Regulatory Affairs, CRF, Inc.

5:00 pm

END OF MONDAY SESSIONS

Tuesday, June 28 (some speaker changes will occur before the event.)

7:30 ам - 5:30 рм	ATTENDEE REGISTRATION East Registration Area, Convention Center Mount Vernon Place Entrance
7:30 ам - 5:30 рм	EXHIBITOR REGISTRATION East Registration Area, Convention Center Mount Vernon Place Entrance
7:30 ам - 5:30 рм	SPEAKER REGISTRATION East Registration Area, Convention Center Mount Vernon Place Entrance
7:30 ам - 8:15 ам	CONTINENTAL BREAKFAST Meeting Rooms 145-147, Concourse Convention Center
9:00 am - 5:30 pm	PROFESSIONALS' POSTER SESSION Exhibit Hall A Entrance, Lower Level, Convention Center
9:00 am - 5:30 pm	EXHIBITS OPEN Exhibit Hall A, B & C, Lower Level, Convention Center
5:00 рм - 6:30 рм	CONSORTIUM OF ACADEMIC PROGRAMS IN CLINICAL RESEARCH MEETING Meeting Room 103B, Convention Center

Session 201 AD - Advertising, MA, PP, TR

8:30 AM - 10:00 AM LEVEL =

Room 202B

Support for CME: How Difficult? How Dangerous?

SESSION CHAIRPERSON

David G. Adams, JD

Partner, Venable LLP

This session will explore the challenges facing the pharmaceutical industry with regard to commercial support of CME. The panel will discuss the standards that have been set by the medical profession and implemented through the ACCME for accredited educational programs. It will also address the broader landscape of potential legal liability associated with support for CME and will consider how compliance with ACCME's Standards for Commercial Support may provide protection from actions brought by state and federal authorities, as well as by whistle-blowers.

Overview of the Professional and Regulatory Environment *David G. Adams, JD* Partner, Venable LLP

ACCME Standards for Commercial Support: A Strategic Asset for CME Providers

Murray Kopelow, MD, MS, FRCPC Chief Executive, Accreditation Council for Continuing Medical Education (ACCME)

Industry as a Stakeholder in CME and the Integrity of CME Marc B. Wilenzick, JD Senior Corporate Counsel, Pfizer Inc

SESSION 202 BT - BIOTECHNOLOGY, NC, VA

8:30 ам - 10:00 ам Room 154АВ

LEVEL = ● CME credits offered

Validation of Immunogenicity Testing Methods

SESSION CHAIRPERSON

Lynne LeSauteur, PhD Scientific Director, Charles River Laboratories - CTBR, Canada Immunogenicity testing is required for peptide and protein-based therapeutics, because of the likelihood that these agents will elicit an immune response and the fact that antibody generation may effect the therapeutics, pharmacokinetics/ pharmocodynamics, safety and efficacy profiles. The assessment of immuno-genicity requires validated assays to detect, isotype, and characterize the antibody response.

Development and Validation of Cell-based Assays for the Detection of Antidrug Neutralizing Antibodies to Biological Therapeutics Shalini Gupta, PhD

Associate Director, Amgen Inc.

SESSION 203 CDM - CLINICAL DATA MANAGEMENT, ECLIN, IS

8:30 AM - 10:00 AM

Room 204BC

CME and Pharmacy credits offered

Electronic Source in Clinical Trials

SESSION CHAIRPERSON

Xander Baroque, CCRC

Clinical Research Professional, Children's Hospital Central California

Clinical research coordinators, monitors, investigators, and other research staff are encouraged to attend this session on the issues of electronic data capture, monitoring, and signatures. We will discuss topics from a coordinator and research department perspective. New regulations address electronic signatures; however, there is much more occurring in the real clinical world.

Electronic Source in Clinical Trials: A Site Perspective Lauro Roberto, MD

Associate Director, Pulmonology; Physician, Children's Hospital Central California

Electronic Source in Clinical Trials: A Site Perspective Xander Baroque, CCRC

Clinical Research Professional, Children's Hospital Central California

Session 204

204 CMC - CHEMISTRY, MANUFACTURING, AND CONTROLS, RA

8:30 ам - 10:00 ам **Room 147A**

OO AM LEVEL = ■ CME credits offered

Updates on CDER CMC Guidances

SESSION CHAIRPERSON

Dhiren N. Shah, PhD Director, US DRA-CMC, sanofi-aventis

In this session, the current status and technical issues associated with CDER CMC guidances from a regulatory as well as an industry perspective will be discussed.

FDA Perspective

Guirag K. Poochikian, PhD, FACP

Associate Director for Regulatory Science, Office of New Drug Chemistry, Office of Pharmaceutical Science, CDER, FDA

Industry Perspective

Richard Poska, MS Director, Regulatory Affairs, Abbott Laboratories

Panel Discussion/Q&A Period

Session 205 CP - Clinical Safety and Pharmacovigilance, CR, RA

8:30 AM - 10:00 AM

Room 207A *CME, Nursing, and Pharmacy credits offered*

Risk Minimization Through Risk Communication: The Impact of New Regulatory Developments in Safety Labeling SESSION CHAIRPERSONS

Stephen A. Goldman, MD, FAPM, FAPA

Managing Member, Stephen A. Goldman Consulting Services, L.L.C Sidney N. Kahn, MD, PhD

President, Pharmacovigilance & Risk Management Inc.

Risk minimization through risk communication is a major public health aspect whose effectiveness has come under increasing regulatory and public scrutiny. As health professional medical product labeling is considered a major tool for communicating safety information to prescribers, this session will discuss how proposed revisions to US FDA labeling regulations/guidances, possible changes in the EU Summary of Product Characteristics (SPC) guidelines on safety information presentation, and the use of MedDRA® may have significant effects on pharmacovigilance and risk communication. Methods for assessing the effectiveness and impact of such public health actions as health professional notifications, focused educational efforts, and practice guidelines will be reviewed.

Minimizing Medical Product Risk Through Effective Public Health Communication Methods

Stephen A. Goldman, MD, FAPM, FAPA Managing Member, Stephen A. Goldman Consulting Services, L.L.C

Medical and Regulatory Implications of Using MedDRA® for Analysis and Communication of Risk *Sidney N. Kahn, MD, PhD* President, Pharmacovigilance & Risk Management Inc.

An Updated Comparison of Safety-related Information in US and EU Health Professional Pharmaceutical Labels *A. Leander Fontaine, MD, PhD* President, Pharmiceutics, LLC

Session 206 CR1 - CLINICAL RESEARCH AND DEVELOPMENT, BT, RA

8:30 AM - 10:00 AM LEVEL =

Room 145B CME and Pharmacy credits offered

Conjugated Vaccines

SESSION CHAIRPERSON

Anne-Marie P. Georges, PharmD

Consultant, AMQuid Pharma, Belgium

This session will present a review and an overview of new conjugate vaccines and related issues.

Panelist

Daniel Brasseur, MD, PhD Chairman of CHMP at EMEA, EU; Ministry of Public Health, Belgium

New Meningitis Vaccines and Correlate for Protection: The Challenge Johan Van Hoof, MD

Chiron Vaccines, Belgium

Staphylococcus Aureus Vaccine Henrik Rasmussen, MD, PhD

Senior Vice President, Clinical Research, Medical and Regulatory Affairs, and Project Management, Nabi Biopharmaceuticals

Interference Between Antigens in Conjugate Vaccines Bernard Fritzell

Vice President, Scientific and Medical Affairs, Wyeth France

SESSION 207 CR2 - CLINICAL RESEARCH AND

8:30 am - 10:00 am

DEVELOPMENT, CP

Room 1464

CME, Nursing, and Pharmacy credits offered

Cardiovascular Safety and QT Assessment

SESSION CHAIRPERSON Lawrence Z. Satin, MD

Chief Medical Officer, Cardiocore Lab

QT interval assessment and cardiovascular safety have become synonymous in the drug development process. Although regulatory guidance continues to evolve, challenges once thought to be daunting now have clear and poignant solutions.

Meeting the Challenges of ECG Acquisition Justin L. Mortara, PhD

Vice President, Sales and Marketing, Mortara Instruments, Inc.

Meeting the Challenges of QT Assessment Lawrence Z. Satin, MD Chief Medical Officer, Cardiocore Lab

Meeting the Challenges of Trial Design and Analysis *Eugene R. Heyman, PhD* Statistical Consultant

SESSION 208 CS - CLINICAL SUPPLIES, CTM

8:30 am - 10:00 am

Room 149AB

LEVEL =

Pharmacy credits offered

Future Trends in Clinical Supplies

SESSION CHAIRPERSON Frank J. Tiano, RPh President, Clinical Supplies Consulting Services

With the current emphasis on implementing effective demand management, speed in responding to clinical protocol requirements, patient-specific therapies, and providing ultimate flexibility, the 21st century clinical supply function is much different from its predecessors. Visionary clinical supply units incorporate proactive management strategies, real-time packaging and labeling strategies, and innovative technology solutions to streamline the drug supply management process.

The Future of Clinical Supplies Angus J. McCulloch Principal, World Class International

Real-time Packaging and Labeling Strategies Brian Moe, PharmD Vice President, CSM-Rx, CSM

WebEZ™: An Innovative Solution to the Drug Supply Management Challenge Donna Christopher

Vice President of Operations, Clinical Trial Services

SESSION 209 CTM - CLINICAL TRIAL MANAGEMENT, CR

8:30 AM - 10:00 AM

Room 140B Nursing credits offered

Strategies for Achieving Recruitment Goals in Pediatric Trials

SESSION CHAIRPERSON

Kate Didio, RN, MBA

Director, Clinical Monitoring Management, Sepracor, Inc.

Meeting timelines for recruitment in pediatric clinical trials is always a challenge. Sepracor completed enrollment for a pediatric asthma study one month ahead of schedule. This session will take a detailed look at the recruitment strategies utilized by Sepracor for accelerated enrollment.

Identifying Key Enrollment Challenges in a Study Design Kate Didio, RN, MBA

Director, Clinical Monitoring Management, Sepracor, Inc.

Best Practices in Recruiting Pediatric Patients Jeannine L. Heinemann Project Manager, Essential

Ensuring Successful Implementation of Recruitment Strategies Across a Multicenter Study to Achieve Project Success Stacy Weil, MS, RDH Associate Director, Clinical Operations, PPD Development

Session 210 DM - DOCUMENT MANAGEMENT/ ESUBMISSIONS, RA

Room 206 Pharmacy credits offered

eCTD: Lifecycle Management

SESSION CHAIRPERSON

8:30 AM - 10:00 AM

Daniel F. Orfe, MS

Associate Director, Worldwide Regulatory Operations, Merck & Co., Inc.

This session will deal with the various implementation and process obstacles faced by sponsors in addressing the lifecycle management aspect of the eCTD. Additionally, discussions and specifics of the rewards resulting from adoption of the eCTD will be covered within the presentations.

eCTD Lifecycle Management: Challenges and Benefits Michael J. Mellott, MS Associate Director, Merck & Co., Inc.

ASSociate Director, Merck & CO., Inc.

Managing the eSubmission Lifecycle Gary G. Walker

Senior Document Management Advisor, Electronic Regulatory Submissions, Regulatory and Technical Services, Quintiles, Inc.

SESSION 211 ECLIN - ECLINICAL, CR, RA

8:30 AM - 10:00 AM LEVEL = •

Room 145A CME credits offered

Electronic Patient-reported Outcomes (ePRO) 2005:

A Town Meeting SESSION CHAIRPERSON John M. Weiler, MD

President, CompleWare® Corporation

This session will consider regulatory issues in the use of ePRO. What's new about PRO guidance from the FDA? How can sponsors, vendors, and sites be compliant with the regulations?

The Sponsor's Perspective

Jay Pearson, PhD

Senior Director, Scientific Staff, Epidemiology Department, Merck Research Laboratories

The Regulator's Perspective Joseph P. Salewski Chief, Bioresearch Monitoring Branch, CBER, FDA

The Vendor's Perspective Valdo Arnera, MD General Manager, Europe, PHT Corporation, Switzerland

SESSION 212 GCP - GOOD CLINICAL PRACTICES

8:30 AM - 10:00 AM

Room 202A

Establish and Maintain a CAPA System

SESSION CHAIRPERSON

Bruce M. Wagman, MBA, RN

Vice President, US Regulatory Affairs and Global Clinical Quality Assurance, Omnicare Clinical Research

Three quality assurance professionals who have established and maintain a CAPA system within their respective companies will discuss how they operated within their business environment. This session will include one cGMP director and two GCP directors to highlight the differences between cGMP and GCP.

CAPA – Definitions for Compliance Standards (Part 1); CAPA for Drug Manufacturers (Part 2) Raymond Regimbal, PhD Director, Regulatory Compliance, Genta Incorporated

CAPA in Clinical Research J. Michael Sobczyk Director, BMRA Compliance, Genzyme

Session 213 IS - Investigator Sites, AHC

8:30 AM - 10:00 AM LEVEL = ■ **Room 101** *CME credi*

m 101 CME credits offered

Revolutionizing the Role of Quality Assurance SESSION CHAIRPERSON

Patricia Brown, PhD, MSN, RN Director, CNS Healthcare

This session will provide an overview of how a structured approach to quality assurance can impact a research site.

A Multifaceted Look at Quality Kelly J. Abernathy Section Head, Clinical Operations and Regulatory Affairs, Lineberry Research Associates

Making the Intangible, Tangible Melissa Parsloe Psychology and Criminal Justice Graduate Student

Revolutionizing the Role of Quality Assurance Patricia Brown, PhD, MSN, RN Director, CNS Healthcare

Session 214 **IT1 - INFORMATION TECHNOLOGY**

8:30 AM - 10:00 AM LEVEL = \blacklozenge

Room 152A

Testing Security in a Regulated Environment: The What, When, and Where

SESSION CHAIRPERSON

Kim R. Truett, MS Senior Clinical Programmer (Independent)

This section will focus on the need for security tests, what goes into a thorough security test, and how the OSSTMM helps facilitate this need.

The Myth of Data Security: Putting a \$100,000 Fence Around a \$50 Horse

Peter V. Herzog

Managing Director, Institute for Security and Open Methodologies (ISECOM), Spain

Balancing Security and Operability: How to Keep a Secure Environment Without Reducing Business Efficiency Kim R. Truett, MS

Senior Clinical Programmer (Independent)

SESSION 215 **IT2 - INFORMATION TECHNOLOGY,** CDM, ECLIN LEVEL = •

8:30 AM - 10:00 AM

Room 146B

Distributed Systems in Clinical Data Management SESSION CHAIRPERSON

Jeffrey C. Phillips, MA

Director, Application Development, Medifacts International

Now that high-speed Internet access is more the rule than the exception, clinical trial data processing can be distributed; sites can enter and clean their own data via electronic data capture; laboratory data can be transmitted directly to databases; and staff all over the world can work on a study database at the same time. Distributed systems are already widely in use for electronic/remote data capture and high-volume processing of lab and imaging data. The advantages of this processing model are obvious. However, systems that are distributed widely and grant access to users outside central facilities carry special burdens: they must be friendly enough for less-trained users in the field, they must be secure enough to handle clinical data in the security-hostile Internet environment, they must perform consistently even when their operating conditions cannot be fully controlled, and they must be very robust, with a high degree of reliability and "up-time."

This session discusses some of the technical issues that surround the use of distributed systems for clinical data management, including security, database design, user interfaces, and fault tolerance. Attendees should come away with a greater appreciation of what it takes to move data collection, management and analysis "out from the center."

Truly Web-based Systems for Clinical Data Management Jeffrey C. Phillips, MA

Director, Application Development, Medifacts International

Challenges of Managing Distributed Systems to Support Remote Medical Image Review Howard W. Foster, MS

Vice President and Chief Technology Officer, Perceptive Informatics, Inc.

Training Considerations for a Clinical Study Using Distributed Remote **Data Capture** Steven C. Rifkin. PhD Chief Application Expert, BioPharm Systems, Inc.

MC - MEDICAL COMMUNICATIONS, CP SESSION 216 8:30 AM - 10:00 AM LEVEL = •

Room 209AB

CME and Pharmacy credits offered

The Role of Medical Communications Departments in Risk **Management Programs**

SESSION CHAIRPERSON

Monica Kwarcinski, PharmD Senior Director, Medical Services, Purdue Pharma L.P.

Risk management programs are an emerging regulatory issue whereby the FDA expects pharmaceutical companies to propose plans that proactively manage the risks in relation to the benefit for their products. Elements of an RMP include training, education, signal detection, and interventions. The medical communications department within a pharmaceutical company can play a significant role in RMPs.

Brief Overview of Risk Management Programs: Their Similarities and Differences

Anne E. Trontell, MD, MPH

Deputy Director, Office of Drug Safety, CDER, FDA

The Role of the Medical Communications Department in a Modifiedrelease Opioid Risk Management Program J. David Haddox, DDS, MD

Vice President, Risk Management and Health Policy, Purdue Pharma L.P.

The Role of Medical Information in the Plenaxis® User Safety (PLUS™) **Program: A Subpart H-approved Product with a Restricted Distribution Risk Management Program** Camille Motta, PhD, MS

Senior Manager, Medical Information, Praecis Pharmaceuticals Incorporated

The Role of Medical Information in the Clozaril National Registry Risk **Management Program**

Richard F. Eschle, PharmD

Director, Neuroscience Medical Information and Communication, Novartis Pharmaceuticals Corporation

SESSION 217 **MW - MEDICAL/SCIENTIFIC WRITING** 8:30 AM - 10:00 AM LEVEL = •

Room 102AB **Document Reviews: Bridge to Quality or Roadblock to**

Completion? SESSION CHAIRPERSON

Linda Kellv

Senior Scientific Communication Associate, Eli Lilly and Company

Reviews are an integral part of the document development process on crossfunctional teams, but they can sometimes become a roadblock to timely document completion. This session will differentiate among various types of document reviews and identify the goals of each type. Specific, practical strategies for improving the value and efficiency of document reviews will be discussed.

Effective Document Review Practices Linda Kellv

Senior Scientific Communication Associate, Eli Lilly and Company

Managing the Art and Science of Team Reviews

Gregory P. Cuppan, MA Managing Principal, McCulley Cuppan LLC

Document Review Challenges: Case Studies Helle-Mai Gawrylewski, MA

Director, Medical Writing and Medical Knowledge Management, Johnson & Johnson Pharmaceutical Research and Development, LLC

Session 218 NC - Nonclinical Laboratory SAFETY, RA

8:30 AM - 10:00 AM LEVEL =

Room 103B

Extrapolating Nonclinical Animal Data to the Clinic

SESSION CHAIRPERSON

David R. Jones, MSc

Principal Scientific Officer, Pharmacotoxicologist, Medicines and Healthcare products Regulatory Agency (MHRA), UK

High attrition rates in early clinical trials continues to be a challenge to the pharmaceutical industry. The session will look at some of the problems and recent strategies employed to improve success rates.

A Regulatory Viewpoint on the Challenges of Extrapolating Preclinical Data to a Safe Starting Dose in Clinical Trials in Man David R. Jones, MSc

Principal Scientific Officer, Pharmacotoxicologist, Medicines and Healthcare products Regulatory Agency (MHRA), UK

Interpretation of Preclinical Data to Support Clinical Trials in Man Paul Baldrick, PhD

Head, Regulatory Affairs, Covance Laboratories Europe, UK

Interspecies Extrapolation of ADME Data to Support First Dose in Man Studies

Doris Weilert, PhD

Research Scientist, PK/PD, Clinical Pharmacology, Quintiles, Inc.

Session 219 NHP - NATURAL HEALTH PRODUCTS, RA, RD

8:30 AM - 10:00 AM LEVEL =

Room 140A

Regulatory Requirements versus Financial Benefit: Justifying Natural Health Products from a Private Sector Perspective

SESSION CHAIRPERSON **Floyd E. Leaders, Jr., PhD** Chairman and CEO, Botanical Enterprises, Inc.

Three interdependent and critical considerations must be evaluated when a private sector enterprise commits the resources necessary to develop a natural health product for treatment of serious and/or life-threatening medical conditions: 1) the safety and efficacy (benefit to risk ratio) of the product; 2) the size and viability of the intended market, and 3) the ability to recoup the significant financial cost of obtaining regulatory approval. This session will explore these three considerations within the context of the Guidance for Industry for Botanical Drugs that was published in June of 2004.

Regulatory Requirements versus Financial Benefit: Justifying Natural Health Products from a Private Sector Perspective Leonard P. Smith, MBA

President, NUTRAssociates, Inc.

Developing a Successful "Cutting Edge" Botanical Drug Business Strategy Thomas M. Hnat

CEO, CuraPharm, Inc.

Safety and Efficacy: Can Previous Human Experience Realistically Be Used to Reduce the Financial Risk of Botanical Drug Development? *Floyd E. Leaders, Jr., PhD*

Chairman and CEO, Botanical Enterprises, Inc.

SESSION 220 OS - OUTSOURCING, FI

8:30 AM - 10:00 AM

Room 150A

Are Changes in Pharmaceutical Outsourcing Meeting the Needs of Investors, Sponsors, and Vendors?

SESSION CHAIRPERSON

Mark A. Hovde, MBA President, Hovde Associates LLC

As the pharmaceutical industry's reliance on CROs has grown, methods for managing the outsourcing process have evolved from no formal outsourcing management to sophisticated online auctions managed by professional contracting groups. Has the evolution improved financial or project operational results? Will the new methods lead to better alignment or more discord among the stated goals and strategies of pharmaceutical development management, leading CROs, and investors?

Overview: Changes in Pharmaceutical Outsourcing Mark A. Hovde, MBA

President, Hovde Associates LLC

Investor's Perspective: Are the Changes Meeting Investor Needs? Michael A. Martorelli, MBA

Research Partner, Fairmount Partners

Vendor's Perspective: Are the Changes Helping Vendors to Better Meet Sponsor Needs? *Tracy Blumenfeld, MBA* Chief Executive Officer, RapidTrials

Session 221 PM1 - Project MANAGEMENT 8:30 AM - 10:00 AM LEVEL = ●

8:30 AM - 10:00 AM Room 143AB

Project Management Institute credits offered

Maintaining the Talent Pipeline: Options for Identifying, Training, and Developing Pharmaceutical Project Managers

SESSION CHAIRPERSONS

Arthur Gertel, MS

Vice President, Clinical Services, Regulatory and Medical Writing, Beardsworth Consulting Group, Inc.

Kathleen J. Warner, PhD, MS

Vice President, Research and Development Practice, Taratec Development Corporation

Tuesday, June 28

Recruiting, training, and developing project managers remains a key challenge for the pharmaceutical industry. There is no single training or certification program that has been identified as the gold standard, and as a result we have seen a plethora of choices evolve. This session provides some guidance on how to not only find the people with the right potential, but also how to train and develop them and provide enough career options to keep them motivated.

Training Priorities for Project Managers in Life Sciences Kathleen J. Warner, PhD, MS

Vice President, Research and Development Practice, Taratec Development Corporation

Naomi Clark-Turner, PhD

Director, Operations, Project Management and Portfolio Planning, Centocor, Inc.

SESSION 222 **PM2 - PROJECT MANAGEMENT**

8:30 AM - 10:00 AM LEVEL =

Room 143C Project Management Institute credits offered

Lead, Follow, or Get Out of the Way!

SESSION CHAIRPERSON

Robin G. Foldesy, PhD

Vice President, Project Management, Wyeth Research

Every successful team is greater than the sum of its parts. It's no coincidence that great teams are led by great leaders. Through the use of case studies from seasoned project management professionals, this session will discuss the characteristics of effective leaders and the successful teams they lead.

Lead, Follow, or Get Out of the Way!

Robin G. Foldesy, PhD Vice President, Project Management, Wyeth Research

Leadership, Decision Making, and Credibility, and the Critical Links **Between Them**

Martin Reeves Vice President, Strategic Planning, Cephalon, Inc.

Roll Up Your Sleeves: Welcome to Biotech Project Management Elizabeth P. Eberhardt Project Leader, ViroPharma Incorporated

SESSION 223 **PP - PUBLIC POLICY/LAW, RA, RD**

8:30 AM - 10:00 AM

LEVEL = •

Room 144ABC Pharmacy credits offered

Medicines and Healthcare: Rebuilding the Trust -**Reshaping the Future – Part 1 of 2**

SESSION CHAIRPERSONS

Raymond G. Starrett, MLS Project Manager, GlaxoSmithKline

Jean Yager, PhD

Director, Department of Methods and Training, Global Project Management, Pfizer Inc

Part 2 of this session will be held on Tuesday at 10:30 AM.

The pharmaceutical industry is facing an unprecedented challenge to restore public confidence in the contribution of pharmaceuticals to healthcare and the value of new drug innovation. Without this confidence, the very fabric of the pharmaceutical and biotech industries and the future of new drug innovation are at risk. The potential long-term impact on patient welfare is enormous.

In this session, panelists representing industry, regulatory authorities, academia, policy makers, media and patients will discuss some of the key issues affecting public perception of the industry. A moderator will guide the panelists through constructive discussion.

Moderator

Kenneth I. Kaitin, PhD

Director, Tufts Center for the Study of Drug Development, Tufts University

Panelists

Billy Tauzin, JD

President and CEO, Pharmaceutical Research and Manufacturers of America, (PhRMA)

Scott Gottlieb, MD

Resident Fellow, American Enterprise Institute for Public Policy Research

Robert J. Temple, MD

Director, Office of Medical Policy and Office of Drug Evaluation, CDER, FDA

Joanne Silberner

Health Policy Correspondent, National Public Radio (NPR)

SESSION 224 **RA1 - REGULATORY AFFAIRS**

8:30 AM - 10:00 AM LEVEL =

Room 146C

New Horizons for the EMEA: Priorities for 2005-2006 SESSION CHAIRPERSON

Thomas Lönngren. MPharm Executive Director, EMEA, EU

The new pharmaceutical legislation in the European Union goes into effect in 2005. Various new legislative tools will be made available to the EMEA and pharmaceutical industry as of November 2005. In addition, the EMEA published its strategy paper for the next years, "The EMEA Road Map to 2010: Preparing the Ground for the Future." It sets out the various initiatives the EMEA will undertake over the next few years in a range of fields, including research and innovation, safety of medicines and transparency and communication.

Thomas Lönngren, MPharm

Executive Director, EMEA, EU

Patrick Le Courtois, MD

Head of Unit, Preauthorization Evaluation of Medicines for Human Use, EMEA, EU

Noël Wathion, Pharm

Head of Unit, Postauthorization Evaluation of Medicines for Human Use, EMEA. EU

SESSION 225

RA2 - REGULATORY AFFAIRS 8:30 AM - 10:00 AM LEVEL = •

Room 151B CME credits offered

Implementation of the August 30, 2003 WTO Decision: Access to Medicines

SESSION CHAIRPERSON

Karolyn S. Lui, MSc

Associate Director, Policy Bureau, Therapeutics Products Directorate, Health Canada

The WTO decision of August 2003 waived certain compulsory licensing obligations to facilitate affordable access to medicines, especially those resulting from HIV/AIDS, tuberculosis, malaria and other epidemics in

developing countries with no or insufficient domestic manufacturing capability. This session will present the background of the WTO agreement as well as how Canada and different countries have responded within this context.

Canada's Implementation of the WTO Decision

Karolyn S. Lui, MSc

Associate Director, Policy Bureau, Therapeutics Products Directorate, Health Canada

The European Union's Implementation of the WTO Decision *Béatrice Kressmann*

Director, European and International Affairs, LEEM (Pharmaceutical Industry Association in France)

Session 226 RA3 - Regulatory Affairs, RD

8:30 AM - 10:00 AM LEVEL =

Room 151A

Global Development: Focus on Asia

SESSION CHAIRPERSON

Eric W. Lewis, MD Director, Clinical Pharmacology, GlaxoSmithKline

As Asia continues to grow economically and to develop into a center of global research and discovery, greater demands will be placed on the global pharmaceutical industry for development in this region. The incorporation of Asia into global development programs can lead to important contributions in

the creation of "well-characterized" clinical data packages. Can Asia Pacific Be the Place for Global Clinical Development? *Xiaogang (XG) Wang, MD*

Director, Business Development, ICON Clinical Research, Japan

Masahiro Takeuchi, MD

Professor, Center for Clinical Pharmacy and Clinical Services, Kitasato University Graduate School, Japan

SESSION 227 RA4 - REGULATORY AFFAIRS

8:30 AM - 10:00 AM

Room 152B

CBER Update

SESSION CHAIRPERSON

Jesse L. Goodman, MD, MPH

Director, Center for Biologics Evaluation and Research, FDA

This session will provide a CBER management overview of important issues. CBER initiatives regarding regulation, review processes, research, and/or safety will be summarized and current issues impacting CBER's mission will be discussed.

An Overall Center Update Jesse L. Goodman, MD, MPH Director, Center for Biologics Evaluation and Research, FDA

Regulations/Policy Update Diane Maloney, Esq. Associate Director for Policy, CBER, FDA

Review Management Update Robert A. Yetter, PhD Associate Director for Review Management, Office of the Director, CBER, FDA

SESSION 228 RD - R&D STRATEGY, FI, OS

8:30 AM - 10:00 AM LEVEL =

Room 150B

Workload Management and Performance Monitoring SESSION CHAIRPERSON

Wolfgang Seifert, PhD, MD

Senior Advisor, Drug Development, Schering AG, Germany

Outsourcing may be selected for various reasons. This session outlines specific performance properties of outsourced work, analyzes the relationship of total cost for in-house and outsourced work, and describes how to get to a cost-optimal workload balance. Earned value analysis as a performance evaluation method tracks the outsourced work and the progress of the total work.

The Role of Outsourcing Over the Clinical Development Phases Cyndy E. Lumley, PhD

Executive Vice President, Corporate Affairs, CMR International Ltd., UK

How to Manage Workload Using a Cost Analysis Model Hermann Kulmann, PhD

Head, Biometry - Europe, Schering AG, Germany

Monitoring External and Internal Performance with Earned Value Analysis Wolfgang Seifert, PhD, MD Scalar Advisor Drug Development, Schering AC, Cormony

Senior Advisor, Drug Development, Schering AG, Germany

SESSION 229 ST - STATISTICS, RA

8:30 AM - 10:00 AM LEVEL = •

Room 201

Statisticians and Standards: Emerging Tools and Processes for Faster, Cleaner Results from Clinic to Submission

SESSION CHAIRPERSON **Russell Helms, PhD, MS** Assistant Director, Biostatistics, Rho, Inc.

Statisticians have an important role in the ever-increasing drive to speed the drug development process. In this session, speakers will discuss ways statistician involvement with new standards and tools can lead to better and faster results.

Implementation of Clinical Reporting Using CDISC Study Data Tabulation Model Steve Light Principal Consultant, DataCeutics, Inc.

The Statistician's Role in Data Review Beth Fetterman, MS Director, Clinical Reporting, PharmaLink FHI, Inc.

Programming and Analysis Specifications: A Detailed SAP Tool *Tara Maddala, PhD* Manager, Biostatistics, Clinmetrics Research Associates, Inc.

Session 230 TR - TRAINING, CR, IS

8:30 am - 10:00 am

LEVEL = •

Room 207B

CME, Nursing, and Pharmacy credits offered

Investigative Site Readiness

SESSION CHAIRPERSON

Nadina C. Jose, MD, CPI President and CEO, Research Strategies, Inc.

Increased enrollment delays, inadequate documentation, and protocol violations are common causes for increased expenditures in clinical research. Rather than having a delayed response to these issues, research sites must be able to go home from an investigator meeting, feeling pumped up and ready to begin the study, knowing they not only understand the protocol, but that they also are fully equipped with the right tools to be able to troubleshoot along the way.

Launching Clinical Trials in a Multisite Hospital Setting David M. Vulcano, MBA, LCSW, CIP

Director, Clinical Trials, Ardent Health Services

Stress: Getting It or Giving It? Ronny K. Schnel, MS Executive Director, Business Development and Client Services, Criterium

Investigative Site Readiness

Nadina C. Jose, MD, CPI President and CEO, Research Strategies, Inc.

SESSION 231 VA - VALIDATION

LEVEL = •

8:30 am - 10:00 am

Room 147B

Validation Methodology

SESSION CHAIRPERSON

Earl W. Hulihan, MEd

Senior Vice President, Regulatory Consulting Services, META Solutions, Inc.

This session will focus on today's clinical trial technology and which steps must be taken to ensure overall accuracy and reliability of data. Reviewing three areas of focus [electronic data capture systems, electronic databases (specifically viewed from the high risk perspective of a safety database), and software development] this session will provide insight and clarification on the measures required for data integrity and reliability.

Life Beyond the Release of Clinical Trial Electronic Data Jean A. Paty, PhD, MS

Chief Quality Officer, invivodata

Validation and Impact Analysis of a Safety Database Earl W. Hulihan, MEd

Senior Vice President, Regulatory Consulting Services, META Solutions, Inc.

SPECIAL EVENT

8:30 am - 12:00 pm

Room 204A

Student Forum

FORUM CHAIRPERSON

Stephen A. Sonstein, PhD

Coordinator, Clinical Research Administration, Eastern Michigan University

The Student Forum has been designed to provide information of interest to students and an opportunity to provide input to the DIA. The agenda for the Student Forum is as follows:

Continental Breakfast for Students (8:30 AM - 9:00 AM)

Perspectives on the Future Workforce for the Clinical Research Enterprise

Kenneth A. Getz, MS, MBA

Research Fellow, Tufts Center for the Study of Drug Development, Tufts University; Chairman, CISCRP

Education and Training Opportunities in Clinical Research Stephen A. Sonstein, PhD

Coordinator, Clinical Research Administration, Eastern Michigan University

Refreshment Break (10:30 AM – 10:45 AM)

A Career in Clinical Research

Theresa K. Musser

Senior Director, Project Management and Clinical Operations, Rigel Pharmaceuticals; Acting President, DIA

Roundtable/Panel Discussion

- · Employment in the pharmaceutical and biotechnology industries
- Need for suitable education
- Role of students in the DIA

Student Forum concludes at 12:00 PM.

10:00 ам - 10:30 ам

REFRESHMENT BREAK

Exhibit Halls ABC, Lower Level Convention Center

Session 232

AD - Advertising, MA, RA

10:30 ам - 12:00 рм Room 202В

CME and Pharmacy credits offered

DTC Update

session chairperson *Lucy Rose, MBA, PA-C* President, Lucy Rose and Associates

LEVEL =

This session will explore the current environment surrounding DTC promotion in the US, including the possible impact of recent drug safety and regulatory concerns. Additionally, the panel will address the issues and concerns regarding global DTC promotion and the likelihood of expanded promotion.

Panelists

Melissa M. Moncavage, MPH

Leader, DTC Review Group, Office of Medical Policy, Division of Drug Marketing, Advertising and Communications, CDER, FDA

Kathryn J. Aikin, PhD

Social Science Analyst, Office of Medical Policy, Division of Drug Marketing, Advertising and Communications, CDER, FDA

Minnie Baylor-Henry, RPh, JD

Vice President, Medical and Regulatory Affairs, Johnson & Johnson Pharmaceutical Research and Development, LLC

SESSION 233 BT - BIOTECHNOLOGY, RA, RD

10:30 ам - 12:00 рм LEVEL =

Room 154AB *CME credits offered*

Current Challenges in the Development of Cell-based Therapies

SESSION CHAIRPERSON

Darin Weber, PhD Senior Consultant, The Biologics Consulting Group, LLC

This session will highlight some of the unique challenges facing developers of cell-based therapies including those related to CMC, preclinical development, and clinical trials. Information resources identifying current FDA thinking in this field, as well as specific strategies for working with the review staff at the FDA, will be described.

FDA Perspective on Current Challenges in the Development of Cell-based Therapies

Kimberly A. Benton Supervisory Microbiologist, Office of Cellular, Tissue and Gene Therapies, CBER, FDA

Experiences in Exploring the FDA Regulatory Path for a Novel Cell-scaffold Combination Product *Timothy A. Bertram, DVM, PhD*

Vice President, Preclinical Science and Technology, Tengion, Incorporated

Essential Tools and Strategies for Overcoming Developmental Challenges for Cell-based Products Darin Weber, PhD

Senior Consultant, The Biologics Consulting Group, LLC

Session 234 CDM - CLINICAL DATA MANAGEMENT, CP

10:30 ам - 12:00 рм LEVEL = •

Room 204BC CME and Pharmacy credits offered

An Introduction to SNOMED CT®: Comprehensive Terminology for eMedical Records

SESSION CHAIRPERSON

Doris McGinness

Terminology Manager, Pharmacy, SNOMED International

SNOMED CT[®] is a comprehensive controlled terminology with over 350,000 concepts that spans all medical specialties and has been recommended as the standard for the electronic health record for the US. The core content is current, dynamic and organized in multiple hierarchies with relationships that capture complex concepts describing diagnoses, complications, therapy, and outcomes. This overview of SNOMED will emphasize the scope, its hierarchical structure, pharmaceuticals, and adverse events.

An Introduction to SNOMED CT[®] (Systemized Nomenclature of Medicine Clinical Terms): Comprehensive Terminology for Electronic Medical Records *Doris McGinness*

Terminology Manager, Pharmacy, SNOMED International

SNOMED CT $^{\otimes}$ Terminology and the United Kingdom's National Health Service

Paul Frosdick, MRPharmS, MBA

Senior Clinical Pharmacist, National Programme for Information Technology (NPf IT) Design Authority, National Health Service, UK

SNOMED CT[®] Terminology and Kaiser Permanente

James Shalaby, PharmD

Manager, Convergent Medical Terminology, Kaiser Permanente Information Technology

Session 235 CMC - CHEMISTRY, MANUFACTURING, AND CONTROLS, RA

10:30 ам - 12:00 рм LEVEL =

Room 147A

Open Forum: Ask CMC Questions on the Latest Hot Topics to the Agency and Industry Experts SESSION CHAIRPERSON

Dhiren N. Shah, PhD

Director, US DRA-CMC, sanofi-aventis

This session will provide attendees with the opportunity to ask questions of our team of experts from industry and the Agency on preselected topics. These topics include: genotoxic impurities, starting material in the manufacture of drug substances, tangible benefits of application of PAT to drug substances and drug products, specification process, first-time approvals, and comparability protocols.

Panelists

Moheb M. Nasr, PhD Director, Office of New Drug Chemistry, CDER, FDA

Chi-wan Chen, PhD Deputy Director, Office of New Drug Chemistry, CDER, FDA

Charles P. Hoiberg, PhD Executive Director, Pfizer Inc

Richard Poska, MS Director, Regulatory Affairs, Abbott Laboratories

Frank O. Holcombe, Jr., PhD Associate Director for Chemistry, Office of Generic Drugs, CDER, FDA

SESSION 236 CP - CLINICAL SAFETY AND PHARMACOVIGILANCE, RA

10:30 ам - 12:00 рм LEVEL =

Room 207A CME and Pharmacy credits offered

Risk Minimization Action Plans

SESSION CHAIRPERSON

Annette Stemhagen, DrPh, FISPE

Vice President, Strategic Development Services, Covance Periapproval Services, Inc.

The FDA final guidance on risk management includes strategies for pre- and postmarketing risk management, and the development of Risk Management Action Plans (RiskMAPs). This session will review key components of risk management: assessment, intervention, communication, and evaluation, and describe both pre- and postmarketing approaches to each of these components.

Strategies for Designing Risk Management Programs Annette Stemhagen, DrPh, FISPE

Vice President, Strategic Development Services, Covance Periapproval Services, Inc.

Risk Management: Practical implications for Pharmaceutical Manufacturers

Mary Ellen Turner, MD, MPH

Vice President, Global Safety Surveillance and Epidemiology, Wyeth Pharmaceuticals

Evaluation of Risk Minimization Action Plans (RiskMAPs) Matthew W. Reynolds, PhD, MS

Senior Director, Risk Management and Safety Services, MetaWorks, Inc.

Session 237 CR1 - CLINICAL RESEARCH AND DEVELOPMENT, RA

10:30 ам - 12:00 рм LEVEL = •

Room 145B *CME, Nursing, and Pharmacy credits offered*

Safer, Better, More Appropriate: Clinical Trial Design for Pediatric Drug Labels

SESSION CHAIRPERSON

William Rodriguez, MD, PhD

Science Director for Pediatrics, CDER, FDA

Off-label use of drugs in pediatrics remains a national and international problem. Congress has mandated the study of drugs in pediatrics, and this legislation provides for the study of both on-patent and off-patent drugs in the pediatric population. This session is designed to delineate the current legislation, to identify partnership opportunities, and to provide information on the design of pediatric clinical trials in order to obtain safety, efficacy, and pharmacokinetic data for pediatric drug labeling.

Regulatory Issues in Pediatric Drug Development Lisa L. Mathis

Commander, USPHS, Medical Team Leader, Division of Pediatric Drug Development, Office of Counter-terrorism and Pediatric Drug Development, CDER, FDA

Creative Clinical Trial Design for Pediatric Drug Development Susan McCune, MD, MA Medical Officer, CDER, FDA

Global Partnerships for Improved Clinical Trials Karen L. Ball

President and CEO, The Sturge-Weber Foundation

Pediatric Clinical Trial Designs: Varied Paths to the Top of the Mountain David M. Cocchetto, PhD

Vice President, Antiviral/Antibacterial Regulatory Affairs, GlaxoSmithKline

SESSION 238 CR2 - CLINICAL RESEARCH AND DEVELOPMENT, IS

10:30 AM - 12:00 PM LEVEL = •

Room 145A

What Patient Recruitment Methods Work Best for Women and Minorities?

SESSION CHAIRPERSON

William W. Gwinn, Jr., MBA

Director, Clinical Trial Solutions, Medstat Inc.

This session is a joint presentation by Medstat, Matthews Media Group, and an independent researcher. It will review clinical trial participation by women and minorities, with broader supplemental views by age and by lifestyle segmentation groups. The session will also present initial survey findings, as well as a proposal for a research study to assess the effectiveness of communitybased recruitment, population-based "sampling" methods, and the use of call centers and the Internet. It will also have advertising examples.

Overview and New Survey Results by Demographic and Lifestyle Segments

William W. Gwinn, Jr., MBA Director, Clinical Trial Solutions, Medstat Inc.

Communication Strategies and Techniques Nancy A. Mulligan

Vice President, Matthews Media Group

A Proposal for a Research Study: Patient Recruitment Methods in Clinical Trials Involving Women and Minorities *Michelle D. Burton, MSHS, CCRP*

Clinical Research Associate, TAP Pharmaceutical Products, Inc./MedFocus LLC

SESSION 239 CR3 - CLINICAL RESEARCH AND

DEVELOPMENT

10:30 ам - 12:00 рм LEVEL =

Room 149AB

Alternative Country Selection

SESSION CHAIRPERSON

Alan Wood, PhD, MPharm

General Manager, Clinical Development Services, Covance Clinical and Periapproval Services, UK

An interactive panel discussion with representatives from India, Latin America, and Eastern Europe offering insight into the practical opportunities and challenges with clinical trial enrollment and management in their respective regions.

Central and Eastern Europe: Maximizing Success Through Rapid Patient Recruitment and Quality Data

Malgorzata Szerszeniewska, MD

Director, Strategic Development, CEE, Covance (Polska) Poland

India and Clinical Development: Some Myths and Facts Rupesh V. Patki, PhD, MPharm

Manager, Clinical Operations, Siro Clinpharm, India

Latin America: Do's and Don'ts in Clinical Trials Sergio Guerrero, MD

Vice President/Chief Operating Officer, Mexican Institute of Clinical Research, Mexico

Session 240 CR4 - Clinical Research and Development

10:30 ам - 12:00 рм LEVEL = •

Room 147B CME and Pharmacy credits offered

Understanding How to Design a Better Placebo-controlled Trial

SESSION CHAIRPERSON

Arlene S. Swern, PhD

Associate Director, Merck Research Laboratories

Many factors contribute to and affect the order of magnitude of the placebo response. Some of these factors may be minimized, and some may not. The intent of this session is to discuss the factors that contribute to the placebo response and to examine what may be done in the design of a trial to minimize the placebo effect.

Strategies for Minimizing the Placebo Response

Arlene S. Swern, PhD Associate Director, Merck Research Laboratories

Baseline Elevation Subterfuge, Meddlesome Measurement, and Other Factors that Affect Subjective Responses in Clinical Trials *Bernard P. Schachtel, MD*

Lecturer, Department of Epidemiology and Public Health, Yale University School of Medicine: Medical Director, Schachtel Research Center

Understanding and Modeling Placebo Effects in Clinical Trials Mani Y. Lakshminarayanan, PhD Director/Statistical Scientist, Dfiar Inc.

Director/Statistical Scientist, Pfizer Inc

SESSION 241 CTM - CLINICAL TRIAL MANAGEMENT

10:30 ам - 12:00 рм LEVEL = •

Pharmacy credits offered

Innovative, Objective, Data-based Approach to Trial Planning and Implementation

SESSION CHAIRPERSON

Room 140B

Rajiv Prasad, MBA

President, Clindata International, LLC

This session deals with innovative, integrated, patient-level longitudinal databased approaches to clinical trial planning and implementation. The use of predictive enrollment for refining protocol inclusion/exclusion criteria, site location and selection and patient recruitment, including the patient's own pharmacists, web-based and IVRS patient screening methods for rapid enrollment, will be discussed.

ROI on Innovations in Data-based Approaches to Trial Planning and Design *Mark A. Hovde, MBA*

President, Hovde Associates LLC

Process for Evaluating Longitudinal Databases for Site Selection *Nancy J. Dynes, MBA*

Data Steward, Global Enrollment Optimization, Eli Lilly and Company

Improving Site Selection Through the Utilization of Innovative Data Sources Matthew J. Wallach, MBA

Chief Marketing Officer, Health Market Science, Inc.

Session 242 DM - DOCUMENT MANAGEMENT/ ESUBMISSIONS, RA

10:30 ам - 12:00 рм LEVEL = •

Pharmacy credits offered

eCTD: Case Studies

SESSION CHAIRPERSON

Alison W. Buno

Room 206

Site Lead, Pfizer Global Research and Development

This basic level session will present real-life experience submitting eCTDs in the US and Europe. Hear how others have worked through challenges and various scenarios to successfully create valid eCTD submissions in the US, Europe, and simultaneously to more than one region.

Practical Experience on Participating in the FDA eCTD Pilot Program Kenneth R. VanLuvanee

President and CEO, Apyx, Inc.

Simultaneous eCTD Assembly Justin DiFebbo Wyeth Research

Submitting an eCTD in Europe Tracy L. Baldwin Associate Director, Pfizer Inc, UK

SESSION 243 GCP - GOOD CLINICAL PRACTICES, RA

10:30 ам - 12:00 рм 🛛 📙

LEVEL =

Room 202A

Nursing credits offered

Town Hall Forum on Current GCP Issues

SESSION CHAIRPERSONS Michael R. Hamrell, PhD, RAC

President, MORIAH Consultants

Beat E. Widler, PhD Global Head, Clinical Quality Assurance, F. Hoffmann-La Roche Ltd., Switzerland As the role of the different parties in clinical research has changed, the types of tasks delegated to third parties has increased. This change has prompted the need for more oversight of the quality of the work conducted. This session will discuss the importance of assessing the quality and performance of vendors and staff as part of your overall quality assurance program in clinical research. Understanding these issues can help to minimize the risk and reduce the exposure for the sponsor and the clinical investigator. This session will discuss recent trends in the inspection of clinical studies.

David A. Lepay, PhD, MD

Senior Advisor for Clinical Science and Director, Good Clinical Practices Programs, OSHC, Office of the Commissioner, FDA

Fergus L. Sweeney, PhD

Principal Administrator, Inspections Unit, EMEA, EU

Jean Saint-Pierre

Coordinator, Good Clinical Practices, National Coordination Center, Inspectorate; Health Products and Food Branch, Health Canada

SESSION 244 IMP - IMPACT, ECLIN, OS

10:30 ам - 12:00 рм LEVEL =

Room 152A

Successful Selection of an ePRO Technology Provider

SESSION CHAIRPERSON Jennifer Aquino Vice President, Voice and Data Systems, Perceptive Informatics, Inc.

This session will focus on the key aspects of the process of selecting suppliers to collect patient self-report data. The focus will be on the need for technology – which ones?; ePRO choices available; establishing the selection criteria; running the selection; the results/reality; and the future shape of the market.

ePRO Selection

Christopher Pitcherella, MBA Clinical Outsourcing Manager, AstraZeneca LP

ePRO Implementation

Daryl S. Kershner Manager, BDS Business Planning and Development, GlaxoSmithKline

ePRO: Fitting the Pieces Together *Paula McHale* Director, EDC Solutions, PAREXEL International

SESSION 245 IS - INVESTIGATOR SITES, CR, CTM

10:30 ам - 12:00 рм 🛛 LEVEL = 🔳

Room 101 *CME credits offered*

Accelerating Subject Enrollment: A Handbook for Sites and Sponsors

SESSION CHAIRPERSON

Louis C. Kirby, MD

Medical Director and Founder, Pivotal Research Centers

This session identifies barriers to timely enrollment and makes specific recommendations for improvement. Sponsors can do a better job of site identification, allocation of resources, budgeting, and preplanning with sites for a successful recruitment campaign. Customization of site interactions, learning from sites, and fostering the individual site strengths can make a world of difference in accelerating enrollment. Sites can discover new and powerful techniques to increase the efficiency of their recruitment efforts and work closely with sponsors to make their capabilities known. This session will clearly and specifically discuss the real-world approaches to reducing recruitment delays in ways that both sponsors and sites can take home and employ tomorrow. Dr. Kirby will be the sole speaker to present the material in detail not easily achieved by multispeaker sessions.

Louis C. Kirby, MD

Medical Director and Founder, Pivotal Research Centers

Session 246 IT - INFORMATION TECHNOLOGY, CTM

10:30 ам - 12:00 рм LEVEL =

Room 146B

Lightweight Integration for Clinical Trial Operations

session chairpersons *William Crawford* President, Crawford Life Sciences

Jean-Remy Behaeghel

Director, IVRS, Perceptive Informatics, Inc.

A panel will discuss the challenges of integrating operations systems with trial management and reporting applications, and provide a report on the development of L2M2, an XML-based secure data model and messaging layer for the conduct of a clinical trial, linking CTMS, IVRS, supply management and other systems on an ad-hoc, trial-by-trial basis.

L2M2: Protocol and Data Model for Lightweight Integration of Clinical Trial Operations *William Crawford*

President. Crawford Life Sciences

Making the Case for Lightweight Clinical Trial Operations Integration Protocol: An In-depth Look at the Clinical Trial Information System Jean-Remy Behaeghel

Director, IVRS, Perceptive Informatics, Inc.

Session 247 MC - MEDICAL COMMUNICATIONS, CR

10:30 ам - 12:00 рм **LEVEL =**

Room 209AB

Integrating Field Medical Liaisons with Clinical Drug Development

SESSION CHAIRPERSON

Ellis H. Wilson, MS, MSA

Study Delivery Director, Neuroscience, AstraZeneca Pharmaceuticals

Field medical liaison professionals are in a special position to contribute significantly to clinical drug development on numerous levels. This session is underpinned by the experience of three well-organized field medical liaison initiatives and is focused on outlining both the potential contributions to drug development programs and the obstacles that must be overcome in order to leverage this important resource.

Capturing and Integrating Field Input to Clinical Development Plans Michael M. Januszeski, PhD

Associate Director, Medical Affairs, Centocor, Inc.

Influencing the Direction of Research Based on Medical Liaison Input Rashmi Yadav-Marya, MPH

Neuroscience Medical Liaison, Eli Lilly Pharmaceuticals

Are We There Yet? Optimizing Field Liaison Contributions to Development *Ellis H. Wilson, MS, MSA*

Study Delivery Director, Neuroscience, AstraZeneca Pharmaceuticals

Session 248 NC/VA - Nonclinical Laboratory SAFETY/VALIDATION, RA

10:30 ам - 12:00 рм LEVEL =

Room 103B

Post Red Apple Conference Update

session chairperson **Earl W. Hulihan, MEd**

Senior Vice President, Regulatory Consulting Services, META Solutions, Inc.

In 1987 the Office of Regulatory Affairs and the National Center for Toxicological Research (NCTR) of the Food and Drug Administration and NCTR Associated Universities, Inc., conducted a workshop on computerized systems used in nonclinical laboratories. The workshop was conducted at the Red Apple Conference Center in Heber Springs, Arkansas. Over sixty persons, representing government, industry, and academia were chosen to participate in the workshop. The purpose of the workshop was to develop a reference document on computer automation in toxicology laboratories that would describe effective means for ensuring the quality of computerized systems. In 1988 the product of the conference was published as "Computerized Data Systems for Nonclinical Safety Assessment: Current Concepts and Quality Assurance." The document became an industry standard for assuring the quality of computerized systems and many of its principles are applicable today. This session will review the reasons for the Red Apple Conference and provide an overview of the resulting document. Presentations will discuss the impact of the document on the regulated industry, its relevance to today's regulated environment, and plans for revisiting the Red Apple Conference.

James F. McCormack, PhD

Vice President, Regulatory Affairs and Compliance, Charles River Laboratories - CTBR

Martin Browning, MS President, EduQuest, Inc.

Karen Raskasky President, Raskasky Group

Session 249 NHP - NATURAL HEALTH PRODUCTS, RA

10:30 ам - 12:00 рм LEVEL =

Room 102AB

The New Legislative Environment for Herbal Products in Europe

SESSION CHAIRPERSON

Hubertus Cranz, PhD

Director General, Association of the European Self-medication Industry (AESGP), Belgium

This session will review legislation and assessment in relation to herbal medicines in Europe.

Impact of the New Directive on Traditional Herbal Medicines Riccardo Sciabica, PharmD, MS

Senior Editor - IDRAC, Thomson Scientific, France

Scientific Evaluation of Medicinal Plants Heribert Pittner. MD

Vice Chair, EMEA Committee of Herbal Medicinal Products, Bundesministerium für Gesundheit und Frausen, Austria

Industry Expectations Hubertus Cranz, PhD

Director General, Association of the European Self-medication Industry (AESGP), Belgium

Session 250 OS - Outsourcing, PM

10:30 AM - 12:00 PM LEVEL =

Room 150A

Exploring Both Sides of the Perfect CRO/Pharmaceutical Partnership

SESSION CHAIRPERSON

Patricia A. Mosher

Senior Director, Clinical Infectious Disease Research, PharmaNet

Managing the relationship and activities between a CRO and a pharmaceutical company is challenging. Expectations, competencies and staffing must be balanced with timelines, flexibility, and resources. The success of a project, i.e., meeting deliverables on time, is contingent on the strength of the team, specific tools used to achieve milestones, and how well the team works together to complete tasks.

Exploring Both Sides of the Perfect CRO/Pharmaceutical Partnership Bryce D. Bartruff, PhD, MBA, RN

Manager, Clinical Infectious Disease Research, PharmaNet

Exploring Both Sides of the Perfect CRO/Pharmaceutical Partnership Audrey Rossow

Senior Project Manager, PAREXEL MMS, Patient and Clinical Communications

Session 251 PM1 - PROJECT MANAGEMENT, RD

10:30 ам - 12:00 рм LEVEL =

Room 143AB Project Management Institute credits offered

Risk Management

SESSION CHAIRPERSON

Jane M. Bainbridge, MSc Vice President, Project Management, Celgene Corporation

Understanding risk is the first step towards realizing the ways to manage and reduce risk in order to tip the risk/reward ratio toward increased value. This session will address the following: portfolio risk, risk in invention/candidate selection, and project risk.

Portfolio Risk Management: The Practical Issues Stephen W. Allport, Cbiol, MIBiol, DMS, DipM, MCIM, MCMI Managing Director, SWA Consulting, UK

From Invention to Development: Reducing the Risk of Starting Projects that Fail

Allen C. Sarapu, PhD President, Value-Added Drug Development, LLC

Practical Approach to Project Risk Management Leah Goldbroch, MBA

Director, Global Project Management, Abbott Laboratories

Session 252 PM2 - Project Management, BT, RD

10:30 ам - 12:00 рм LEVEL =

Room 143C

Project Management Institute credits offered

Alliance Management: From Partner Selection to Joint Program Teams

session chairperson Julie G. Bukar, MBA, RD

Principal, JGB BioPharma Consulting

Corporate alliances are an excellent way for companies to join forces on a program or research area, such that goals are achieved faster than they could be by either company individually. However, partner selection and alliance management are key to success. This session will focus on both of these aspects in relation to achieving productive corporate alliances.

Strategic Alliances with Big Pharma *Kelly L. Longo, MA, MBA* Associate Director, Strategic Alliances, Pfizer Inc

Creating a Good Alliance: Hints in Strategy, Valuation, Negotiation and Contracts *Linda M. Pullan, PhD*

Vice President, Business Development, Kosan Biosciences

How to Run an Effective Alliance *Cynthia Perettie, MS, MBA* Senior Director, Product Planning, Genentech, Inc.

SESSION 253 PP - PUBLIC POLICY/LAW, RA, RD

10:30 ам - 12:00 рм	LEVEL = •

Room 144ABC Pharmacy credits offered

Medicines and Healthcare: Rebuilding the Trust – Reshaping the Future – Part 2 of 2 SESSION CHARPERSONS

Raymond G. Starrett, MLS Project Manager, GlaxoSmithKline

Jean Yager, PhD

Director, Department of Methods and Training, Global Project Management, Pfizer Inc

Part 1 of this session will be held on Tuesday at 8:30 AM.

The pharmaceutical industry is facing an unprecedented challenge to restore public confidence in the contribution of pharmaceuticals to healthcare and the value of new drug innovation. Without this confidence, the very fabric of the pharmaceutical and biotech industries and the future of new drug innovation are at risk. The potential long-term impact on patient welfare is enormous.

In this session, panelists representing industry, regulatory authorities, academia, policy makers, media and patients will discuss some of the key issues affecting public perception of the industry. A moderator will guide the panelists through constructive discussion.

Moderator

Kenneth I. Kaitin, PhD

Director, Tufts Center for the Study of Drug Development, Tufts University

Panelists Billy Tauzin, JD

President and CEO, Pharmaceutical Research and Manufacturers of America, (PhRMA)

Scott Gottlieb, MD Resident Fellow, American Enterprise Institute for Public Policy Research

Robert J. Temple, MD Director, Office of Medical Policy and Office of Drug Evaluation, CDER, FDA Joanne Silberner

Health Policy Correspondent, National Public Radio (NPR)

Session 254 RA1 - REGULATORY AFFAIRS

10:30 ам - 12:00 рм LEVEL =

Room 146C CME credits offered

New Pharmaceutical Legislation – Part 1 of 3: Tools for Quick Access to Medicines

SESSION CHAIRPERSONS

Yves M. Juillet, MD, PhD

Senior Advisor, LEEM (Pharmaceutical Industry Association in France)

Patrick Le Courtois, MD

Head of Unit, Preauthorization Evaluation of Medicines for Human Use, EMEA, EU

Part 2 of this session will be held on Tuesday at 1:30 pm; Part 3 will be held on Tuesday at 3:30 pm.

Within the scope of the New Pharmaceutical Legislation, which will enter into force in the 25 Member Sates of the European Union in October-November 2005, more focus will be placed on the procedures under the responsibility of the European Medicines Agency (EMEA). In particular, any product in oncology, diabetes, HIV or in neurodegenerative diseases will have to follow the centralized procedure, as the compulsory registration route. This will be extended to other therapeutic areas in the future. It is therefore important to understand the strategic and practical issues relating to these important changes, such as faster access to new innovative medicines on one side, and issues relating to assessment, availability of scientific expertise, or postauthorization procedures and systems like pharmacovigilance. In this respect, two sessions are proposed addressing the tools for quick access to medicines, as well as other practical aspects, with intervention from the key stakeholders, i.e. EMEA, CHMP and industry.

NML Implementation in EU and at the EMEA Francesco Pignatti

Scientific Administrator, EMEA, EU

NML Implementation: Industry Views

Christine-Lise Julou, PharmD Manager, Scientific and Regulatory Affairs, EFPIA, Belgium

NML Implementation in EU Member States John A. Lisman, MPharm, LLM

Policy Advisor, Medicines Evaluation Board, Netherlands

Panelist

Eric Abadie, MD, MBA Vice Chairman, CHMP, EMEA, EU; AFSSAPS, France

SESSION 255 RA2 - REGULATORY AFFAIRS, CP, MC

```
10:30 AM - 12:00 PM LEVEL = •
```

Room 151B

CME and Nursing credits offered

Self-medication and OTCs

SESSION CHAIRPERSON

Mohammed Razdar Khan Director, Synergex Consulting, Canada

Concurrent use of multiple OTC formulations by consumers is putting them at the risk of inadvertent overdosing, and not infrequently, with serious consequences. It is perhaps time that we gave serious thought to assessing the adequacy of product labeling and consumer education needs.

Self-medication and OTCs: Perspective on the Canadian OTC Market Mohammed Razdar Khan

Director, Synergex Consulting, Canada

Consumer Health Product Safety: A US Perspective, with a Focus on Botanicals and Other Natural Products Freddie Ann Hoffman. MD

Chief Executive Officer, HeteroGeneity, LLC

Self-medication Risks of OTC Drugs and Herbal Products: Special Focus on Sensitive Populations

Harpal S. Buttar, DVM, PhD, MSc

Senior Scientist and Adjunct Professor, Therapeutic Products Directorate, Health Canada

Session 256 RA3 - Regulatory Affairs, CR 10:30 AM - 12:00 PM LEVEL = •

Room 151A *CME, Nursing, and Pharmacy credits offered*

Public Clinical Trials Data: Preparing for the Registry SESSION CHAIRPERSON

Lee H. Evans

Director, Strategic Planning and Portfolio Management, Clinical and Regulatory Information Services, Merck & Co., Inc.

This session addresses the latest information from industry, legal challenges from state and federal governments, and the potential impact on regulatory strategies related to public clinical trials data. These issues are considered within the context of a logical technology framework for the aggregation, staging, and transmittal of data points for inclusion in a registry.

Merck's Approaches to Publication and Registration of Clinical Trials *Laurence J. Hirsch, MD*

Executive Director, Medical Communications, Merck Research Laboratories

Regulatory Risks, Operational Considerations, and Overall Impact of Public Clinical Trial Registries

Annetta C. Beauregard, MBA, MS

Regulatory Consultant, Office of Scientific and Regulatory Policy, Global Regulatory Affairs, Eli Lilly and Company

Issues in Reporting Results of Clinical Trials Deborah A. Zarin, MD

Director, ClinicalTrials.gov, National Library of Medicine Assistant Director, Clinical Research Projects, National institutes of Health

SESSION 257 RA4 - REGULATORY AFFAIRS

10:30 ам - 12:00 рм LEVEL = •

Room 152B

Labeling and Drug Development: Product Information and Company Core Data Sheet

SESSION CHAIRPERSON

Concettina I. Cordaro, MD

Head, Central Product Information-Group Regulatory Affairs, Bracco Imaging S.p.A., Italy

Labeling is region-specific. However, the generation and use of CORE prescribing information can ensure consistent information throughout regions. Understanding format and content of the regional labeling requirements in the USA, EU, Japan, and Canada will facilitate devising and updating the company core data sheet, as an effective global tool for reaching consistency.

US, European, Canadian, and Japanese Package Inserts and Linkage to the Company Core Data Sheet *Diana E. Fordyce, PhD, RAC*

Senior Regulatory Affairs Scientist, Cato Research, Ltd.

Compiling the Efficacy Part of the European, USA, and Japanese Prescribing Information

Concettina I. Cordaro, MD

Head, Central Product Information-Group Regulatory Affairs, Bracco Imaging S.p.A., Italy

Link Between the CCDS/CCSI and the Approved Prescribing Information Joseph Kappel

Head, Global Product Information and Marketed Products, Novartis Pharma AG, Switzerland

SESSION 258 RA5 - REGULATORY AFFAIRS, IT

10:30 ам - 12:00 рм LEVEL = •

Room 146A

Structured Clinical Trial Protocol

SESSION CHAIRPERSON

Joe E. Jenkins

Marketing Director, Life Sciences, Arbortext, Inc.

Structured Clinical Trial Protocol (SCTP) is an evolving XML-based initiative to define a standard representation for the content and structure of clinical trial protocol information. The initiative is being driven through a team consisting of industry, agency, and software representatives. Attendees of this session will learn about the SCTP initiative, the role XML will play, and the benefits organizations can achieve when using structured content.

Overview of the Structured Clinical Trial Protocol Initiative *Joe E. Jenkins*

Marketing Director, Life Sciences, Arbortext, Inc.

Business Implications of SCTP: Is Your Organization Ready? *Vivian Bruner, MS*

Team Leader, Scientific Communications, Eli Lilly and Company

SESSION 259 RA6 - REGULATORY AFFAIRS

10:30 ам - 12:00 рм

Room 140A

PM LEVEL = ■ CME credits offered

Update from China

SESSION CHAIRPERSONS

Wenzhuang Cao

Director General, Department of Drug Registration, State Food and Drug Administration, China

Ling Su, PhD

Medical and International Pharma Development Director, Shanghai Roche Pharmaceuticals Ltd., China

In this session, speakers from the Chinese regulatory agency, State Food and Drug Administration, will discuss recent developments in regulatory policies and regulations in China, with a focus on drug registration and clinical trial areas.

Overview of Drug Registration in China Wenzhuang Cao

Director General, Department of Drug Registration, State Food and Drug Administration, China

Review and Approval of Clinical Trials in China Jianhua Ding

Deputy Director, Division of Pharmaceuticals, Department of Drug Registration, State Food and Drug Administration, China

SESSION 260 RD - R&D STRATEGY, PM

10:30 ам - 12:00 рм LEVEL =

Room 150B

Managing the Discovery-development Transition SESSION CHAIRPERSON

Thomas Senderovitz, MD

Vice President, Experimental Medicine, Ferring Pharmaceuticals A/S, Denmark

This session will provide an overview of a way to manage the research/discovery/ early development process and a discussion focusing on the importance of the corporate culture rather than only on technologies.

Why Is It Important to Focus on Discovery-development Transition? Thomas Senderovitz, MD

Vice President, Experimental Medicine, Ferring Pharmaceuticals A/S, Denmark

Transition of Molecules from R to D in a Project-centric Organization Lars Guldbaek Karlsen

Senior Vice President, Product Development, Novo Nordisk A/S, Denmark

Critical Path Initiative: Importance in the Discovery-development Transition

Shiew-Mei Huang, PhD, FCP

Deputy Director for Science, Office of Clinical Pharmacology and Biopharmaceutics, CDER, FDA

SESSION 261 ST - STATISTICS, CR

10:30 ам - 12:00 рм LEVEL = •

Room 201 CME credits offered

Design and Analyses Issues in Prevention Trials SESSION CHAIRPERSON

Mohamed AI Osh, PhD, MS Biostatistics Team Leader, CDER, FDA

This session considers some of the issues that arise in prevention trials across different clinical areas. Among these issues are selection of the patient population, low incident rates and their impact on study power, long study duration and the use of surrogate endpoints, and multiple and composite endpoints.

Study Design Issues in Prevention Trials Kathleen S. Fritsch, PhD Division of Biometrics III, Office of Biostatistics, CDER, FDA Mohamed Al Osh, PhD, MS Biostatistics Team Leader, CDER, FDA

Preventing Alzheimer's Disease: The PREADVISE Experience Richard J. Kryscio, PhD

Professor, Saunders-Brown Center on Aging, University of Kentucky

Piggyback Large Prevention Trials for Cancer Biomarker Discovery and Evaluation

Ziding Feng, PhD Member/Professor of Biostatistics, Division of Public Health Science, Fred Hutchinson Cancer Research Center

Session 262 TR - TRAINING, CR

10:30 AM - 12:00 PM LEVEL =

Room 207B

The Career Trends and Challenges for Clinical Research Professionals

SESSION CHAIRPERSON

Joan A. Kroll-Chambers

Director of Strategic Marketing and Development, Tufts Center for the Study of Drug Development, Tufts University

Since 1998, trends and challenges have been tracked within the clinical trials employment market. This session provides a detailed review and discussion of the trends surrounding clinical research positions and the evolution of responsibilities and skill sets required to perform these positions. This session will offer a first-hand look at three positions from three different professionals in the roles of a CRA, regulatory/QA, and CRC and how their roles and responsibilities have evolved because of the changing R&D paradigm and market pressures.

A Look at Industry Trends Impacting Clinical Research Positions Joan A. Kroll-Chambers

Director of Strategic Marketing and Development, Tufts Center for the Study of Drug Development, Tufts University

Personal Perspectives Discussed on How Roles and Responsibilities Have Evolved in Response to Industry Changes *Laurie Halloran, MS* President, Halloran Consulting Group, Inc.

Personal Perspectives Discussed on How Roles and Responsibilities Have Evolved in Response to Industry Changes *Cindy Baxter*

Therapeutic Director, AmericasDoctor, Inc.

LUNCHEON

Lunches will be distributed from 12:00 PM to 1:00 PM in Exhibit Hall C, Lower Level, Convention Center

Session 263 AD - Advertising, CR, RA

1:30 рм - 3:00 рм

12:00 рм - 1:30 рм

LEVEL =

Room 202B CME and Pharmacy credits offered

Clinical Database Registries

SESSION CHAIRPERSON

Minnie Baylor-Henry, RPh, JD

Vice President, Medical and Regulatory Affairs, Johnson & Johnson Pharmaceutical Research and Development, LLC

Clinical trial registries demonstrate the pharmaceutical companies' commitment to providing healthcare professionals and patients worldwide with meaningful information about the science behind the products. It is working towards a goal of transparency. This session will discuss a number of issues including:

- Can a global company have only one clinical trials registry?
- How do we decide what studies to post on this registry?
- Can the studies contain the conclusions of the clinical trial or just the data?
- Are these sites promotional? Do you need the package insert? For which country?

- What is the time commitment for posting the study data for a marketed product?
- What should the industry be doing for investigational drug clinical trials?

Kathleen Meriwether, JD

Assistant US Attorney

Thomas E. Costa, JD

Vice President, International Policy and Government Affairs, Bristol-Myers Squibb

SESSION 264 BT - BIOTECHNOLOGY, CMC, RD

1:30 рм - 3:00 рм LEVEL =

Room 154AB *CME credits offered*

Hot Topics in Biotechnology

SESSION CHAIRPERSONS *George F. Steinfels, PhD, MBA* President, Genomic Strategies *Barney King, MD, MBA* President, Macnas Consulting International

This session will focus on the latest important topics in the field of biotechnology. Topics to be considered in the session will include changes in GMPs and their impact on biotechnology processes, the impact of recent California initiatives in the area of stem cell research, and the latest regulatory and clinical topics.

New cGMP Initiative and Impact on Biotechnology Products Barney King, MD, MBA

President, Macnas Consulting International

Stem Cell Initiatives Judi Weissinger, PhD President and CEO, Weissinger Solutions, Inc.

Session 265 CDM - CLINICAL DATA MANAGEMENT 1:30 PM - 3:00 PM LEVEL = •

Room 204BC

A Discreet Professional Discipline: What Initiated the Evolution/Revolution of Clinical Data Management SESSION CHAIRPERSON

C. Michael Bailey Project Manager, Biotechnical Services, Inc.

This session addresses how the discreet profession of clinical data management developed, as well as emerging needs during the discipline's evolution.

A Brief History of Clinical Data Management C. Michael Bailey

Project Manager, Biotechnical Services, Inc.

The New CDM: EDC's Impact on the Role of the Clinical Data Manager *William Gluck, PhD*

Director, Clinical Data Management, Gilead Sciences, Inc.

What Is Next for Clinical Data Management Donald F. Fortin, MD President and CEO, Versagenics

SESSION 266 **CMC - CHEMISTRY, MANUFACTURING,** AND CONTROLS, RA

1:30 рм - 3:00 рм LEVEL =

Room 147A

Quality by Design

SESSION CHAIRPERSON

Ajaz S. Hussain, PhD

Deputy Director, Office of Pharmaceutical Science, CDER, FDA

It is well recognized that quality cannot be tested into a product and that it has to be built in by design. Use of the phrase "quality by design," or QbD in the pharmaceutical context, raises many responses such as "It is a great concept, but can we afford it?" and "How does one achieve and demonstrate QbD?" This suggests a lack of clear understanding of this concept, when it essentially has been the foundation of current regulations. This session will elaborate on this concept and describe how we are currently achieving or falling short of achieving QbD, seek to describe the minimal level of QbD that is necessary, and describe how a higher level of QbD may be leveraged to provide regulatory flexibility for continuous improvement.

An FDA Perspective

Ajaz S. Hussain, PhD Deputy Director, Office of Pharmaceutical Science, CDER, FDA

An Industry Perspective

Robert A. Reed, PhD

Senior Director, Pharmaceutical Analysis and Control, Merck Research Laboratories

Panel Discussion/Q&A Period

Session 267 **CP - CLINICAL SAFETY AND**

PHARMACOVIGILANCE, RA

1:30 pm - 3:00 pm

Room 207A

Regulatory Changes in EU Pharmacovigilance SESSION CHAIRPERSONS

LEVEL =

Noël Wathion, Pharm

Head of Unit, Postauthorization Evaluation of Medicines for Human Use, EMEA, EU

In this session, the following aspects will be presented and discussed:

- The impact of the new Community legislation on the EU pharmacovigilance activities with the main focus on new risk management and minimization activities, the reinforced EMEA coordination role in the pharmacovigilance networking model, and strengthening the partnership with competent authorities in the Member States in the EU.
- The EMEA Roadmap to 2010 and EMEA's vision on postauthorization activities focusing on a proactive conduct of pharmacovigilance, throughout the lifecycle of a medicinal product in order to further strengthen public health in an enlarged EU.
- Collaboration between EMEA and FDA in the area of pharmacovigilance.

Panos Tsintis

Head of Sector for Pharmacovigilance and Postauthorization and Efficacy, EMEA, EU

Ingemar Persson CHMP, EMEA, EU

Gaby L. Danan, MD, PhD

Head, Pharmacovigilance and Epidemiology Department, sanofi-aventis, France

SESSION 268 **CR1 - CLINICAL RESEARCH AND** DEVELOPMENT LEVEL = •

1:30 pm - 3:00 pm

Room 149AB

Innovative Recruitment and Retention Techniques in Europe SESSION CHAIRPERSON

Emma Sergeant, RN

President, Fast4wD Ogilvy, UK

This session will provide a deeper understanding of the use of innovative techniques for patient recruitment and retention in Europe and how to incorporate these techniques into clinical study plans. It will provide insight into the challenges of ethical approval of these types of programs across Europe's culturally diverse populations and give guidance on how to make allowances for these challenges in both planning and rescue situations.

Accelerated Patient Recruitment: Practical Approaches for US and **European Trials**

Bill Byrom, PhD Product Development Director, ClinPhone, Inc., UK

Competitive Recruitment in Global Multicenter Trials: Different Perspectives Laura Luchini, PhD, MD

Executive Director, Eurotrials Brazil Consultores Científicos, Brazil

Optimizing Patient Recruitment in Central and Eastern Europe Suzanne Pozsonyi, MPH

Senior Director, Account Management, PAREXEL International, Netherlands

SESSION 269 **CR2 - CLINICAL RESEARCH AND DEVELOPMENT, PP**

1:30 pm - 3:00 pm LEVEL = •

Room 145A CME and Nursing credits offered

Prevention of Fraud and Noncompliance in Clinical Research: What Was and Is Being Done? SESSION CHAIRPERSON

Kenneth A. Getz. MS. MBA

Research Fellow, Tufts Center for the Study of Drug Development, Tufts University; Chairman, CISCRP

The incidence of noncompliant and fraudulent activity by institutions and investigative sites continues to rise. Recent regulatory changes in disclosure and privacy have the potential to drive higher levels of noncompliance. This session reviews recent and historical inspection audit reports issued by FDA and OHRP and discusses new approaches that regulatory agencies, research sponsors, and investigative sites are pursuing to prevent noncompliance and fraud in the future.

Review and Update of FDA Inspection Results Kenneth A. Getz, MS, MBA

Research Fellow, Tufts Center for the Study of Drug Development, Tufts University; Chairman, CISCRP

An Examination of Why Fraud and Noncompliance Occurs Paul W. Goebel, Jr., CIP

President and Founder, Paul W. Goebel Consulting, Inc.

Preventing Fraud and Noncompliance Gary L. Chadwick, PharmD, MPH

Executive Director, Office of Human Subject Protection, University of Rochester

Session 270 CR3 - Clinical Research and Development, RA, RD

1:30 рм - 3:00 рм LEVEL =

Room 145B

Managing Late Phase in the Global Environment SESSION CHAIRPERSON

Carol A. Collins, PhD, MBA

Corporate Vice President, Clinical Research Services, PAREXEL, UK

There are strong directional forces driving internationalization of late phase clinical research in Europe and a trend towards more global programs. This paper examines the unique issues and major challenges of running these large-scale studies; meeting the needs of both strategic and local medico-marketing divisions, as well as physicians, patients and regulatory authorities.

The Changing Paradigm of Late-phase Research Carol A. Collins, PhD, MBA

Corporate Vice President, Clinical Research Services, PAREXEL, UK

Managing through the Global Environment Nayan Nanavati, MS

President and Chief Operating Officer, Suven Life Sciences

Maximizing Returns on Late-phase Studies Jeffrey P. Trotter, MS President, Ovation Research Group

SESSION 271 CR4 - CLINICAL RESEARCH AND DEVELOPMENT, CS

1:30 рм - 3:00 рм LEVEL =

Room 147B

Drug Supply Doesn't Always Have to Be Rate Limiting in Clinical Development

SESSION CHAIRPERSON

David F. Bernstein, PhD

Vice President, Pharmaceutical Science and Regulatory Compliance, Cato Research West

The procurement of CTM (clinical supply materials; IMP = investigational medicinal product in the EU) is often perceived as rate limiting to the initiation of clinical research programs. This session provides pro-active suggestions to identify likely rate-limiting steps and how they can be circumvented. The presentations are from the perspectives of a clinical research physician, a clinical research consultant, and a clinical supply manufacturing and packaging coordinator.

Clinical Supplies or Clinical Surprise Sam L. Teichman, MD, FACC, FACP Principal, WinPharm Associates

Essential CTM for Busy Research Professionals Harold D. Doshan, PhD

President, Pharmaconsult Associates

Clinical Research Is from Venus; Clinical Supplies Are from Mars David F. Bernstein, PhD

Vice President, Pharmaceutical Science and Regulatory Compliance, Cato Research West

SESSION 272 CR5 - CLINICAL RESEARCH AND DEVELOPMENT

1:30 pm - 3:00 pm LEVEL = •

Room 146A Pharmacy credits offered

FDA Labeling Update: Target Product Profile

SESSION CHAIRPERSON

Jeanne M. Delasko, RN, MS

Label Initiatives Specialist, Study Endpoints and Label Development, Office of New Drugs, CDER, FDA

This session provides an update/overview of the role and utility of a target product profile (TPP) in the drug development process in terms of product labeling goals. A description of what TPP is, what it is not, and use of a TPP at meetings between the sponsor and FDA will be discussed in addition to the benefits and challenges of using a TPP.

TPP: An FDA Update

Jeanne M. Delasko, RN, MS

Label Initiatives Specialist, Study Endpoints and Label Development, Office of New Drugs, CDER, FDA

TPP: The Benefits and Challenges

Sharon N. Olmstead

Vice President, Regulatory Liaison and Policy, Global Regulatory Affairs, Schering-Plough Research Institute

TPP: An Industry Perspective

Linda S. Carter

Senior Director, Regulatory Affairs, Johnson & Johnson Pharmaceutical Research and Development, LLC

SESSION 273 CTM - CLINICAL TRIAL MANAGEMENT, FI, PM

1:30 рм - 3:00 рм LEVEL =

Room 140B

Achieving Win/Win Results for Sponsors and Sites: Metrics and Budgeting Practices that Encourage Partnership and Performance

SESSION CHAIRPERSONS *Linda Martin, MBA* Principal, KMR Group, Inc. *Cathy A. White* Global Chief Executive Officer, Neeman Medical International

As sponsors continue to focus on efficiencies, targeting time reductions as great as 50%, there is a critical need to support participating sites with accurate upfront expectations, patient recruitment techniques, systems to accurately estimate study costs, and metrics that serve as navigational tools to assure that both the sponsor and the site can establish a partnership that achieves a shared success.

Developing Study Budgets that Achieve Results for Sponsor, CRO, and Site *Cathy A. White*

Global Chief Executive Officer, Neeman Medical International

Setting Standards on Metrics to Manage and Drive Performance at Clinical Sites

Scott Martin, MA, JD Principal, KMR Group, Inc.

Effective Site Selection and Management: A Sponsor Perspective James P. Kremidas

Global Enrollment Optimization, Eli Lilly and Company

SESSION 274 DM - DOCUMENT MANAGEMENT/ ESUBMISSIONS, RA

1:30 PM - 3:00 PM LEVEL = •

Room 206

eCTDs: Regional Progress and Lessons Learned from the Regulatory Authority Perspective

SESSION CHAIRPERSON Mary L. Collins

Director, Regulatory Affairs, Image Solutions, Inc.

This session will provide the regulatory authority perspective on progress achieved and lessons learned as the number of eCTD submissions and our experience continues to grow. Topics will include authority readiness, initiatives to support eCTD review and evaluation, and regional specific challenges and opportunities.

eCTD: US Perspective

Gary Gensinger

Director, Review Technology Staff, Office of Information Management, CDER, FDA

eCTD: EU Perspective

Timothy Buxton, LLB Head of Sector, Project Management, EMEA, EU

eCTD: Japan's Perspective Hitoshi Matsui

Executive Consultant, CAC Corporation, Japan

SESSION 275 GCP - GOOD CLINICAL PRACTICES, CR, RA

1:30 рм - 3:00 рм

Room 202A

Clinical Development for Drug-device Combination Products SESSION CHAIRPERSON

Charma Konnor, RPh, RAC

Senior Consultant/Manager, Phoenix Regulatory Association, Ltd.

LEVEL =

There are an increasing number of products being developed that are regulated as combination products. This can raise questions about the role of GCP expectations for drug-device products and how to best achieve a quality clinical study that meets the differing regulatory requirements. Questions also arise concerning the FDA's review of such products.

Drug versus Device Clinical Trials, and Now the Combination! Charma Konnor, RPh, RAC

Senior Consultant/Manager, Phoenix Regulatory Associates, Ltd.

GCP Compliance Considerations for Drugs and Biologics Michael R. Hamrell, PhD, RAC President, MORIAH Consultants

Clinical Trials for Combination Products: An FDA Perspective Ashley B. Boam Supervisory Biomedical Engineer, CDRH, FDA

SESSION 276 IS - INVESTIGATOR SITES, AHC

1:30 рм - 3:00 рм LEVEL =

Room 101

CME credits offered

Effective Operation of Clinical Research Units SESSION CHAIRPERSON

Gary L. Steinman, MSEE Chief Executive Officer, Medexetech; President, GLS & Associates This presentation will describe approaches to examining the operational productivity of clinical research sites that encompass safety, quality, and timeliness as well as money. Some common problems encountered at typical clinical sites will be discussed, and some potential solutions will be offered.

Principles and Practices

Gary L. Steinman, MSEE Chief Executive Officer, Medexetech; President, GLS & Associates

Site Perspective and Experience

Antoni A. Piergies, MD, MSEE Unit Director; Vice President, Clinical Pharmacology, PAREXEL International

Session 277 IT1 - INFORMATION TECHNOLOGY, OS

1:30 рм - 3:00 рм

Room 152A

Integrating Multivendor Clinical Trial Systems

LEVEL = •

session chairperson Joseph J. Donaghy, Jr., MS

Technical Project Manager, PharmalinkFHI

Clinical trials amass data from multiple sources such as clinical data management systems, central labs, safety databases, and trial management systems. This session will focus on approaches to integrating multiple electronic clinical trial data. Approaches and techniques that provide validated integration systems for re-use from trial to trial will be discussed.

An Integrated Approach to Clinical Data Warehousing *Glen De Vries, PhD* Chief Technology Officer, Medidata Solutions, Inc.

Clinical Data Management Systems' Database Structure versus Reporting Systems' Database Structure *Robert B. Stephens* Software Developer, Integrated Clinical Systems, Inc.

Creating Specifications to Auto-generate Data Files, FDA Listings, and Interactive Reporting Systems Input from EDC Systems Joseph J. Donaghy, Jr., MS Technical Project Manager, PharmalinkFHI

Session 278 IT2 - INFORMATION TECHNOLOGY

LEVEL =

1:30 рм - 3:00 рм

Room 146B

PhRMA IMPACC's Strategic View of the Future of Healthcare IT and Associated Implications for the Biopharmaceutical Industry

SESSION CHAIRPERSON

Diana McKenzie

Senior Director, Development Information Systems, Amgen Inc.

In this session, the leadership of PhRMA's Information Management Policy and Affairs Coordinating Committee will present their strategic view of the biopharmaceutical landscape from the perspective of the broader healthcare system and related e-health initiatives. The session will include an overview of advances in the area of e-prescribing, electronic health records and the establishment of regional health organizations and will address potential implications to policy, information standards, industry level IT infrastructure and biopharmaceutical operating models. A panel discussion will cover the key elements of the strategy and how it relates to other significant IT strategies emerging across the regulatory and health care landscape.

A Strategic View of eHealth and the Biopharmaceutical Industry: Commercial Perspective *Mike Curnyn*

Senior Director, Commercial IS, AstraZeneca PLC

A Strategic View of eHealth and the Biopharmaceutical Industry: R&D Perspective

Albert W. Kellenbenz, MS, MBA Vice President, Research Information Services, Wyeth Pharmaceuticals

Panelists Shawn E. Ramer, PhD Vice President, Informatics, Bristol-Myers Squibb

Thomas Scarnecchia, MS

Vice President, Corporate Informatics, Millennium Pharmaceuticals, Inc.

SESSION 279 MC - MEDICAL COMMUNICATIONS, MA

1:30 рм - 3:00 рм LEVEL = •

Room 209AB CME and Pharmacy credits offered

Survey of Medical Liaison Practices Across the Pharmaceutical Industry

SESSION CHAIRPERSON

Christopher Marrone, PharmD

Medical Liaison Consultant, Eli Lilly and Company

Roles and responsibilities of persons in field-based medical liaison positions may differ across the pharmaceutical industry. In an effort to assess trends in the area of medical liaisons, a survey was administered to medical liaison management across the industry.

Medical Liaison Survey Overview

Christopher Marrone, PharmD Medical Liaison Consultant, Eli Lilly and Company

Medical Liaison Survey Results: Part 1 of 2

J. Lynn Bass, PharmD

Regional Medical Liaison II, Amgen Inc.

Medical Liaison Survey Results: Part 2 of 2 Craig J. Klinger, RPh

Medical Liaison Consultant, Eli Lilly and Company

SESSION 280 MW - MEDICAL/SCIENTIFIC WRITING,

ST

1:30 рм - 3:00 рм LEVEL = •

Room 102AB

Medical Writing and Biostatistics: A Significant Interaction

SESSION CHAIRPERSON Kerry Gordon, PhD

Director, Biostatistics and Medical Writing (UK), Quintiles Ltd., UK

This session will explore the importance of the biostatistician and the medical writer as members of the core project team. In particular, key interactions between biostatisticians and medical writers will be discussed.

Numbers and Words: Positive Collaborations Improve Regulatory Submissions MaryAnn Foote, PhD, MS

Director, Global Regulatory Writing, Amgen Inc.

Partnering with Biostatisticians Mike W. Colopy, PhD Biostatistician, GlaxoSmithKline

Medical Writing Review of Statistical Analysis Plans Kerry Gordon, PhD

Director, Biostatistics and Medical Writing (UK), Quintiles Ltd., UK

SESSION 281 NC - NONCLINICAL LABORATORY SAFETY, CR, RA

1:30 рм - 3:00 рм LEVEL =

Room 103B

Update on the Use of Juvenile Animals for Safety Assessment of Pediatric Drugs

SESSION CHAIRPERSON

Beatriz Silva Lima, PhD

Professor and Faculty, University of Lisboa and National Institute of Pharmacy and Medicines (INFARMED), Portugal

The use of juvenile animals in the context of safety assessment of pediatric drugs will be discussed in line with the currently available guidance in the US and in preparation in the EU. The experience gained from the more recent assessment and advisory procedures will be presented and discussed by regulators and industry.

Regulatory Initiatives in Europe: The Guideline on the Need for Nonclinical Testing of Human Pharmaceuticals in Juvenile Animals *Beatriz Silva Lima, PhD*

Professor and Faculty, University of Lisboa and National Institute of Pharmacy and Medicines (INFARMED), Portugal

The US FDA Perspective and Experience

Karen Davis-Bruno, PhD

Pharmacologist, Division of Metabolic and Endocrine Drug Products, Office of New Drugs, CDER, FDA

The European Experience on Assessing and Requesting Studies in Juvenile Animals: Examples from Centralized Applications and Scientific Advice

Bert Haenen, PhD Senior Assessor, National Institute of Public Health & Environment, Netherlands

Ongoing Industry Experience on Safety Studies in Juvenile Animals Mark E. Hurtt, PhD

World Wide Safety Sciences, Pfizer Global Research and Development

SESSION 282 OS - OUTSOURCING

1:30 рм - 3:00 рм LEVEL =

Room 150A

High-tech Outsourcing: Computerizing the Selection Process SESSION CHAIRPERSON

Rikki Hansen Bouchard, MPA

President and CEO, RH Bouchard & Associates, Inc.

Sponsor companies have been investigating new methods for selecting service providers. Amgen's Strategic Sourcing and Procurement organization has taken this to a new level by mandating the use of an on-line tool and electronic sourcing process for the selection of all providers. In 2004, Amgen launched an initiative to select prequalified CRO service providers using this tool. This session will explore the tool, its benefits, drawbacks, and how the providers reacted to its use.

Panel Discussion - Interactive Discussion of eSourcing: A Case Study

Ann G. Kilrain

Senior Manager, Strategic Sourcing and Procurement, Amgen Inc.

David F. Fenske Senior Director, Contracts and Proposals, ICON Clinical Research

Session 283 PM - PROJECT MANAGEMENT, CR, PP, RA, RD

1:30 рм - 3:00 рм

Room 143AB Project Management Institute credits offered

LEVEL =

PLENARY SESSION

Transforming the Product Development Lifecycle: Where Are the Opportunities and What Happens if We Don't Start Changing the Way Drugs Are Developed? SESSION CHAIRPERSONS

SESSION CHAIRPERSONS

Michele C. Livesey

Head, Project Management, Barrier Therapeutics

Martin D. Hynes, III, PhD

Director, Quality and Operations, Pharmaceutical Product Research and Development, Eli Lilly and Company

Current challenges within the pharmaceutical industry include increased R&D spending with a reduction of the new chemical entities that make it to approval. Obviously, this is a formula which cannot be sustained. What happens if our industry continues in this manner? What can be gleaned from other industries and past experiences in order to transform how business is being done today? What can be done to transform the industry and what role does the project manager play in helping companies succeed?

In this session, we will explore through case studies what it takes to transform an industry and what happens when companies don't evolve. Additionally, current practices which are making a difference will be explored.

Kenneth I. Kaitin, PhD

Director, Tufts Center for the Study of Drug Development, Tufts University

Project Management's Role in the Transformation of the Pharmaceutical Industry *Robin G. Foldesy, PhD* Vice President, Project Management, Wyeth Research

SESSION 284 PP - PUBLIC POLICY/LAW, CR, RA

1:30 рм - 3:00 рм

LEVEL =

Room 144ABC CME and Pharmacy credits offered

Publication and Availability of Clinical Trial Results: Ethical, Public Health, Confidentiality, Commercial and Other Critical Issues – A Panel Discussion

SESSION CHAIRPERSON

Juhana E. Idänpään-Heikkilä, MD

Secretary General, Council for International Organizations of Medical Sciences (CIOMS), c/o World Health Organization, Switzerland

Requests that the results of clinical trials be made publicly available are increasing. The session will discuss the challenging role of investigators, ethics committees, drug regulators, and industrial sponsors of clinical trials in facilitating the increased transparency of clinical trials.

Panelists

Greg Koski, MD, PhD

Associate Professor of Anesthesia, Massachusetts General Hospital Partners Healthcare System

Marcia Angell, MD

Former Editor, *New England Journal of Medicine*; Senior Lecturer on Social Medicine, Harvard Medical School

Bert A. Spilker, MD, PhD President, Bert Spilker and Associates

Robert J. Temple, MD Director, Office of Medical Policy and Office of Drug Evaluation, CDER, FDA

SESSION 285 RA1 - REGULATORY AFFAIRS

1:30 рм - 3:00 рм LEVEL =

Room 146C CME credits offered

New Pharmaceutical Legislation – Part 2 of 3: Decentralized Procedure and Mutual Recognition Procedure

SESSION CHAIRPERSONS

Truus Janse-de-Hoog, PharmD

Coordinator, Mutual Recognition Procedures; Medicines Evaluation Board, Netherlands

Anu Tummavuori-Liemann

EU Enlargement Coordinator, F. Hoffmann-La Roche Ltd., Switzerland

Part 1 of this session will be held on Tuesday at 10:30 AM; Part 3 will be held on Tuesday at 3:30 PM.

In this session, the most important changes in Mutual Recognition Procedures will be highlighted. The view from MRFG/national authorities and industry expectations will be presented.

Overview of Changes in Mutual Recognition Procedure after Implementation of New Legislation

Truus Janse-de-Hoog, PharmD

Coordinator, Mutual Recognition Procedures, Medicines Evaluation Board, Netherlands

The New Decentralized Procedure

Peter Bachmann

Head of Unit, Mutual Recognition Procedures, Federal Institute for Drugs and Medical Devices, (BfArM), Germany

Industry View on the New Decentralized Procedure Nicole Dillier

LEVEL = •

Head, EU Regulatory Intelligence, Novartis Pharma AG, Switzerland

SESSION 286 RA2 - REGULATORY AFFAIRS, CR, NC

1:30 рм - 3:00 рм

Room 151B

Regulatory Impact in Drug Development of Integrating Toxicogenomics into Nonclinical Development SESSION CHAIRPERSON

Sydney A. Gilman, PhD

Vice President, Regulatory Affairs, Gene Logic Inc.

Toxicogenomics and pharmacogenomics offer the possibility of influencing nonclinical and clinical information for pharma, CROs, regulatory authorities, and domestic and international organizations in the strategic planning in drug development. This session will discuss the regulatory impact of genomics on the drug development program and ways that the impact may lead to streamlining the pathway to approval.

Ongoing FDA Activities in Pharmacogenomics and Biomarker Validation *Gualberto Ruaño, MD, PhD*

President and CEO, Genomas

Pharmaceutical Industry View on the Impact of Genomics on Drug Safety

Rakesh Dixit, PhD, DABT Section Head, Toxicokinetics and Biomarker Laboratories, Merck & Co., Inc.

Attenuation of Ventricular Remodeling Associated with Heart Failure in an Animal Model: Use of Microarray Data in Support of a Hypothetical Drug Submission

Thomas Papoian, PhD, DABT

Senior Pharmacologist, Cardio-renal Drug Products, CDER, FDA

SESSION 287 **RA3 - REGULATORY AFFAIRS, PP**

1:30 рм - 3:00 рм

LEVEL = • Pharmacy credits offered

Room 151A

Drug Importation: At What Cost?

SESSION CHAIRPERSON

Amjad Iqbal, PharmD

Postdoctoral Fellow - Regulatory Affairs, St. John's University

The issue of drug importation is one that directly and indirectly affects nearly every aspect of healthcare and has far-reaching economic and clinical implications. The decisions that are made today regarding the importation of drugs have the potential to compromise the integrity of our drug supply chain. Discussing this topic from a variety of perspectives will provide insight into this issue.

The Springfield Success Story: A Model for America

Michael J. Albano, MS, MPA, DH President, Michael Albano & Associates

Douglas B. Farquhar Principal, Hyman, Phelps & McNamara, PC

SESSION 288 **RA4 - REGULATORY AFFAIRS**

1:30 рм - 3:00 рм LEVEL =

Room 152B

CDER Hot Topics - Part 1 of 2: FDA Risk Minimization Guidances

SESSION CHAIRPERSON

Paul J. Seligman. MD. MPH

Director, Office of Pharmacoepidemiology and Statistical Science, CDER, FDA

Part 2 of this session will be held on Wednesday at 1:30 PM.

On March 24, 2005, FDA released three final drug safety guidances -"Premarketing Risk Assessment," "Development and Use of Risk Minimization Action Plans," and "Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment." This session will describe the scope and key issues in the three guidances and will discuss drug safety considerations for all stages of clinical development of medical products.

Premarketing Risk Assessment

Robert J. Meyer, MD Director, Office of Drug Evaluation II, CDER, FDA

Development and Use of Risk Minimization Action Plans Anne E. Trontell, MD, MPH

Deputy Director, Office of Drug Safety, CDER, FDA

Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment Julie G. Beitz, MD

Deputy Director, Office of Drug Evaluation III, CDER, FDA

RA5 - REGULATORY AFFAIRS SESSION 289 LEVEL =

1:30 рм - 3:00 рм

Room 140A

Clinical Trials in China: Progress and Future Perspective

SESSION CHAIRPERSONS

Jianhua Ding

Deputy Director, Division of Pharmaceuticals, Department of Drug Registration, State Food and Drug Administration, China

Edmund Tsuei, PhD

Head, Pharmaceutical Development Operations - Asia, Roche Products Pty Ltd., Australia

In this session, speakers from the regulatory agency and the industry will discuss recent activities in regulation and supervision of clinical trials, as well as the experience of conducting multinational trials, in China.

Implementation of GCP in China

Cai Cao

Assistant Committee Director and Division Director, Certification Committee of Drugs, State Food and Drug Administration, China

Experience of Multinational Clinical Trials in China

Ling Su, PhD

Medical and International Pharma Development Director, Shanghai Roche Pharmaceuticals Ltd., China

Global Drug Clinical Development in China: An Industry Perspective lames Cai

Vice President, Research and Development, AstraZeneca Pharmaceutical Co. Ltd., China

SESSION 290 **RD - R&D STRATEGY**

1:30 рм - 3:00 рм	LEVEL =
-------------------	---------

Room 150B

Increase in Expected Net Present Value Through Design **Modifications**

SESSION CHAIRPERSON

Jonathan R. Smith, PhD, MSc Executive Director, Strategic Development, Biostatistics, Quintiles, Inc.

The presentations within this session will identify and discuss areas where large gains in expected net present value (NPV) can be obtained through particular design modifications to a drug development program. Examples covered will include: (a) running more than two phase III trials in parallel; (b) conducting a more definitive dose-ranging trial; and (c) incorporating certain recently developed adaptive designs within the program.

Carl-Fredrik Burman, PhD

Statistical and Mathematical Science, AstraZeneca R&D, Sweden

Moving Statistics Beyond the Individual Clinical Trial: Using Simple **Decision Science to Optimize a Clinical Development Plan** Steven A. Julious, PhD

Senior Lecturer, Medical Statistics Unit, Institute of General Practice and Community Care, University of Sheffield Community Sciences Centre, Northern General Hospital, UK

Jonathan R. Smith, PhD, MSc

Executive Director, Strategic Development, Biostatistics, Quintiles, Inc.

SESSION 291 ST - STATISTICS, CR

1:30 рм - 3:00 рм

Room 201

LEVEL = •

CME and Pharmacy credits offered

Genomic Statistical Approaches for the Use and Validation of Genomic Biomarker Information

SESSION CHAIRPERSONS

Sue Jane Wang, PhD, MA, MS

Expert Mathematical Statistician, US FDA Intercenter Pharmacogenomics and Pharmacogenetics Initiative WG, Office of Biostatistics, OPaSS, CDER, FDA

Lutz Edler, PhD

Head, Biostatistics Unit, German Cancer Research Center, Germany

Quantitative information from genotyping patients and identifying genes that are differentially expressed in various situations is becoming routinely integrated into clinical trials for new and better treatment. The identification of new biomarkers for novel therapeutic targets requires efficient statistical use of functional genomic data. This session will cover statistical design and analysis methods for the development of diagnostic and/or therapeutic pharmacogenomic products.

Statistical Designs for Validating High-dimensional Pharmacogenomic **Signatures in Drug Development** Richard M. Simon, DSc

Chief, Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health

Statistical Methods for Proteomic Biomarker Data Dr. Francoise Seillier-Moiseiwitsch

Director, Biostatistics and Bioinformatics Shared Resource Lombardi Cancer Center, Georgetown University Medical Center

Discussants

Sue Jane Wang, PhD, MA, MS

Expert Mathematical Statistician, US FDA Intercenter Pharmacogenomics and Pharmacogenetics Initiative WG, Office of Biostatistics, OPaSS, CDER, FDA

Lutz Edler, PhD

Head, Biostatistics Unit, German Cancer Research Center, Germany

SESSION 292 **TR - TRAINING, IS**

1:30 рм - 3:00 рм

LEVEL = •

Room 207B

CME, Nursing, and Pharmacy credits offered

Status of Study Nurse Qualification in Europe and the US SESSION CHAIRPERSON

Wolfgang Seifert, MD, PhD

Senior Advisor, Drug Development, Schering AG, Germany

Requirements from academia and industry for study nurses will be presented, and the approaches in different countries will be shown.

Education Programs for Study Nurses in European Countries Kerstin Breithaupt-Groegler, MD

Clinical Pharmacologist, KBR Clinical Pharmacology Services, Germany

Study Nurse Training Courses in the US Beth D. Harper, MBA

Senior Vice President, Global Operations, D. Anderson & Company

What Industry, CRO and Academia Require from Their Clinical Trial Staff Karen Kragt, MSc

Manager, International Business, DOCS International, The Netherlands

3:00 рм - 3:30 рм

REFRESHMENT BREAK

Exhibit Halls ABC. Lower Level Convention Center

SESSION 293 AD - ADVERTISING, MA, RA

3:30 рм - 5:00 рм

I FVFI =

Room 202B

Pharmacy credits offered

Getting the Claims You Want

SESSION CHAIRPERSON

Teresa P. Dowling, PharmD Director, Promotional Regulatory Affairs, AstraZeneca The development of claims occurs in various stages throughout a product's life cycle. Getting the claims that you want for your product requires the integration of input from the marketing, clinical development, regulatory affairs, and legal departments within the company and negotiations with the regulatory agency.

Introduction

Teresa P. Dowling, PharmD

Director, Promotional Regulatory Affairs, AstraZeneca

Nancy Kline Leidy, PhD President and CEO, MEDTAP Institute at UBC

The Label and the Claims: Managing Expectations **Christine Duffy Smith**

Director, Promotional Regulatory Affairs, Oncology, AstraZeneca

SESSION 294 **BT** - **BIOTECHNOLOGY**, **TR**

3:30 рм - 5:00 рм LEVEL = •

Room 154AB

The State of Biopharmaceuticals: Where the Jobs Are SESSION CHAIRPERSON

Mark D. Dibner, PhD, MBA President, BioAbility, LLC

This session will provide an overview of the biopharmaceutical industry as it stands today and where it is going, with insights on employment needs and opportunities from the point of view of an HR expert and president of a search firm, and a HR director of Human Genome Sciences, a major biotech or pharmaceutical company. There will be discussions on industry needs, valuable skill sets, as well as how to best sell yourself and secure a job. An overview of the biopharmaceutical industry as it now stands and issues facing the industry, including those that lead to new job formation, will also be presented.

The Biopharmaceutical Industry Today and Tomorrow, and New Job **Opportunities**

Mark D. Dibner, PhD, MBA President, BioAbility, LLC

Managing Your Career: Landing the Right Job in Biopharmaceuticals David G. Jensen, FACP

Managing Director, CTI Executive Search, a unit of CareerTrax Inc.

SESSION 295 **CDM - CLINICAL DATA MANAGEMENT,**

PM 3:30 рм - 5:00 рм

LEVEL =

Room 204BC

Multiple Inputs/Multiple Destinations: How Project Management Can Help

SESSION CHAIRPERSON Harry J. Fisher President, PQ Consulting

This session will highlight the challenges and solutions from the new data management paradigm of "multiple inputs/multiple destinations." The role of project management will be explored as an enabler, facilitator, and driver of the various DM components.

The Methodology of Process Metrics in Leading an Organization to Success

David A. Evans, MS

Executive Vice President and Chief Technical Officer, First Genetic Trust

Session 296 CMC - Chemistry, Manufacturing, and Controls, RA

Room 147A

Challenges and Opportunities in Setting Specifications SESSION CHAIRPERSON

Charles P. Hoiberg, PhD

Executive Director, Pfizer Inc

The FDA and the pharmaceutical industry have been exploring new approaches for setting specifications for process controls, the drug substance and the drug product given the "desired state" that is being advocated. The "desired state" at the PQRI Workshop encompassed the objectives that the product quality and performance should be achieved and assured by design of effective and efficient manufacturing processes; that the product specification should be based on the mechanistic understanding of how formulation and process factors impact product performance; and that the manufacturers have the ability to effect continuous improvement. These concepts will be discussed.

An Innovator Industry Perspective

Charles P. Hoiberg, PhD Executive Director, Pfizer Inc

FDA Perspective Chi-wan Chen, PhD Deputy Director, Division of New Drug Chemistry III, CDER, FDA

Panel Discussion/Q&A Period

SESSION 297 CP - CLINICAL SAFETY AND

PHARMACOVIGILANCE, PP, RA

Room 207A

3:30 рм - 5:00 рм

LEVEL = ● CME, Nursing, and Pharmacy credits offered

FDA Office of Drug Safety: Update on Regulatory

Initiatives SESSION CHAIRPERSON

Paul J. Seligman. MD. MPH

Director, Office of Pharmacoepidemiology and Statistical Science, CDER, FDA

This will be a panel discussion with Office of Drug Safety senior management to discuss recent regulatory initiatives relating to drug safety, including a discussion of high profile risk management programs, advisory committee deliberations, and other issues relating to reducing medical error.

Current Safety Topics of Interest

Paul J. Seligman, MD, MPH

Director, Office of Pharmacoepidemiology and Statistical Science, CDER, FDA

Isotretinoin Update Anne E. Trontell, MD, MPH Deputy Director, Office of Drug Safety, CDER, FDA

Antidepressant Use in Children

Andrew D. Mosholder, MD Medical Officer, CDER, FDA

Session 298 CR1 - Clinical Research and Development, IS

3:30 pm - 5:00 pm LEVEL = ■

Room 146A *Nursing credits offered*

Town Meeting on Patient Enrollment: What Do We Know? What Can We Do?

SESSION CHAIRPERSON Mark A. Hovde, MBA

President. Hovde Associates LLC

Most managers of clinical trials recognize the crucial importance of timely patient enrollment. This interactive meeting will review tactics for managing several major causes of poor enrollment, including excessively restrictive enrollment criteria, inadequate patient referrals, insufficient site capacity, and deficient physician motivation.

Recruitment, Retention, and Patient Preference

Audrey Rossow

Senior Project Manager, PAREXEL MMS, Patient and Clinical Communications

Predicting Enrollment

James P. Kremidas Global Enrollment Optimization and Innovation, Eli Lilly and Company

Options for Enrollment Acceleration Mark Eisenach, MBA Chief Executive Officer, Acurian, Inc.

SESSION 299A CR2 - CLINICAL RESEARCH AND DEVELOPMENT

3:30 рм - 5:00 рм Room 145А

CME and Pharmacy credits offered

Applying Medical Imaging in Cardiovascular Drug Development

LEVEL = \blacklozenge

SESSION CHAIRPERSON

Philip T. Sager, MD, FACC, FAHA

Senior Director, Cardiac Research, Medical Science Director, AstraZeneca LP

According to a recent survey there are 123 new medicines in development for cardiovascular disease, which is recognized as the leading cause of death in the United States. Medical imaging techniques can play a critical role in the development of these new medicines, but there is a range of available modalities with varying strengths.

Regulatory and Core Imaging Laboratory Issues *Philip T. Sager, MD, FACC, FAHA* Senior Director, Cardiag Research, Medical Science, Director, Astro-7

Senior Director, Cardiac Research, Medical Science Director, AstraZeneca LP

Vascular Imaging for Drug Development

Bradley T. Wyman, PhD Manager, Worldwide Clinical Platforms, Pfizer Global Research and Development

The Role of Cardiac Imaging in Clinical Trials Neil Weissman, MD

Director, Cardiac Ultrasound and Ultrasound Core Laboratories, Washington Hospital Center

SESSION 299B CR3 - CLINICAL RESEARCH AND DEVELOPMENT, RA

Room 145B

Integrated Placebo Database: An Idea Whose Time Has Come SESSION CHAIRPERSON

Ronald J. Innerfield, MD

Senior Medical Director, Medical and Scientific Affairs, PharmaNet

There is a wealth of information that we obtain in our clinical research that may not be put to the best possible use. One example of this is the plethora of cross-sectional information obtained from studies of placebo groups in any disease process. The clinical research community could rectify this situation by contributing resources and information to establish a database of this information across all disease spectra.

Adventures with a Placebo Database I

John R. Senior, MD

Medical Officer, Office of Pharmacoepidemiology and Statistical Science, CDER, FDA

Adventures with a Placebo Database II Robert Tipping, MD

Director, Department of Clinical Research, Merck Research Laboratories

Integrated Placebo Database: Hows, Whys, and Wherefores Ronald J. Innerfield, MD

Senior Medical Director, Medical and Scientific Affairs, PharmaNet

SESSION 299C CR4 - CLINICAL RESEARCH AND DEVELOPMENT, PP, RA

3:30 рм - 5:00 рм LEV

LEVEL =

Room 147B CME, Nursing, and Pharmacy credits offered

Emerging Regulatory Trends in Human Research Protection: Accrediting Institutions and the Use of Data Monitoring Committees

SESSION CHAIRPERSON

Esther Emard

Chief Executive Officer, Partnership for Human Research Protection; Chief Operating Officer, NCQA

This session will focus on addressing the various approaches of the comprehensive recommendations coming out of federal agencies. The session is informative and explores future potential collaborations and innovations in HRP programs.

This session will address the various regulatory strategies designed to enhance patient protection. Faculty will review current guidance surrounding the use of Data Monitoring Committees and will outline current efforts in clinical trial patient safety. The session will also focus on identifying how accreditation activities support compliance with and go beyond regulations. The presentation will conclude with faculty offering their perspectives on how best to move forward using available tools to both optimally protect human subjects and to meet the emerging regulatory standards.

Jonathan Seltzer, MD, MA, MBA

Director, Clinical Research, Main Line Health Heart Center

Margaret VanAmringe

Public Policy Support, PHRP; Vice President, External Affairs, Joint Commission on Accreditation of Healthcare Organizations

Eileen Hilton, MD President and Chief Executive Officer, Biomedical Research Alliance of New York

Session 299D CR5 - Clinical Research and Development 3:30 PM - 5:00 PM LEVEL = ●

3:30 рм - 5:00 рм **Room 149AB**

Pharmacy credits offered

Multicenter Trials Done in Phase I Clinical Research Units SESSION CHAIRPERSON

Stephan de la Motte, MD

Chief Medical Officer, Harrison Clinical Research, Germany

Clinical research units can be utilized for large multicenter trials which can substantially facilitate the performance of difficult or complex trials. Specific logistical aspects, types of studies and patient populations, advantages, and limitations will be presented in this session.

Global Lipid-lowering Phase III Trial in Phase I Units: Experiences of the Sponsor

Graham Price

European Clinical Development Director, Takeda Europe R&D Centre, Ltd., UK

Global Lipid-lowering Phase III Trial in Phase I Units: Experiences of the CRO Monika Pietrek, MD, PhD, MSc

Senior Vice President, Global Medical and Safety Services, PRA International GmbH, Germany

Global Lipid-lowering Phase III Trial in Phase I Units: Experiences of the Phase I Unit Stephan de la Motte, MD

Chief Medical Officer, Harrison Clinical Research, Germany

SESSION 299E CTM - CLINICAL TRIAL MANAGEMENT

3:30 рм - 5:00 рм LEVEL = ●

Room 140B

Evaluation, Implementation, and Integration of a Clinical Trials Management System

SESSION CHAIRPERSON

Andrew D. Linegang Systems Manager, Procter & Gamble Company

As clinical operations evolve, it is possible for numerous tools and databases to be developed to meet study planning and tracking requirements. Companies may find these tools to be highly disconnected, independent, and laborintensive leading to duplication of data and difficulty analyzing the information that is captured, especially across projects and therapeutic areas. Clinical trial management systems offer an opportunity to address these problem areas.

In this session, we will discuss aspects of the selection and implementation process, including some evaluation strategies. We will also share a perspective on the challenges involved in implementing a clinical trial management system. And finally we will provide some insight on how to manage the change to your organization and gain acceptance for the trials management system.

Evaluation, Implementation, and Integration of a Clinical Trials Management System Andrew D. Linegang Systems Manager, Procter & Gamble Company

Implementation of a CTMS at MedImmune Laura Sandler, MPH Clinical Systems Analyst, MedImmune

Successful Campaign Message for Standardizing the Management of Clinical Trials Magaly Woolard Associate Director, Research Planning and Integration, Merck & Co., Inc.

SESSION 299F **DM - DOCUMENT MANAGEMENT/ ESUBMISSIONS, RA**

LEVEL = • 3:30 рм - 5:00 рм

Room 206

Building, Submitting, and Maintaining an Electronic IND in eCTD Format

SESSION CHAIRPERSON

Robin L. Zumbrunnen

Associate Director, Regulatory Operations, Ouintiles, Inc.

When the FDA's draft guidance for submitting CTD submissions electronically was published in 2003, it opened the door for electronic INDs to be submitted to CDER and CBER in eCTD (XML backbone) format. This session will explore the benefits of filing eINDs electronically using this format, as well as how to organize for, prepare, submit, and maintain these INDs electronically.

eIND - Past, Present, and Future: The Transition from Paper to eIND in the eCTD Format

Christopher R. Patterson Senior Consultant, Life Sciences, IBM Global Services

The IND: A Makeover Story

Lynne B. Miller Regulatory eSubmissions Team Leader, EPIX Pharmaceuticals

Jeanie Kwon Associate Director, eDocument Services, Image Solutions, Inc.

Making the Move to eCTD

Matthew J. Neal, MA Manager, Regulatory Affairs, Amgen, Inc.

SESSION 299G **GCP - GOOD CLINICAL PRACTICES, TR**

3:30 рм - 5:00 рм

Room 202A

Training in QA Issues According to GCP

LEVEL = •

SESSION CHAIRPERSON

Hans F. Poland, ScD Head, Corporate Clinical Quality Assurance, Schering AG, Germany

This session deals with ongoing training necessities in quality issues for personnel working in the area of clinical development. Current needs and training approaches under different views and for different groups will be presented.

Who, How, and When to Refresh GCP Understanding Hans F. Poland, ScD

Head, Corporate Clinical Quality Assurance, Schering AG, Germany

Use of GCP Audit Results in GCP Training of Sponsor Personnel and Investigators

Ursula Streicher-Saied

Vice President, Head Global Medical Quality Management, Bayer HealthCare AG, Germany

QA's Contribution to Ongoing GCP Training

Alexander Both, MS

Associate Director, Corporate Clinical Quality Assurance, Berlex

SESSION 299H **IS - INVESTIGATOR SITES, CR, OS** LEVEL =

3:30 рм - 5:00 рм

Room 101

The Site Is the Client

SESSION CHAIRPERSON Daniel M. Ulrey, MBA

President and Chief Executive Officer, Midwest Clinical Support, Inc.

This session will present current, as well as innovative, clinical research processes designed to improve both sponsor and site productivity and decrease sponsors' cost of clinical trials while increasing the total revenue reimbursed to sites. The widely held view by many sponsors and CROs that sites and their patients are commodities continues to result in poor productivity for all parties. The speakers will present many of the major site complaints about sponsors and CROs, as well as major complaints by sponsors and CROs about sites. The speakers will also present how they are addressing these complaints in an attempt to improve both sponsor and site productivity by viewing each other as mutual clients. Audience participation will be welcome.

A Site Perspective

Daniel M. Ulrey, MBA

President and Chief Executive Officer, Midwest Clinical Support, Inc.

A CRO Perspective

Leslie M. Cate, MS Vice President, Patient/Site Management Services, Quintiles, Inc.

A Sponsor Perspective

Peter A. DiBiaso. MPH

Director, Clinical Trial Recruitment Services, Development Operations, Pfizer Global Research and Development

IT - INFORMATION TECHNOLOGY SESSION 2991

3:30 рм - 5:00 рм LEVEL = •

Room 146B

Building Reliable, Secure IT Infrastructures in the Pharma Industry

SESSION CHAIRPERSON

Munish Mehra, PhD, MSc

Chief Information Officer, Medifacts International

This presentation shares our experience in building a reliable, scalable, and secure IT infrastructure. The initiative initially started as an effort to ensure 21 CFR 11 compliance and provide access to locations worldwide but eventually resulted in our recognizing its benefit beyond the regulatory requirement.

A Roadmap to Successful Post-merger IT Integration: The Journey to Day 1 Gareth D. Creasey

Director, Research Informatics, Pfizer Inc

A Risk-based Approach to Infrastructure Validation Laura Araujo

Senior Director, Quality and Support Services, Perceptive Informatics, Inc.

Use Cases as a Backbone for Requirements and Validation Spencer Dillard

Partner, Conscientia, Inc.

SESSION 299J **MC - MEDICAL COMMUNICATIONS,** CR, RA LEVEL = •

3:30 рм - 5:00 рм

Room 209AB CME, Nursing, and Pharmacy credits offered

Developing Risk Communications: The ABCs of Health Literacy

SESSION CHAIRPERSON

Nancy M. Ostrove, PhD

Senior Risk Communication Advisor, Office of Planning, Office of the Commissioner, FDA

Written materials are a primary method of communicating risk to patients and healthcare providers. The FDA communicates risk to patients through review of written materials such as Patient Package Inserts and Medication Guides. Fundamental to the success of these risk communications is the use of principles that provide information in an efficient and effective manner to facilitate understanding and use; therefore, the FDA is acknowledging the usefulness of health literacy in the development of information for patients. The purpose of this session is to discuss the importance of health literacy in developing written risk communication materials.

Risk Information: What Do Patients Understand and Remember? Ruth S. Day, PhD

Director, Medical Cognition Laboratory, Duke University

Health Literacy

Cynthia Baur, PhD

Senior Health Communication and eHealth Advisor, Office of Disease Prevention and Health Promotion, US Department of Health and Human Services

Industry Perspective: Incorporating Learnings from Patients in Risk Communication

Kala L. Paul, MD President, The Corvallis Group LLC

FDA Risk Communication Initiatives

Toni Piazza-Hepp, PharmD

Deputy Director, Division of Surveillance, Research and Communication Support, Office of Drug Safety, CDER, FDA

SESSION 299K **MW - MEDICAL/SCIENTIFIC WRITING**

3:30 рм - 5:00 рм

Room 102AB

Adding Value: The Role of Technical Editors in Crossfunctional Document Development Teams of **Biopharmaceutical Organizations**

LEVEL = •

SESSION CHAIRPERSON

Lori Thomae, MA

President, LAB Communications, Inc.

This session examines the expanding role of technical editors in the crossfunctional document development teams of biopharmaceutical organizations. Specialists from technical writing, medical writing, and regulatory affairs will discuss how technical editors support standardization initiatives, troubleshoot technical issues of electronic submissions, ensure regulatory compliance, and expedite the document review process.

Development of Report Writing and Review Processes from a Regulatory Affairs Perspective

Mark A. De Rosch, PhD Director, Regulatory Affairs, Vertex Pharmaceuticals Incorporated

Templating: Practical Tips from a Publisher's Perspective Stacy Tegan

Regulatory Business Analyst, Apyx Inc.

SESSION 299L **NC - NONCLINICAL LABORATORY** SAFETY, CR, RA

3:30 рм - 5:00 рм LEVEL =

Room 103B

Can Single Dose Toxicity Study Support First Dose in Humans?

SESSION CHAIRPERSONS

Klaus Olejniczak, DVM, FACP

Preclinical Assessor, Federal Institute for Drugs and Medical Devices (BfArM), Germany

Per Spindler, DVM Head of BioLogue®, University of Copenhagen, Denmark

The state of the nation for the use and the nonuse of single dose toxicity studies to support initial clinical trials will be discussed. Scientific progress, industry needs and trends, and regulatory positions will also be covered.

US Industry Perspective

Joseph J. DeGeorge, PhD Vice President, Safety Assessment, Merck & Co., Inc.

European Industry Perspective

Gerd Bode, MD Head, Pathology and Toxicology, ALTANA Pharma AG, Germany

Regulatory Perspective

David R. Jones, MSc Principal Scientific Officer, Pharmacotoxicologist, Medicines and Healthcare products Regulatory Agency (MHRA), UK

SESSION 299M **NHP - NATURAL HEALTH PRODUCTS,** CMC

3:30 рм - 5:00 рм

Room 140A

Controlling the Quality of Natural Health Products SESSION CHAIRPERSON

LEVEL =

Willem K. Scholten, PharmD, MPA, MSc

Head, Office of Medicinal Cannabis, Ministry of Health, Welfare and Sport, Netherlands

Both FDA and WHO issued documents that recognize the standardization of cultivation and primary processing recently. WHO did this in its good agricultural and collecting practices (GACP, 2003) and FDA in its guidance for industry, botanical drug products (June 2004). GXP has come to stand for good agricultural (and collecting) practices, good manufacturing practices, good laboratory practices, and good clinical practices. But the trick is to turn the "X" into excellence.

Natural Health Products on the Guided Path

Anna Marie C. McSorley

Senior Manager, Quality Assurance, i3 Research

Evaluation Problems Arising from Different Compendial Requirements for Plant Materials

Urszula Krawczyk, PharmD, MPharm National Institute of Public Health, Poland

Standardization of Herbal Starting Materials: It Can Be Done Willem K. Scholten, PharmD, MPA

Head, Office of Medicinal Cannabis, Ministry of Health, Welfare and Sport, Netherlands

SESSION 299N **OS - OUTSOURCING**

3:30 рм - 5:00 рм LEVEL = •

Room 150A

Does Consolidation Among Outsourcing Firms Matter? SESSION CHAIRPERSON

Michael A. Martorelli, MBA

Research Partner, Fairmount Partners

Consolidation certainly matters to all employees of outsourcing firms, as well as to study coordinators and medical directors dealing with those providers. But does it matter to the efficiency or effectiveness of the drug development process, or the success of the drug development industry?

Impact of Consolidation in Other Industries George A. Laszlo, MS

Director, Life Sciences, CSC Global Health Solutions

Views from a Sponsor

Barry A. Sachais, PhD Vice President, Clinical Development, Neuromed

Session 2990 PM1 - PROJECT MANAGEMENT, RD

3:30 рм - 5:00 рм LEVEL =

Project Management Institute credits offered

Sources of Failure in Drug Development Projects

SESSION CHAIRPERSON

Room 143AB

Peter H. Blake, PhD Managing Partner, Pharmaceutical Performance Institute

The absence of one or more of four critical processes is identified as the reason drug development projects fail to meet schedule goals 85% of the time. These are: 1) process basics, 2) team development and support, 3) risk management, and 4) schedule validation and management. By using this framework as a lens for identifying what's missing in a drug development program, one can pinpoint and make changes that will have maximum impact on improving drug development results.

Sources of Failure in Drug Development Projects Peter H. Blake, PhD

Managing Partner, Pharmaceutical Performance Institute

Sources of Failure: Risk and Schedule Design and Management David J. Hulett, PhD

President, Hulett and Associates, LLC

Sources of Failure: Work Environment Management Brian P. Reger, MBA President, Brighton Consulting Group

SESSION 299P **PM2 - PROJECT MANAGEMENT**

3:30 рм - 5:00 рм

Room 143C

LEVEL = •

Project Management Institute credits offered

Working Remotely: Project Management Challenges with **Virtual Teams**

SESSION CHAIRPERSON Kathleen C. Greer, PMP Vice President, Professional Services, DataCeutics, Inc. This presentation will show evidence that working remotely with a strong project management methodology will improve customer satisfaction and reduce time to complete deliverables. It will also give samples of materials needed to project manage successfully.

Working Remotely: Project Management Challenge - But Does It **Improve Customer Satisfaction? Curtis Wolf**

Lead Consultant, DataCeutics, Inc.

Human Collaboration and Virtual Teams: Project Management Implications Jonathan Gardner, MA

Head of the Behavioural Change Management Practice, The Chalfont Project, Ltd., UK

Project Management Skill Center as Remote Team Ralf Eulentrop, MS

Head, Global Project Management, Merck KGaA, Germany

PP - PUBLIC POLICY/LAW, RA SESSION 299Q

LEVEL =

3:30 рм - 5:00 рм

Room 103A

Pharmacy credits offered

Pharmaceutical Product Liability in Drug Development and Regulation

SESSION CHAIRPERSON

Sandy M. Eisen, MD, MA, FRCS, Dip Pharm Med Vice President, Clinical, PAREXEL Consulting, UK

Pharmaceutical product liability is an increasingly important concern for both companies and regulators. This session aims to survey the topic of product liability in relation to pharmaceutical products covering both the EU and the US perspective. The session will include risk management and defensive approaches that may be appropriate for many companies, as well as examples taken from cases in the public domain. The focus will be on liability issues during product development and the role of the regulators in this area.

Product Liability for the Drug Regulator Peter Feldschreiber, MD, LLB(Hons), FFPM, RCP

Senior Medical Assessor and Special Litigation Coordinator, Medicines and Healthcare products Regulatory Agency (MHRA), UK

Liability Issues in Drug and Clinical Trial Regulation: US and Europe Anne Ware, LLB

Product Liability Lawyer and Partner, Covington and Burling, UK

The Emergence of Pharmaceutical and Medical Product Liability Litigation in Europe

Grant H. Castle, PhD Associate, Covington and Burling, UK

SESSION 299R **RA1 - REGULATORY AFFAIRS**

3:30 рм - 5:00 рм Room 146C

LEVEL = CME credits offered

New Pharmaceutical Legislation - Part 3 of 3: **Other Practical Aspects**

SESSION CHAIRPERSONS

Noël Wathion. Pharm

Head of Unit, Postauthorization Evaluation of Medicines for Human Use, EMEA, EU

Jacques C. Mascaro, PhD

Director, European Regulatory Affairs and Liaison, F. Hoffmann-La Roche Ltd., Switzerland

Part 1 of this session will be held on Tuesday at 10:30 AM; Part 2 will be held on Tuesday at 1:30 PM.

Within the scope of the New Pharmaceutical Legislation, which will enter into force in the 25 Member Sates of the European Union in October-November 2005, more focus will be placed on the procedures under the responsibility of the European Medicines Agency (EMEA). In particular, any product in oncology, diabetes, HIV or in neurodegenerative diseases will have to follow the centralized procedure, as the compulsory registration route. This will be extended to other therapeutic areas in the future. It is therefore important to understand the strategic and practical issues relating to these important changes, such as faster access to new innovative medicines on one side, and issues relating to assessment, availability of scientific expertise, or postauthorization procedures and systems like pharmacovigilance. In this respect, two sessions are proposed addressing the tools for quick access to medicines, as well as other practical aspects, with intervention from the key stakeholders, i.e. EMEA, CHMP and industry.

EMEA Point of View

Panos Tsintis

Head of Sector for Pharmacovigilance and Postauthorization and Efficacy, EMEA, EU

CHMP Point of View

Daniel Brasseur, MD, PhD Chairman of CHMP at EMEA, EU; Ministry of Public Health, Belgium

Industry Point of View

Michael J. Doherty

Global Head, Regulatory Affairs, F. Hoffmann-La Roche, Ltd., Switzerland

Panelist

Eric Abadie, MD, MBA Vice Chairman, CHMP, EMEA, EU; AFSSAPS, France

SESSION 299S RA2 - REGULATORY AFFAIRS

3:30 рм - 5:00 рм

LEVEL = ■ CME credits offered

Room 151B

Comparison of Alternatives for Transferring Personal Data Outside the EU

SESSION CHAIRPERSON

Judith E. Beach, PhD, JD

Vice President and Senior Associate General Counsel for Regulatory Affairs; Chief Privacy Officer and Coordinator, Government Affairs, Quintiles Transnational Corporation

In this session, the various permissible alternatives for transferring personal data outside the European Union (EU) will be discussed in detail. The pros and cons of several alternatives will be compared including Data Transfer Agreements (Model Contracts), Informed Consents, Binding Corporate Rules, and Certification to the US Department of Commerce Safe Harbor (for US entities). Additionally, differences among national laws and court interpretations and recent enforcement actions will be presented.

Legal Issues and Practical Considerations in Using Informed Consents and Data Transfer Agreements to Satisfy the EU Data Protection Directive for Exporting Personal Data Outside the EU Nancy Strehlow, JD

Special Counsel for Health Law and Policy Affairs, Quintiles Transnational Corp.

US-EU Safe Harbor and Binding Corporate Rules Deemed as Adequate Level of Protection Under the EU Data Protection Directive for Transfer of Personal Data Outside the EU

Judith E. Beach, PhD, JD

Vice President and Senior Associate General Counsel for Regulatory Affairs; Chief Privacy Officer and Coordinator, Government Affairs, Quintiles Transnational Corporation

Transfer of Personal Data Outside the EU: A European Perspective Ulrich Wuermeling, JD, LLM

Partner, Latham & Watkins, L.L.P., Germany

Session 299T RA3 - Regulatory Affairs, MA 3:30 PM - 5:00 PM LEVEL = ■

Room 152A

CME and Pharmacy credits offered

Effective Switching from Prescription to Over-the-counter Status: Role in Product Life Cycle Development

SESSION CHAIRPERSON

Neil Edwards

Director, Drug Development Consulting Practice, PAREXEL Consulting, UK

The pressure on innovator companies to maximize the return on their commercial investment is ever increasing. At the same time, governmental pressures to control healthcare costs give rise to a regulatory environment that is receptive to proposals for innovative switches of medicines from prescription control to OTC status. These two complementary pressures mean that there is increasing opportunity for innovator companies to consider the potential for legal reclassification of their compounds as a central element of their product life cycle planning.

Topics to be covered include development of an effective pan-European and US switch strategy, case study presentations from companies on successful POM to OTC switches, an agency perspective on issues encountered in assessment of OTC switch applications and proposals on how to optimize data presentation in OTC switch applications, and US Time and Event Application/OTC monograph procedure – potential to use OTC marketing experience gained outside the US to leverage US OTC approval.

Development of an Effective Pan-European OTC Switch Strategy, Including UK Experiences with Simvastatin Cheryl J. Hall, FIMLS, FTOPRA

Senior Director, Regulatory Affairs Europe, McNeil Ltd., UK

FDA Perspective on OTC Switching *Curtis Rosebraugh, MD, MPH* Deputy Director, Office of New Drugs, Office of Drug Evaluation V, CDER, FDA

Successful OTC Switches in the US: Industry Perspective Edwin L. Hemwall, PhD

Vice President, Global Regulatory and Scientific Affairs, Merck Research Laboratories

Session 299U

J RA4 - REGULATORY AFFAIRS, CR LEVEL = •

3:30 рм - 5:00 рм Room 152В

CME and Pharmacy credits offered

Progress and Challenges with Combination Product Development

SESSION CHAIRPERSON

Andrea C. Masciale, JD

Associate Director, Global Regulatory Affairs and Quality Assurance, Johnson & Johnson Pharmaceutical Research and Development, LLC

This session will provide you with highlights of progress made in the OCP, lessons learned from case studies, and areas that still need to be resolved, and possible next steps.

The Role of and Current News Regarding the Office of Combination Products

Mark D. Kramer, MS

Director, Office of Combination Products, Office of the Commissioner, FDA

Case Study on a Drug/Device Combination Using lontophoresis (with CDER as the Lead)

George Baskinger

Manager, Quality Management and Regulatory Compliance, Vyteris

SESSION 299V RA5 - REGULATORY AFFAIRS, CR

3:30 рм - 5:00 рм

LEVEL = •

Room 151A

The Target Product Profile Practical Implementation: FDA and Sponsor Perspective

SESSION CHAIRPERSON

Cheryl Beal Anderson, PharmD, RAC

Director, US Regulatory Affairs, Eli Lilly and Company

The target product profile (TPP) is an FDA-PhRMA endorsed initiative to increase efficiency between FDA and sponsors and expedite drug development. A TPP is a nonbinding document that sponsors voluntarily submit to the FDA to facilitate discussion of the strategic intent and labeling goals of a clinical drug development program. The objective of this session is to provide practical advice by FDA and PhRMA companies on developing and using a TPP.

TPP: An FDA Perspective

Laurie Beth Burke, RPh, MPH

Director, Study Endpoints and Label Development, Office of New Drugs, CDER, FDA

TPP Implementation: Considerations for FDA Interactions Peter J. DiRoma

Director, Worldwide Regulatory Affairs, Pfizer Global R&D

TPP Implementation: Considerations for Pharmaceutical Companies David M. Cocchetto, PhD

Vice President, Antiviral/Antibacterial Regulatory Affairs, GlaxoSmithKline

SESSION 299W ST - STATISTICS, CP

LEVEL = •

CME credits offered

How Can Statistics Contribute to Pharmacovigilance?

SESSION CHAIRPERSON

3:30 рм - 5:00 рм

Room 201

Jürgen Kübler, PhD

Director, Global Statistical Science, Bayer HealthCare AG, Germany

ICH E5 on Good Clinical Practice is widely regarded as the guideline that establishes the role of statisticians in drug development. As of today, the application of statistical methods in the pharmaceutical industry has mainly been devoted to planning and analysis of clinical trials. Surprisingly, statisticians are a rare species in other areas of drug development. There is also an obvious desire for more sophisticated statistical approaches in these areas. As an example, we explore the field of statistical safety. In this session we will explore different fields of application and demonstrate the broad methodological spectrum in this field. Finally, we will touch on the development of new statistical methods.

Missing Data in Safety Evaluation: Analyses and Issues Satish C. Misra, PhD Mathematical Statistician, CDER, FDA

Discovery of Medication Errors in a Vaccine Safety Database Using Data Mining *Vitali Pool, MD*

Medical Epidemiologist, Immunization Safety Branch, Centers for Disease Control and Prevention

Sample Size Estimation in Postmarketing Safety Studies with Incorporation of External Data *Yu-Te Wu, PhD, MPH* Yale University

LEVEL = •

SESSION 299X TR - TRAINING, CR

3:30 рм - 5:00 рм

Room 207B

Clinical Research Is a Contact Sport

SESSION CHAIRPERSON

Mary E. Briggs President and Chief Training Officer, FOCUS, Inc.

Let's face it - confused dialogue, virtual teams, and failure to ask for clarification can create peril for clinical trial professionals. Using a football metaphor, this session combines humor and drama to help clinical trial professionals turn frustrating communications into successful exchanges. This is a great all-purpose communication session that explores ways to "connect" with CRAs, site professionals, patients, and co-workers.

Nadina C. Jose, MD

President and CEO, Research Strategies, Inc.

Mary E. Briggs

President and Chief Training Officer, FOCUS, Inc.

5:00 рм

END OF TUESDAY SESSIONS

5:00 рм - 6:30 рм

CONSORTIUM OF ACADEMIC PROGRAMS IN CLINICAL RESEARCH MEETING

Meeting Room 103B, Convention Center

Wednesday, June 29 (some speaker changes will occur before the event.)

7:30 ам - 3:30 рм	ATTENDEE REGISTRATION East Registration Area, Convention Center Mount Vernon Place Entrance
7:30 ам - 3:30 рм	EXHIBITOR REGISTRATION East Registration Area, Convention Center Mount Vernon Place Entrance
7:30 ам - 3:30 рм	SPEAKER REGISTRATION East Registration Area, Convention Center Mount Vernon Place Entrance
7:30 ам - 8:15 ам	CONTINENTAL BREAKFAST Meeting Rooms 145-147, Concourse Convention Center
9:00 am - 3:30 pm	EXHIBITS OPEN Exhibit Halls A, B & C, Lower Level, Convention Center

SESSION 301 **AHC - ACADEMIC HEALTH CENTERS,** CR, IS 8:30 AM - 10:00 AM LEVEL =

Room 103B CME and Pharmacy credits offered

Human Subject Protection: Organization and Training of **IRBs and Clinical Sites**

SESSION CHAIRPERSON Shirley Suresh, MD

Head, Quality Assurance, Clinical Trials and Epidemiology Research Unit, Singapore

Human subject protection is a basic requirement of clinical research. With the rapid advancement in biomedical research, the issues faced by IRBs and the clinical profession in addressing and overseeing clinical research are becoming more complex. IRBs and clinical sites are being reorganized to streamline their processes to improve efficiency and to meet regulatory requirements. Training of IRB members and clinical investigators is an essential component that is being addressed. This session will highlight the organization and training programs of IRBs and investigative sites to meet regulatory requirements in three Asian countries.

Working and Training of IRBs and Investigative Sites in China Yishi Li, MD

Director, Center of Clinical Pharmacology, Fu Wai Hospital and Cardiovascular Institute, CAMS and PUMC, China

Transforming the Ethical Review Process Jieun Shyard Wong, MBBS

Director, Clinical Programs, Professional Policy and Planning/Research and Development Office, National Healthcare Group, Singapore

Quality Improvement and Assurance for Ethical Review Mechanism in India

Vasantha Muthuswamy, MD, DGO, FAIBMS

Senior Deputy Director General and Chief, Division of Basic Medical Sciences, Indian Council of Medical Research, India

SESSION 302 **BT - BIOTECHNOLOGY, CR**

8:30 AM - 10:00 AM LEVEL = Room 154AB

CME credits offered

Integrating Pharmacogenetics in Clinical R&D: From Data Acquisition to Data Management and Exchange

SESSION CHAIRPERSONS

Lee H. Evans

Director, Strategic Planning and Portfolio Management, Clinical and Regulatory Information Services, Merck & Co., Inc.

Athanasios Zavras, DMD, MS, DrMedS

Senior Scientist, Pharmacogenetics, Ingenix Research

The primary aim of this session is: a) to identify distinct phases in the life cycle of a drug where pharmacogenetic research can provide value; b) to provide practical advice about different PGx study designs and some of the scientific, economic or logistical issues involved; and c) to discuss methods and present examples of how the combination of pharmacogenomic and traditional clinical data can be properly resolved through the use of biomedical data exchanges.

The Science and Practice of Applied Pharmacogenomics Athanasios Zavras, DMD, MS, DrMedS

Senior Scientist, Pharmacogenetics, Ingenix Research

Genetic and Molecular Pharmacoepidemiology Stephen E. Kimmel, MD, MS

Associate Professor, University of Pennsylvania School of Medicine

Pharmacogenomics and Clinical Data: Bridging the Chasm Lee H. Evans

Director, Strategic Planning and Portfolio Management, Clinical and Regulatory Information Services, Merck & Co., Inc.

SESSION 303 **CDM - CLINICAL DATA MANAGEMENT** LEVEL =

8:30 AM - 10:00 AM

Room 202B

Data Management and the Globalization of the Japanese **Clinical Trial Industry**

SESSION CHAIRPERSON Cliona O'Donovan

Director, Data Services, Quintiles Pty Ltd., Australia

This session will be an exploration of the globalization of the Japanese clinical trial industry on current practices in data management. ICH subscribers are USA, Europe and Japan. We will explore some of the success factors to consider in the data management of multinational studies that include sites in and outside of Japan.

Working with Japanese Investigative Sites Julie Olszewski

Data Management Expert, Banyu Pharmaceutical Co. Ltd., Japan

Data Management and the Globalization of the Japanese Clinical Trial Industry

Tetsunari Kihira. PhD

Senior Reviewer, Office of New Drugs Evaluation III, Pharmaceuticals and Medical Devices Agency (PMDA), MHLW, Japan

A Swiss View of Japanese CTDs Based on Trials in Japan, Australia, America, and Europe David W. Warne, PhD, MSc

Associate Director, Biostatistics, Serono International, Switzerland

Session 304 CMC - CHEMISTRY, MANUFACTURING, AND CONTROLS, RA

8:30 AM - 10:00 AM LEVEL =

Room 147A

Updates on FDA GMP Initiatives and Guidances

SESSION CHAIRPERSON

Joseph C. Famulare

Director, Division of Manufacturing and Product Quality, Office of Compliance, CDER, FDA

This session will focus on advancements and developments in the CGMP Compliance and Inspection Programs that are advancing since the final announcement of the CGMP initiative in September 2004. Key areas of discussion will be process validation and the recent revision of the 1987 Process Validation Guidance coming as a draft guidance, furthering the update on FDA's Compliance Policy Guide which was published on March 17, 2004, updating the preapproval Inspection Compliance Program, additional enhancements of the risk-based site selection program, among other areas. Developments in forming the Pharmaceutical Inspectorate, incorporating product specialists on inspections, and updates on the status of Part 11 will also be discussed, illustrating technical advancements and the input of science in the CGMP programs.

Update on Compliance CGMP Initiatives: Upcoming PAI Program Changes, Integration across Quality Regulation – Review, Inspection, Compliance, Progress on the Pharmaceutical Inspectorate Joseph C. Famulare

Director, Division of Manufacturing and Product Quality, Office of Compliance, CDER, FDA

Continuous Improvement under Modern Quality Systems and CGMPs Richard L. Friedman, MS

Consumer Safety Officer, Division of Manufacturing and Product Quality, Office of Compliance, CDER, FDA

Role of the Annual Review and the Life-cycle Approach to Validation Grace E. McNally

Consumer Safety Officer, Division of Manufacturing and Product Quality, Office of Compliance, CDER, FDA

Panel Discussion/Q&A Period

SESSION 305 CP - CLINICAL SAFETY AND

Pharmacovigilance, RA

8:30 AM - 10:00 AM LEV

AM LEVEL =

Room 207A CME, Nursing, and Pharmacy credits offered

The CIOMS VI Project on Managing Clinical Trial Safety

SESSION CHAIRPERSON

Arnold J. Gordon, PhD

Pharmaceutical Consultant

The CIOMS VI Working Group has developed principles and proposals for the collection, evaluation, and reporting of safety information obtained during clinical trials to all appropriate stakeholders. Included are new considerations on ethics, terminology and definitions, recommendations on statistical approaches, and a systematic approach to risk management and pharmacovigilance, especially for a drug development program. A summary of the key proposals, some of which represent departures from current regulations, will be presented.

The Scope and Objectives of CIOMS VI Arnold J. Gordon, PhD Pharmaceutical Consultant

Proposals and Recommendations from CIOMS VI: An Industry Perspective Wendy P. Stephenson, MD, MS, MPH Principal, Wendy Stephenson & Associates LLC

Proposals and Recommendations from CIOMS VI: A Regulatory Perspective *Gottfried Kreutz, MD*

Director and Professor; Head, Department of Clinical Pharmacology, BfArM, Germany

Panelist

Gerald J. Dal Pan, MD, MHS

Director, Division of Surveillance, Research and Communication Support, Office of Drug Safety, CDER, FDA

Session 306

CR1 - CLINICAL RESEARCH AND DEVELOPMENT

8:30 AM - 10:00 AM

Room 140B

The Secret Code for Efficient Clinical Research

SESSION CHAIRPERSON

Norman M. Goldfarb, MBA, CRCPA

Managing Partner, First Clinical Research, Inc. Chairman, MAGI, the Model Agreement Group Initiative

Existing coding systems can be used to improve communication between sponsors and sites and the efficiency of clinical research. For example, physicians use CPT procedure codes and ICD-9 diagnostic codes for clinical reimbursement. Sponsors can use these same codes to unambiguously communicate eligibility criteria and study procedures to investigators. Two new coding systems will be presented: Clinical Research Terminology (CRT) codes specify study activities that are not covered by CPT codes. Protocol Deviation and Violation (PDV) codes differentiate between deviations, violations and other errors. These and other coding systems that will be described facilitate the collection and use of metrics. Metrics are the foundation of systematic performance and process improvement. "You can't manage what you can't measure." (This session is not about billing third-party payors.)

The Secret Code for Efficient Clinical Research Norman M. Goldfarb, MBA, CRCPA Managing Partner, First Clinical Research, Inc.

Chairman, MAGI, the Model Agreement Group Initiative

Metrics for Effective Site Selection Melissa Hutchens

Consultant, KMR Group, Inc.

Metrics for Effective Site Management and Process Improvement *Alan S. Taggart, MS*

Principal, Life Sciences Business Group, Pittiglio Rabin Todd & McGrath

SESSION 307 CR2 - CLINICAL RESEARCH AND DEVELOPMENT, RA

8:30 ам - 10:00 ам

Room 145A *CME and Pharmacy credits offered*

Clinical and Regulatory Update on Imaging in Oncology Trials

LEVEL =

SESSION CHAIRPERSON

Richard Jacobs, MD

Vice President and Chief Medical Officer, Perceptive Informatics, Inc.

This session provides an update on a very well attended session from the 2004 annual meeting. Key updates will include new guidance from FDA now being made final and publicly available, outcomes of FDA workshops on cancer trial endpoints, and ongoing initiatives on imaging in oncology drug development from NCI and FDA.

Understanding the Current Status of Regulatory Initiatives Pertaining to Imaging in Oncology Drug Development Jerry M. Collins, PhD

Director, Division of Clinical Pharmacology Research, CDER, FDA

Understanding New Clinical Developments in Applying Imaging Endpoints in Oncology Trials: Part 1 *Giles L. Boland, MD*

Vice Chair, Department of Radiology, Massachusetts General Hospital

Understanding New Clinical Developments in Applying Imaging Endpoints in Oncology Trials: Part 2

Lawrence H. Schwartz, MD

Director of Magnetic Resonance Imaging, Memorial Sloan Kettering Cancer Center

Session 308 CR3 - Clinical Research and Development, RA

8:30 AM - 10:00 AM LEVEL =

Room 145B

Experiences with the New Ethics Committee Systems in Europe

SESSION CHAIRPERSON

Ingrid Klingmann, MD

President, Pharmaplex bvba, Belgium

The Clinical Trials Directive has enforced the implementation of new ethics committee systems, including new roles and responsibilities of ethics committees in different European countries. First experiences are now available. This session will provide an opportunity to understand the challenges and solutions in different European countries.

The Variety of Ethics Committee Systems in Europe: An Introduction Ingrid Klingmann, MD

President, Pharmaplex byba, Belgium

The German System of Ethics Committees Under the EU-based Regulations

Elmar Doppelfeld, MD

Chairman of the Permanent Working Group, Research Ethics Committees in Germany

Impact of the EU Clinical Trials Directive on the Ethics Committee Systems in Hungary and Other CEE Countries *Prof. Tamás L. Paál, PhD, MA*

FIUL TAINAS L. FAAL, FIID, MA

Director General, National Institute of Pharmacy, Hungarian Health Authority, Hungary

Session 309

CR4 - CLINICAL RESEARCH AND DEVELOPMENT

8:30 am - 10:00 am

Room 146A

How to Establish and Successfully Run Data Monitoring Committees

LEVEL = •

SESSION CHAIRPERSON

Doris Kolb

Director, Data Pooling and Analysis Center, PRA International, Germany

Various national and internal guidelines are available for data monitoring committees (DMC). However, practical experience shows limited operational implementation. To successfully set up and conduct a data monitoring committee, the DMC charter clearly needs to define roles and responsibilities of all involved parties as well as the associated processes.

Planning and Development of Charters for Data Monitoring Committees Doris Kolb

Director, Data Pooling and Analysis Center, PRA International, Germany

Statistical Considerations for Data Monitoring Committees *Lisa M. LaVange, PhD*

Vice President, Biostatistics and Data Management, Inspire Pharmaceuticals

Data Monitoring Committees from the Regulatory Perspective Susan S. Ellenberg, PhD

Professor of Biostatistics, Associate Dean for Clinical Research, University of Pennsylvania School of Medicine

SESSION 310 CTM - CLINICAL TRIAL MANAGEMENT, CR, PP

8:30 AM - 10:00 AM

Room 101 CME credits offered

Differing Viewpoints? An In-depth Look at Patients' Experiences in Clinical Trials versus Media Coverage of the Clinical Trials Industry and Its Impact on Public Perception and Patient Participation Rates

session chairperson Daniel McDonald

Vice President, Thomson CenterWatch

This session will examine and compare the findings from two Thomson CenterWatch studies conducted in late 2004/early 2005 that shed light on the factors affecting public perception, participation and retention levels, and level of care. The first study looks at media coverage of the clinical trials industry. The second study looks at the experiences of patients who have actually participated in a clinical trial. Findings of both studies will be presented and discussed. The results will help industry professionals understand the attributes that shape public perception of clinical research, the impact upon participation levels and areas of misinterpretation.

Examining Media Coverage of the Clinical Trials Industry and Its Impact on Public Perception and Patient Participation Rates Daniel McDonald

Vice President, Thomson CenterWatch

Understanding Clinical Trial Volunteer Experiences Mary Jo Lamberti, PhD

Senior Manager, Market Intelligence, Thomson CenterWatch

Session 311 DM - DOCUMENT MANAGEMENT/ ESUBMISSIONS, RA

8:30 AM - 10:00 AM LEVEL =

Room 206

Managing the Living Global Dossier

session chairperson **Teresa Torello-Lincoln** Submission Project Lead, AstraZeneca

Explore the concept of creating a Dossier Management Center of Excellence (DMCE). The DMCE provides concentrated knowledge and expertise dedicated to growing and managing a Living Global Dossier. The Living Global Dossier is implemented at the beginning of a project to support strategy around document and module reuse. Incorporation of people, content, regulatory knowledge, project management, document management, and technology are essential to the success of the DMCE and to the drug program that is supported by the DMCE.

Wednesday, June 29

Cultivating a Global Dossier Group Teresa Torello-Lincoln Submission Project Lead, AstraZeneca

Planting the Seeds for a Successful Global Dossier *Michelle A. McGuinness, MS* Director, Solution Business Development, Octagon Research Solutions, Inc.

Propagation and Maintenance of Your Living Global Dossier

John W. Kiser Associate Director, Abbott Laboratories

SESSION 312 GCP - GOOD CLINICAL PRACTICES, OS

8:30 AM - 10:00 AM

Room 202A

Virtual Realities: Quality Considerations when Using Contract Organizations

SESSION CHAIRPERSON

Deborah A. Waltz, MS, CIP

Senior Director, R&D Quality, King Pharmaceuticals Research and Development

Sponsors sometimes wrongly assume that quality assurance is less of a concern or responsibility when they have contracted responsibilities to outside organizations. This session will provide information on FDA expectations for the responsibility of assuring GCP compliance as well as practical steps that can be implemented by sponsor organizations to improve quality outcomes when working with outsource providers.

Quality and Compliance in a Virtual Environment: Enforcement Trends and Expectations

Joseph P. Salewski Chief, Bioresearch Monitoring Branch, CBER, FDA

Selecting CROs: What to Look for, What to Run from Erin H. Krohl. MS. MPH

President. EHKrohl Consulting. Inc.

Strategies for Optimizing Quality when Using CROs

Deborah A. Waltz, MS, CIP Senior Director, R&D Quality, King Pharmaceuticals Research and Development

Session 313 IT - INFORMATION TECHNOLOGY

8:30 AM - 10:00 AM LEVEL = •

Room 146B

Web Services: The Glue for a Fractured Infrastructure SESSION CHAIRPERSON

James Langford, MBA, MS

President, DataLabs, Inc.

Clinical development uses many different systems that frequently do not communicate, creating an inefficient process for drug development. The use of web services and CDISC now provides a powerful tool for stitching together these systems in a way that provides significant cost and time savings.

The Technology and Value of Web Services and an Open Architecture Jason A. Burke, MA

Life Sciences Industry Strategist, Microsoft Corporation

The Value and Use of Web Services in a Global CRO John F. Morgan

Senior Vice President, Information Technology, United Biosource Corporation (UBC)

How to Use Web Services and CDISC ODM to Connect Disparate Systems *Richard Gleeson*

Vice President, Enterprise Solutions, DataLabs, Inc.

Session 314 MA - MARKETING AND SALES, RD

8:30 AM - 10:00 AM LEVEL = •

Room 204BC

Value Optimization of Medical Products Reflecting Development and Marketing Strategies

session chairperson Toshio Nagae

President, CMIC MPSS Company, Ltd., Japan

Who are decision makers and what are the critical factors to determine value of medical products? Product attributes, price, and promotion (3P) would be major factors reflecting development/marketing strategies and implementations. This session will highlight alternative strategies leading to different commercial value for your best decision making.

Optimizing the Profiles of the Emerging Pharmaceutical Pipeline *François Kerendi, MBA*

Senior Director, Commercial Development, Global Business Operations, Schering-Plough Corporation

A Successful Product Launch: Commercial Evaluation and Prelaunch Marketing to Maximize Value *Robert S. Livesay, MBA*

Senior Director, New Products Commercialization, Thrombosis/Cardiology, sanofi-aventis

Value Optimization of Medical Products Reflecting Development and Marketing Strategies Malcolm Lloyd, MD

Commercial Team Leader, Surgery Business, The Medicine Company

Session 315 MC - Medical Communications, MA 8:30 AM - 10:00 AM LEVEL = ■

Room 209AB

CME and Pharmacy credits offered

Field-based Medical Involvement Beyond Scientific Thought Leaders: Reaching Out to Help Healthcare Decision Makers SESSION CHAIRPERSON

Keith L. Steward, MD, MBA

Vice President, Medical Education, Medical Affairs RBU, sanofi-aventis Pharmaceuticals

Decisions impacting patient healthcare and the value of pharmaceutical treatment options have continued to evolve over time. This requires medical personnel within the pharmaceutical industry to demonstrate considerable flexibility in meeting the needs of customers that directly impact healthcare. Field-based medical personnel are uniquely positioned to meet these needs and their specific role in the process will be addressed.

The Scientific Interface between Field Medical Organizations and Managed Health Care Organizations *Eric M. Hillson, PhD, MBA, RPh*

Director, Economic, Clinical and Health Outcome (ECHO) Scientist Group, Medical Affairs Department, Centocor, Inc.

SESSION 316 MW - MEDICAL/SCIENTIFIC WRITING, CR

8:30 AM - 10:00 AM

Room 102AB

Discovering and Reporting Safety Issues in Clinical Trial Data SESSION CHAIRPERSON

Margaret Boe, RN

Director, Medical Writing, Image Solutions, Inc.

Accurate interpretation of safety research data is imperative for those in decision-making positions. Medical writers must have a broad-based knowledge of current trends in safety issues to understand which data should be discussed in clinical study reports, and to thoroughly interpret safety data to assist sponsors with discovering pertinent trends in their data. Likewise, regulatory agency reviewers must have a means of rapidly compiling and reviewing the safety data.

This session will present three areas of concern and interest to medical writers and others who are responsible for reviewing, interpreting, and/or reporting clinical trial safety data. The first speaker will present an overview of the concerns regarding drug products that affect electrocardiogram QT intervals. The second speaker will discuss some of the electronic tools currently being used or considered for use at CDER to facilitate and expedite their safety data reviews. The third speaker will present issues and best practices for writing patient safety narratives for global submissions.

QTc Intervals: Why the Fuss? *Margaret Boe, RN*

Director, Medical Writing, Image Solutions, Inc.

Premarketing Safety Assessment: Data Standards and the Safety Review Guidance Armando Oliva, MD Associate Director for Policy, Office of New Drugs, CDER, FDA

The Art of Writing Safety Narratives Sandra J. Hecker, RAC

President, Hecker and Associates, LLC

Session 317 NHP - NATURAL HEALTH PRODUCTS, AD, RA

8:30 AM - 10:00 AM LEVEL = •

Room 140A

Postcards from the Edge: Avoiding Regulatory Blunders in Promoting Natural Health Products

SESSION CHAIRPERSON

Enid Doggett

Director, Communications Department, American Federation of Government Employees, AFL-CIO

Knowing where the line is drawn between dietary supplement and "disease" claims can be difficult for those who are marketing natural health products (NHPs). In the US, products are regulated by their "intended use." "Intended use" is defined by the label and the labeling claims made on the product. This session will explore the regulatory criteria for making food, dietary supplement and drug claims for naturally-derived products, which can be regulated in more than one category. Making a selection between these different routes to market, along with other factors determines what you can say about the product.

What You Say Is What You Are: The Food-drug Paradox for Natural Health Products *Freddie Ann Hoffman, MD*

Chief Executive Officer, HeteroGeneity, LLC

Basic Principles of Drug Advertising: How Do They Apply to Natural Health Products

Peter H. Rheinstein, MD, JD, MS President, Severn Health Solutions

How the Federal Trade Commission Can Help You - the Manufacturer of Natural Health Products

Daniel Kaufman, JD

Staff Attorney, Division of Advertising Practices, Bureau of Consumer Protection, Federal Trade Commission

Session 318 OS - Outsourcing, RD

8:30 AM - 10:00 AM LEVEL =

Room 150A

The CRO Response to Emerging Drug Development Trends Using New Technology and Best Business Practices SESSION CHAIRPERSON

Mark Levine, MBA

Director of Business Development, Averion Inc.

Contract research organizations are integrating new technologies and business practices to meet the demand for accelerated drug approval timelines. This session will discuss the latest trends in this area.

Using Technology to Streamline Clinical Trials Michael O. Regentz

Managing Director, Winchester Business Systems, Inc.

Managing Day-to-day Operations: Getting Your Hands Dirty *Christine B. Philput, PhD, MS* Chief Clinical Officer, Averion Inc.

Implementing Technology: Easier Said than Done William Jacobson, PhD Director Project Management, Wyeth Research

LEVEL = •

Session 319 PM1 - PROJECT MANAGEMENT, OS

8:30 am - 10:00 am

Room 143C

Project Management Institute credits offered

Does Breaking Up Have to Be Hard to Do? Dissolving Partnerships, Changing CROs

SESSION CHAIRPERSON

Carolyn H. Kruse, MSc

President, Kruse Consulting Group, Inc.

This session will discuss practical means for "changing horses in the middle of the development and marketing stream." Speakers with experience in keeping projects on track while companies dissolved or changed codevelopment agreements and/or switching CROs will discuss some of the pitfalls.

Opening Remarks *Carolyn H. Kruse, MSc* President, Kruse Consulting Group, Inc.

Regulatory Perspectives on Contracts and Partnership: Your Contract as a Prenuptial Agreement *Nadine M. Qashu Lim, MS* Consultant, SNK Associates

What to Do if Your Horse Won't Move in the Middle of the Stream *Roberta L. Schneider, MD, FACEP* President, Tudox Consulting, Inc.

Session 320 PM2 - PROJECT MANAGEMENT

8:30 am - 10:00 am

LEVEL = •

Room 143AB

B Project Management Institute credits offered

Critical Chain Project Management in Pharmaceuticals Development

SESSION CHAIRPERSON

Michelle R. Smith

Senior Project Manager, Procter & Gamble Pharmaceuticals

Critical Chain Project Management (CCPM) is based on the Theory of Constraints (TOC). It utilizes aggressive durations and buffers to decrease project cycle time. When integrated across a portfolio of projects, CCPM leads to improved resource management and increased business productivity.

Theory of Constraints

Lawrence P. Leach, MME, PMP President, Advanced Projects, Inc.

Flow-based Management of Pharmaceutical R&D: Increasing Speed Throughput and Reducing Risks *Jaideep Srivastav*

Director, Implementations, Realization

CCPM Experiences in Pharmaceuticals R&D

Bernard L. Rosato

Section Head, Global Project Management and Planning, Procter & Gamble Pharmaceuticals

SESSION 321 RA1 - REGULATORY AFFAIRS, CR

- 8:30 ам 10:00 ам
- AM LEVEL =

Room 152A CME credits offered

The European Situation on Pediatrics within a Global Environment

SESSION CHAIRPERSONS

Françoise de Crémiers, PharmD, MS, ML

Vice President, Worldwide Regulatory Affairs-Europe, Wyeth Research, France **Daniel Brasseur, MD, PhD**

Chairman of CHMP at EMEA, EU; Ministry of Public Health, Belgium

This session will address the New European Pediatric Regulation within the global context of drug development, most particularly in the US. The pediatric regulation will be described and its impact assessed from a global industry viewpoint.

European Situation

Daniel Brasseur, MD, PhD Chairman of CHMP at EMEA, EU; Ministry of Public Health, Belgium

US Industry Viewpoint

Richard M. Tresley, MD, PhD Johnson & Johnson Pharmaceutical Research and Development, LLC

EU Industry Viewpoint

Françoise de Crémiers, PharmD, MS, ML

Vice President, Worldwide Regulatory Affairs-Europe, Wyeth Research, France

SESSION 322 RA2 - REGULATORY AFFAIRS, CR

8:30 AM - 10:00 AM LEVEL =

Room 151B *CME credits offered*

Lessons Learned from Hormone Therapy: WHI Experience

Joseph S. Sonk, PhD Vice President, US Regulatory Affairs, Berlex, Inc. New medical information about a drug can have a profound effect on the messages sent to healthcare providers and patients alike. The publication of the WHI trial results affected the view of hormone therapy and its perceived risks and benefits. This session will review the processes employed to integrate the new information into product labeling.

Barbara Alving, MD, MACP

Deputy Director, National Heart, Lung, and Blood Institute, National Institutes of Health

Tara Parker-Pope

Medical/Health Columnist, The Wall Street Journal

Daniel Shames, MD

Director, Division of Reproductive and Urologic Drug Products, CDER, FDA

SESSION 323 RA3 - REGULATORY AFFAIRS, CP, CR

8:30 AM - 10:00 AM

Room 146C *CME, Nursing, and Pharmacy credits offered*

Case Studies in Risk Management

SESSION CHAIRPERSON

Walter E. Chalkley, MA Associate Editor, IDRAC, Thomson Scientific

To assist sponsors in risk management activities, in May 2004 the FDA published three interrelated risk management draft guidances. Case studies will be presented on different phases of risk management, including clinical development and postmarketing activities.

Identifying and Communicating Risks During Clinical Trials Helen McFarland, PharmD

Pharmacy Clinical Specialist, Oncology Investigational Drug Service, Johns Hopkins Oncology Center

Postmarketing Pharmacovigilance and Risk Management Deborah S. Kirby, MD

Vice President, Risk Management Site Head, Safety and Risk Management, Worldwide Development, Groton/New London, Pfizer Inc

Session 324 RA4 - Regulatory Affairs, CR

8:30 AM - 10:00 AM LEVEL =

Room 151A *CME credits offered*

Is Data Privacy Possible? A 360° View

SESSION CHAIRPERSON

Michael Owings

Vice President, Quality and Regulatory Compliance, Phase Forward

This session will survey the subject of data privacy and patient protection from three very diverse perspectives – technology, healthcare, and the European regulatory environment.

Patient Confidentiality and Privacy in European Clinical Trials: The Background to the Development of European Guidelines *Francis P. Crawley, PhD*

Secretary General and Ethics Officer, European Forum for Good Clinical Practice, Belgium

Privacy, Confidentiality and Human Subject Protections Marjorie A. Speers, PhD

Executive Director, Association for the Accreditation of Human Research Protection Programs, Inc.[®] (AAHRPP[®])

EDC and the HIPAA Security Rule *Michael Owings*

Vice President, Quality and Regulatory Compliance, Phase Forward

SESSION 325 RA5 - REGULATORY AFFAIRS, RD

8:30 AM - 10:00 AM

Room 152B

The Effect of Japanese Pharmaceutical Affairs Law's Revision and PMDA's Activities on Pharmaceutical Industries

SESSION CHAIRPERSONS

Tamaki Fushimi, MS

Director, Office of Safety, Pharmaceuticals and Medical Devices Agency (PMDA), MHLW, Japan

This session will provide updated information on implementation of the recently revised PAL and activities of newly established PMDA. It will also provide discussions about the effects of PAL revision and PMDA's establishment on pharmaceutical industries.

Review Activities of the PMDA/MHLW Kazuhiko Mori, MS

Director, Office of New Drugs Evaluation I, Pharmaceuticals and Medical Devices Agency (PMDA), MHLW, Japan

Vigilance Activities of the PMDA/MHLW

Tamaki Fushimi, MS

Director, Office of Safety, Pharmaceuticals and Medical Devices Agency (PMDA), MHLW, Japan

Session 326 RA6 - Regulatory Affairs, FI

8:30 AM - 10:00 AM LEVEL = •

Room 147B

Don't Sweat SOX: Implementing Reporting for Sarbanes-Oxley (SOX)

SESSION CHAIRPERSON

Christine Oh, PharmD, RPh

Regulatory Compliance Manager, AstraZeneca Pharmaceuticals LP

The Sarbanes-Oxley Act calls for the CEO and CFO to certify the accuracy of their company's financial results, internal controls over financial reporting, and disclosure controls. This session will highlight the importance of the Sarbanes-Oxley Act and its impact on the regulatory affairs department both locally and globally. It will consist of brief presentations and a panel discussion.

Scott Cunningham, JD Associate, Covington & Burling

Ann Booth-Barbarin Senior Counsel, AstraZeneca

SESSION 327 RD - R&D STRATEGY, CR

8:30 AM - 10:00 AM LEVEL = •

Room 150B

Implementing Clinical Modeling and Simulation: A Practical Guide

SESSION CHAIRPERSON

Helena U. Enahoro, PhD, MSc

Senior Consultant, IBM Business Consulting Services

This session presents the issues and challenges to making modeling and simulation relevant in the decision-making processes in an organization and discusses the possible organizational structures to support the use of modeling and simulation in decision making. Modeling and Simulation in Clinical Development *Kevin H. Dykstra, PhD* Senior Scientist, Pharsight Corporation

Organizing for Modeling and Simulation *Helena U. Enahoro, PhD, MSc* Senior Consultant, IBM Business Consulting Services

Integration of Modeling and Simulation into the Pharmaceutical Industry Environment: Successes and Challenges *William E. Pullman, PhD, MB, FRACB* Senior Vice President, sanofi-aventis

SESSION 328 ST - STATISTICS, CR

8:30 AM - 10:00 AM Room 201

CME credits offered

LEVEL =

Randomization

SESSION CHAIRPERSON

Scott A. Hamilton, PhD, MS

Clinical Assistant Professor, Stanford University Medical Center; President, Dynarand, LLC

Several novel methods of randomization for clinical trials will be presented and discussed.

Assess Pros and Cons for Using Rerandomization Designs for Clinical Studies

Cornelia Dunger-Baldauf, PhD Senior Biostatistician, Novartis Pharma AG, Switzerland

A List-based/Dynamic Hybrid Model for Two-stage Randomization David B. Sundin, MS, MBA, MPH Director, Client Services, Dynarand, LLC

Session 329 TR - TRAINING, PM

8:30 AM - 10:00 AM LEVEL =

Room 207B

Facilitation Magic: Conjuring Up Extraordinary Results in Teams and Groups

SESSION CHAIRPERSON

Barry Sagotsky, MBA

Managing Director, Magnolia Lane Consulting

Whether you have to plan for and facilitate a team meeting, kickoff, lessons learned, training session, or other meeting requiring involvement, open discussion, and decision making, the skills demonstrated and practiced in this session will provide a solid foundation for getting the results you want. Topics include preparation, giving instructions, managing discussions, managing personalities and conflict involving participants, and building and deepening relationships and trust. As the title implies, the session will utilize magic effects to demonstrate principles and techniques and involve participants. This is a participative learning experience.

Facilitation Magic: Conjuring Up Extraordinary Results in Teams and Groups

Barry Sagotsky, MBA

Managing Director, Magnolia Lane Consulting

Ira Spector, MBA

Vice President, Clinical Trial Operations; Vice Chief of Operations, Wyeth Research

SESSION 330 **VA - VALIDATION, RA**

8:30 AM - 10:00 AM LEVEL =

Room 103A

Current International Regulatory Issues SESSION CHAIRPERSON

Teri E. Stokes, MT (ASCP), MS, PhD Director, GXP International

In this session, speakers will share their views on the practical aspects of deploying validated systems in the regulated environments of Europe and Japan. Speakers have many years of experience in industry actually working to validate systems in their respective regions. They have also faced the challenge of working with North American colleagues who might see the world differently. This session provides the opportunity to see computer validation from a non-US perspective.

Implementing and Maintaining Global Validated Clinical Trial Systems in Europe

Jan W. Kesteloot

Associate Director, Computer System Validation, Johnson & Johnson Pharmaceutical Research and Development, LLC, Belgium

Computerized System Regulatory Requirements in Japan: Practical Approach to Preparing Global Validation Policy and Standards Hitoshi Matsui

Executive Consultant, CAC Corporation, Japan

10:00 AM - 10:30 AM

REFRESHMENT BREAK

Exhibit Halls ABC, Lower Level Convention Center

Session 331 **AHC - ACADEMIC HEALTH CENTERS,** CR, IS

10:30 AM - 12:00 PM LEVEL = •

Room 103B

Clinical Trials from the Pharmaceutical Company (Sponsor) Viewpoint

SESSION CHAIRPERSON

Scott B. H. Davis

Sponsored Programs Administrator, Office of Research Administration, University of Oklahoma Health Sciences Center

This discussion will cover clinical trials from the beginning to the end of contract signing. Why do both parties want everything signed yesterday?

Clinical Trial Agreements: The Sponsor Perspective Stacie S. Switzer, JD

Counsel, Takeda Pharmaceuticals North America, Inc.

Clinical Trial Agreements: Academic Health Center's Perspective Scott B. H. Davis

Sponsored Programs Administrator, Office of Research Administration, University of Oklahoma Health Sciences Center

Session 332 **BT - BIOTECHNOLOGY, CR, OS**

10:30 AM - 12:00 PM LEVEL = •

Room 154AB

ECGs on First, EDCs on Second, and CROs on Third: **Creating Teamwork Between Clinical Service Providers** SESSION CHAIRPERSON

Bruce L. Maloff, PhD Vice President, Business Development Services, Invitrogen Biotechnology companies rely on an array of different research service companies for clinical trials. Service providers may excel at their individual skills, but few address their ability to orchestrate trials with other vendors. Their ability to play well together can accelerate a study and minimize management cost to the sponsor. This session defines the performance metrics needed to win as a team.

Taking Partnerships to the Next Level Barbara J. Birch Alliance Business Director, i3 Statprobe

Taking Partnerships to the Next Level Cynthia R. Rutgers, MS Manager, Medical Affairs Outsourcing, Amgen Inc.

Maximizing the Efficiency of Centralized Electronic Data Management **Services in Clinical Trials** Gary K. Zammit, PhD President and CEO, CliniLabs

CDM - CLINICAL DATA MANAGEMENT, SESSION 333

RA 10:30 AM - 12:00 PM LEVEL = Room 202B

CME credits offered

Advancing Data Quality in the 21st Century

SESSION CHAIRPERSON

Kit A. Howard, MPh Principal, Kestrel Consulting, Inc.

Tremendous effort goes into creating high quality data, and in the end we do not know how to assess the quality because we lack the right tools. In 1999, the Institute of Medicine, working with the FDA, conducted a meeting that produced a report outlining the current state of data quality research. This session will summarize advances in data quality since the IOM report, present a roadmap for researching the issues raised, and discuss the perspectives of the FDA and of clinical practice in achieving data quality.

Defining Data Quality: The FDA Perspective Janet Woodcock, MD

Acting Deputy Commissioner of Operations, FDA

Defining Data Quality in Medical Practice Paul V. Miles, MD

Director of Quality, American Board of Pediatrics

Achieving Data Quality: The Role of DQRI Kaye H. Fendt, MPH

Adjunct Associate Professor, School of Medicine, UNC-Chapel Hill; Director, Data Quality Research Institute

SESSION 334

CMC - CHEMISTRY, MANUFACTURING, AND CONTROLS, RA

10:30 AM - 12:00 PM Room 147A

CME and Pharmacy credits offered

Combination Products: Challenges and Opportunities

SESSION CHAIRPERSON John E. Simmons. PhD

Director, Division of New Drug Chemistry, CDER, FDA

LEVEL =

Combination products have experienced steady growth over the past decade. The number of products that must be evaluated by two (or more) centers has grown to the point where the Office of Combination Products was established at the Commissioner's level to deal with jurisdictional issues and facilitate the process. Drug-device, drug-biologic, and biologic-device combinations present many challenges as well as opportunities for the future of therapy. The primary mode of action of the combination product must be established, and the

primary center for review must be decided early in the process, so that the Agency can bring the most qualified and appropriate review staff together to evaluate and approve the product. Inspection issues must also be weighed, as each center operates under different inspection regulations.

The Agency strives to bring the appropriate disciplines together as early into the process as possible to allow sufficient time for in-depth evaluation, communications with the applicant, and schedule appropriate facilities evaluations.

Drug eluting stents will serve as an example of how the Agency successfully deals with issues and resolves disputes. Speakers representing a cross-section of centers will present perspectives and observations.

FDA Perspective

John E. Simmons, PhD Director, Division of New Drug Chemistry, CDER, FDA

Industry Perspective

Chris Cramer, MBA, MS Consultant, Manager, PRTM

Panel Discussion/Q&A Period

Kasturi Srinivasachar, PhD

Chemistry Team Leader, Division of Cardio-renal Drug Products, CDER; Consultant for Stents Reviews, CDRH, FDA

Steven R. Koepke, PhD President, SRK Consulting, LLC

Session 335 CP - CLINICAL SAFETY AND PHARMACOVIGILANCE, RA

10:30 ам - 12:00 рм

Room 207A *CME and Pharmacy credits offered*

Data Mining and Signal Detection: Where Are We?

SESSION CHAIRPERSON

Manfred Hauben, MD, MPh

Medical Director, Risk Management Strategy, Pfizer Inc

LEVEL =

Computational, computer-assisted signal detection algorithms, also known as data mining algorithms (DMAs), have received considerable attention as potentially attractive options for assisting expert safety reviewers responsible for screening large volumes of aggregate postmarketing safety data (SRS) in search of drug-event associations that may warrant further investigation ("signals.")

Most experience to date has involved application of DMAs to SRS data. Residual questions remain about this particular mode of application, but researchers are now exploring whether the relevant database environments and queries in data mining may be extended to additional applications in drug safety, pharmacovigilance, and pharmacoepidemiology.

This session will use recent experience with both SRS data and emerging applications to update pharmacovigilance specialists and pharmacoepidemiologists on the state-of-the-art of data mining in drug safety and pharmacovigilance.

Data Mining to Enhance Vaccine Safety Robert Ball, MD

Chief, Vaccine Safety Branch, CBER, FDA

Data Mining: To Shrink or Not to Shrink Charles Gerrits, PhD, PharmD, MS

Schering Plough Corporation

Recent Improvements in Data Mining at the UMC Andrew Bate, PhD

Program Leader, Signal Research Methodology, Uppsala Monitoring Centre, Sweden

Session 336 CR1 - Clinical Research and Development 10:30 AM - 12:00 PM LEVEL = ■

Room 146A CI

A CME and Pharmacy credits offered

Integrating Pharmacogenomics into Clinical Trials SESSION CHAIRPERSON

David M. Weinreich, MD, MBA

Vice President, Clinical Affairs, Gene Logic, Inc.

Pharmacogenomics offers the possibility of providing a wealth of information to aid in decision making regarding clinical development of a drug. These include identifying the MOA of a drug, patient stratification to improve development success rates, and identifying markets or submarkets for development of a compound. This session will discuss the integration of pharmacogenomics into clinical drug development while minimizing risk to and alteration of the underlying drug development plan.

Expression Profiling in Clinical Pharmacogenomic Studies Michael E. Burczynski, PhD

Principal Research Scientist II, Molecular Profiling and Biomarker Discovery, Biological Technologies, Wyeth Research

Applications of Genomics to Biomarker Discovery for Research & Development

Harsukh Parmar, MD

Executive Director, Global Discovery Medicine, Respiratory and Inflammation Area, AstraZeneca R&D, UK

SESSION 337 CR2 - CLINICAL RESEARCH AND DEVELOPMENT, GCP

10:30 AM - 12:00 PM LEVEL = •

Room 145A

GCP Compliance Considerations for Drugs, Devices and Biologics, and Combination Products

SESSION CHAIRPERSON Michael R. Hamrell, PhD, RAC

President, MORIAH Consultants

There are an increasing number of products being developed that are regulated as combination products. This can raise questions about the role of GCP expectations for the different products and how to best achieve a quality clinical study that meets the differing regulatory requirements.

General GCP Compliance for Drugs and Biologics Michael R. Hamrell, PhD, RAC President, MORIAH Consultants

Clinical Issues and Regulatory Strategy for Combination Products in the EU

Sandy M. Eisen, MD, FRCPC, MA, MBA Vice President, Clinical, PAREXEL International Corporation, UK

Clinical and Regulatory Strategy in the Development of Combination Products

Michael Gross, PhD, RAC Vice President, Regulatory Affairs, QLT Inc., Canada

Session 338 CR3 - Clinical Research and Development, AHC

10:30 ам - 12:00 рм LEVEL = •

Room 145B

How to Navigate the NIH for Grants and Contracts SESSION CHAIRPERSON

Anne Zajicek, MD, PharmD

Pediatric Medical Officer, National Institute of Child Health and Human Development, National Institutes of Health

Knowledge of the NIH funding mechanisms is crucial for academic success. This session will explain in detail how to find out about grant opportunities and contract solicitations, how to submit grants and respond to contract solicitations, and how to obtain further information from the NIH in these areas.

Government Grants: Where to Look, How to Apply Anne Zajicek, MD, PharmD

Pediatric Medical Officer, National Institute of Child Health and Human Development, National Institutes of Health

Government Contracts: The Other Funding Frontier Perdita Taylor-Zapata, MD

Pediatric Medical Officer, National Institute of Child Health and Human Development, National Institutes of Health

Making a Living in the World of Grants Marianne Garland. MB. ChB

Neonatology Attending, Columbia University, Physicians and Surgeons

Session 339 CTM - CLINICAL TRIAL MANAGEMENT, CR

10:30 AM - 12:00 PM LEVEL = •

Room 101 *CME, Nursing, and Pharmacy credits offered*

Clinical Trials: More Sensible Arrangements for Dealing with Serious Adverse Events

SESSION CHAIRPERSON

Richard O. Day, AM, MD, FRACP

Clinical Pharmacologist and Rheumatologist, University of New South Wales, St. Vincent's Hospital, Australia

Investigators, IRBs, clinical trial auditors, CROs, and sponsors are increasingly distracted by an exponential increase in paperwork involved in dealing with serious adverse event (SAEs) reports. CIOMS VI is attempting to reintroduce some balance to the system of dealing with these. This might better reflect the purpose of communicating about SAEs to investigators and IRBs – to enhance the safety of clinical trials. There is a concern that the SAE "system" has lost sight of this purpose.

Richard O. Day, AM, MD, FRACP

Clinical Pharmacologist and Rheumatologist, University of New South Wales, St. Vincent's Hospital, Australia

Vish S. Watkins, MD

Project Leader, Program Phase and Pharmacovigilance, Global Product Safety, Oncology/Infectious Diseases Therapeutic Area, Eli Lilly and Company

Yvonne Ditoro, RN, MBA

Senior Director, Global Safety, Surveillance and Epidemiology, Wyeth

SESSION 340 DM - DOCUMENT MANAGEMENT/ ESUBMISSIONS, RA 10:30 AM - 12:00 PM LEVEL = ●

Room 206 *Pharmacy credits offered*

eCTD: The Impact on the Organization

SESSION CHAIRPERSON

Betsy A. Fallen, RN

Manager, Worldwide Regulatory Coordination, Merck & Co., Inc.

In this session, you will learn how to prepare for the migration to electronic publishing of the CTD format for worldwide paper and electronic eCTD dossiers and components. You will be presented with an overview of the process of revising the authoring and publishing procedures to support the CTD format. The evolution of CTD/eCTD has, for the first time, initiated harmonization of dossier format across ICH regions. Simultaneously, the trend in industry has been toward globalization and centralization, developing more effective and efficient operations. With the implementation of eCTD, specialized views of the data for various reviewers have become important. Those who inspect clinical trial sites have a different need than medical and statistical reviewers. Facilitating this access has been focused on by regulators and industry and has resulted in application of the proposed processes.

$\label{eq:composition} \ensuremath{\mathsf{Developing CTD}}\xspace/{\mathsf{eCTD Formatted Submissions and Submission}} \\ \ensuremath{\mathsf{Components}}\xspace$

Carol M. Stretch

Senior Manager, Clinical Information and Technology (CITy), Novo Nordisk Inc.

Industry Changes and Their Impact on Submission Management Jean L. Supplee

Associate Director, Dossier Management, AstraZeneca LP

Implementation of eCTD Initiative by Collaboration Daniel F. Orfe, MS

Associate Director, Worldwide Regulatory Operations, Merck & Co., Inc.

SESSION 341 GCP - GOOD CLINICAL PRACTICES, TR

10:30 AM - 12:00 PM LEVEL = ■ Room 202A *CME credi*

CME credits offered

Training Late-phase Investigators: GCP Still Matters!

SESSION CHAIRPERSON

Alicia Pouncey, MEd

Managing Director, Aureus Research Consultants, LLC

Late-phase clinical trials are growing at an unprecedented rate. This session will discuss the unique differences between early- and late-phase trials and emphasize the importance of training this group of investigators and sites in GCP. A case study will also be presented.

Late-phase Investigator Training: The Critical Components *Alicia Pouncey, MEd*

Managing Director, Aureus Research Consultants, LLC

Incorporating Investigator Training into Your Late-phase Trial: A Sponsor's Perspective

Victor M. Montalvo-Lugo

Manager, Medical Research, Global Medical Affairs, Amgen Inc.

Session 342 IMP - IMPACT, CP, RA

10:30 am - 12:00 pm LEVEL = •

Room 149AB CME and Pharmacy credits offered

Use of Drug Utilization Data for Risk Assessment and **Risk Management**

SESSION CHAIRPERSON

Laura Governale, PharmD, MBA

Drug Utilization Specialist Team Leader, Office of Drug Safety, CDER, FDA

This session will present an overview of current drug utilization resources available to FDA, and examples of their use in assessing and managing risks associated with drug products.

Managing Risks Through Limited Distribution Laura Governale, PharmD, MBA

Drug Utilization Specialist Team Leader, Office of Drug Safety, CDER, FDA

Duration of Therapy as a Risk Management Tool David Moeny, USPHS, RPh

Drug Data Utilization Specialist, Office of Drug Safety, Division of Surveillance, Research and Communication Support, CDER, FDA

Nuances of Claims Data and Its Impact on Risk Assessment Aaron B. Mendelsohn, PhD, MPH

Epidemiologist, Office of Drug Safety, Division of Surveillance, Research and Communication Support, CDER, FDA

Session 343 **IT - INFORMATION TECHNOLOGY**

10:30 AM - 12:00 PM LEVEL =

Room 146B

Industry Standards and Web Services: Are We Ready for an **Industry Architecture?**

SESSION CHAIRPERSON

Jason A. Burke, MA

Life Sciences Industry Strategist, Microsoft Corporation

The advancement of information and technology standards within and beyond the life sciences industry currently provides for a simple flow of clinical and operational data between systems and organizations. But can the industry effectively define and implement electronic business processes that leverage these standards? We will examine how several organizations have explored this, and the implications for developing broader industry architecture(s) to support electronic business in healthcare.

The Pharmaceutical Perspective

Martin H. Brodbeck. MS Director, Pfizer Global Pharmaceuticals

The Technology Perspective Sandy Sharma Vice President, Technology and Strategy, Immedient

The Services Perspective Ashif Jiwani Capgemini

Session 344 **MA - MARKETING AND SALES**

10:30 AM - 12:00 PM LEVEL = •

Room 204BC

Salud! Reaching Foreign-born Patients in the US Market SESSION CHAIRPERSON Mary F. Stober, MBA

President, Global Project Resources, LLC

Immigration patterns are changing the ethnic makeup of the patient and provider populations in the US, presenting powerful new marketing needs and opportunities. This session will study ethnic marketing campaigns, with industry practitioners presenting strategies and tactics for market preparation, market research, and program implementation.

Patients and Providers in the US: An Overview of Diverse Needs Mary F. Stober, MBA President, Global Project Resources, LLC

Pharmaceutical Marketing to Diverse Communities: Solutions for **Translation Success** Inna Kassatkina President, Global Language Solutions

Salud es Vida - Enterate! Improving Health Through Targeted Multimedia Jorge Daboub Univision TV Group

SESSION 345 **MC - MEDICAL COMMUNICATIONS, MA** LEVEL = •

10:30 AM - 12:00 PM

Room 209AB CME, Nursing, and Pharmacy credits offered

Thinking Outside the Medicine Box: Creative Ways of **Getting Health Information to Consumers**

SESSION CHAIRPERSON John A. Friel, JD

Deputy Director, Office of Training and Communications, CDER, FDA

FDA's Center for Drug Evaluation and Research has recognized the need to educate consumers on the safe and effective use of medicines. The session will focus on message development, dissemination, and evaluation of several FDA consumer education campaigns.

CDER Public Information Campaigns

Ellen Shapiro

Director, Division of Public Affairs, Office of Training and Communications, CDER, FDA

The California Health Communication Partnership

R. William Soller. PhD

Executive Director, Center for Consumer Self Care, University of California-San Francisco School of Pharmacy

Educational Programs of the Peter Lamy Center

Nicole Brandt, PharmD

Director, Clinical and Educational Programs, University of Maryland School of Pharmacy

SESSION 346 **MW** - MEDICAL/SCIENTIFIC WRITING, CR

LEVEL = • 10:30 am - 12:00 pm

Room 102AB

Clinical Trial Registry: Build It and They Will Come? SESSION CHAIRPERSON

Arthur Gertel, MS

Vice President, Clinical Services, Regulatory and Medical Writing, Beardsworth Consulting Group, Inc.

In September 2004, a statement from the International Committee of Medical Journal Editors (ICJME) was published in JAMA (15 Sept, 2004), to suggest a clinical trial registry for posting negative clinical trial information. Included was a policy statement to the effect that member journals would not publish submitted manuscripts unless critical clinical protocol information was published on a publicly accessible website. Subsequently, there have been bills introduced in

Wednesday, June 29

Congress to propose a "Fair Access to Clinical Trials Act." PhRMA has come out with guidance to its members and individual pharmaceutical companies have established their own websites. Existing registries (clinicaltrials.gov and the NCI PDQ registry) address some aspects. Decisions will be made with respect to type and complexity of information, timing, audience, proprietary concerns, maintenance of the database, funding, and oversight. This may have a significant effect on the medical writer, given the need to prepare documentation to fulfill these obligations. The panel will review case histories and lessons learned in the construction of current registries, and implications of the proposed registry will also be addressed.

Building the Registry: Lilly's Experience Annetta C. Beauregard, MS, MBA

Regulatory Consultant, Office of Scientific and Regulatory Policy, Global Regulatory Affairs, Eli Lilly and Company

NCI's PDQ Clinical Trials Registry as a Model: Successes and Challenges Lakshmi M. Grama, MA, MLS

Technical Information Specialist/PDQ Database Project Manager, Cancer Information Products and Systems, National Cancer Institute, National Institutes of Health

The FDA Perspective

Patricia C. Delaney

Associate Director, Cancer Liaison Program, Office of Special Health Issues, Office of the Commissioner, CDER, FDA

SESSION 347 NHP - NATURAL HEALTH PRODUCTS, CR

10:30 ам - 12:00 рм

Room 140A

Strategies for Improving Botanical Medicine Acceptance in a Conventional Medical Setting

SESSION CHAIRPERSON Daniel Labriola, ND

Naturopathic Consultant, State of Washington Department of Health

LEVEL = •

This session addresses the issues affecting the acceptance of botanical medicine in a conventional medical setting as well as strategies for improvement. The importance of evidence-based protocols will be addressed with attention to presenting data with formats and controls that have meaning for conventional providers.

Clinical Trials Database: Prejudice or Full Disclosure? Anna Marie C. McSorley

Senior Manager, Quality Assurance, i3 Research

Efficacy Testing to Prove a Claim for a Multiple Ingredient NHP *Mark T. Goldberg, PhD*

Principal, GlobalTox International Consultants, Canada

Strategies for Improving Botanical Medicine Acceptance in a Conventional Medical Setting Daniel Labriola, ND Naturopathic Consultant, State of Washington Department of Health

SESSION 348 OS - OUTSOURCING

10:30 AM - 12:00 PM LEVEL =

Room 150A

Functional Partnerships: A New, Robust Model for Pharmaceutical Industry-CRO Contracting

SESSION CHAIRPERSON

James R. Schnieders, MS Vice President, Astellas Pharma, Inc. Pharmas and CROs are constantly searching for new and more effective ways to work together. Full-service outsourcing partnerships, preferred providers and other models have been tried with mixed success. Astellas Pharma Inc. has examined all of these models, as well as unique approaches such as the Wyeth-Accenture partnership, and has derived a new and comprehensive approach to pharma-CRO partnering.

The functional partnership model is a comprehensive function-by-function model that is being implemented across multiple functions within Astellas R&D in the US. It balances the pharma's need for long-term staffing stability and quality with the CRO's need for long-term financial stability. It accounts for the functional strengths of each partner CRO and uses a comprehensive governance structure to make sure that all parties benefit from the relationship.

In this session, we will look at functional partnerships from both a pharma and CRO perspective and discuss the practical aspects of implementing functional partnerships across an entire organization.

Functional Partnerships: A New Outsourcing Approach David S. Zuckerman, MS

President, Customized Improvement Strategies, LLC

Implementing Functional Partnerships Across a Pharmaceutical Industry R&D Organization

James R. Schnieders, MS Vice President, Astellas Pharma, Inc.

Making Functional Partnerships Work for a CRO Lee Spurgin, PhD Vice President, Clinimetrics

Session 349 PM1 - PROJECT MANAGEMENT

10:30 am - 12:00 pm	LEVEL =
---------------------	---------

Room 143AB Project Management Institute credits offered

Strategic Planning for Drug Development Projects SESSION CHAIRPERSON

David J. Fontana, PhD, PMP

Head, Project Management and Regulatory Affairs, Archemix Corporation

Operational effectiveness and strategy are both critical to high project performance, which is the goal of any project management effort. This session will explore strategy development and scenario planning at the project level. Best practices in setting strategy, trade-offs, and option planning as applied to drug development, will be highlighted.

A Framework for Project Strategy Planning: What's Important and When? David J. Fontana, PhD, PMP

Head, Project Management and Regulatory Affairs, Archemix Corporation

Scenario and Option Planning: Critical Practices Scott J. Mahoney, MBA Director, PRTM

Session 350 PM2 - PROJECT MANAGEMENT

10:30 AM - 12:00 PM LEVEL = ■ **Room 143C** Project Ma

Project Management Institute credits offered

Are Portfolio Management Processes Really Working in Dealing with Current Issues within the Pharmaceutical Industry?

SESSION CHAIRPERSON Krish Ghosh, PhD Director Portfolio Planning and Information

Director, Portfolio Planning and Information, Wyeth Research

Managing and prioritizing projects in a pharmaceutical company pipeline portfolio is getting harder and harder, mostly due to immense challenges that the industry is currently facing. R&D productivity, which is a good indicator of the company/industry performance, is declining. Productivity is mostly influenced by the number of project starts, development cycle times, success rates, development costs, and value. Understanding the root causes of the current trends and high variability in these factors is key to improved portfolio management and decision making. Drawing on the experiences of the experts in the industry, this session will discuss current portfolio management processes, its major drawbacks, and the vision of the future of the portfolio management.

Richard J. Heaslip, PhD

Vice President, Project and Portfolio Management, Wyeth Research

Krish Ghosh, PhD Director, Portfolio Planning and Information, Wyeth Research

SESSION 351 PP - PUBLIC POLICY/LAW, CR, FI

10:30 ам - 12:00 рм LEVEL =

Room 103A

Impact of Significant Payments of Other Sorts (SPOOS) on Clinical Research

SESSION CHAIRPERSON

Michael A. Swit, JD

Vice President, Life Sciences, THE WEINBERG GROUP

Disclosure of financial interests of investigators continues to be a key issue for the clinical research community. This session will examine both how significant payments of other sorts (SPOOS) can create the appearance – or reality – of bias for the clinical investigator and how to deal with such situations both before – and after – they arise.

Michael A. Swit, JD

Vice President, Life Sciences, THE WEINBERG GROUP

Linda Strause, PhD Executive Director, Site Development, CancerVax Corporation

Session 352 RA1 - Regulatory Affairs

10:30 AM - 12:00 PM LEVEL = •

Room 147B CME credits offered

Voluntary Pharmacogenetics Data Submissions 1 Year Later SESSION CHAIRPERSON

Barbara Kolb

Director, Global Regulatory Affairs and Quality Assurance, Johnson & Johnson Pharmaceutical Research and Development, LLC

Pharmacogenomics holds the promise of individualizing medicine. To enhance the Agency's understanding of scientific issues associated with this field, FDA issued a guidance requesting sponsors to voluntarily submit pharmacogenomic data, when such data are not required to be submitted to an IND, NDA, or BLA. FDA and industry perspectives on the first year of experience with such submissions, called Voluntary Genomic Data Submissions (VGDS), will be explored in this session.

Felix W. Frueh, PhD

Associate Director for Genomics, CDER, FDA

Richard Deane Hockett, MD

Senior Clinical Research Physician, Eli Lilly and Company

Panelists Mark L. Watson, MD Therapeutic Area Director, GlaxoSmithKline

Brian B. Spear, PhD Director, Pharmacogenetics, Abbott Laboratories

SESSION 353 RA2 - REGULATORY AFFAIRS, CR

10:30 AM - 12:00 PM LEVEL = ●

Room 151B Nursing and Pharmacy credits offered

Reporting and Assessing Inclusion of Subpopulations in Clinical Trials

SESSION CHAIRPERSON

Katherine A. Hollinger, DVM, MPH, DACVPM

Senior Supervisory Health Promotions Officer, Office of Women's Health, Office of the Commissioner, FDA

This session will review the history of the FDA's policy on gender inclusion and assessments of subpopulation inclusion in clinical trials. An overview of the FDA's assessments of subpopulation inclusion in clinical trials will be presented.

HHS Policy on Inclusion and History Katherine A. Hollinger, DVM, MPH, DACVPM

Senior Supervisory Health Promotions Officer, Office of Women's Health, Office of the Commissioner, FDA

Review of 2002 IND Submissions and Inclusion and Exclusion Criteria *Ellen E. Pinnow, MS*

Fellow, Office of Women's Health, Office of the Commissioner, FDA

Representing and Identifying Patient Populations in the CDISC SDTM Model *Wayne R. Kubick, MBA*

Vice President, Lincoln Technologies, Inc.

Differences in Subpopulation Risk: Should it Affect Trial Design? Jonathan G. Levine ORISE Fellow, FDA

SESSION 354 RA3 - REGULATORY AFFAIRS, CR

10:30 ам - 12:00 рм LEVEL = •

Room 151A

The Radioactive Drug Research Committee: Academic Research or Drug Development Tool?

SESSION CHAIRPERSON

Orhan Suleiman, PhD, MS, FAAPM Senior Science Policy Advisor, CDER, FDA

In the United States, clinical research using radiolabeled drugs can be conducted without an FDA Investigational New Drug (IND) application under the authority of an FDA Radioactive Drug Research Committee (RDRC). This FDA program, promulgated in 1975, is very similar to microdosing, a recent drug development initiative championed in Europe. A review of RDRC requirements will be presented, along with their relationship to FDA's Critical Path initiative, microdosing, and imaging.

The University of Pittsburgh Experience with the Radioactive Drug Research Committee

Dennis P. Swanson, RPh, MS, BCNP

Director, Research Conduct and Compliance Office, University of Pittsburgh Medical Center

Drug Research Initiatives: The Critical Path, Exploratory IND and Microdosing

Jerry M. Collins, PhD

Director, Division of Clinical Pharmacology Research, CDER, FDA

The Radioactive Drug Research Committee: 1975 and Today Steven M. Larson, MD

Chief, Nuclear Medicine Service, Weill Medical College of Cornell University, Memorial Sloan-Kettering Cancer Center

SESSION 355 RA4 - REGULATORY AFFAIRS, CR

10:30 ам - 12:00 рм LEVEL = •

Room 152A *CME credits offered*

Pediatric Medicine: New Challenge in Japan

SESSION CHAIRPERSON

Toshinobu Iwasaki, PharmD Manager, Pharmaceutical Affairs Division, Shionogi & Co., Ltd., Japan

Japan will take action to approve over 100 unauthorized medicines for pediatric patients for the next five years. Japanese industries, pediatric academia, and regulatory authorities will collaborate to establish the way to conduct rational pediatric trials. This session will demonstrate how each organization handles off-label use and facilitates pediatric studies.

Update on Japanese Pediatric Action in Drug Evaluation Junko Sato, PhD

Principal Reviewer, Office of New Drug I, Center for Product Evaluation, Pharmaceuticals and Medical Devices Agency, Japan

Development of a Clinical Research Framework for Medicines for Children in Japan

Hidefumi Nakamura, MD, PhD

Director, Division of Clinical Research, National Center for Child Health and Development, Japan

Regulatory Innovations for Pediatric Medicines in Japan: Pharmaceutical Industrial Aspect

Yoshitaka Ike

Manager, Medical Regulatory Affairs, Otsuka Pharmaceutical Co., Ltd., Japan

SESSION 356 RA5 - REGULATORY AFFAIRS

10:30 ам - 12:00 рм LEVEL =

Room 152B

Current Issues with 505(B)(2) Applications

SESSION CHAIRPERSON

J. Christopher Prue, RPh, MBA

Senior Director, Regulatory Affairs, Purdue Pharma L.P.

There are many factors to consider in deciding between a 505(b)(1) and 505(b)(2) application. This topic is an important consideration in the development strategy for a new product involving an active ingredient that has been previously approved. The session will approach this issue from the regulatory and legal perspectives.

Legal Perspectives with 505(b)(2) Applications *Kelly N. Reeves, JD*

Attorney, King and Spalding LLP

Current Issues with 505(b)(2) Applications *J. Christopher Prue, RPh, MBA* Senior Director, Regulatory Affairs, Purdue Pharma L.P.

SESSION 357 RA6 - REGULATORY AFFAIRS, CR

10:30 ам - 12:00 рм LEVEL = ◆

Room 146C

CME credits offered

Regulation of Clinical Research in the EU: Impact of the Clinical Trials Directive

SESSION CHAIRPERSON

Carolyn L. Hynes, PhD

Regulatory Affairs Manager, Johnson & Johnson Pharmaceutical Research and Development, LLC, UK

This session highlights some of the practical experiences of companies with conducting research in Europe under the Clinical Trials Directive, which has now been in force for one year. It also reviews the experiences of the EMEA in developing the EudraCT database of European clinical trials and of the Commission in developing guidance documents to facilitate the harmonized implementation of the Directive throughout the Community.

Industry Experiences with Conducting Clinical Trials in Europe Under the Directive

Carolyn L. Hynes, PhD

Regulatory Affairs Manager, Johnson & Johnson Pharmaceutical Research and Development, LLC, UK

Development of the EudraCT Database: Experiences to Date and Future Plans

Fergus L. Sweeney, PhD Principal Administrator, Inspections Unit, EMEA, EU

Harmonization of the European Procedures for Clinical Trials: Where Do We Stand Today?

Birka Lehmann, MD Pharmaceutical Unit, European Commission, Belgium

SESSION 358 RD - R&D STRATEGY

10:30 ам - 12:00 рм LEVEL =

Room 150B

Innovation or Stagnation: When the Obvious Choice Is Also the More Difficult Choice

SESSION CHAIRPERSON **David Handelsman** Lead Strategist, Clinical R&D, SAS

The need to accelerate the development and application of new medical technologies is well known, and grows increasingly urgent. This session will feature speakers who are utilizing innovative methodologies in the marketplace, and shortening the critical path for new medical products.

Risk and Reward: Implementing New Technologies for the Life Sciences *David Handelsman*

Lead Strategist, Clinical R&D, SAS

Maximizing the Value Proposition of EDC Through Proper Workflow *Jeffrey A. Green, PharmD* President and Chief Executive Officer, DATATRAK International, Inc.

Unifying Data Management, Statistical Analysis and Document Management Using a Collaborative Environment

Steven Kramer

Program Director, Clinical Informatics, Regeneron Pharmaceuticals, Inc.

SESSION 359 ST - STATISTICS

10:30 ам - 12:00 рм Room 201

1 CME credits offered

Analysis of Responder Data

SESSION CHAIRPERSON

Chih Stan Lin, PhD

Statistical Team Leader, Office of Biostatistics, CDER, FDA

LEVEL =

In clinical trials, the treatment response outcome often has been dichotomized into success or failure, response or nonresponse, cure or no cure, etc. When the data are analyzed, the outcome variable is often treated as a Bernoulli variable, regardless of the distribution of the original response variable. Recent research accommodates the distribution information, and sensitivity evaluation of the dichotomization proved to be an improvement to the naïve analysis.

Compare Responder Rates Without Data Dichotomization Yi Tsong, PhD

Mathematical Statistician, CDER, FDA

Odds Ratio for a Continuous Outcome Variable Barry Kurt Moser, PhD Deputy Director, CALGB Center, Duke University Medical Center

Discussant

Gary G. Koch, PhD Professor, Biostatistics, University of North Carolina

Session 360 TR - TRAINING, CR

10:30 AM - 12:00 PM LEVEL = •

Room 207B

Training and Development of New and Experienced CRAs SESSION CHAIRPERSON

Michelle L. Pearsall, CCRA

Associate Director, Staff Training and Development, Inveresk

The presentation and discussion will revolve around methods of training new CRAs to the clinical research industry and methods of developing experienced CRAs. The focus will include the technical materials to be covered in new CRA training as well as the soft skills required to handle the CRA's responsibilities. The presentation will also include innovative ways to provide continuing education and development to experienced CRAs.

Training and Development of the New CRA Michelle L. Pearsall, CCRA Associate Director, Staff Training and Development, Inveresk

CRA Leader: Advancing Your Career to the Next Level

Louis Grue, RN, CCRA CPCRA Research Unit Manager, Social and Scientific Systems

Building the Effective Study Team Sara M. Brandon

Chief Financial Officer, Carolinas Research Associates, Inc.

12:00 рм - 1:30 рм

LUNCHEON

Lunches will be distributed from 12:00 PM to 1:00 PM in Exhibit Hall C, Lower Level, **Convention Center**

Session 361 **AHC - ACADEMIC HEALTH CENTERS, IS**

1:30 pm - 3:00 pm

LEVEL =

Room 103B

Financial Checks and Balances: Making Sure You're **Getting What You Negotiate** SESSION CHAIRPERSON

James Wynn

Director of Business Development, Clinical Financial Services, Inc.

Every academic health center is concerned about negotiating the best agreement with the best budget, but how does it know if it's really getting paid the correct amount? Because of the complexity of different agreements, errors are more likely to occur in the clinical trials industry than in most others. We will explore this issue and discuss some accounting techniques that can be applied to assure that all research dollars are accounted for, paid in a timely manner and paid in full ... and why it's important.

Life Cycle of Clinical Trials: A Financial Perspective Richard Hlenski, MBA

Director, Finance and Strategic Planning, Columbia University Medical Center-NY Presbyterian Hospital

Financial Performance from the Clinical Site Perspective James R. Kilgore, PhD

President and Chief Executive Officer, Clinical Research Consultants, Inc.

SESSION 362 **BT - BIOTECHNOLOGY, RA** LEVEL =

1:30 pm - 3:00 pm

Room 154AB

Current Process for Follow-on Proteins in Europe: The Biosimilars Products

SESSION CHAIRPERSONS

Louis-Christian Clauss, PharmD, MBA, MPharm

Director, Regulatory Affairs, Global NPD Biologics, Baxter, France

Jacques C. Mascaro, PhD

Director, European Regulatory Affairs and Liaison, F. Hoffmann-La Roche Ltd., Switzerland

Learn the latest development and understand the situation regarding follow-on proteins in Europe - the biosimilars - what is happening and what should be done from the point of view of the innovator company, the competitors, and the authorities.

Biosimilars in Europe: The Point of View of the Innovator Company Jacques C. Mascaro, PhD

Director, European Regulatory Affairs and Liaison, F. Hoffmann-La Roche Ltd., Switzerland

Case Studies in Comparability of Biological Medicinal Products: Consequences for Products Claimed to Be Similar to Another One Already Marketed

Chris J. Holloway, PhD Group Director, Regulatory Affairs, ERA Consulting Group, Germany

Biosimilars in Europe: The Regulatory Authorities' Point of View Maria-Sol Ruiz

Head, Biotechnology Unit, Spanish Medicines Agency, Spain

SESSION 363

1:30 pm - 3:00 pm Room 202B

Experiences with MedDRA® Translations

SESSION CHAIRPERSON

Anna Zhao-Wong, PhD, MD

Medical Review Officer, Northrop Grumman Corporation

MedDRA in Japanese (MedDRA/J) has been available for six years. MedDRA non-English EU language translations have been released for three years. It is time to exchange experiences and discuss lessons learned among regulators and pharmaceutical companies concerning the use of non-English MedDRA.

Working with MedDRA in Various Languages

Nancy H. Woo, PhD Principal, Woo Consulting

Japanese Translation of MedDRA Tomoko Maeda

Manager, MedDRA Support and Maintenance, Quintiles Transnational Japan K.K., Japan

CDM - CLINICAL DATA MANAGEMENT LEVEL = CME and Nursing credits offered

Working with MedDRA in Europe Philippe Thouvay, MD

Head, EU Pharmacovigilance, Amgen Inc., UK

SESSION 364 **CMC - CHEMISTRY, MANUFACTURING,** AND CONTROLS, RA

1:30 PM - 3:00 PM

LEVEL =

Room 147A

IND CMC Issues

SESSION CHAIRPERSON

Charles P. Hoiberg, PhD Executive Director, Pfizer Inc

Updates and perspectives on FDA guidelines currently under development will be presented, along with a discussion on best approaches for meeting with the Agency and on what the desired content of submission should be at various phases of the IND.

FDA Perspective

Guirag K. Poochikian, PhD, FACP

Associate Director for Regulatory Science, Office of New Drug Chemistry, Office of Pharmaceutical Science, CDER, FDA

Industry Perspective Leslie Bloom, PhD Director, Global R&D, Pfizer Inc

Panel Discussion/Q&A Period

Session 365 **CP - CLINICAL SAFETY AND**

PHARMACOVIGILANCE, CR

1:30 PM - 3:00 PM LEVEL = Room 207A CME and Pharmacy credits offered

COX-2 Inhibitors: Where Are We in 2005?

SESSION CHAIRPERSON

Richard O. Day, AM, MD, FRACP

Clinical Pharmacologist and Rheumatologist, University of New South Wales, St. Vincent's Hospital, Australia

The future of the COX-2 inhibitors is uncertain in the light of the withdrawal of VIOXX and the finding of a risk of thrombosis with Celebrex and Bextra. Questions are now also being raised on the cardiovascular risks of traditional NSAIDs (e.g., naproxen). The clinical, commercial, and political consequences for the medicines industry and its regulation are immense, and the drug development landscape, especially for new COX-2 candidates, will alter substantially. This session will chart the history of the development and marketing of the COX-2 inhibitors from the perspective of the quality of the science, data, and decisions that underpinned the highs and lows of the COX-2 saga. Was the reliance on event-driven, randomized, blinded, and controlled trials with sufficient power misplaced? For drugs with emerging safety questions, has the time come to undertake sequential meta-analyses on trial data as they become available? How can we resolve concerns about bias and inadequate rigor of postmarketing, epidemiologic studies in comparison to large-scale randomized controlled trials? Do we know the risk factors for thrombotic events, and if so, was there a better, faster way to resolve uncertainties concerning the relative risk in different patients taking these drugs? These important questions will be addressed.

Richard O. Day, AM, MD, FRACP

Clinical Pharmacologist and Rheumatologist, University of New South Wales, St. Vincent's Hospital, Australia

Daniel E. Furst, MD

Professor, Rheumatology, University of California at Los Angeles

CR1 - CLINICAL RESEARCH AND SESSION 366 **DEVELOPMENT, RD**

1:30 pm - 3:00 pm

Room 140B

LEVEL = •

Pharmacy credits offered

Global Expanded Access Program: The Ins and Outs SESSION CHAIRPERSON

Robert V. Riccio, PhD

Vice President, Periapproval Services, PAREXEL International

The benefit of expanded access for a patient who is running out of hope is clear, but what about pharmaceutical companies? What is the benefit to them?

Panelists

Kenneth Watters, MD

Vice President, Clinical Development and Regulatory Affairs, Europe, Celgene Europe Limited, UK

Wayne Dankner, MD Senior Medical Director, PAREXEL International

Hua Dupre, MD Director, Clinical R&D, Tibotec BVBH (a J&J Company), Belgium

Richard Pazdur, MD Director, Division of Oncology Drug Products, CDER, FDA

SESSION 367

CR2 - CLINICAL RESEARCH AND DEVELOPMENT, BT, RA

1:30 pm - 3:00 pm LEVEL =

Room 145A

Generic Biologics: Fact or Fiction?

SESSION CHAIRPERSON Allen Cato, PhD, MD

President, Cato Research, Ltd.

As another year of experience is gained, several biological products have moved past the time for patents to expire. Is there a scientific basis for some biological products to become generic? Significant financial incentives create opposing sides to this issue and thereby potentially inhibit resolution.

The Evolving Landscape for Follow-on Biologics in the US and Biosimilar **Products in the EU**

David G. Shoemaker, PhD

Vice President, Regulatory Affairs and Project Management, Cato Research, Ltd.

Considerations of the Scope of Preclinical Safety Programs for a **Follow-on Biologic** Joy A. Cavagnaro, PhD President, Access BIO

Navigation Studies in the Uncertain Seas of Follow-on Biologics Janet M. McNicholas, PhD

Partner, McAndrews, Held & Malloy

SESSION 369 **CR4 - CLINICAL RESEARCH AND DEVELOPMENT, RA**

1:30 рм - 3:00 рм LEVEL = •

Room 145B CME and Pharmacy credits offered

Imaging of Alzheimer's and Other Neurodegenerative Diseases: Role in Clinical Trials

SESSION CHAIRPERSON

Michael W. Weiner, MD

Director, Magnetic Resonance Unit, San Francisco VAMC, University of California, San Francisco

This session focuses on use of MRI (to a lesser extent PET) imaging to monitor disease progression and determine treatment effects in Alzheimer's trials and potentially in other neurodegenerative diseases. Speakers will present an academic, industry, and FDA perspective.

Use of Imaging in Clinical Trials of Alzheimer's Disease: The NIA Alzheimer's Disease Neuroimaging Initiative Michael W. Weiner, MD

Director, Magnetic Resonance Unit, San Francisco VAMC, University of California, San Francisco

Imaging to Optimize CNS Drug Discovery **Richard Hargreaves, PhD**

Vice President, Imaging, Merck & Co., Inc.

FDA Perspective on the Use of Imaging to Determine Treatment Effects in Alzheimer's Disease Clinical Trials

Russell G. Katz. MD

Director, Division of Neuropharmacologic Drug Products, Office of New Drugs, CDER, FDA

SESSION 370 **CTM - CLINICAL TRIAL MANAGEMENT,** CR

1:30 рм - 3:00 рм LEVEL = •

Room 101

CME credits offered

Why Would You Want to Do a Registry?

SESSION CHAIRPERSON

Elizabeth Fraulo, RN

Project Leader, Duke Clinical Research Institute

Randomized clinical trials are often slow, always expensive and labor-intensive, and occasionally do not answer the question they were designed to answer. Registries, on the other hand, are less expensive, faster, and less encumbered by paperwork. This session will address registries as an option from the perspective of the FDA, a site coordinator, and a sponsor.

Why a Registry? An Academic Healthcare Organization's Point of View Amy L. Kessenich

Administrative Director, Heart Center, Duke Medical Center

Registries: Current FDA Perspectives

Allen Brinker, MD

Lead Medical Officer, Epidemiology, Office of Drug Safety, Division of Drug Risk Evaluation, CDER, FDA

Real World Data - Real World Impact Michael Moye

Senior Marketing Manager, Millennium Pharmaceuticals, Inc.

SESSION 371 **DM - DOCUMENT MANAGEMENT/ ESUBMISSIONS, RA** 1:30 рм - 3:00 рм LEVEL = •

Room 206 Pharmacy credits offered

Guidance-compliant eCTDs - Part 1 of 2

SESSION CHAIRPERSON

Gary Gensinger

Director, Review Technology Staff, Office of Information Management, CDER, FDA

Part 2 of this session will be held on Wednesday, at 3:30 PM.

This session is Part I of Guidance-compliant eCTDs and will provide an overview of FDA's eCTD Guidance and a practical discussion on developing a guidancecompliant format for an eCTD submission.

Gary Gensinger

Director, Review Technology Staff, Office of Information Management, CDER, FDA

Norman R. Schmuff, PhD Deputy Director, Division of New Chemistry III, CDER, FDA

Stephen E. Wilson, DrPH, Capt. USPHS Deputy Director, Division of Biometrics II, CDER, FDA

Armando Oliva, MD Associate Director for Policy, Office of New Drugs, CDER, FDA

Bronwyn E. Collier, RN Associate Director of Regulatory Affairs, CDER, FDA

Kenneth Edmunds IT Specialist, CDER, FDA

GCP - GOOD CLINICAL PRACTICES, SESSION 372 **ECLIN, CR**

LEVEL = 1:30 pm - 3:00 pm

Room 202A

Planning for Electronic Data Quality in Clinical Trials SESSION CHAIRPERSON

Teri E. Stokes, MT (ASCP), MS, PhD Director, GXP International

Source data in clinical trials is quickly moving to electronic status. The US Health Information Technology initiative is driving towards a national electronic medical record (EMR). Protocol teams must integrate measures for electronic data quality into their design and planning process for GCP trials going forward, and this session discusses a practical approach.

Compliance and Process Issues in ePatient Data Collection and eSource Documentation Solutions for Clinical Studies: The Sponsor Perspective Pamela A. Rose. RN-FNP

Director, Research Quality Assurance, TAP Pharmaceuticals

Integrating Electronic Data Quality at the Study Site: The Site View Yvonne P. McCracken, DH, CCRC, MPH Chief Executive Officer, Carolinas Research Associates

Managing the Quality of eData Technology in Clinical Studies: The Technology View Teri E. Stokes, MT (ASCP), MS, PhD Director, GXP International

SESSION 373 IMP - IMPACT, CR, RA

1:30 рм - 3:00 рм

LEVEL =

Room 149AB CME, Nursing, and Pharmacy credits offered

Update on FDA's Draft Guidance on Patient-reported Outcomes

SESSION CHAIRPERSON

Jane A. Scott, PhD, MA

Endpoint Reviewer, Office of New Drugs, IO/SEALD, CDER, FDA

FDA invited comments on a draft guidance for industry regarding Patient-reported Outcome (PROs) Measures: Use in Medical Product Development to Support Claims. This session will provide a summary of the issues addressed in the draft guidance and an overview of the comments received to date.

Comments on the Draft PRO Guidance: The Role of PROs in Medical Product Development

Margaret L. Rothman, PhD

Executive Director, HE&PP, PGSM, Johnson & Johnson Pharmaceutical Services, LLC

Comments on the Draft PRO Guidance: Development and Validation of PROs for Clinical Trials

Donald L. Patrick, PhD, MSPH

Professor and Director, Social and Behavioral Sciences Program, School of Public Health and Community Medicine, University of Washington

Comments on the Draft PRO Guidance: Implementation and Analysis of PROs in Clinical Trials

Jeffrey A. Sloan, PhD

Professor of Biostatistics, Professor of Oncology, Mayo Clinic

Session 374 IT - INFORMATION TECHNOLOGY, CTM

1:30 рм - 3:00 рм LEVEL =

Room 146B

Advancing Patient Recruitment with Technology and Metrics SESSION CHAIRPERSON

David Fox

President and CEO, Praxis

The purpose of the presentation is to demonstrate the efficiencies gained in time, money, and knowledge by applying technological advances to patient recruitment for clinical trials. Increasing demands on study coordinators' time, as well as rising drug development costs, necessitate the implementation of measures to improve, yet simplify, the patient recruitment process. Applying technological advances to the patient recruitment process is the most efficient way of accomplishing this, while providing additional benefits to sites and sponsors alike.

Using Technology and Metrics to Select Investigators and Identify Site Locations

William W. Gwinn, Jr., MBA Director, Clinical Trial Solutions, Medstat Inc.

Using Technology and Metrics: A Sponsor's Perspective

Frederick K. Lovelace, Jr. Associate Manager, Pfizer Inc

Using Technology and Metrics: A Site's Perspective *Kenneth R. Thomas*

Clinical Research Coordinator, Rx R&D

SESSION 375 MA - MARKETING AND SALES

1:30 рм - 3:00 рм LEVEL =

Room 204BC

Moving to Higher Levels of Launch Excellence

SESSION CHAIRPERSON Leo G. Dodds, MBA

Solution Partner, BusinessEdge Solutions

A major goal of pharmaceutical companies is the acceleration of new product commercialization and excellence in the execution of product launch processes. In today's competitive, cost-conscious environment, there must be efficiency and effectiveness throughout launch preparation. This session will cover the prerequisites of launch success and describe the linkage to responsibilities and processes. Also, a case study will be discussed with a focus on key determining factors for operations.

Launch Mobilization: Experiences and Lessons Learned Raymond J. Suehnholz, MBA

Vice President, New Business Development, North American Pharmaceutical Centers of Excellence, Division of Ortho-McNeil, Johnson & Johnson

Excellence in Medical Education: A Key to Launch Success Roseann Peluso Nguyen, PharmD Director, Medical Education, Janssen Medical Affairs, L.L.C.

Tracking and Communicating Progress: A Foundation for Teamwork Leo G. Dodds, MBA

Solution Partner, BusinessEdge Solutions

Session 376	MC - MEDICAL	COMMUNICATIONS,
	OS	

1:30 рм - 3:00 рм LEVEL =

Room 209AB

Outsourcing Medical Communications Services

SESSION CHAIRPERSON

Stacey M. Fung, PharmD

Senior Medical Communications Scientist, Genentech, Inc.

The decision to outsource projects or operational services involves a number of considerations. The use of vendors may have potential cost-savings and may increase the opportunities for department staff. The presentations will discuss making the initial assessment and decision to outsource, what can be outsourced, identifying potential vendors, the selection process, and developing working SOPs. Training and maintenance considerations will also be reviewed. Other issues will include how to sell this option to management, ensure quality service and products, and essential "must-haves" when making agreements.

Basics of Outsourcing Partnerships

Stacey M. Fung, PharmD Senior Medical Communications Scientist, Genentech, Inc.

Maintaining Quality Outsourced Professional Services Mario F. Sylvestri, PharmD, PhD

Senior Director, Regulatory and Medical Information, Amylin Pharmaceuticals, Inc.

Expectations of Relationships for All Stakeholders for Field-based Outsourcing *Joyce Morrell*

Managing Director, Ventiv Pharma Services

SESSION 377 MW - MEDICAL/SCIENTIFIC WRITING, NC, RA

1:30 рм - 3:00 рм LEVEL =

Room 102AB

Nonclinical Regulatory Writing

SESSION CHAIRPERSON

Linda Fossati Wood, RN, MPH President, MedWrite, Inc.

High-quality documentation of nonclinical testing is essential to support product registration. Allocation of writing services to nonclinical scientists is often insufficient, as few medical writers are familiar with the components of nonclinical research and the regulatory documents that govern it. This session will serve as a review of the regulatory environment surrounding this fascinating area of product development, will describe the good laboratory practice (GLP) report, and will discuss the application of techniques used in clinical writing to generate the GLP report.

Regulatory Guidance for Nonclinical Documents Theresa A. Thompson-Hoffman, PhD

Medical Writer, Image Solutions, Inc.

Good Laboratory Practice Nonclinical Study Reports: Essential Elements James F. McCormack, PhD

Vice President, Regulatory Affairs and Compliance, Charles River Laboratories - CTBR

Applying Techniques Used in Clinical Study Reports to Nonclinical Study Reports

Linda Fossati Wood, RN, MPH President, MedWrite, Inc.

Session 378 NHP - NATURAL HEALTH PRODUCTS

1:30 рм - 3:00 рм LEVEL =

Room 140A

Botanical Drug Development: It Starts at the Beginning – Control of the Plant

SESSION CHAIRPERSON

Edward M. Croom, Jr., PhD Chief Executive Officer, Croomia

In developing a botanical as an ethical drug, one of the key attributes of a natural product that must be addressed early in the process is establishing batch-to-batch consistency. This level of control begins at the beginning, with the genetic make-up of the plant, where and how the plant is grown, and how it is handled during the growing period and during harvesting. This session will explore current guidances that address "good agricultural practices," and real-life examples of how these principles are being addressed in the manufacture of botanical drug products.

Good Agricultural and Collection Practices for the Production of Botanical Drugs *Edward M. Croom, Jr., PhD* Chief Executive Officer, Croomia

Phytoneering: Research of Plant-based Medicines – from the Seed, to Cultivation, to Clinical Efficacy Michael A. Popp, PhD Chief Executive Officer, Bionorica AG, Germany

Controlling the Plant through Hydroponics *Ilya Raskin, PhD* Professor, Rutgers University

SESSION 379 OS - OUTSOURCING, CR

1:30 рм - 3:00 рм LEVEL =

Room 150A

The State of Clinical Outsourcing: Industry Practices and Perceptions

SESSION CHAIRPERSON

Patricia Leuchten

President, The Avoca Group

This session will present quantitative and qualitative data based on industry research and focused on the state of clinical outsourcing. Information presented will include current practices for purchasing clinical services and industry perceptions about what constitutes a "best practice," problems and challenges with current approaches, opportunities that exist for achieving cost savings without sacrificing high quality and projected trends for the future.

Panel Discussion

R. Adrian Otte, MB, FFPM

Senior Vice President, Worldwide Business Operations, Pfizer Inc

Paula Brown Stafford, MPH

Executive Vice President, Client and Site Operations for Clinical Development Services Americas, Quintiles Transnational Corporation

Cynthia J. Kearney

Vice President, Global R&D Pharmaceutical Sourcing, Johnson & Johnson Pharmaceutical Research and Development, LLC

Session 380 PM1 - PROJECT MANAGEMENT

1:30 рм - 3:00 рм

LEVEL = •

Room 143AB

Project Management Institute credits offered

Who Reads the Development Plan Anyway!

SESSION CHAIRPERSON

Pauline A. Goldsmith, MS

President, Goldsmith Consulting

Getting frustrated spending hours, even days, updating your development plans? Wonder why you are doing this if no one ever reads it? Tired of hearing scathing remarks from management, who do not understand the need for a plan, never mind look at it? Join us for a lively discussion with representatives from R&D, new product planning-marketing and strategic planning-business development. You will be surprised who wants to read your development plan.

Peter Elliott, PhD

Executive Vice President, Product Development, Combinatorx Inc.

James Reilly, MSc Director, New Product Marketing, ZLB Behring LLC

Pauline A. Goldsmith, MSc President, Goldsmith Consulting

Session 381 PM2 - PROJECT MANAGEMENT

1:30 рм - 3:00 рм **Room 143C**

LEVEL =
Project Management Institute credits offered

Project Management's Role in the Pharmaceutical Industry of the Future SESSION CHAIRPERSON Richard J. Heaslip, PhD

Vice President, Project and Portfolio Management, Wyeth Research

This session will focus on two challenges facing project management professionals as we define our new role in the pharmaceutical industry of the future, the establishment of new expectations and competency models for project management performance within the R&D environment, and the definition of an emerging role for project management as leaders of operational and strategic planning within the pharmaceutical industry.

Aligning Your Organization for Project Management Success Jan J. Malek, MBA

PA Consulting Group

Role of the Project Manager in a Complex Environment: Aligning Expectations, Deliverables, Skills, and Core Competencies Laurie H. May, MPH

Director, Product Portfolio Management, Genentech, Inc.

Preparing for Change in the Pharmaceutical Industry: The New Skills Required for Project Management Professionals *Richard J. Heaslip, PhD*

Vice President, Project and Portfolio Management, Wyeth Research

SESSION 382 PP - PUBLIC POLICY/LAW, IMP

1:30 PM - 3:00 PM LEVEL = •

Room 103A

Formulary Decisions in the US and UK

SESSION CHAIRPERSON

Joshua P. Cohen, PhD

Senior Research Fellow, Tufts Center for the Study of Drug Development, Tufts University

This session will draw comparisons between the US and UK with respect to the decision-making process underlying drug reimbursement and pharmaceutical care management. In the US, there is no standardized approach to drug reimbursement, formulary design, and pharmaceutical care management. Private and public payers use different therapeutic classification systems to devise formularies, cover different sets of FDA-approved drugs, and apply a variety of clinical practice guidelines aimed at improving the (cost) effectiveness of pharmaceutical care. In the UK, there is one predominant payer, the National Health Service, and one list of MHRAapproved medicines that British healthcare providers may prescribe from, the British National Formulary. Moreover, there is one organization, the National Institute for Clinical Excellence, responsible for providing national guidance on treatments and care for those using the NHS. NICE's mandate is to develop authoritative guidance on the clinical- and cost-effectiveness of (pharmaceutical) care.

The Impact of Clinical Programs on Formulary Compliance Mark Rubino

Chief Pharmacy Officer, Aetna, Inc.

NICE Impact on Drug Reimbursement Decisions Peter Littlejohns

Chief Clinical Officer, National Institute of Clinical Excellence, UK

US-UK Comparison of Pharmacoeconomic Assessments of 70 Recently Approved High-cost, High-impact Drugs Joshua P. Cohen, PhD

Senior Research Fellow, Tufts Center for the Study of Drug Development, Tufts University

SESSION 383 RA1 - REGULATORY AFFAIRS

1:30 рм - 3:00 рм LEVEL =

Room 144ABC

US-EU Agreement to Exchange Scientific Advice: A Status Report

SESSION CHAIRPERSONS

Marie A. Dray, MBA

Executive Director, Global Regulatory Policy, Merck Sharp & Dohme (Europe), Inc., Belgium

Brenton E. James, FBIRA

Consultant, UK

In September 2003, the FDA and the European Commission/EMEA signed a wide-ranging agreement to share information on a large number of regulatory topics. Other agreements or Memoranda of Understanding (MOUs) have been established for similar purposes between other regulatory authorities. In this session, speakers will provide greater details on the practical aspects of implementation of these agreements.

Panelists

Steven K. Galson, MD, MPH Acting Director, CDER, FDA

Thomas Lönngren, MPharm Executive Director, EMEA, EU

Jesse L. Goodman, MD, MPH Director, Center for Biologics Evaluation and Research, FDA

Mathias Hukkelhoven, PhD

Senior Vice President, Global Head, Regulatory Affairs, Novartis Pharmaceuticals

SESSION 384 RA2 - REGULATORY AFFAIRS, CR

1:30 рм - 3:00 рм LEVEL =

Room 152A

Outlook for Changes in Japanese Regulatory and Clinical Development Environment – Part 1 of 2

SESSION CHAIRPERSONS

Jean-David Rafizadeh-Kabe, MD, JD, MS

Associate Director, Global Regulatory Strategy, Bristol-Myers Squibb Pharmaceutical Research Institute

Noriaki Murao, MS

Representative Director, Schwarz Pharma Japan

Part 2 of this session will be held on Wednesday at 3:30 PM.

This session will provide an update on the regulatory environment in Japan, including the regulatory review process and performance, implementation of ICH guidelines and CTD, and the ways they impact on clinical development. The session will also address the future perspectives for clinical development and regulatory strategy with global development programs in Japan.

Current Environment of Clinical Study in Japan Tetsuto Nagata

Chairperson, Clinical Evaluation Subcommittee, Drug Evaluation Committee, JPMA, Japan

Regulatory Review Performance in Japan *Shunsuke Ono, PhD*

Reviewer, Pharmaceutical and Medical Devices Agency (PMDA), MHLW, Japan

Companies' Perspective on the PMDA *Orie Asaka, PhD*

Research Fellow, Office of Pharmaceutical Industry Research, Japan; Pharmaceutical Manufacturers Association (JPMA), Japan

SESSION 385 **RA3 - REGULATORY AFFAIRS, CR**

1:30 рм - 3:00 рм

LEVEL =

Room 151A

CME and Pharmacy credits offered

Development of Oncology Products in the US and EU: More Stagnation than Innovation?

SESSION CHAIRPERSON

Ionel Mitrica, PhD, MS

Senior Scientist, Cato Research, Ltd.

It is increasingly apparent that the scientific advances of the last decade are not quickly converted into innovative pharmaceutical products. This trend applies to the field of oncology too, and happens despite continuous increases in the funding available for medical research in the field. This session will attempt a comparative review of regulatory experience, current tools/ procedures, and future plans for facilitating the development of oncology products in the US and EU regulatory regions.

Ramzi N. Dagher, MD

Lead Medical Officer, CDER, FDA

Michele D. Bronson, PhD, RAC

Director, Regulatory Affairs Oncology, Chiron Corporation

Francesco Pignatti Scientific Administrator, EMEA, EU

SESSION 386 **RA5 - REGULATORY AFFAIRS**

LEVEL =

1:30 рм - 3:00 рм Room 147B

Managing Communications with Regulatory Agencies in Global Decentralized Matrix Organizations

SESSION CHAIRPERSON

Robert Butz, PhD

Vice President, Global Regulatory Affairs, MDS Pharma Services

Many pharmaceutical companies, and most global CROs, operate as decentralized matrix organizations to accommodate variations in national laws, clinical practices, and cultures around the world. Within this type of organizational structure, there remains the need to establish practical operating standards for the management of communications with the various national regulatory agencies. Such communications may more frequently involve clinical operations physicians, study directors, statisticians, and QA auditors than regulatory affairs staff, and the degree of formality with which such communications occur may vary considerably. In addition to corporate SOPs, effectively managing these interactions requires an ongoing program of training, monitoring, documentation, and communication. This session will discuss best-practice approaches to successfully address this complex challenge.

Managing Regulatory Communications within a Phase I Clinical and **Bioanalytical CRO**

Heimo W. Scheer, PhD Vice President, North American Regulatory Affairs, MDS Pharma Services

Balancing Local and Global Regulatory Communications in Multinational Pharmaceutical Companies and CROs

M. Lynn Pritchard, PhD King Pharmaceuticals Research & Development, Inc.

Interpreting FDA Communicated Expectations and Developing an Appropriate Corporate Response James P. Burns, PhD Senior Vice President, Regulatory Consulting Worldwide, PharmaNet

RA6 - REGULATORY AFFAIRS SESSION 387

1:30 pm - 3:00 pm LEVEL =

Room 152B

CDER Hot Topics - Part 2 of 2: FDA Drug Safety Initiative SESSION CHAIRPERSON

Susan K. Cummins, MD, MPH Executive Director, Drug Safety Oversight Board, CDER, FDA

Part 1 of this session will be held on Tuesday at 1:30 PM.

The FDA's drug safety initiative is a comprehensive program to address the safety of medical products. This session will provide an overview of the initiative, and will discuss various steps announced in the past few months to address the issues.

Several representatives from CDER, FDA will participate as discussants in this session.

SESSION 388 **RD - R&D STRATEGY**

LEVEL = \blacklozenge 1:30 рм - 3:00 рм

Room 150B

Intercompany Auditing Agreement as Part of Strategic Risk Management SESSION CHAIRPERSON

Brian B. O'Neill, PhD

Global Head, COA External Alliances, F. Hoffmann-La Roche AG, Switzerland

There is scope for sponsor companies to maximize efficiencies and avoid or reduce duplication of effort related to risk management of R&D by cooperating strategically in the planning of vendor audits of mutual interest and sharing the reports of such audits. There are also advantages for vendors who may hope to reduce the number of similar audits to which they are subjected by pharmaceutical sponsor companies. The results of a pilot study set up as proof of concept are presented.

Pharma Development Quality Management of Third-party Service Providers Timothy J. Highman, MS

Associate Director, Worldwide Development Quality Assurance, Pfizer Global Research and Development

Intercompany Auditing Agreement as Part of Strategic Risk Management Brian B. O'Neill, PhD

Global Head, CQA External Alliances, F. Hoffmann-La Roche AG, Switzerland

A Central Laboratories View on Sharing Audit Findings with **Collaborating Sponsor Companies** Linda Yare, MSc

Global Head of Sales, CentraLabS Clinical Research, Inc.

SESSION 389

ST - STATISTICS, CR, RA

1:30 рм - 3:00 рм

LEVEL = • Room 201 CME and Pharmacy credits offered

Statistical Considerations in the Evaluation of Red Blood

Cell Products

SESSION CHAIRPERSON Tie-Hua Ng, PhD Lead Mathematical Statistician, CBER, FDA This session discusses the FDA's requirements for autologous 24-hour posttransfusion in vivo survival studies in the evaluation of RBC products. Sample size calculation and statistical power consideration will be given.

Evaluation of RBC Products Ping He, MD Medical Officer, CBER, FDA

FDA Requirements for in vivo Survival Studies Tie-Hua Ng, PhD Lead Mathematical Statistician, CBER, FDA

Statistical Considerations Jessica Kim, PhD

Mathematical Statistician, CBER, FDA

Sample Size Calculation and Statistical Power Consideration Paul Hshieh, PhD Mathematical Statistician, CBER, FDA

3:00 рм - 3:30 рм

REFRESHMENT BREAK

Exhibit Halls ABC, Lower Level Convention Center

SESSION 390 **AHC - ACADEMIC HEALTH CENTERS,** CR, MW

LEVEL = • 3:30 рм - 5:00 рм Room 103B

CME credits offered

The Right to Publish: A Sword of Many Blades

SESSION CHAIRPERSON Patricia K. Hodgson

Director of Communications, DCRI Communications

The right to publish is a contractual clause required by academic research organizations. It is a source of considerable controversy, and there are numerous viewpoints among the players in the issue. During this interactive session, those players will provide their perspectives on the right to publish.

I'm in Academic Research: Why Does This Matter to Me? David R. Holmes, Jr., MD

Consultant, Internal Medicine and Cardiology, Mayo Clinic and Foundation

I Sponsor Clinical Research: How Does This Affect Me? Laurence J. Hirsch, MD

Executive Director, Medical Communications, Merck Research Laboratories

I'm a Journal Editor: How Does This Affect What I Publish? Hal Sox, MD

Editor-in-Chief, Annals of Internal Medicine

Session 391 **BT - BIOTECHNOLOGY, RD**

3:30 рм - 5:00 рм LEVEL = •

Room 154AB

CME and Pharmacy credits offered

Use of Toxicogenomics for Drug Candidate Selection, **Rescuing and Biomarker Discovery** SESSION CHAIRPERSON

Donna Mendrick, PhD

Vice President, Toxicogenomics, Gene Logic, Inc.

The cost of developing successful drugs continues to rise, thus putting additional pressure for early selection of the most promising candidates and for understanding the mechanism of toxicity should it be discovered later in the pipeline. Toxicogenomics is proving to be an important addition to the pharmaceutical toolbox. In this session, the potential of toxicogenomics in compound toxicity prediction, mechanism of toxicity, and biomarker discovery will be explored.

Use of Toxicogenomics to Predict Nephrotoxicity Cindy Afshari, PhD, DABT Associate Director, Toxicology, Amgen Inc.

Investigating Drug-related Toxic Mechanisms Using Genomics Peter G. Lord, PhD

Director, Mechanistic Toxicology, Johnson & Johnson Pharmaceutical Research and Development, LLC

Use of Genomics to Identify and "In Silico" Validate Biomarkers of Toxicity

Donna Mendrick, PhD Vice President, Toxicogenomics, Gene Logic, Inc.

SESSION 392 **CDM - CLINICAL DATA MANAGEMENT**

3:30 рм - 5:00 рм LEVEL =

Room 202B

Data Management Models for Multicenter and Multinational Clinical Trials: Case Histories

SESSION CHAIRPERSON Stefano Marini, MD General Manager, Dimensione Ricerca s.r.l., Italy

This session will present the different views and experiences on the use of electronic means in data collection for clinical trials, with representatives from the Ministry of Health, industry, and a CRO.

From EDC to Clinical Trials: Twenty Years of Experience Using Internet in the Management of Clinical Trials and Epidemiological Registries Marisa De Rosa, PhD

Head, Systems and Services for Health Department (SISS), CINECA -Consorzio Interuniversitario; Member, Clinical Trials Committee of AIFA, Italian National Medicines Agency, Ministry of Health, Italy

Some Experiences in Implementing Electronic Data Capture for Clinical Development

Tommy Pedersen, MSc

Director, Clinical Data Operations, Lundbeck SA, France

SESSION 393 **CMC - CHEMISTRY, MANUFACTURING,** AND CONTROLS, RA

LEVEL = 3:30 рм - 5:00 рм

Room 147A

Follow-on Biotechnology/Biological Products

SESSION CHAIRPERSON Keith Webber, PhD

Acting Director, Office of Biotechnology Products, CDER, FDA

As protein manufacturing technologies and analytical methodologies have advanced, the potential for one manufacturer to produce its own version of another manufacturer's protein product is on the horizon. However, given the wide variety of types of biotechnology products currently on the market, it may be expected that some products will be more challenging than others. This session will explore the scientific factors that may need to be considered when assessing the similarity of these types of products.

FDA Perspective

Steven Kozlowski, MD

Medical Officer, Office of Biotechnology Products, Office of Pharmaceutical Science, CDER, FDA

Industry Perspective

Dr. Martina Weise

Head, Section on Endocrinology and Diabetes, BfArM, Germany

Panel Discussion/Q&A Period

Session 394 CP - CLINICAL SAFETY AND PHARMACOVIGILANCE, CR

3:30 рм - 5:00 рм LEVEL = ■

Room 207A CME credits offered

Unblinding: Need to Know Basis?

SESSION CHAIRPERSON

L. Paul Starkey, MD, FAAFP

Senior Medical Director, Global Medical and Safety Services Americas, PRA International

Unblinding during a clinical trial can be used in emergent medical situations to protect a patient, but more often unblinding occurs because of a regulatory requirement. Jurisdictional regulations with regard to unblinding are often very different, and sometimes very vague. This session will explore these differences and requirements.

Unblinding: What's the Problem?

Andrzej Czarnecki, MD, PhD, MSc

Medical Fellow, Associate Medical Director, Global Product Safety, Oncology, Eli Lilly and Company, Ltd., UK

What Are Decision Trees for?

David I. Goldsmith, MD, FISPE President, Senior Consultant, Goldsmith Pharmacovigilance and Systems

Session 395 CR1 - CLINICAL RESEARCH AND DEVELOPMENT

3:30 рм - 5:00 рм

Room 145B *CME and Pharmacy credits offered*

LEVEL = •

Conducting Clinical Trials in Erectile Dysfunction (ED)

SESSION CHAIRPERSON

Ronald Harning, PhD

Executive Director, Clinical Affairs, Palatin Technologies, Inc.

Erectile dysfunction (ED) is a therapeutic area of immense scientific and pharmacologic interest. The treatment of ED may be approached from both the peripheral vasculature and the central nervous system, using a variety of pharmacologic agents or medical devices. However, the clinical development of drugs for the treatment of ED follows a very specific path. This seminar is designed to discuss the etiology of ED, issues in study design, clinical development plans, and clinical site management.

The Etiology of Erectile Dysfunction

Ronald Harning, PhD Executive Director, Clinical Affairs, Palatin Technologies, Inc.

Protocol Development for Erectile Dysfunction

Lisa E. Diamond, PhD Associate Director, Clinical Development, Palatin Technologies, Inc.

Clinical Site Issues in Erectile Dysfunction Trials *Michael S. Willett, PharmD* President and Chief Executive Officer, Advanced Biomedical Research, Inc.

Session 396 CR2 - Clinical Research and Development, RA 3:30 PM - 5:00 PM LEVEL = ■

Room 144ABC CME and Pharmacy credits offered

Application of Critical Path Principles to the Development of Drugs for Menopausal Symptom Therapy After the Women's Health Initiative SESSION CHAIRPERSON

Daniel Shames. MD

Director, Division of Reproductive and Urologic Drug Products, CDER, FDA

Publication of results from the Women's Health Initiative over the last several years has caused confusion and anxiety for all stakeholders in the area of menopausal symptom therapy (MST). The Division of Reproductive and Urologic Drug Products is applying 'critical path" principles to the clinical evaluation of drugs for MST. The results of these initiatives will be guidance to sponsors regarding more efficient development of therapies with optimal modes and regimens of administration.

Vasomotor Symptom Modeling Stephan Ortiz, RPh, PhD

Clinical Pharmacologist, CDER, FDA

Alternative Methods for Assessing Endometrial Protection Gerald D. Willett, MD

Medical Officer, Division of Reproductive and Urologic Drug Products, CDER, FDA

Construction of Critical Paths for Development of Drugs for Menopausal Symptom Therapy Daniel Shames, MD

Director, Division of Reproductive and Urologic Drug Products, CDER, FDA

SESSION 397 CR3 - CLINICAL RESEARCH AND DEVELOPMENT, RD

3:30 рм - 5:00 рм **Room 140B**

Pharmacy credits offered

LEVEL = •

Incorporating Formal Economic Analysis in Evaluating Trial, Development, and Portfolio Strategies

SESSION CHAIRPERSON *Christy Chuang-Stein, PhD* Senior Director, Pfizer Inc

Economic analysis with an emphasis on the net present value (NPV) has been increasingly used in portfolio evaluations. In this session, we will demonstrate that in addition to portfolio evaluations, such analysis is equally relevant when assessing different development strategies. We will also show that such considerations have a role in adaptive designs when a sponsor is facing the trade-off between the desire for a high statistical power and the need to maximize the expected NPV.

Incorporating Formal Economic Analysis into Clinical Ttrial Design Cyrus R. Mehta, PhD

Cytel Software Corporation

Option Values of Two-stage Adaptive Designs: A Financial Benefit-risk Evaluation

Qing Liu, PhD Statistical Science, Johnson & Johnson Pharmaceutical Research and Development, LLC

The Use of Economic Valuations in R&D Portfolio Management Jay Andersen, PhD

Decision Sciences, Eli Lilly and Company

SESSION 398 **CR4 - CLINICAL RESEARCH AND** DEVELOPMENT

3:30 рм - 5:00 рм LEVEL =

Room 146A CME and Pharmacy credits offered

New Expectations for Drug Development: Lessons Learned from the COX-2 Inhibitors

SESSION CHAIRPERSONS

Arnold J. Gordon, PhD

Pharmaceutical Consultant

This session will feature regulators and industry professionals discussing new expectations for drug development in the aftermath of COX-2 inhibitor safety concerns.

John K. Jenkins, MD

Director, Office of New Drugs, CDER, FDA

Noël Wathion, Pharm

Head of Unit, Postauthorization Evaluation of Medicines for Human Use, EMEA, EU

SESSION 399A **CR5 - CLINICAL RESEARCH AND** DEVELOPMENT

LEVEL = 3:30 рм - 5:00 рм

Room 143C

Skating to Where the Puck Is Going: Understanding Tomorrow's Challenges in Oncology Drug Development and **Creating Infrastructure to Pave the Way** SESSION CHAIRPERSON

Kim McDonald-Taylor, MSc

Vice President, Operations, Endpoint Research, Canada

Over the past decade, oncology drug development has become increasingly competitive and global in scope. Companies developing oncology drugs now face tremendous competition for study subjects as well as market opportunity. This session will address the international landscape for oncology drug development and examine specific initiatives designed to address challenges.

Current Opportunities and Challenges in Oncology Drug Development Kim McDonald-Taylor, MSc

Vice President, Operations, Endpoint Research, Canada

The Globalization of the Oncology Drug Development: The Case of **Central and Eastern Europe**

Miroslav Reljanovic, MD

Chief Executive Officer and President, Ergomed Group, Frankfurt Biotechnology Innovation Center, Germany

Infrastructure Programs to Support Oncology Clinical Trials Robert A. Phillips, PhD

President and Chief Executive Officer, Ontario Cancer Research Network, Canada

Accessing National Oncology Networks William T. McGivney, PhD Chief Executive Officer, National Comprehensive Cancer Network

SESSION 399B **CTM - CLINICAL TRIAL** MANAGEMENT, BT, RD

3.30 PM - 5.00 PM

Room 101

LEVEL = Nursing credits offered

Sometimes It Takes Two or More to Tango: Managing Trials in a Global Collaboration

SESSION CHAIRPERSON

Angela Carroll, MLS

Manager, Clinical Affairs, Genentech, Inc.

More pharmaceutical and biotechnology companies are forming partnerships in the development of new drug products. The focus of this session is to review best practices in managing and conducting clinical trials within global sponsor collaborations. While there are many efficiencies afforded through collaborations, there are also differences which should be anticipated and addressed prior to beginning a clinical trial.

Multisponsor Collaborations in Global Drug Development Steve D. Thorne, PhD

Operations Project Leader, Roche Products Limited, UK

Preparing for a Global Collaboration Victor K. Chan Senior Clinical Trials Manager, Biogen IDEC

Lessons Learned from a Global Collaboration Angela Carroll, MLS

Manager, Clinical Affairs, Genentech, Inc.

SESSION 399C **DM** - DOCUMENT MANAGEMENT/

ESUBMISSIONS, RA 3:30 рм - 5:00 рм LEVEL = •

Pharmacy credits offered

Guidance-compliant eCTDs - Part 2 of 2

SESSION CHAIRPERSON **Gary Gensinger**

Room 206

Director, Review Technology Staff, Office of Information Management, CDER, FDA

Part 1 of this session will be held on Wednesday at 1:30 PM.

This session is Part 2 of Guidance-compliant eCTDs and will provide continued overview of FDA's eCTD Guidance and a practical discussion on developing a guidance-compliant format for an eCTD submission.

Garv Gensinger

Director, Review Technology Staff, Office of Information Management, CDER, FDA

Bronwyn E. Collier, RN Associate Director of Regulatory Affairs, CDER, FDA

Armando Oliva, MD Associate Director for Policy, Office of New Drugs, CDER, FDA

Norman R. Schmuff, PhD Deputy Director, Division of New Chemistry III, CDER, FDA

Kenneth Edmunds IT Specialist, CDER, FDA

Stephen E. Wilson, DrPH, Capt. USPHS Deputy Director, Division of Biometrics II, CDER, FDA

SESSION 399D **GCP - GOOD CLINICAL PRACTICES, RA**

3:30 рм - 5:00 рм

LEVEL = •

Room 202A

CME, Nursing, and Pharmacy credits offered

Preparing for and Surviving an FDA Inspection: US and International Perspectives from Industry and Regulators

SESSION CHAIRPERSON

Donald W. Ashbrook, PhD, RAC Chief Executive Officer, GPA International

This session will address strategies for preparation to survive FDA/regulator inspections in the US or abroad. Industry and FDA/regulator perspectives will be presented. International and US inspection findings trends will be discussed. An interactive discussion will take place on what the FDA expects to see from an audit perspective.

Preparing for an FDA Inspection of International Studies: An Industry Perspective

Donald W. Ashbrook, PhD, RAC Chief Executive Officer, GPA International

Preparing for an FDA Inspection: What Everyone Wants to Know Sherri A. Hubby

Associate Director, Clinical Quality Assurance, North America, PPD Development

US and International FDA Inspections: Current Focus, Findings and Concerns

Joseph P. Salewski

Chief, Bioresearch Monitoring Branch, CBER, FDA

SESSION 399E **IT - INFORMATION TECHNOLOGY**

3:30 рм - 5:00 рм LEVEL = •

Room 146B

IT Services: Delivering High Value in the New Pharmaceutical Environment

SESSION CHAIRPERSON

Samuel Goldman

Co-founder and Chief Technology Officer, Intrasphere Technologies, Inc.

IT services are critical to pharmaceutical companies' ability to deliver new medicines to patients. Yet, the "taken for granted" nature of infrastructure and critical applications often makes them "visible" only when there is a problem. The resulting perception among users and executives is that IT does not provide high value. This session will describe approaches used by pharmaceutical companies to counter these perceptions by delivering high-value services and aligning IT with corporate goals.

Imitate, then Innovate: A Holistic Look at Automation Thomas P. Haskell

Vice President, Pharmaceutical Solutions, Idea Integration

Experts without Borders: How Technology Can Overcome Geography in **Global Drug Development Teams** Mark H. Bradshaw, PhD Managing Director, GCP MB, Inc.

Samuel Goldman

Co-founder and Chief Technology Officer, Intrasphere Technologies, Inc.

SESSION 399F **MC - MEDICAL COMMUNICATIONS**

3:30 рм - 5:00 рм Room 209AB

CME and Pharmacy credits offered

Discovering and Meeting Customer Expectations of Medical Communications

SESSION CHAIRPERSON

Nina Barchha, PharmD

Senior Medical Information Associate, Eli Lilly and Company

LEVEL = •

This session will present both qualitative and quantitative market research that medical communications groups have conducted to obtain feedback from customers on satisfaction and expectations of their services and/or medical responses. Feedback and customer preferences will be shared from different perspectives and improvements that have been made and standards that have been set based on customer feedback will be described.

Assessing Customer Needs Via an Internet-based Survey Stacey M. Fung, PharmD

Senior Medical Communications Scientist, Genentech, Inc.

What Do Customers Really Want from Industry-based Drug Information Services?

Robert P. Baker, PharmD

Director, Professional Product Information, Roche Laboratories, Inc.

Improvement of Medical Letter Quality Based on Results of Market Research

Helen M. Hochstetler. PharmD Senior Medical Information Associate, Eli Lilly and Company

SESSION 399G **NHP - NATURAL HEALTH PRODUCTS**

3:30 рм - 5:00 рм

Room 140A

Exploring Natural Health Products: Promotion and International Coordination

LEVEL =

SESSION CHAIRPERSON

Pulok K. Mukherjee, PhD, MPharm, RPh, FIC

Director, School of Natural Product Studies, Jadavpur University, India

For the promotion and development of botanicals, quality, validated processes of manufacturing, customer awareness, and postmarketing surveillance are major criteria to rationalize their use. Regulations and promotional aspects for NHP vary from country to country and this makes it difficult to maintain uniform standards for NHP. This session will highlight various aspects of promotion and development of NHP for their regulation and control with international coordination.

Present Status of Natural Products Research and Development in Latin America: Experience of CYTED Program

Mahabir P. Gupta, PhD

International Coordinator, Iberoamerican Program for Science and Technology for Development CYTED, University of Panama, Panama

The LatinPharma Project

Diana Flores

Visiting Professor, Scientific University of South Lima; WTO Consultant, LatinPharma Project, International Trade Centre UNCTAD, Peru

Exploring Indian Systems of Medicine (ISM) Drugs for Their Assessment and Evaluation

Pulok K. Mukherjee, PhD, MPharm, RPh, FIC Director, School of Natural Product Studies, Jadavpur University, India

SESSION 399H OS - OUTSOURCING, CR

3:30 рм - 5:00 рм LEVEL = ●

Room 150A

Calculation Comparison of Pharma Internal Costs and Outsourced CRO Costs

SESSION CHAIRPERSON

Maria Fernández Freire, MD

Director, Thywill LatAm Solutions, Argentina

It is very common to hear from sponsors that CROs double or triple the costs compared to doing the tasks internally. Usually the calculation is "We just pay our employees their salaries." An adequate comparison could make cooperation between sponsors and external providers more profitable.

Cost Benefit Assessment for Outsourcing Clinical Trial Services John A. Gilly, PhD

President, North American Division, Premier Research Group PLC

CRO Monitoring Costs Versus Internal Costs Peter A. Lyn Project Liaison Manager, Novartis Oncology

Comparing CRO and Cost Estimates: The Truth Behind the Clinical Development Program Budget

Barbara J. Geiger, RN

President and Clinical Director, Clinical Research Management Services, Inc.

Session 399I PM1 - PROJECT MANAGEMENT

3:30 рм - 5:00 рм

LEVEL =

Room 149AB

Project Management Institute credits offered

Ten Things You Never Thought I Would Say (About Leading Teams)

SESSION CHAIRPERSON

Jeffrey Antos

President, Beacon Hill Technologies, Inc.

This provocative session provides unconventional wisdom for leading project teams to success. Project leadership tools are described, demonstrated, and experienced in this hands-on workshop. After an overview presentation, participants will form small groups to learn and use team leadership methods.

Jeffrey Antos President, Beacon Hill Technologies, Inc.

SESSION 399J PP - PUBLIC POLICY/LAW, RA, RD

3:30 рм - 5:00 рм LEVEL = ●

```
Room 103A
```

A Community Response to the Critical Path SESSION CHAIRPERSON Raymond L. Woosley, MD, PhD

President, The C-Path Institute

The FDA's Critical Path Initiative calls for partnerships between the FDA, academia and commercial sector. C-Path is a nonprofit organization created to host this type of partnership. The research and educational programs of C-Path designed to speed the development of safe medications will be presented.

The C-Path Institute: A Partnership to Advance the Development of Medicines *Raymond L. Woosley, MD, PhD*

President, The C-Path Institute

Innovations in Drug Development from Disciplines Other than Biosciences *Walter Moos*

Vice President, Biosciences, SRI International

FDA Partnerships in the Critical Path Initiative Janet Woodcock, MD Acting Deputy Commissioner of Operations, FDA

SESSION 399K RA1 - REGULATORY AFFAIRS

3:30 рм - 5:00 рм LEV

LEVEL = •

Room 146C

Use of Color Coding/Branding on Pharmaceutical Product Labels, Labeling, and Packaging

SESSION CHAIRPERSON

Carol Holquist, RPh

Director, Division of Medication Errors and Technical Support, CDER, FDA

Color coding is the systematic application of color or colors to a label, package, or container to help classify and identify drug products. However, there is very limited research to demonstrate that color coding is an effective tool in reducing medication errors. In fact, it has been suggested that the use of color coding may actually contribute to medication errors, including ophthalmic, dental, and insulin products.

Wiley A. Chambers, MD

Deputy Director, Division of Anti-inflammatory, Analgesic and Opthalmologic Drug Products, CDER, FDA

Carol Holquist, RPh

Director, Division of Medication Errors and Technical Support, CDER, FDA

Mary C. Gross

Policy Analyst, Office of Drug Safety, CDER, FDA

SESSION 399L RA2 - REGULATORY AFFAIRS, CR

3:30 рм - 5:00 рм

Room 152A

Outlook for Changes in Japanese Regulatory and Clinical Development Environment – Part 2 of 2

session chairpersons Hiroshi Matsumori, MS

Global Regulatory Leader, PGRD La Jolla, Pfizer Japan Inc., Japan Robert R. Fike. PhD

Assistant Vice President, Regulatory Affairs Japan, Wyeth Pharmaceuticals

Part 1 of this session will be held on Wednesday at 1:30 PM.

LEVEL =

This session will provide an update on the regulatory environment in Japan, including the regulatory review process and performance, implementation of ICH guidelines and CTD, and their impacts on clinical development. The session will also address the future perspectives for clinical development and regulatory strategy with global development programs in Japan.

The Next Stage of Global Development (Postbridging Strategy in Japan) Kazuhiko Mori, MS

Director, Office of New Drugs Evaluation I, Pharmaceuticals and Medical Devices Agency, Japan

Experience of Global Study by the Company in Japan: Experience 1

Kaoru Ishiyama

Clinical Planning, Clinical Support, Clinical Development, Scientific Affairs, Sanofi-Aventis Group, Aventis Pharma Ltd., Japan

Experience of Global Study by the Company in Japan: Experience 2

Yoshihiko Ono

Senior Manager, Regulatory Policy and Intelligence, PGRD Tokyo Laboratories, Pfizer Japan Inc., Japan

SESSION 399M RA3 - REGULATORY AFFAIRS, CR

3:30 рм - 5:00 рм

LEVEL =

Room 151A CME and Nursing credits offered

Clinical Trials Directive: EU Remains Attractive for Clinical Research

SESSION CHAIRPERSON

Barbara Schnurr, PhD

Chief Quality Assurance Manager, Harrison Clinical Research GmbH, Germany

This session will discuss the background, key content, and legal implications of the EU Clinical Trials Directive as well as its implementation status in some key EU Member States. The impact of the changes and the resulting opportunities will be reviewed.

Basic Principles of the Clinical Trials Directive Barbara Schnurr, PhD

Chief Quality Assurance Manager, Harrison Clinical Research GmbH, Germany

Implementation of the CT Directive into National Legislation Overview of the Situation of the Most Important EU Member States Benedikt Van Nieuwenhove, PhD

General Manager, European Centre for Clinical Research Training, Belgium

Advantages and Disadvantages of Performing Clinical Studies in the EU from the US Perspective Jules T. Mitchel, PhD, MBA President, Target Health Inc.

Session 399N RA4 - Regulatory Affairs

3:30 рм - 5:00 рм

LEVI

Room 151B

Various Roles and Implementation Techniques of Quality Systems in a Regulatory Agency

SESSION CHAIRPERSON

Lana L. Pauls, MPH

Director, Quality Assurance Staff, CDER, FDA

The intent of this session is to help individuals understand how using a QS approach as an approach for accomplishing their daily activities can actually facilitate their work, make it more effective, and thus more efficient. Several types of QS approaches will be discussed, as well as implementation processes in different industries.

Lana L. Pauls, MPH Director, Quality Assurance Staff, CDER, FDA

Patricia Maroney-Benassi, PhD

Consumer Safety Officer, DHHS, Office of Regulatory Affairs, FDA

Diann Sims

Environmental Scientist, US Environmental Protection Agency

LEVEL = •

Session 3990

O RA5 - REGULATORY AFFAIRS

3:30 рм - 5:00 рм

Room 147B

Research in Developing Drug Interactions and Dose Adjustments Model and Terminology Assessment for Drug Labeling

SESSION CHAIRPERSON

Katherine A. Hollinger, DVM, MPH, DACVPM

Senior Supervisory Health Promotions Officer, Office of Women's Health, Office of the Commissioner, FDA

Representation of the content of a package insert (also known as the Comprehensive Prescribing Information or the drug label) in computer applications representing machine readable/processable label information has been difficult because of the complexity of the information found in many labels. As part of an effort to make clinically relevant label content more accessible to computer applications, the FDA is researching the development of a computable representation of label content that will enhance digital clinical applications, specifically for drug interactions and dose adjustments, particularly for better management of subpopulation differences in product safety and effectiveness.

Terminology Analysis for the Drug Labeling Conceptual Model John S. Carter, MBA

Director, Consulting Services, Apelon, Inc.

Katherine A. Hollinger, DVM, MPH, DACVPM Senior Supervisory Health Promotions Officer, Office of Women's Health, Office of the Commissioner, FDA

RA6 - REGULATORY AFFAIRS

SPL and Drug Labeling Sandra L. Boyer Independent Consultant, Australia

SESSION 399P

3:30 рм - 5:00 рм

Room 152B

Scientific Advice in Europe: State of the Art

LEVEL =

SESSION CHAIRPERSON

Gopalan Narayanan, MD, FRCP, MFPM

Medical Assessor, Biologicals and Biotechnology Unit, Licensing Division, Medicines and Healthcare products Regulatory Agency (MHRA), UK

Advice on drug development is increasingly being sought by companies engaged in manufacturing through to development and marketing of pharmaceutical/biotechnology medicinal products. This session will discuss some of the current procedure(s), the experience gained, how to use the procedure(s) to get maximum value and the future direction in the European Union.

Experience of a Member State: United Kingdom *Ian Hudson, MD, MRCP*

Director, Licensing Division, Medicines and Healthcare products Regulatory Agency (MHRA), UK

Past, Present, and Future: EMEA's Position

Agnès Saint-Raymond, MD, PhD

Head of Sector, Orphan Drugs and Scientific Advice: Preauthorization Evaluation of Medicines for Human Use, EMEA, EU

View from the Industry

Paul Huckle, PhD

Senior Vice President, European and International Regulatory Affairs, GlaxoSmithKline R&D, UK

SESSION 399Q **RD - R&D STRATEGY, CR**

3:30 рм - 5:00 рм

Room 150B

LEVEL =

CME and Pharmacy credits offered

Developing Medications in Ethnically Diverse Populations

SESSION CHAIRPERSON Eric W. Lewis, MD

Director, Clinical Pharmacology, GlaxoSmithKline

This session will focus on the various scientific and logistic aspects of the development of a product for a global regulatory marketplace. Type 2 diabetes has been selected as a model disease, largely because of the well-established primary endpoints and the medical importance of this disease.

Clinical Pharmacology and Drug Development in Populations of Diverse Ethnicity

Annette S. Gross, PhD

Director, Ethnopharmacology, Clinical Pharmacology and Discovery Medicine, GlaxoSmithKline, Australia

Edmund Lee, MD

Professor, Pharmacology Department, National University of Singapore

SESSION 399R **ST - STATISTICS**

3:30 рм - 5:00 рм

LEVEL = •

Room 201

CME and Pharmacy credits offered

Clinical Data to Information to Knowledge

SESSION CHAIRPERSONS

Douglas M. Okamoto. PhD

Senior Director, Biostatistics, Clinimetrics Research Associates, Inc.

Yin Yin, PhD

Director, Statistics Data Sciences, MV CEDD Leader, GlaxoSmithKline

The purpose of this session is to evaluate the clinical development process from a statistical perspective. In the past ten years, electronic data capture at the front end and electronic filing at the back end have transformed the way we collect our clinical data and submit our new drug and biologic license applications to the regulatory authorities. Biopharmaceutical industry standards are emerging for clinical data management and electronic submissions, but what about the rest of the data-to-information-to-knowledge paradigm? Biostatisticians have a leadership role to play from clinical trial design to interpretation of safety and effectiveness data for decision-making before and after product approval.

Quantitative Issues and Statisticians' Role in the Clinical Development Plan

Yin Yin. PhD

Director, Statistics Data Sciences, MV CEDD Leader, GlaxoSmithKline

On the Generation and Ownership of Alpha in Medical Studies Vance W. Berger, PhD

Mathematical Statistician, National Cancer Institute, National Institutes of Health

Food for Thought: Statistical Thinking, Strategic Thinking, Systems Thinking

Douglas M. Okamoto, PhD

Senior Director, Biostatistics, Clinimetrics Research Associates, Inc.

Discussant Ralph Harkins, PhD Vice President, Biometrics, Otsuka Maryland Research Institute

SESSION 399S TR - TRAINING, CR

3:30 рм - 5:00 рм LEVEL =

Room 207B

Training Approaches for MedDRA®

SESSION CHAIRPERSON Patricia Mozzicato, MD

Medical Officer USA, Northrop Grumman/MedDRA MSSO

One of the most significant aspects of MedDRA implementation is training of personnel involved in a variety of organizational functions. Organizations that have been the most successful in MedDRA implementation have incorporated training of personnel as a cornerstone of their overall implementation strategy. This session will focus on lessons learned from organizations that have faced the challenge of MedDRA training.

MedDRA Training: A Mentor-protégé Approach and Skill Maintenance Program

Sonja Brajovic, MD Medical Coding Manager, PSI International, Inc.

Enlightenment Yields Acceptance JoAnn Medbery

Manager, Dictionary Management, Johnson & Johnson

5:00 PM

END OF WEDNESDAY SESSIONS

Thursday, June 30 (some speaker changes will occur before the event.)

7:30 ам - 10:30 ам	ATTENDEE REGISTRATION East Registration Area, Convention Center Mount Vernon Place Entrance
7:30 ам - 10:30 ам	SPEAKER REGISTRATION East Registration Area, Convention Center Mount Vernon Place Entrance
7:30 ам - 8:15 ам	CONTINENTAL BREAKFAST Meeting Rooms 145-147, Concourse Convention Center
12:30 рм - 4:30 рм	MEDDRA® USER GROUP MEETING Meeting Room 140A, Concourse Convention Center

Session 401 AHC - ACADEMIC HEALTH CENTERS, CR

8:30 AM - 10:00 AM LEVEL = ●

Room 103B CME and Pharmacy credits offered

Remote Management of Rural Diabetic Patients Using a Web-based Monitoring Device

SESSION CHAIRPERSON

Bonne Farberow

Project Manager, Division of Cardiology, University of Pennsylvania

Diabetes is a complex, chronic, and challenging disease. The risk of death among people with diabetes is about two times, and healthcare costs are three times, that of people without diabetes. Sequelae of poorly-managed diabetes mellitus (DM) include cardiovascular disease, renal failure, blindness, and amputation, with increased hospitalization and decreased quality of life. The intensity of provider knowledge, system resources, patient adherence, and patient self-care required to manage diabetes is a challenge for healthcare practitioners and patients alike. This challenge is amplified in rural and frontier areas, where access to care may be severely limited. Strategies will be presented to overcome these barriers in frontier and rural areas by integrating several Internet-based technologies with skilled nursing care to facilitate patients' adherence to diabetes self-care regimens and to provide remote monitoring, care management, and comprehensive oversight.

Focused Disease Management in the Medically Frail Diabetic David Chess, MD

President and Chief Executive Officer, Enhanced Care Initiatives

Use of a Medication Adherence and Electronic Patient Diary Device to Monitor Diabetic Patients and Improve Patient Drug Safety Bruce A. Kehr, MD Chairman and Chief Executive Officer, InforMedix, Inc.

Digitally Monitored Objective and Subjective Data and Automated Feedback for Remote and Self-management of Patients with Diabetes John K. Holland

President and Chief Executive Officer, LifeLink Monitoring

SESSION 402 BT - BIOTECHNOLOGY

8:30 am - 10:00 am LEVEL = ◆

Room 154AB *CME and Pharmacy credits offered*

Viral Safety: Impact of Advances in Technology

SESSION CHAIRPERSON Cecil Nick, MSc

FTOPRA Director, PAREXEL Consulting, UK

Emerging viral threats have always been a concern. The introduction of advanced therapies such as gene and cell therapy and of new manufacturing methods employing human cells and transgenic animals spotlights viral safety as an area for ever-increasing focus. This session will examine the threats from viruses and how these can be countered by progress in the methodology for testing starting materials and for in-process viral clearance.

An Introduction to Advanced Viral Clearance Technologies and Meeting the Demands for Production of Advanced Therapeutic Products *Cecil Nick, MSc*

FTOPRA Director, PAREXEL Consulting, UK

Risks Associated with Advanced Therapy and Need for New Viral Clearance Technology *Philip Minor, PhD* Head, Department of Virology, National Institute for Biological Standards and Control, UK

The Importance of New Viral Clearance Technologies in Meeting Regulatory Demands: Now and in the Future *Jeri-Ann Boose. PhD*

Senior Director, Analytical and Viral Clearance Services, BioReliance Corporation

Session 403 CDM - CLINICAL DATA MANAGEMENT, RA

8:30 AM - 10:00 AM LEVEL = •

Room 103A

Clinical Data Management: An Integral Part of the Drug Development Process

SESSION CHAIRPERSON

Linda S. King, MT

Team Leader, Global Clinical Data Management, Eli Lilly and Company

Electronic data capture and patient-reported outcomes, multiple data platforms, ancillary data, data standards application, comprehensive data review and submission strategies ... the world of data management is becoming more complex, and the role of the data manager is ever-expanding and key in the drug development process. Throughout the process, the partnership with statistics, the clinical team and regulatory ensures a well-defined data strategy leading to a high-quality submission.

Key Role of Data Managers in an Optimized Study Development Process

Linda S. King, MT

Team Leader, Global Clinical Data Management, Eli Lilly and Company

The Data Manager's Role in an Organization with Distributed Study and Project Teams

Claudia M. Lehmann

Head, Clinical Data Management, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany

The Regulatory Submission Process and the Key Role Data Managers Can Play

Donna R. Park, MA

Associate Director, Clinical Data Management and Regulatory Operations, Procter & Gamble Pharmaceuticals

SESSION 405 CP - CLINICAL SAFETY AND

PHARMACOVIGILANCE

8:30 am - 10:00 am

Room 145B

The Use of Multilanguage MedDRA® in a Global Environment

SESSION CHAIRPERSON

Carla Hagelberg, PhD, MSc Director, Innometrica Ltd., UK

Global pharmaceutical companies need to ensure that the translation of clinical, safety, and product information data from international studies is done to the highest standard and consistency, so that the underlying meaning of the data is not compromised. With the availability of sophisticated technologies and the introduction of multilanguage versions of MedDRA®, the whole process of translation can be significantly improved.

A Multilingual Data Management and Coding Environment: Technical and Functional Requirements *Robbert P. Van Manen, MSc*

Worldwide Technical Director, Phase Forward

MedDRA® Hierarchy and Translation: Impact on the Reporting of Safety Data *Nancy H. Woo, PhD* Principal, Woo Consulting

Use of MedDRA® in a Multilanguage Environment to Analyze and Report Safety Data *E. Stewart Geary, MD*

Director, Medical Regulatory Affairs and Pharmacovigilance, Eisai Co., Ltd., Japan

SESSION 406 CR1 - CLINICAL RESEARCH AND DEVELOPMENT

8:30 AM - 10:00 AM LEVEL =

Room 140B

What Sponsors and CROs Need to Know About Accreditation

SESSION CHAIRPERSON

Marjorie A. Speers, PhD

Executive Director, Association for the Accreditation of Human Research Protection Programs

As the number of accredited organizations within the clinical research enterprise increases, both sponsors and CROs need to be more fully aware of the impact of accreditation on those research entities with which they work, as well as on their own organization. Sponsors and CROs should have an understanding of the whats, whys, and hows of accreditation.

Efficient and Effective Human Research Protections and Risk Management Oversight *Matthew D. Whalen, PhD*

Co-founder and Chief Development Officer, Chesapeake Research Review, Inc.

Perspectives from CROs

Courtney Gray Haupt

Senior Associate, Government Relations and Special Projects, Association of Clinical Research Organizations (ACRO)

Perspectives from Sponsors

Michael J. Werner, JD

Chief of Policy, Biotechnology Industry Organization

SESSION 407 CR2 - CLINICAL RESEARCH AND DEVELOPMENT, RA

8:30 AM - 10:00 AM LEVEL =

Room 145A

Integrated Clinical Development

SESSION CHAIRPERSON

Ira Spector, MBA

Vice President, Clinical Trial Operations; Vice Chief of Operations, Wyeth Research

This session will publicly unveil the newly integrated clinical development organization at Wyeth Research, which combines clinical R&D, global medical affairs, vaccines and experimental development operations into one cohesive group. Very few, if any, large pharmaceutical companies have adopted this approach. Wyeth will explain the rationale for this major change and the vision for this new approach to conducting clinical research.

Ira Spector, MBA

Vice President, Clinical Trial Operations; Vice Chief of Operations, Wyeth Research

Peter Carberry, MD Vice President, Clinical Operations, Genentech, Inc.

R. Adrian Otte, MB, FFPM Senior Vice President, Worldwide Business Operations, Pfizer Inc

SESSION 408 CTM - CLINICAL TRIAL MANAGEMENT

8:30 AM - 10:00 AM LEVEL =

Nursing credits offered

Burnout, Workload, and Job Satisfaction in Clinical Trial Coordinators

SESSION CHAIRPERSON

Room 101

Clement Gwede, PhD, MPH, RN

Assistant Professor, Moffitt Cancer Center, University of South Florida

A large number of clinical trial coordinators (CTCs) work in emotionally and psychologically challenging settings at investigative sites. Yet there is a dearth of literature on the prevalence of burnout, work overload, and job-related distress among CTCs. This presentation explores issues and patterns of burnout, workload, and professional satisfaction among CTCs.

Burnout and Job Satisfaction in Clinical Trial Coordinators Clement Gwede, PhD, MPH, RN

Assistant Professor, Moffitt Cancer Center, University of South Florida

Workload Issues for Clinical Trial Coordinators

Kathie Roche, RN, CCRP

Manager, Clinical Trials and Epidemiology, Toronto Sunnybrook Regional Cancer Center, Canada

Session 409 DM - DOCUMENT MANAGEMENT/ ESUBMISSIONS, RA

8:30 AM - 10:00 AM LEVEL = •

Room 152A

Compliance Portals: The Gateway to eSubmissions

session chairperson Kevin O'Leary

President, QUMAS, Ireland

This session will focus on creating e-submissions in a web-based electronic content management system. The discussion will focus on Part 11 as it relates to the eCTD. Along with speakers from Microsoft and a representative from industry, we will cover content creation from remote locations, review and approval of the content, and assembly into a final CTD or eCTD.

Compliance Portals: The Gateway to eSubmissions Warren Perry Product Manager, QUMAS

Information-driven Applications: Using Web Services to Improve Submissions and Compliance *Jason A. Burke, MA*

Life Sciences Industry Strategist, Microsoft Corporation

Session 410 IT - INFORMATION TECHNOLOGY, CR

8:30 AM - 10:00 AM LEVEL = •

Room 146B

FIREBIRD: Implementing an Electronic Global Investigator Registry

SESSION CHAIRPERSON

William A. Rosen, MS

Executive Director, Worldwide Regulatory Affairs, SRMS, Pfizer Inc

The National Cancer Institute has advanced a pilot project known as FIREBIRD. FIREBIRD will be a collaborative effort among industry, government, and academia to establish a more cost-efficient flow of high-quality clinical research data to regulatory authorities. It will instantiate a trusted hosting service that will provide a sustainable, secure infrastructure for electronic submissions. The pilot will focus on the development of an electronic global investigator registry.

Towards a Shared Clinical Infrastructure *Sue Dubman, MA*

NCICB Director, Applications, National Cancer Institute, Center for Bioinformatics, National Institutes of Health

FIREBIRD: Moving Concepts to Reality Kamal Narang, MS

Project Manager, Mission Phoenix/FIREBIRD, CTIS, Inc.

SAFE (Secure Access for Everyone): An Update on Progress Gary W. Secrest, MS

Director, Worldwide Information Security, Johnson & Johnson

SESSION 411 IT/CDM - INFORMATION TECHNOLOGY/ CLINICAL DATA MANAGEMENT, ECLIN 8:30 AM - 10:00 AM LEVEL =

Room 149AB

The CDISC Operational Data Model (ODM): It's Not Just Data Exchange!

SESSION CHAIRPERSON

David Iberson-Hurst

Chief Executive Officer, Assero Limited, UK

CDISC was designed to provide a vendor-neutral, platform-independent means of exchanging and archiving electronic clinical data. However, the inherent power within the model has been leveraged to extend the scope of application of the model. This session presents a number of use cases that demonstrate the power and flexibility of the ODM and the roles that the model can perform within the clinical trial enterprise from data acquisition through submission to data archive.

The ODM: From Protocol to Submission

Mark L. Wheeldon Chief Executive Officer, Formedix, UK

The ODM and Electronic Submission William J. Qubeck, MBA, MS

Electronic Submission Data Group Leader, Pfizer Inc

LEVEL =

The ODM: Easing the Regulatory Burden? David Iberson-Hurst

Chief Executive Officer, Assero Limited, UK

SESSION 412 MC - MEDICAL COMMUNICATIONS, MA

8:30 am - 10:00 am

AIVI - 10.00 AIVI

Room 202B

Assessing Value-based Performance in the Eyes of Our Customers (Thought Leaders) SESSION CHAIRPERSON

Machelle Manuel, PhD

Director, Medical and Scientific Affairs Field Operations, Sankyo Pharma, Inc.

Establishing value for field-based medical programs with key internal stakeholders can be a challenge given the intent of the positions in building relationships with thought leaders and supporting their needs for medical information. This session will discuss how value for field-based medical programs is assessed across the industry and innovative approaches for assessing value through external customer feedback.

Evaluating the Impact of Medical Liaisons: The Customer's Voice Brian E. Wagner, PharmD

Operations Manager, US Medical Information and Communication Services, US Medical, Eli Lilly and Company

Assessing the Value of Your FBMP Through the Eyes of Your Customer Beth A. Price

Executive Vice President, Science Oriented Solutions (SOS)

MW - MEDICAL/SCIENTIFIC WRITING SESSION 413

8:30 AM - 10:00 AM LEVEL =

Room 102AB

The Future of Medical Writing

SESSION CHAIRPERSON

Susanna J. Dodgson, PhD

Director, Graduate Biomedical Writing Program, University of the Sciences in Philadelphia

Drug development, and thus the environment of medical writers, is a highly dynamic area. Drug development processes, the regulatory environment, and the industry itself are constantly evolving. This session will discuss the impact of changes in these areas on medical writing as a profession. Furthermore, future skill requirements will be examined.

Chances and Challenges: Outlook on the Future Environment of Medical Writers

Dan Benau, PhD

Medical Writing Consultant, Emerald Swift, LLC

Laying the Ground: How to Prepare for Future Requirements Susanna J. Dodgson, PhD

Director, Graduate Biomedical Writing Program, University of the Sciences in Philadelphia

Panelists

Réginald Hulhoven, MD, PhD, FFPM

Senior Medical Advisor, Clinical Pharmacology/Experimental Medicine, UCB, Belgium

Virginia I. Watson

Director, Clinical Writing, Cardinal Health, UK

SESSION 414

NC - NONCLINICAL LABORATORY SAFETY, CR, RA

8:30 AM - 10:00 AM LEVEL =

Room 147B

Nonclinical Testing Strategies to Support Clinical Trials SESSION CHAIRPERSONS

Per Spindler, DVM

Head of BioLogue®, University of Copenhagen, Denmark

Klaus Olejniczak, DVM, FACP

Preclinical Assessor, Federal Institute for Drugs and Medical Devices (BfArM), Germany

Planned topics for this session include the following: stage gate systems, decision trees, and bottleneck analysis; importance of making a strategy, handling uncertainty; strategic integration with other scientific disciplines, screening IND, trap-doors from too hasty early development, nonclinical strategy after initiation of clinical trials - a life after death?, assessment of US and EU possibilities - a global vision; use of regulatory scientific advice procedures as part of strategy, model systems and new models to facilitate nonclinical assessment.

Nonclinical Testing Strategy I Herman Van Cauteren, DVM Tibotec BVBA, Belgium

Nonclinical Testing Strategy II Per Spindler, DVM, MSc Head of Biologue®, University of Copenhagen, Denmark

The Regulatory System: Providing Directions and Facilitation Klaus Olejniczak, DVM, FACP

Preclinical Assessor, Federal Institute for Drugs and Medical Devices (BfArM), Germany

SESSION 415 **NHP - NATURAL HEALTH PRODUCTS**

8:30 AM - 10:00 AM LEVEL = •

Room 140A

Chinese Herbal Medicines Development

SESSION CHAIRPERSON Carmen Tamayo, MD

Research and Development Consultant, Canada

Natural health product development is an evolving area of research around the world. Researchers in Canada and in other countries strive to be more rigorous and to be taken seriously. As part of evidence-based medicine it is essential to recognize both how NHP research is similar to, and how it differs from conventional drug research. Traditional philosophies and traditional health practices often differ significantly from conventional medicine. It has been widely recognized that the variety and complexity of traditional herbal medicines must be recognized and considered in any development program.

Several challenges to traditional Chinese medicine (TCM) research have been identified in the literature and modifications and adjustments to conventional methods have been developed. However, there are still major gaps with respect to evaluating safety and efficacy of whole healing systems such as TCM. In this session information about current international initiatives and collaborations between TCM practitioners, manufacturers, researchers and regulators will be presented.

Individual contributions will emphasize practical approaches to good agricultural practices of Chinese herbal medicines, preclinical and clinical evaluation and protocol and data management used in the evaluation of promising Chinese herbal medicines. In addition, the speakers will address the continuum of thought that is involved in an evidence-based approach to TCM research and implementation.

Challenges in Product Development Involving Chinese Medicinal Herbs: A Canadian-Chinese Perspective

Edmund M.K. Lui, PhD

Associate Professor, Department of Physiology and Pharmacology, University of Western Ontario, Canada

A Case Study of Good Agriculture Practice (GAP): Challenges and Solutions in Manufacturing Chinese Herbal Medicines in China Zhuohan Hu, PhD

CEO/CSO, Research Institute for Liver Diseases; Professor, School of Pharmacy, Fudan University, China

Methodological Issues in Studying Herbs

Adriane Fugh-Berman, MD

Associate Professor, Department of Physiology and Biophysics, School of Medicine, Georgetown University

SESSION 416 **OS - OUTSOURCING, RD** LEVEL = •

8:30 AM - 10:00 AM

Room 150A

Capturing Drivers of Outsourcing Growth and Quantifying Outsourcing Value

SESSION CHAIRPERSON

Kenneth A. Getz, MS, MBA

Research Fellow, Tufts Center for the Study of Drug Development, Tufts University; Chairman, CISCRP

This session explores metrics that capture key operating and economic factors that have driven the increased use of outsourcing during the past decade. In addition, a quantitative assessment of the impact and value of outsourcing in drug development will be reviewed and discussed.

R&D Trends Driving Past and Projected Changes in the Clinical **Outsourcing Market**

Kenneth I. Kaitin, PhD

Director, Tufts Center for the Study of Drug Development Tufts University

Overview of CRO Marketplace and Its Changing Operating Environment

Douglas Peddicord, PhD Legislative Director, Association of Clinical Research Organizations

A Look at New Research Quantifying the Impact of Outsourcing Kenneth A. Getz, MS, MBA

Research Fellow, Tufts Center for the Study of Drug Development, Tufts University; Chairman, CISCRP

SESSION 417 **PM1 - PROJECT MANAGEMENT**

8:30 AM - 10:00 AM

LEVEL =

Room 143C

Project Management Institute credits offered

Cross-cultural Challenges in Multinational Pharmaceutical Companies: Differences in Communication and Decisionmaking Practices Between Japan and the West

SESSION CHAIRPERSON

Atsushi Tsukamoto, MSc

Project Manager, Sankyo Pharma Development

The session will begin with an overview of cross-cultural communication issues in the global context, followed by presentations about challenges and lessons learned about the role of cross-cultural differences in business practices and expectations among global drug development team members, from the perspective of a western and a Japanese pharmaceutical company, respectively.

Dimensions of Cross-cultural Communication Among Nationals of US, Europe, and Japan

Bhaskar Pant, MS

Managing Director, World Learning for Business

West-Japan Integration: From a US Parent Company Perspective Craig A. Davenport, RPh Managing Director and Director of Drug Development, Eli Lilly Japan KK, Japan

West-Japan Integration: From a US Subsidiary of a Japanese Parent

Company Perspective Atsushi Tsukamoto, MSc

Project Manager, Sankyo Pharma Development

SESSION 418 **PM2 - PROJECT MANAGEMENT**

8:30 AM - 10:00 AM

LEVEL = •

Room 143AB

Project Management Institute credits offered

Approaches to Reducing Risk and Improving Success in **R&D Project Management**

SESSION CHAIRPERSON

Jeffrey S. Handen, PhD

Associate Director, Business Performance Improvement, Merck Research Laboratories

It is more important than ever to manage the risks associated with drug discovery and development across the entire portfolio, to identify those candidates at highest risk as early as possible and to concentrate scarce resources on addressing those risks. Drug development success can then be better predicted by understanding the risks associated with a particular compound/project at each step of the discovery and development life cycle.

Minimizing Risk during Outsourcing and Off-shore Clinical Development

Michael M. Rossi, PhD

Medical Monitor, Medifacts International Consultants LLC

The Project Management Office as a Tool for Risk Management in **Pharmaceutical R&D Projects** Jay J. Armstrong, MS

Director - Project Management, Benefit Risk Management, Johnson & Johnson Pharmaceutical Research and Development, LLC

Reducing Risk in R&D from an IT Perspective Janet L. Gagnon, PhD

Associate Director, Development IT, Novartis Pharmaceuticals

SESSION 419 **PP - PUBLIC POLICY/LAW, RA**

8:30 AM - 10:00 AM LEVEL = •

Room 150B

Recent and Pending Case Law in the EU SESSION CHAIRPERSON

John A. Lisman, MPharm, LLM

Policy Advisor, Medicines Evaluation Board, Netherlands

The legal framework for marketing authorizations and for parallel import within the EU is evolving rapidly. Without a good understanding of rulings of the ECJ and the CFI, interpretation of the EU legislation is not possible. This session gives an update on the most important actual issues.

Introduction of the Legal System in the European Union John A. Lisman, MPharm, LLM

Policy Advisor, Medicines Evaluation Board, Netherlands

Case Law in the EU: Focus on Data Exclusivity and Generic Applications Carla Schoonderbeek, JD

NautaDutilh N.V., Netherlands Case Law in the EU: Focus on Parallel Import, Harmonization, and Other Issues

David Van Passel, JD Covington & Burling, Belgium

SESSION 420 **RA1 - REGULATORY AFFAIRS**

LEVEL = • 8:30 AM - 10:00 AM

Room 146A

CDER Town Meeting – Part 1 of 2

SESSION CHAIRPERSON Nancy D. Smith, PhD

Director, Office of Training and Communications, CDER, FDA

This interactive session will allow members of the audience to submit questions to senior leaders from the Center for Drug Evaluation and Research. The topics discussed will depend on the interests of the audience.

Panelists

Randy Levin, MD Director, Office of Information Management, CDER, FDA

Robert J. Temple, MD Director, Office of Medical Policy and Office of Drug Evaluation, CDER, FDA

Paul J. Seligman, MD, MPH Director, Office of Pharmacoepidemiology and Statistical Science, CDER, FDA

John K. Jenkins, MD Director, Office of New Drugs, CDER, FDA

Steven K. Galson, MD, MPH Acting Director, CDER, FDA

SESSION 421 **RA2 - REGULATORY AFFAIRS, PP** LEVEL =

8:30 AM - 10:00 AM

Room 151B

How to Avoid Trademark-related Delays of NDA Approvals: The FASLODEX Experience

SESSION CHAIRPERSON

Kathleen R. Gans-Brangs, PhD, MS

Director, Regulatory Affairs, AstraZeneca Pharmaceuticals LP

During NDA review consults by the Division of Medication Error and Technical Support (DMETS) of proposed labeling, packaging and trademarks, theoretical risks of confusion between trademarks are often identified along with improvements in labeling and packaging that may avoid medication errors. As a result of this consult, approximately 30% of submitted trademarks are identified as being at risk of theoretical confusion between trademarks. This session will present information on the evolution and current status of FDA postmarketing commitments in medication error reporting, a case study of the completed FASLODEX 2-year postmarketing medication error commitment, and a closer look at the role of trademarks in medication error reporting to determine when they are the cause and when they are simply the code.

Role of Postmarketing Commitments for Medication Error Thomas G. "Jerry" Phillips, RPh President, Drug Safety Institute

How to Avoid Trademark-related Delays of NDA Approvals: The FASLODEX Experience

Kathleen R. Gans-Brangs, PhD, MS Director, Regulatory Affairs, AstraZeneca Pharmaceuticals LP

Are Trademarks the Causes or the Codes in Medication Errors? George Di Domizio, JD President, Gemini Trademark Services

SESSION 422 **RA3 - REGULATORY AFFAIRS, CR**

8:30 AM - 10:00 AM LEVEL = •

Room 151A CME, Nursing, and Pharmacy credits offered

DSMBs from an IRB Perspective

SESSION CHAIRPERSON

Nora M. Cavazos, MD, CIP Director, DSM Services, Western Institutional Review Board DSMBs and similar committees play an important role in the protection of human subjects. The roles and interactions of IRBs and DSMBs ought to be discussed to avoid duplication of functions in the continuing review of research and to support the implementation of DSMB recommendations. The session will present the views of IRB professionals, regulators, and industry sponsors.

Gary L. Chadwick, PharmD, MPH, CIP

Executive Director, Office of Human Subject Protection, University of Rochester

Andreas Sashegyi, PhD

Research Scientist, Statistics, Eli Lilly and Company

SESSION 423 **RA4 - REGULATORY AFFAIRS, CR**

8:30 AM - 10:00 AM I FVFI =

Room 144ABC

European Clinical Trials Directive Implementation: An Actual Status

SESSION CHAIRPERSON

Miguel-Angel Salcedo, PharmD, MBA

Managing Director, MDS Pharma Services, Spain

Each Member State should include in its local legislation a new European Clinical Trials Directive 2001/20/CE. For example, in Spain, the Spanish Drug Agency worked and agreed with all actors involved in the clinical research arena to launch the Royal Decree 223/2004. From the industry point of view, a major concern to set up new clinical studies is how swift a country can recruit the first patient. Reducing the timeframe from protocol finalization to FPI is an important metric to pay attention to, when making decisions about the best countries to participate in a global, pan-European or local pivotal clinical study. European Clinical Trials Directive 2001/20/EC simplifies IRB's approval process and guarantees a timeframe to obtain an answer (positive or negative) in each Member State. Within 60 days a multisite clinical study protocol has to be approved or denied for the IRB in each participant country. Some European Members have already implemented the European Directive and is applicable assuming that all clinical study protocols will be reviewed within 60 days after clinical study protocol submissions. Is Europe achieving the European Directive goals from a timelines point of view? Actual industry experience will illustrate the current situation.

How the Implementation of the European Directive Has Impacted a **Spanish Pharmaceutical Company Working Through Europe** Xavier Luria, MD

Medical Director, Almirall Prodesfarma, Spain

Impact of the Directive on Industry and Suggestions for Future Improvements

Carolyn L. Hynes, PhD Regulatory Affairs Manager, Johnson & Johnson Pharmaceutical Research and Development, LLC, UK

Implementation of the EU GCP Directive: A Scandinavian Perspective Alistair Bone

Director of Quality Assurance and Training, TFS Trial Form Support, Sweden

Perspective in Eastern Europe Prof. Jozef Glasa, MD, PhD

Chairman, Central Ethics Committee, Ministry of Health, Slovak Republic

Session 424 RA5 - Regulatory Affairs

8:30 am - 10:00 am

LEVEL =

Room 152B

CME and Pharmacy credits offered

Prescription Drug Labeling: Implementation of FDA's New Regulation for the Content and Format of the USPI and an Update on the Status of the USPI Guidance Documents SESSION CHAIRPERSONS

Steven W. Bass, PhD

Director, Global Labeling and Promotion Compliance, Global Regulatory Sciences, Bristol-Myers Squibb

Melody L. Eble, PharmD

Director, Regulatory Affairs, Global Regulatory Information, Johnson & Johnson Pharmaceutical Research and Development, LLC

One of the FDA's recent major initiatives was its proposal to revise the format and content of the USPI, issued as a proposed regulation on December 22, 2000. This new format is intended to make important information available in a clear, consistent and readable manner. The FDA believes that this new userfriendly format also has the potential to help reduce errors in drug prescribing. This session will review the new regulation, the time frame for implementation of the "new format" and will discuss the major changes from the Current Regulations for the content and format of the US Package Insert (CFR 201.56 and CFR 201.57). The session will also provide a forum to discuss both the FDA's and industry's questions and expectations regarding its implementation.

In addition, the industry and FDA panel will answer questions regarding draft (i.e, adverse reactions, clinical studies section) and proposed guidance documents to support various sections of the package insert. We will also discuss the implication of the new format on the Content of Labeling (FDA e-Labeling Final Rule of December 11, 2003), on the PhRMA Paperless Labeling Initiative and on its use in Direct-to-consumer Brief Summaries.

This new format is a major change to the way we have been delivering safety and efficacy information to healthcare providers and to the patient. This should be a fascinating and interactive session.

Background and Overview

Steven W. Bass, PhD

Director, Global Labeling and Promotion Compliance, Global Regulatory Sciences, Bristol-Myers Squibb

Presentation of the Final Rule: Overview, Expectations and Implications

SESSION 425 ST - STATISTICS

8:30 am - 10:00 am

LEVEL = •

Room 146C

CME credits offered

Statistical Considerations in Human Drug Abuse Potential Studies

SESSION CHAIRPERSON

Yi Tsong, PhD

Mathematical Statistician, CDER, FDA

Data from relevant preclinical studies, clinical safety-efficacy trials, and human pharmacology studies are needed for FDA review and are necessary for evaluation of the abuse potential of new chemical entities. Such data are included in the new drug applications (NDAs) and frequently provide the basis for drug scheduling decisions. Several aspects of the human pharmacology drug abuse potential studies are unique with regard to design and analysis. Subject population, inclusion and exclusion criteria, dosing regimen, selection of positive controls, outcome measures and timing of measurements, pharmacokinetics of the drug, reliability of scales, and statistical approaches are important to interpretation of results. Regarding statistical considerations, these trials are often designed with Latin Square with multiple treatments (test and positive control of different dose levels) and placebo. Appropriate length of washout period becomes crucial in design and analysis. This session will address such issues as selection of response variables and study designs.

The Objectives of a Drug Abuse Potential Human Laboratory Study. Michael Klein, PhD

Pharmacologist, Controlled Substance Staff, CDER, FDA

The Clinical and Statistical Considerations in Clinical Trial Design, Planning and Analysis from the Consultant Point of View Donald R. Jasinski, MD

Professor, Department of Medicine; Chief, Center for Chemical Dependency, Johns Hopkins University

Statistical Considerations in Design and Analysis of Drug Abuse Clinical Trial

Ling Chen, PhD

Mathematical Statistician, Quantitative Methods Research Staff, Office of Biostatistics, CDER, FDA

Discussant

Deborah B. Leiderman, MD, MA

Director, Controlled Substance Staff, Office of the Center Director, CDER, FDA

Session 426 TR - TRAINING

8:30 AM - 10:00 AM LEVEL =

Room 147A

Did the Training Do What It Was Supposed to Do? Evaluating the Employee and the Training Program SESSION CHAIRPERSON

Kimberly N.M. Andrews, MEd

Performance Consulting Manager, PPD Development

The presentations within this session will address the most commonly recognized model for evaluating training, evaluating the individual training participant's comprehension of the content covered within the program, and evaluating the transfer of the training to the job or the on-the-job behavioral change based on the training program.

Evaluating the Effectiveness of Training *Claudia Lappin, JD, MS*

Associate Training Consultant, Eli Lilly and Company

Did the Employee Learn the Content of the Training Program? How to Create and Use a Level 2 Evaluation *Melissa O. Ockert, MS* Program Director, Clinical Trials Research Associate Programs, Durham Tech

Community College

Did the Employees Transfer the Training to Their Behavior on the Job? How to Create and Use a Level 3 Evaluation *Kimberly N.M. Andrews, M Ed*

Performance Consulting Manager, PPD Development

10:00 am - 10:30 am

REFRESHMENT BREAK

Meeting Rooms 145-147, Concourse Convention Center

SESSION 427 **AHC - ACADEMIC HEALTH CENTERS,** IS, RA

LEVEL = 10:30 AM - 12:00 PM

Room 103B CME and Pharmacy credits offered

Regulatory Obligations of an IND Sponsor-investigator

SESSION CHAIRPERSON

Harvey M. Arbit, PharmD, MBA

Director, IND/IDE Assistance Program, University of Minnesota

A clinical researcher who files an IND application becomes the sponsor of that IND as well as the investigator. The FDA regulations at 21 CFR 312 Subpart D specify the responsibilities of sponsors and investigators that must be followed to be in compliance. These obligations will be presented from three perspectives: FDA, academia, and legal.

IND Sponsor-investigator Obligations from an FDA Perspective Patricia A. Holobaugh, MS

Consumer Safety Officer, CBER, FDA

IND Sponsor-investigator Obligations from an AHC Perspective Harvey M. Arbit, PharmD, MBA Director, IND/IDE Assistance Program, University of Minnesota

IND Sponsor-investigator Obligations from a Legal Perspective David B. Clissold, JD, MA Attorney, Hyman, Phelps & McNamara, P.C.

Session 428 **BT - BIOTECHNOLOGY, CR**

10:30 ам - 12:00 рм LEVEL =

Room 154AB

Pharmacy credits offered

Overcoming Hurdles to Develop Clinically Validated Standardized, Quantitative, Quality Controlled, Next Generation, Multigene Expression Biomarker Assays **Suitable for Clinical Trials**

SESSION CHAIRPERSON Terry Osborn, PhD, MBA

President and CEO, Gene Express, Inc.

Pharmacogenomics is clearly an area of great promise, but how do we turn tomorrow's promise into today's reality? This session addresses some of the fundamental questions and regulatory hurdles that need to be addressed in the development of clinically validated and successful multigene expression assays for biomarkers for use in clinical trials. A comparison of three different cancer tissues analyzed with different quantitative gene expression methods. Biomarker assays to diagnose lung cancer and to evaluate a multigene set in normal subjects will be described.

Review of FDA Guidance for Pharmacogenomic Biomarker Data Submission Relative to Strengths and Weaknesses of Gene Expression **Measurement Technologies** James C. Willey, MD

Professor of Medicine and Pathology, Medical College of Ohio

Comparison of a Five-gene Biomarker in Three Different Cancer Tumor Tissues with Different Quantitative Gene Expression Methods to Meet Reproducibility, Robustness, and the Other Characteristics of the New FDA Pharmacogenomic Biomarker Guidance **Richard Deane Hockett, MD**

Senior Clinical Research Physician, Eli Lilly and Company

SESSION 429 **CDM - CLINICAL DATA MANAGEMENT,** IMP LEVEL =

10:30 AM - 12:00 PM

CME credits offered Room 103A

Evidence-based Medicine: Evaluating the Data from Outcome-based Clinical Trials SESSION CHAIRPERSON

Marguerite Fisher, RN, MSN

Team Leader, Data Management, Eli Lilly and Company

This session will explore the nature of outcome-based clinical trials, how clinical endpoints are managed and used to evaluate whether a clinical trial's objectives have been met, and the current regulatory environment surrounding outcomebased clinical trials and the use of DMCs/CECs. Perspectives on this trend will be provided from the view of the sponsor, the members of the adjudication board, and the Data Analysis Group (DAG).

Design and Operational Features for Trials with Clinical Events as the **Primary Study Endpoints** Andreas Sashegyi, PhD

Research Scientist, Statistics, Eli Lilly and Company

Developing a Safety Profile for the Data Monitoring Committee when **Clinical Events Are the Primary Study Endpoints** Patrick D. O'Meara, PhD President, Pat O'Meara Associates, Inc.

SESSION 430 **CP - CLINICAL SAFETY AND**

PHARMACOVIGILANCE

10:30 am - 12:00 pm LEVEL =

Room 145B CME credits offered

Analyses Using MedDRA®-coded Data

SESSION CHAIRPERSON

Patricia Mozzicato, MD

Medical Officer USA, Northrop Grumman/MedDRA MSSO

During MedDRA® implementation, most organizations initially put great emphasis on the "input" aspects of MedDRA usage, i.e., the encoding of information such as adverse events, medical histories, etc. At some point, these organizations are faced with having to analyze this encoded data in some fashion. The focus of this session will be on postretrieval steps such as tabular presentation of data, use of primary versus secondary system organ classes (SOCs), and statistical considerations.

Good Data Retrieval Practices: What Does the PtC Document **Contribute?**

Reinhard Fescharek, MD

Head of Medicine, Bayer Healthcare AG, Germany

Panos Tsintis Head of Sector for Pharmacovigilance and Postauthorization and Efficacy, EMEA, EU

MedDRA's Characteristics and Their Impact on Retrieval and **Presentation of Coded Data** Patricia Mozzicato, MD

Medical Officer USA, Northrop Grumman/MedDRA MSSO

Session 431 CR1 - CLINICAL RESEARCH AND DEVELOPMENT

10:30 ам - 12:00 рм LEVEL = ◆

Room 140B CME and Pharmacy credits offered

Clinical Studies in Psychiatry: New Variations on the Placebo Response

SESSION CHAIRPERSON

Ellis H. Wilson, MS, MSA

Study Delivery Director, Neuroscience, AstraZeneca Pharmaceuticals

There is consensus that placebos will remain an important part of clinical research. The frequency of statistically significant placebo response rates in some clinical trials, particularly in psychiatry, is a subject of substantial concern across the drug development community. This session is designed to review the conventional wisdom surrounding the placebo response and to provide details on new theories, approaches, and technologies designed to identify and mitigate this effect.

The Influence of Clinical Trial Design Features and Patient Characteristics on Placebo Response and the Outcome of Antidepressant Trials *Charles G. Lineberry, PhD*

CEO, Lineberry Research Associates, LLC

Impact of Factors Associated with Clinician Ratings on Placebo Response and Signal Detection *Kenneth Kobak, PhD* Vice President, Research, MedAvante, Inc.

Placebo Response in Depression Studies: Lessons from a Large Depression Database *Richard A. Entsuah, PhD* Senior Director, Wyeth Research

Session 432 CR2 - CLINICAL RESEARCH AND DEVELOPMENT

10:30 AM - 12:00 PM LEVEL =

Room 145A *CME, Nursing, and Ph*

CME, Nursing, and Pharmacy credits offered

Patient Safety: Ethics, Pharmaceuticals for Children, and Human Research Protections

SESSION CHAIRPERSON

Melvyn Greberman, MD, MS, MPH

Director, Public Health Resources, LLC

This session will address patient safety research issues of importance to government, healthcare providers and consumers, researchers, and industry. They include ethical and other issues relevant to clinical research, publicprivate sector collaborative efforts to improve the safety and effectiveness of drugs for pediatric use, and federal human subject protection regulations. Undertaking human research without the requisite oversight can create regulatory, legal, and ethical hazards, and it is important to determine whether or not proposed projects should be considered research subject to IRB approval. Since drugs are frequently prescribed for children even though they have not been tested in them, there is concern about adverse effects in pediatric age groups that are not anticipated from adult studies. To address such concerns, NIH is working closely with FDA and other public and private sector organizations to implement the Best Pharmaceuticals for Children Act. In addition, the Institute of Medicine issued a report on Ethical Conduct of Clinical Research Involving Children in 2004 recommending clarification of the definitions that appear in 45 CFR Part 46 Subpart D: Additional DHHS Protections for Children Involved as Subjects in Research. In response to this recommendation, the Secretary's Advisory Committee on Human Research

Protections (SACHRP) has developed guidance to aid in the interpretation of the requirements of Subpart D. The guidance that SACHRP has proposed will be discussed in this session.

Medical, Ethical, and Economic Issues that Impact the Development and Use of Pharmaceuticals for Children *Stanley A. Edlavitch, PhD, MA*

Professor of Epidemiology and Director, Epidemiology Research, University of Missouri at Kansas City School of Medicine

Implementation of the Best Pharmaceuticals for Children Act: Public and Private Sector Collaboration

Donald R. Mattison, MD, MS

Senior Advisor to the Directors of the National Institute of Child Health and Human Development and the Center for Research for Mothers and Children, NIH, HHS

Research Involving Children: Emerging Human Protection Issues Judith Brooks, MS, RN, CIP

Public Health Analyst, Division of Education and Development, Office for Human Research Protections, HHS

SESSION 433 CTM - CLINICAL TRIAL MANAGEMENT, MC

10:30 ам - 12:00 рм LEVEL =

CME, Nursing, and Pharmacy credits offered

Patient Insights from the Frontlines of Medical Communications

SESSION CHAIRPERSON

Room 101

Sarah Ebner, MBA, MPH

Director, Business Development, Phone Screen

Critical insights and trends related to patient habits, demographics, medications, call scripts, therapeutic areas, and cultural barriers are meticulously documented every day by skilled professionals who are on the front lines of medical communications. This session will cover key findings and tips derived from direct contact with hundreds of thousands of patients and providers representing more than 50 disease states.

The Call Center Perspective Jim Ringstad Senior Project Manager, Phone Screen

The Research Site Perspective *Pamela Kivitz-Keenan* Director, Patient Recruitment, Altoona Center for Clinical Research

The Advocacy Group Perspective Julie Totten, MBA President and Founder, Families for Depression Awareness

Session 434

DM - DOCUMENT MANAGEMENT/ ESUBMISSIONS, RA

10:30 ам - 12:00 рм LEVEL = •

Room 152A

Structured Product Labeling (SPL): Requirements, Challenges, and Best Practices SESSION CHARPERSON

Andrew Glemser

Chief Technology Officer, Glemser Technologies Corporation

Regulatory authorities around the world are requiring product labeling documents to be submitted in XML format, such as SPL and PIM. Join us at this session to understand the regulatory requirements of XML-based product labeling, discuss issues and challenges, review implementation options, define a document and data migration strategy, review an implementation roadmap, and discuss best practices.

An Overview of SPL, the Regulatory Requirements and Implication Timeframe, and Future Plans for SPL

Steven Gitterman, MD, PhD Deputy Director, Director of Special Pathogens and Immunologic Drug Products, CDER, FDA

The Current Environment, Challenges, and Approach to Addressing SPL and PIM

Kristofer J. Spahr

Associate Director, Regulatory and Labeling Applications, Wyeth Pharmaceuticals

Improving Business and Public Health Through Open Standards Thomas Moore, MPA

Vice President, Document Management Practice, Intrasphere Technologies, Inc.

SESSION 435 GCP - GOOD CLINICAL PRACTICES

10:30 ам - 12:00 рм LEVEL = •

Room 149AB Nursing credits offered

Risk Management Focus in Clinical QA

SESSION CHAIRPERSON

Mary Kay Denham, MS

Director, Worldwide Regulatory Compliance - GCP, Bristol-Myers Squibb PRI

The clinical research environment has become less predictable in recent years, with an increase in high-risk areas which include vulnerable populations, complaints, higher-risk protocols and products. QA professionals need to take a more risk-based approach in conducting audits, internal reviews, and training. This session will focus on the different aspects of how to prioritize critical issues to enhance performance.

Managing Risks in Clinical Investigator Audit Strategy Mary Kay Denham, MS

Director, Worldwide Regulatory Compliance - GCP, Bristol-Myers Squibb PRI

Risk-based Approach to Vendor Audits: Why, When, How, and What? Richard M. Siconolfi, MS

Director, Computer Systems Validation and System Lifecycle, Procter & Gamble Pharmaceuticals, Inc.

Protocol Complexity as a Factor in Clinical Compliance Risk: Case Studies

Marta H. Fields, MBA

Associate Director, Global Head, Therapeutic Area Quality Leaders, Clinical Quality Assurance, Amgen Inc.

Session 436 IMP/CP - IMPACT/CLINICAL SAFETY AND PHARMACOVIGILANCE, ECLIN

10:30 AM - 12:00 PM LEVEL = •

Room 152B CME and Pharmacy credits offered

The Use and Impact of Patient-level Electronic Data in Healthcare Decision Making

SESSION CHAIRPERSON

Robert M. A. Thwaites, MA, MCom

Director, Healthcare Information Factory, GlaxoSmithKline Research and Development, UK

Following a brief introduction covering the development and extent of the use of patient-level electronic data in healthcare decision making, the speakers will provide examples of the growing value of these data in decisions across different types of healthcare organizations.

The Impact of Patient-level Data on Decision Making in an Integrated Healthcare Organization

K. James Ehlen, MD Halleland Health Consulting

The Impact of Patient-level Data on Decision Making in a Pharmaceutical Company

Robert M. A. Thwaites, MA, MCom

Director, Healthcare Information Factory, $\mathsf{GlaxoSmithKline}$ Research and Development, UK

Session 437 IT/CDM - INFORMATION TECHNOLOGY/ CLINICAL DATA MANAGEMENT

10:30 ам - 12:00 рм LEVEL =

Room 146B

Assessing Global Adoption of Electronic Data Collection Technologies

SESSION CHAIRPERSON

Rebecca D. Kush, PhD President, CDISC

The use of and attitudes towards new electronic data collection technologies and data interchange standards were explored in 2002 and 2003 through two major global research projects. A subsequent project, conducted by CDISC and completed in 2004, explored the issues raised in the preceding efforts, specifically to update the adoption and attitudes around technologies that collect case report form data (eCRF) and those that collect patient-reported outcomes (ePRO) and to assess the adoption of standards in more depth. This research project was sponsored by 16 pharmaceutical companies, CROs, and technology providers and was supported by nonprofit organizations to reach users of these new technologies and standards for their opinions. Key findings, trends and comparisons will be presented with a goal of assisting companies in their implementation of new technologies and standards.

Global Industry Adoption of Data Interchange Standards *Frank T. Newby*

Vice President, Education and Member Relations, CDISC

Adoption of New Technologies by Trial Sponsors and Technology Providers David Iberson-Hurst

Chief Executive Officer, Assero Limited, UK

Adoption of New Technologies by Investigative Sites Kenneth A. Getz, MS, MBA

Research Fellow, Tufts Center for the Study of Drug Development, Tufts University; Chairman, CISCRP

Session 438	MW - MEDICAL/SCIENTIFIC WRITING,
	DM

```
10:30 ам - 12:00 рм LEVEL =
```

Room 102AB

Re-engineering Document Preparation: Setting the Stage for Study Tagging Files

session chairperson Victoria E. Seidenberger

Director, Document Quality and Technology, Wyeth Research

This session will review the implementation of study tagging files which has implications for the way industry plans and prepares documents and for adjustments to electronic publishing processes.

Building an eCTD: A Model in Cross-functional Area Cooperation Ryan R. Claringbold

Global Dossier Leader, Johnson & Johnson Pharmaceutical Research and Development, LLC

Impact of the STF Format on Document Preparation Susan Nielsen, PhD Associate Director, Clinical Writing and Resource Management, Wyeth Research

Study Tagging Files: The Outsourcing Perspective Christina M. Rogers, PhD

Director, Medical Writing, ReSearch Pharmaceutical Services, Inc.

Session 439 NC - Nonclinical Laboratory Safety, RA

10:30 ам - 12:00 рм LEVEL =

Room 147B

Immunotoxicity Testing of Human Pharmaceuticals SESSION CHAIRPERSON

Jan Willem Van der Laan, PhD

Head, Preclinical Assessment Group of the Medicines Evaluation Board, National Institute for Public Health and the Environment, Netherlands

In November 2004, the ICH agreed upon a Step 2 document on Immunotoxicity Testing of Human Pharmaceuticals. The main issue is the cause-for-concern approach that is now adopted by all parties. Two speakers will present their views on this process. A third speaker will highlight the pathological aspects of the issue.

The ICH Step 2 Immunotoxicity Testing from a European Regulatory Perspective

Jan Willem Van der Laan, PhD

Head, Preclinical Assessment Group of the Medicines Evaluation Board, National Institute for Public Health and the Environment, Netherlands

The ICH Step 2 Immunotoxicity Testing from an Industrial Perspective Stephen K. Durham

Executive Director, Pharmaceutical Research Institute

Session 440 NHP - NATURAL HEALTH PRODUCTS, RA

10:30 AM - 12:00 PM LEVEL = •

Room 151B

Regulatory Issues in the Development of Heterogeneous Products: Town Hall Meeting with the FDA CDER Botanical Review Team and Center for Biologics

SESSION CHAIRPERSONS

Shaw T. Chen, MD, PhD

Team Leader, Botanical Review Team, Associate Director, Office of Drug Evaluation V, CDER, FDA

Julienne M. Vaillancourt, MPH, RPh

Regulatory Reviewer, Project Manager, CBER, FDA

Probiotics are live, bacterial preparations often marketed as dietary supplements and considered to have beneficial health effects. However, when used to treat or prevent disease, they are biological products, specifically live biotherapeutic products, and subject to pertinent regulatory requirements. This session will present the regulatory issues and challenges faced in the development of probiotics and other live biotherapeutic products for clinical indications and use within the US. Regulation of Probiotics and Other Live Biotherapeutic Products as Biologics

Julienne M. Vaillancourt, MPH, RPh Regulatory Reviewer, Project Manager, CBER, FDA

Status Report from the Botanical Review Team, FDA Center for Drug Evaluation and Research

One of the participants from FDA will present.

FDA Town Hall on Natural Health Products: Question & Answer Panel Regarding Heterogeneous Drug Development

Discussants Jinhui Dou, PhD Pharmacologist, Botanical Reviewer, Office of Drug Evaluation V, CDER, FDA

Leslie A. Vaccari, RAC Regulatory Project Manager, CDER, FDA

SESSION 441 OS - OUTSOURCING, IT

10:30 ам - 12:00 рм LEVEL = •

Room 150A

The Real World of Outsourcing: Outsourcing Fact and Fiction

SESSION CHAIRPERSON

Paul Hodge

Vice President, Practice Manager (Pharmaceuticals), Intrasphere Technologies, Inc.

Pressures in the pharma industry are forcing organizations to drive down their IT project costs, while increasing value and reducing project timeframes. In recent years, part of the solution to these seemingly irreconcilable priorities has been to deploy global delivery models. Using a real-world case study, involving outsourced IT services to a large pharma company, this session will offer a unique opportunity to explore the lessons learned on the road to establishing an off-shore IT model.

An Introduction to the Real World of Outsourcing Vivek Agrawal

Country Manager, Intrasphere Information Technologies Pvt, Ltd., India

International Best Practices Dr. Chetan Tamhankar

General Manager, SIRO Clinpharm Pvt Ltd., India

Session 442 PM1 - PROJECT MANAGEMENT

10:30 ам - 12:00 рм LEVEL =

Room 143C Project Management Institute credits offered

Drug Development Projects: A Vehicle for Organizational Learning

SESSION CHAIRPERSON

Jonas Roth, PhD, MSc

Head, Knowledge Management and Communications, AstraZeneca R&D, Sweden

This session will present innovative approaches to managing project knowledge and how drug development projects can be the focal point for individual, team, and organizational learning to create business value. Practical examples and tools will be given, as well as provocative evidence that challenges existing theories about how individuals, teams, and organizations learn.

Project Work Is About Creating New Knowledge David Williamson

Wenell Management, Sweden

A Practical Method for Knowledge-sharing Between Projects Lena Berg, MSc

Director, AstraZeneca Research and Development, Sweden

Projects: The Vehicle for Organizational Learning

Jonas Roth, PhD, MSc Head, Knowledge Management and Communications, AstraZeneca R&D, Sweden

Session 443 PM2 - PROJECT MANAGEMENT

10:30 AM - 12:00 PM

LEVEL =

Room 143AB Project Management Institute credits offered

Increased Productivity Through Effective Resource Management

SESSION CHAIRPERSON Scott J. Mahoney, MBA Director, PRTM

This session will explore how effective resource management practices can contribute to increased productivity at both the strategic and tactical levels. Additionally, industry case studies will explore varying approaches organizations are employing to avoid common resource management pitfalls.

Practical Application of Resource Management: Diary of a Journey Chris Clement, PhD

Director/Head, Project Office, Millennium Pharmaceuticals, Inc.

Capacity Management: Delivering the "Holy Grail" of Resource Management

Patrick A. Grogan, MBA Senior Director, Global Project Management, Pfizer Inc

Resource Management in an Ever-changing Portfolio Colleen K. Dixon

Project Management Consultant, Eli Lilly and Company

SESSION 444 PP - PUBLIC POLICY/LAW, RA

10:30 AM - 12:00 PM LEVEL =

Room 150B *CME credits offered*

FDAMA Part 113: ClinicalTrials.gov - Where Are We Now?

SESSION CHAIRPERSON

Maureen Morgan, MS

Associate Director, Regulatory Affairs, AstraZeneca Pharmaceuticals LP

In this session, you will hear from a major pharmaceutical company that has developed a best-practice approach for both the decision making and the process of posting clinical trials to this website.

This session will also review FDA's compliance report for the year 2002 and will provide new information regarding compliance for the year 2004 for one disease state. In addition, the patient advocacy community's position on the usefulness of the ClinicalTrials.gov data base will be discussed.

ClinicalTrials.gov: FDA's Perspective

Theresa A. Toigo, RPh, MBA

Assistant Commissioner for Special Health Issues, Office of the Commissioner, FDA

ClinicalTrials.gov: An Industry Perspective Michelle Folz, RN, MSN

Manager, US Regulatory Affairs Operations, Eli Lilly and Company

ClinicalTrials.gov: The Patient Advocate Perspective Jane Reese-Coulbourne, MS, ChE Staff, ALCASE (Alliance for Lung Cancer)

SESSION 445 RA1 - REGULATORY AFFAIRS

10:30 ам - 12:00 рм LEVEL = •

Room 146A

CDER Town Meeting – Part 2 of 2

SESSION CHAIRPERSON Nancy D. Smith, PhD

Director, Office of Training and Communications, CDER, FDA

Part 1 of this session will be held on Thursday at 8:30 AM.

This interactive session will allow members of the audience to submit questions to senior leaders from the Center for Drug Evaluation and Research. The topics discussed will depend on the interests of the audience.

Randy Levin, MD Director, Office of Information Management, CDER, FDA

Robert J. Temple, MD Director, Office of Medical Policy and Office of Drug Evaluation, CDER, FDA

Paul J. Seligman, MD, MPH Director, Office of Pharmacoepidemiology and Statistical Science, CDER, FDA

John K. Jenkins, MD Director, Office of New Drugs, CDER, FDA

Steven K. Galson, MD, MPH Acting Director, CDER, FDA

SESSION 446 RA3 - REGULATORY AFFAIRS, ECLIN, IS

10:30 ам - 12:00 рм LEVEL =

Room 151A *CME credits offered*

21 CFR Part 11 and Electronic Medical Records Used as Investigational Source Documents

session chairperson David M. Knepper, MS

Executive Director, Clinical Research, PharmaNet

21 CFR Part 11 draft guidance documents have been published and then withdrawn. Questions regarding the application of these regulations to electronic medical records systems at investigational sites remain, and industry has adopted widely varying policies for electronic source documentation requirements and controls. This session will explore the challenges surrounding the application of Part 11 requirements to investigational sites and discuss solutions that are both legal and practical.

Academic Health Centers and FDA Electronic Records Regulations: Do the 21 CFR 11 Requirements Apply to Me? *Gregg J. Fromell, MD*

Executive Director, Office of Human Research, University of Pennsylvania, School of Medicine

Meeting Existing Investigator Data Integrity Requirements in the New Electronic Environment: Is Part 11 Redundant? David M. Knepper, MS

Executive Director, Clinical Research, PharmaNet

SESSION 447 **RA4 - REGULATORY AFFAIRS**

10:30 AM - 12:00 PM LEVEL =

CME credits offered

Clinical Trials in Latin America: A Review of the Regulatory Framework

SESSION CHAIRPERSON

Room 144ABC

Manuel Fresno, MBA

Managing Director, Latin America, MDS Pharma Services, Argentina

Latin America has recently become one of the most active regions for clinical trials in the world. The regulatory environment of Latin America has improved over the last few years and increasingly operates in accordance with international standards and guidelines. This session will present a review of the approval process across the main countries in Latin America.

Regulatory Framework for Clinical Trials in Argentina Graciela C. Racaro

Regional Clinical Development Liaison, Latin America, Serono International S.A., Argentina

Regulatory Framework for Clinical Trials in Brazil Eduardo Motti, MD

Clinical Research Manager, Schering AG, Brazil

Regulatory Framework for Clinical Trials in Mexico Sergio Guerrero, MD

Vice President/Chief Operating Officer, Mexican Institute of Clinical Research, Mexico

SESSION 448 **ST - STATISTICS**

10:30 ам - 12:00 рм LEVEL = ◆

Room 146C

Global Development Program and Data Quality from the Japanese Point of View

SESSION CHAIRPERSONS

Shunsuke Ono, PhD

Reviewer, Pharmaceutical and Medical Devices Agency (PMDA), MHLW, Japan Takatoshi Sato, PhD President, Hyclips K.K., Japan

The objective of this session is to understand the issues of global development from the perspective of Japanese pharmaceutical industry representatives and authorities of the US, EU, and Japan. We need to learn how the concepts of these authorities differ, and about the practical circumstances of clinical study from a data quality point of view.

The Concept of Global Development and Data Quality from the Japanese Authorities' Point of View

Shunsuke Ono, PhD

Reviewer, Pharmaceutical and Medical Devices Agency (PMDA), MHLW, Japan

Global Development Programs in Eisai Co., Ltd. E. Stewart Geary, MD

Director, Medical Regulatory Affairs and Pharmacovigilance, Eisai Co., Ltd., Japan

Global Development Programs and Data Quality in Sankyo Co., Ltd. Hironobu Saito, MBA

Manager, Clinical Development Department, Sankyo Co., Ltd., Japan

Panel Discussion

SESSION 449 **TR - TRAINING**

10:30 AM - 12:00 PM LEVEL = •

Room 147A

Communication Tools/Practices that Work SESSION CHAIRPERSON

Debra A. Jendrasek, MBA

Manager, US EDC Solutions, Chiltern international

Change is ongoing in today's work environment. For most of us, this requires us to accomplish more work in less time. When communication goes astray, productivity is impacted. Good communication and influence skills can help us be more effective in getting our work done with and through others more efficiently. In this session, we will discuss communication tools that organizations have found to be most effective in keeping their monitoring staff, investigators, and vendors focused, on task and apprised of the best practices in clinical trials.

Electronic Performance Enhancement Tools for the Pharmaceutical Industry

Joan E. Pastor Clinical Research Training Consultant, Pastor Consulting, Inc.

Project Success: Focus on the Fundamentals Jessica A. Whittaker Senior Consultant, Glemser Technologies Corporation

Best Practice: Rapid Application Prototyping to Align Business Units around Enterprise Project Management

Gus Cicala, MS President and Chief Executive Officer, Project Assistants, Inc.

12:00 рм END OF THURSDAY SESSIONS **ANNUAL MEETING ADJOURNED** 12:00 рм 12:30 рм - 4:30 рм MEDDRA® MSSO USER GROUP MEETING Meeting Room 140A, Concourse, Convention Center

Join us next year

June 18-22, 2006 | Philadelphia, PA

42nd Annual Meeting

Pennsylvania Convention Center

PROGRAM CHAIRPERSON Charles C. Depew, PharmD GlaxoSmithKline